[
  {
    "page": 1,
    "source": "text",
    "content": "Environmental, Social & Governance (ESG)\nProgress Report 2021/2022"
  },
  {
    "page": 2,
    "source": "text",
    "content": "2 Overview\n3 A letter from our CEO\n5 Our Company\n6 Our ESG approach\n7 ESG focus areas\n14 Access to Health\n18 Employees\n21 Environmental Sustainability\n23 Ethics & Values\n25 References\n26 GRI/SASB disclosures\n27 General disclosures\n52 Economic\n83 Environmental\n124 Social\n178 Indices\n178 Global Reporting Initiative (GRI)\n186 Sustainability Accounting\nStandards Board (SASB)\n189 UN Global Compact\n190 UN Sustainable Development\nGoals (SDGs)\n192 Culture of Health for Business (COH4B)\n194 World Economic Forum (WEF)\nAbout this report\nStakeholder Capitalism Metrics\nThis is the 2021/2022 Environmental, Social & Governance (ESG) Progress Report of Merck & Co., Inc., Rahway, NJ,\nUSA, which is known as MSD outside the United States and Canada. This report also serves as our Communication\non Progress to the United Nations Global Compact (UNGC). All data is current as of December 31, 2021, unless\notherwise noted. Information on documents filed with the Securities and Exchange Commission (SEC), such as\nour 2021 Form 10-K and 2022 Proxy Statement, can be found on our corporate website, which is intended only\nfor residents of the U.S. and Canada.\nTo align with U.S. government reporting requirements, the ESG data for gender diversity in this report uses the\nterms men and women. We recognize and embrace the gender spectrum and diversity in our employees, and have\ninternally established voluntary Self-ID options for employees to self-report on their gender identity. The totals\nin this report may not equal 100 percent due to rounding or employees who have not reported their gender and/\nor race/ethnicity.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 2"
  },
  {
    "page": 3,
    "source": "text",
    "content": "A letter from Dear Stakeholders,\nAt Merck, we’re proud to use the power of leading-edge science to save and improve lives\nour CEO\naround the world. This is our purpose, and it anchors every decision we make. Although our\nglobal community has faced no shortage of challenges in recent years, our ability to navigate and\nrespond to these difficulties with speed, agility and ingenuity has demonstrated the power of our\npurpose and has made our Company stronger and more resilient. We’re excited and energized\nabout the road ahead as we continue to enable a safe, sustainable, and healthy future for people\nand communities everywhere.\nAn ongoing strength of our Company has been our enduring commitments to operating\nRobert M. Davis responsibly and creating value for society. For more than 130 years, our global team has\nChief Executive Officer\npursued environmental, social and governance (ESG) excellence. Today, our ESG approach helps\nand President\npropel and enable our business strategy in ways that make us a better company—and a better\ncorporate citizen.\nOur four ESG focus areas are 1) expanding access to health; 2) developing and rewarding a\ndiverse, inclusive and healthy workforce; 3) protecting the environment; and 4) operating with\nthe highest standards of ethics and values. We have specific goals in each area, and I am pleased\nto share our continued progress in this report, along with these critical highlights:\nExpanding access to health\nMerck has a long track record of making our medicines and vaccines accessible and affordable\nglobally, and we began executing on a comprehensive supply and access strategy early on in the\npandemic to accelerate equitable global access to LAGEVRIO™ (molnupiravir), an investigational\noral antiviral COVID-19 medicine. Our approach includes investing at risk to produce millions of\ncourses of therapy; tiered pricing based on the ability of governments to finance health care;\nentering into supply agreements with governments of approximately 40 markets worldwide;\nallocating 3 million courses of therapy for distribution through UNICEF to low- and middle-\nincome countries; and granting voluntary licenses to multiple generic manufacturers and to the\nMedicines Patent Pool to make generic molnupiravir available in more than 100 low- and middle-\nincome countries following approvals or emergency authorization by local regulatory agencies.\nDeveloping and rewarding a diverse, inclusive and healthy workforce\nWe’ve remained intensely focused on building a more diverse and inclusive workforce.\nOur team’s diversity fuels innovation, and we’ve made ambitious commitments to increase\nrepresentation at all leadership levels with strategies to elevate historically underrepresented\nethnic groups (UEGs). From 2020 to 2021, we grew our total UEG representation,\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 3"
  },
  {
    "page": 4,
    "source": "text",
    "content": "including a five percent increase in senior management in the U.S. We’ve also initiated several\ncollaborations with external partners and joined key initiatives to ensure we continue to accelerate\nand expand our efforts in this area.\nProtecting the environment and operating sustainably\nIn environmental sustainability, we made progress toward our climate action goals last year and are also\ndeveloping the tools and processes needed to lower our Company's carbon footprint. We’re on track to\nachieve carbon neutrality by 2025, and we're working towards transitioning to renewables to meet our\n2025 renewable energy target as well.\nOperating with the highest standards of ethics and values\nAt Merck, we operate responsibly every day, with an unrelenting commitment to conducting ourselves\naccording to the highest standards. Our code of conduct is at the core of our character, helping us to\nmaintain our reputation as a trustworthy company. To that end, we maintain 100 percent compliance\nto regulatory requirements for active incident monitoring, risk/harm analysis and on-time notification\nof data breaches. We also foster a culture where employees are encouraged to speak up and ensure\nour ethics and values are represented in everything we do.\nAs a signatory to the UN Global Compact, Merck remains committed to improving our communities\nglobally, engaging locally and building sustainability across all our business operations. We continue\nto support environmental protections, human rights, labor protections and anti-corruption efforts\nworldwide. In December 2021, we announced the issuance of our inaugural $1 billion sustainability\nbond, which will support projects and partnerships in our priority ESG areas and contribute to the\nadvancement of the UN Sustainable Development Goals.\nLastly, but certainly not least, I want to thank my Merck colleagues around the world for their\nunwavering dedication and passion for creating and sustaining societal value. And on behalf of Team\nMerck, I want to express my deepest and sincerest appreciation and thanks for your interest, support\nand partnership. We recognize that ESG is not a destination, but instead a journey. While we’re pleased\nwith our progress, we know we have more work to do. We look forward to embracing opportunities,\nwith all our internal and external stakeholders, that enable us to gain momentum, deliver on our\ncommitments and make even greater strides in the years to come.\nVery best regards,\nRob Davis\nChief Executive Officer and President\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 4"
  },
  {
    "page": 5,
    "source": "text",
    "content": "Our Company\nWe use the power of leading-edge science to save and improve lives\naround the world.\nAt Merck, known as MSD outside of the United States and Canada, we are unified around\nour purpose: We use the power of leading-edge science to save and improve lives around\nthe world. For more than 130 years, we have brought hope to humanity through the\ndevelopment of important medicines and vaccines. We aspire to be the premier research-\n79% of\nintensive biopharmaceutical company in the world—and today, we are at the forefront of\nresearch to deliver innovative health solutions that advance the prevention and treatment countries\nof diseases in people and animals. We foster a diverse and inclusive global workforce and\naround the world\noperate responsibly every day to enable a safe, sustainable and healthy future for all people\nreached with\nand communities.\nour products1\nHow we operate\nWe have two operating segments: Pharmaceutical and Animal Health. 68,000\nOur Pharmaceutical segment includes human health pharmaceutical\nemployees2\nand vaccine products. Our human health pharmaceutical products consist of\ntherapeutic and preventive agents generally sold by prescription. Our human\nhealth vaccine products consist of preventive pediatric, adolescent and adult\nvaccines. We sell these products to a variety of public and private medical\ninstitutions to aid in the prevention and treatment of human disorders.\n$12.2 billion\nOur Animal Health segment offers one of the widest ranges of veterinary\npharmaceuticals, vaccines, and health management solutions and services, in R&D spend\nas well as an extensive suite of connected technology that includes identification,\ntraceability and monitoring products. This business is dedicated to preserving\nand improving the health, wellbeing, and performance of animals and the people\nwho care for them in all livestock and companion animal species.\nResearch and products\nWe bring a diversity of thought, leadership and perspective together to\ntransform world-class science into life-changing products. Our scientists are\nrevolutionizing how we discover and develop medicines and vaccines to address\nunmet medical needs, including in the areas of oncology, vaccines, infectious\ndiseases, cardio-metabolic disorders, and other diseases affecting animals\nand humans.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 5"
  },
  {
    "page": 6,
    "source": "text",
    "content": "Our ESG Our purpose, which serves as the foundation of our Company’s overall strategic framework, is to use the power of leading-edge science to\nsave and improve lives around the world. Encompassing our commitment to ESG, the strategic framework sets our growth and direction\nagainst the backdrop of a rapidly changing health care ecosystem.\napproach\nMerck’s strategic framework includes our commitment to operate responsibly to enable a safe, sustainable, and healthy future for people\nand communities. Building on our legacy of stewardship, and in line with our ESG materiality assessment, we direct resources to drive\nprogress in the four long-standing ESG focus areas that matter most to our Company and create value for our stakeholders: Access to\nHealth, Employees, Environmental Sustainability, and Ethics & Values. We continue to strategically embed actions in each of these areas\nacross our business operations to support and lift our purpose through our ESG approach.\nOur Strategic Framework\nOur Priorities\nDemonstrate value to\nInvest in, augment,\nOur our stakeholders and Drive innovation, Invest in the growth,\nand accelerate our\nextend access to solutions growth and productivity success, and wellbeing\npipeline to deliver\nPurpose that address unmet enabled by digital and data of our people\nlife-changing products\nmedical needs\nWe use the power of\nleading-edge science to Our Ways of Working\nsave and improve lives\naround the world\nOur\nAspiration Win as Focus on Act with Experiment, learn Embrace diversity Speak up and be\none team what matters urgency and adapt and inclusion open-minded\nWe aspire to be the\npremier research-intensive\nOur Values\nbiopharmaceutical company\nPatients First Ethics and Integrity Respect for People Innovation and Scientific Excellence\nWe operate responsibly every day to enable a safe, sustainable and healthy future for people and communities everywhere\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 6"
  },
  {
    "page": 7,
    "source": "text",
    "content": "Our ESG focus areas\nAccess Employees Environmental Ethics\nto Health Sustainability & Values\nIn collaboration with key We recognize that our We consider the impacts of Through our unwavering\nstakeholders, we work to ability to excel depends on our operations and strive commitment to\nensure our science advances the integrity, knowledge, to operate our business transparency, we earn\nhealth care, and our products imagination, skill, sustainably to support the the trust and confidence\nare accessible and affordable to diversity and wellbeing health of our planet and of our stakeholders.\nthose in need. of our employees. its people.\nTo learn more, see page 14. To learn more, see page 18. To learn more, see page 21. To learn more, see page 23.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 7"
  },
  {
    "page": 8,
    "source": "text",
    "content": "ESG goals and performance\nOur ESG goals represent our public commitments to delivering greater value to society. Included below is the progress we made in 2021.\nGOAL PROGRESS\nAccess\nto Health\nFurther advance health equity by reaching\n30 million people in low- and middle-income\n15 million people reached4\ncountries and in U.S. underserved populations with\nour social investments, by 2025.3\nReach at least 75% of countries around the world\n79% of countries reached in 2021\nannually with our products.5\nRead more about our\naccess to health progress Enable 100 million more people to access our\nand results on pages 14-17. innovative portfolio globally, through access Enabled access for 66.7 million people4\nstrategies, solutions and partnerships, by 2025.6\nGOAL PROGRESS\nEmployees\nIncrease representation in senior management roles,7\nby 2024:\nWomen globally to 40%, up from 31% in 2020. 36% women\nBlack/African Americans in the U.S. to 10%,\n7% Black/African Americans in the U.S.\nup from 3% in 2020.\nHispanics/Latinos in the U.S. to 10%,\n6% Hispanics/Latinos in the U.S.\nup from 5% in 2020.\nMaintain or exceed our current inclusion index score,\nOn track\nby 2025.8\nRead more about\nour employee progress Maintain or exceed our current employee\nOn track\nand results on pages 18-20. engagement index score, by 2025.9\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 8"
  },
  {
    "page": 9,
    "source": "text",
    "content": "ESG goals and performance (continued)\nGOAL PROGRESS\nEnvironmental\nSustainability\nReduce our operational greenhouse gas (GHG)\n9% reduction in Scope 1 and 2 emissions\nemissions (i.e., Scopes 1 & 2) 46% by 2030,\nfrom 2019 baseline\nfrom a 2019 baseline.10\nAchieve carbon neutrality across our operations In progress. Any remaining emissions will be\nby 2025 (Scopes 1 & 2 emissions).10 offset with high-quality offsets in 2025.\nSource 100% of our purchased electricity from 41% of purchased electricity sourced\nrenewables by 2025.11 from renewables in 2021\nRead more about\nour environmental Reduce our value chain (Scope 3) GHG emissions by 9% increase in Scope 3 emissions from\nsustainability progress 30% by 2030, from a 2019 baseline.12 2019 baseline\nand results on pages 21-22.\nGOAL PROGRESS\nEthics & Values\nFoster a “Speak Up” culture by maintaining or\nexceeding our current percentage of employees\nOn track\nresponding favorably to the “Willingness to Report”\nquestion in the Pulse survey as an annual average.13\nMaintain 100% compliance to regulatory\nRead more about\nrequirements for active incident monitoring,\nour ethics and values 100% compliance maintained\nprogress and results risk/harm analysis and on-time notification\non pages 23-24. of data breaches.14\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 9"
  },
  {
    "page": 10,
    "source": "text",
    "content": "ESG materiality\nA framework for\nUnderstanding and prioritizing the ESG issues that matter most to our business and stakeholders enables\nthe greater good\nus to focus, act and report on them effectively and transparently. Our ESG materiality assessment process\nIn December 2021, we launched our offers insight into future trends and potential business risks and opportunities that influence our ability\nSustainability Financing Framework to create value. It helps us determine where we should be prioritizing our efforts in order to maximize the\nto raise and direct funds to the most benefit for our stakeholders, our Company and the world.\ncritical projects we’re supporting\nto meet our ESG goals and support\nour overall ESG strategy. Our first\noffering under this framework was\na $1 billion sustainability bond, which\nOur priority topics\nwe intend to use to support projects\nand partnerships in our priority From our ESG materiality assessment conducted in 2021, we identified the following top priorities for\nESG areas. our stakeholders from among the 32 most significant ESG topics for our sector. We perform these\nassessments every two years to ensure continuing alignment across stakeholders. Our next assessment\nThese projects and partnerships range\nwill take place in 2023.\nfrom increasing access to essential\nhealth care services to water and\nwaste management initiatives. We’re\nexcited about the potential to pair the\n• Access to • Employee health\nmeaningful impact of this framework\nmedicine and safety\nwith our broader business objectives.\nAccess\n• Product quality • Employee engagement\nEmployees\nand safety to Health and diversity\n• Public health risks\n• Climate change • Business ethics\n• Ethics in R&D\nEnvironmental Ethics\nSustainability & Values • Data security\nand privacy\n• Governance structures\nand mechanisms\nTo learn more about our ESG materiality process, please see page 48.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 10"
  },
  {
    "page": 11,
    "source": "text",
    "content": "Sustainable Development\nGoals (SDGs)\nThe SDGs represent the international community’s plan of action for\n“people, planet and prosperity.” The 2030 Agenda for Sustainable\nDevelopment, adopted by all United Nations Member States in 2015,\nprovides a shared blueprint for peace and prosperity for people and the\nplanet, now and into the future. At its heart are the 17 SDGs, which are\nan urgent call for action by all countries in a global partnership.\nAt Merck, we believe we have an important role and responsibility to help\nreduce the burden of disease and improve access to medicines and vaccines\naround the world. That is why SDG 3 (Good Health and Well-being) is\nat the core of our business and is aligned with our purpose to save and\nimprove lives. While all of the SDGs are essential to fostering sustainable\ndevelopment, we have prioritized eight global goals where we are positioned\nto have the biggest impact.\nA full SDG index can be found on page 190.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 11"
  },
  {
    "page": 12,
    "source": "text",
    "content": "Select awards and recognition\nFortune Disability:IN® 3BL Media\nWorld’s Most Best Places to Work 100 Best Corporate\nAdmired Companies for Disability Inclusion Citizens of 2021 and 2022\n2021 and 2022 2021 and 2022 Ranked #1 in the\nPharmaceuticals, Biotechnology\nRanked #2 most admired 8th year in a row\n& Life Sciences category\ncompany in the Pharmaceutical\ncategory for both years\nJust Capital / Forbes Newsweek Forbes\nJust 100 List 2021 America's Most America’s Best\nand 2022 Responsible Companies Employers 2021\nRanked #1 in the 2021 and 2022 and 2022\nPharmaceuticals & Biotech\nRanked #9 in 2022 8th year in a row\ncategory for both years\nThe Human Rights Bloomberg Barron's\nCampaign Foundation\nGender-Equality 100 Most Sustainable\nBest Places to Work Index 2021 and 2022 Companies 2021\nfor LGBTQ+ Equality 3rd year in a row and 2022\n2021 and 2022 Ranked #1 in the\n9th year in a row Pharmaceuticals category\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 12"
  },
  {
    "page": 13,
    "source": "text",
    "content": "How our ESG priorities contribute\nto a better and healthier society\nOver the past year, we challenged ourselves to innovate and make ambitious\ncommitments within each of our ESG focus areas. Through collaborative partnerships\nand a holistic approach, we’re creating scalable solutions to major global issues.\nThe following pages highlight why each of our ESG focus areas matter to our\nsuccess, the results we’ve achieved and our goals for the future. Access\nto Health\nEmployees\nEnvironmental\nSustainability\nEthics\n& Values\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 13"
  },
  {
    "page": 14,
    "source": "text",
    "content": "ESG focus area:\nAccess to Health\nWe aspire to improve access to health by discovering, developing\nand providing innovative products and services that save and improve\nlives. We also recognize a robust health care ecosystem expands\nMerck’s impact, opportunities and value.\nDiversity in clinical trials\nOur Public Policy and Responsibility Council (PPRC), an internal body\nof senior leaders who govern our policy and ESG efforts, guides our\nIn the many countries where we conduct clinical trials, one of our most important\nglobal approach to access in tandem with our Access to Health Guiding\nongoing efforts is to design studies that reflect the diverse populations we serve.\nPrinciples. We embed strategies and actions across the Company to\nThis process begins with selection of clinical trial sites in communities serving\nenable access.\nunderrepresented ethnic groups. We plan and conduct our trials in a way that\nincorporates enrollment and other diversity-focused goals, to help drive inclusion\nand access across our programs with our clinical trial sites.\nAdditionally, we continue to be a vocal contributor and participant in various\npartnerships and sponsorships intended to connect with, support and train\nAccess to Health\nmore U.S.-based clinicians from diverse backgrounds to help drive access\nGuiding Principles:\nto clinical research at the community level. This makes our continued work\nas a co-sponsor of the Improving Patient Access to Cancer Clinical Trials\n• Discovery • Affordability\n(IMPACT) study at the Lazarex Cancer Foundation even more important.\nand Invention\n• Strengthening Systems IMPACT is a 3-year pilot study that strives to improve patient enrollment,\n• Availability and Addressing Inequity retention, minority participation and equitable access in oncology trials.\nWe’ve also developed and implemented novel tools and approaches intended\nto build relationships and reach potential study participants within their\nown communities, including partnerships with local pharmacies and mobile\nstudy sites.\nDiscovery and invention\nMerck discovers and invents medicines and vaccines that address\nvital global health needs where we can have the greatest impact,\nnow and in the future. In 2021 alone, our research and development and vaccines and the appropriateness of our products to improve public\n(R&D) spend was $12.2 billion. We systematically evaluate our R&D health. Understanding where health system infrastructure and funding\ncandidates to identify the potential to address significant public mechanisms are in place is an important component of enabling safe\nhealth challenges and unmet medical needs of patients, including in and effective usage and facilitating meaningful patient access. This\nresource-constrained settings. Our approach involves assessing the process informs our product access solutions with the goal of making\nexisting burden of disease, the availability of alternative medicines our medicines and vaccines available to as many people as possible.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 14"
  },
  {
    "page": 15,
    "source": "text",
    "content": "Availability\nMerck makes available a reliable, safe global supply of quality\nmedicines and vaccines, and invests in solutions to enable timely\naccess to our products in a responsible and sustainable manner. We\nhave strict quality standards and effective supply chain management\nto ensure the safety and security of our products, no matter where\nthey are manufactured.\nGoal\nWe are committed to reaching at least 75% of\ncountries around the world annually with our products.\nA new rabies contract for Animal Health Expanded manufacturing capabilities\nfor broad, equitable vaccine access\nIn May, our Company won the rabies tender for the World\nOrganisation for Animal Health (WOAH, founded as OIE)\nMerck’s partnership with UNICEF and Gavi, the Vaccine Alliance to\nVaccine Bank to provide rabies vaccines as a part of initiatives\nbring human papillomavirus (HPV) vaccines to those most in need\nto eliminate human deaths from dog-mediated rabies for the\nhas been longstanding, with Merck most recently committing to\nyears 2022-2025. The WOAH Rabies Vaccine Bank is co-\nprovide 91.5 million doses for use in Gavi-supported countries from\nfunded by donors and partners of WOAH. This bank supports\n2021 to 2025. Expansions to our Elkton, Virginia, manufacturing\nvital distribution of the rabies vaccine to dogs in countries\nfacility were completed in 2022 to increase capacity and supply of\nwhere the disease is endemic. The program provides access\nHPV vaccines following regulatory reviews and approvals. With\nto countries to these vaccines for targeted vaccination\nplans for additional expansions to existing and new facilities, we\nprograms with at-risk populations. Over the first five years\nexpect supply of HPV vaccines to double between 2020 and 2023.\nof its existence (2012-2016), the WOAH Rabies Vaccine Bank\ndelivered almost 16 million doses of rabies vaccine, making a\nsignificant impact on animal and human health.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 15"
  },
  {
    "page": 16,
    "source": "text",
    "content": "Affordability\nWe aspire to enable solutions and shape an ecosystem that\ndelivers sustainable access to innovative medicines for patients.\nWe collaborate with different stakeholders, including private,\ngovernmental, multilateral and non-profit organizations, to design\nand deliver solutions that address the access challenges at the\npayer, provider and patient levels.\nWhen market-based solutions are inadequate or unavailable,\nwe pursue programs to provide direct access to our medicines\nand vaccines, including product donations and patient\nassistance programs. As the war in Ukraine continues, we’re\ncommitted to getting life-saving support, medicines, vaccines\nand supplies to those who need them most. In the first half\nof 2022, we committed donations of more than $93 million\nin essential products and funds15 to various organizations,\nworking in tandem with our own subsidiary in the region to\nensure that refugees and those who remain inside the country\nhave access to health care.\nGoal\nBy 2025, our goal is to enable\n100 million more people to\naccess Merck’s innovative\nportfolio globally, through Our current portfolio of projects focused on dedicated\naccess strategies, solutions sustainable access solutions is global, inclusive of the U.S. and\nand partnerships. low- and middle-income countries (LMICs). These projects are\nin various stages of development, from diagnosing the access\nchallenges to delivering solutions in the market.\nLearn more about these efforts on page 59.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 16"
  },
  {
    "page": 17,
    "source": "text",
    "content": "Strengthening systems\nand health equity\nOur approach to expanding access and patient reach is built on the\nbelief that broadening our impact requires sustained effort and is best\nachieved through solving underlying health care system challenges.\nWe have a long history of partnering to strengthen health systems\nand address health equity. Since 1957, our Company’s Foundation\nhas contributed nearly $1 billion to support programs that address\nimportant global health and societal needs.\nMerck for Mothers\nMerck for Mothers is our global initiative to help create a world\nwhere no woman has to die while giving life. Applying our business\nand scientific expertise, we are working across sectors to improve\nthe health and wellbeing of women during pregnancy, childbirth\nand postpartum. We’re proud to announce that following the 10th\nanniversary of our initial $500 million investment, we have extended\nthe program with an additional investment of $150 million, with a goal\nof reaching 25 million women by 2025.\nGoal\nWe are committed to advancing health equity by reaching\n30 million people in LMICs and in U.S. underserved\npopulations with our social investments, by 2025.3\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 17"
  },
  {
    "page": 18,
    "source": "text",
    "content": "ESG focus area: Global diversity\nEmployees\nand inclusion (GD&I)\nOur ability to accomplish our GD&I objectives is linked to our GD&I\nStrategy—our framework for a sustainable competitive advantage. Through\nOur ability to excel depends on the integrity, knowledge, imagination,\nit, we aim to create an environment of belonging, engagement, equity and\nskill, diversity and teamwork of our employees.\nempowerment that aligns with our purpose to save and improve lives.\nThe success of our Company is built on a culture that embraces Ultimately, our globally diverse and inclusive workforce uses this foundation\ndifferent perspectives and values the contributions of each individual, as a means to improve patient health.\nand we recognize that our competitiveness is strengthened by a\nOur diversity and inclusion efforts focus on:\ndiverse, skilled and engaged workforce.\n• Our People: Strengthen the foundational elements of diversity\nWe take a thoughtful approach to workplace inclusion and belonging.\n• Our Culture: Ensure accountability to drive an inclusive culture\nOur Company invests in employee development and wellbeing. These\n• Our Business: Continue to leverage diversity and inclusion to ensure\ninvestments are guided by our global diversity and inclusion strategy\nbusiness value\nas well as our Pulse survey, which is conducted multiple times a year.\n• Our World: Transform the environment, culture and business landscape\nThese business objectives are fully aligned to drive long-term, sustainable\nbusiness performance. Our GD&I Center of Excellence (CoE) is composed\nProgress towards pay equity\nof five diversity ambassador teams to oversee this alignment. Each team\nOur commitment to fair and equitable pay for all employees is brings together leaders from across functional areas to ensure integration\nconsistent with our core values, and we engage external partners throughout the business.\nannually to ensure this commitment is carried out in the U.S.\nand abroad. As of 2021, approximately 75 percent of our global GD&I is a commitment at the highest levels of the Company. Our CEO\nemployee population has undergone a pay equity study. We routinely reviews diversity metrics to ensure progress against goals, and\nanticipate these pay equity studies will achieve nearly global drives accountability with Company leaders.\nworkforce coverage by the end of 2022.\nRead more about our efforts toward pay equity in GRI 405\non page 149.\n>99% pay equity\nin the U.S. for female and male employees, and\nfor non-white (including Black, Hispanic and\nAsian employees) and white employees, in each\ncase, in equivalent positions\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 18"
  },
  {
    "page": 19,
    "source": "text",
    "content": "Expanding our pipeline of diverse talent\nIn the past year, we greatly expanded outreach to Historically Black\nColleges and Universities (HBCUs) by partnering with several\norganizations, including the College Diversity Network and the\nNational Urban League, to focus on building deep partnerships\nwith colleges, students, faculty and alumni of HBCUs.\nWe also focus on systemic barriers that limit the candidate\npool based on geographic location of open positions and talent\nresidency, and on job prerequisites of having prior pharmaceutical\nexperience. To broaden our access to diverse talent, we post some\npositions with an option to work virtually, offer relocation services\nand are agnostic about prior pharmaceutical experience.\nFor more on how our GD&I strategic framework aligns with\nAccountability in leadership\nour priorities, see GRI 405 on page 148.\nOur Company’s Board of Directors believes in the business value of having\ndiverse perspectives in the boardroom and is deliberate in ensuring the\nBoard has the right mix of perspectives, skills and expertise to address\nthe Company’s current and anticipated needs as opportunities and\nchallenges facing the Company evolve. Today, 43 percent of our Company's\nBoard members are female and 21 percent are from underrepresented\nethnic groups.\nFrom a management perspective, women represent 36 percent of our senior\nmanagement teams and 44 percent of all managers. Forty-two percent of\nour executive team and 25 percent of our senior management teams are\nfrom underrepresented ethnic groups.\nGoals\nOur goals are to continue to increase representation in senior\nmanagement roles by 2024:\n• Women globally to 40%, up from 31% in 2020\n• Black/African Americans in the U.S. to 10%, up from\n3% in 2020\n• Hispanics/Latinos in the U.S. to 10%, up from 5% in 2020\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 19"
  },
  {
    "page": 20,
    "source": "text",
    "content": "A culture of wellbeing\nAs a company that aspires to improve access to health and save and\nimprove lives, we know that to be truly successful, we must prioritize\nthe health, wellbeing and safety of our employees. We placed a special\nemphasis on employees’ mental health during the pandemic, and we’re\nkeeping true to that commitment moving forward.\nWe focus our comprehensive approach to wellbeing on four pillars:\nprevention, balance, fuel and movement. These represent a continuum\nof actions focused on creating healthy habits and changing behaviors\none step at a time. It includes physical, emotional and mental health,\nfinancial wellbeing and safety. It gives our employees and their families\na wide range of programs, resources, tips and tools to help make\nhealthy choices and enrich their lives.\nOur Pulse surveys, which are conducted multiple times a year, allow us\nto measure our employees' perceptions on inclusion and other critical\nworkforce issues. These surveys are just one of the avenues we use to\ndirectly engage employees and remain accountable to their needs. By\nprioritizing our employees, we will continue to attract and retain highly\nqualified people who better serve our stakeholders and contribute to\nthe long-term success of our ESG performance and our business.\nEquipping managers to respond to mental\nhealth challenges\nMerck promotes a culture of mental health and wellness—one that\nsurrounds employees with the environment, programs and services\nthat support making healthy choices. Managers play a critical role in Goals\nsupporting team members who may be experiencing mental health Our goals are to maintain or exceed\nissues and challenges. To equip our managers further, we provide a our current inclusion index and\nMental Health Awareness for Managers e-Learning module as support employee engagement index scores\nbefore starting any conversation with an employee about mental by 2025, by continuing to respond\nwellbeing. Launched in September 2020, the e-Learning program R U to employee feedback on workforce\nOK? provides facts, talking points and tips managers can use to discuss issues and integrating their input into\ndecision-making.\nemotional wellbeing and mental health in a safe, nonjudgmental way.\nOver 4,000 employees have completed the training and approximately\n2,000 employees have signed the Stamp Out the Stigma pledge.\nTo learn more about how we support employee wellbeing, please see\nGRI 405 on page 153.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 20"
  },
  {
    "page": 21,
    "source": "text",
    "content": "ESG focus area:\nGoals\nEnvironmental\n• We will achieve a 46% reduction of operational greenhouse\ngas emissions (i.e., Scopes 1 & 2), by 2030, from a\nSustainability 2019 baseline\n• Achieve carbon neutrality across our operations by 2025\n(Scopes 1 & 2 emissions)\nA healthy planet is essential to human health and the sustainability\n• We will source 100% of our purchased electricity from\nof our business, while also enhancing opportunities for product\nrenewables by 2025\ninnovation and reducing cost and risk.\n• We will achieve a 30% reduction in Scope 3 GHG emissions\nOur Company has a long history of environmental stewardship and by 2030, from a 2019 baseline\ncompliance, and we realize that our strategy and efforts need to\ncontinuously evolve in the face of a changing climate.\nOur environmental sustainability strategy has three focus areas:\n• Driving operational efficiency\nLow Carbon Transition Playbook\n• Designing new products to minimize environmental impact\nIn 2021, we launched Merck’s Low Carbon Transition Playbook—\n• Reducing any impacts in our upstream and downstream value chain\na tool to help create a site strategy by identifying gaps, uncovering\nA primary focus in each of these areas is on climate action. In last year’s opportunities and creating a common platform for assessment of\nreport, we established climate goals to meet and exceed the evolving levers and resource deployment across a range of sustainability\nexpectations of our stakeholders and employees. In 2021, our Scopes 1 initiatives. It also details how employees and stakeholders\n& 2 and Scope 3 reduction targets were verified by the Science-Based can accelerate the Company’s environmental work, along with\nTargets initiative (SBTi). explanations of the collective benefits of these actions for the\nbusiness and for stakeholders.\nWe expect functions across the Company to take advantage of\nthis document to strategize and develop new ways to meet many\nof our broader sustainability goals and streamline our tracking and\nreporting of specific metrics and categories.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 21"
  },
  {
    "page": 22,
    "source": "text",
    "content": "Partnering for progress\nacross our value chain\nIn October 2021, we were one of\n10 pharmaceutical companies to sign on\nto Schneider Electric’s Energize program, a\npioneering collaboration to help pharmaceutical\nand health care suppliers address their own\noperational Scope 2 greenhouse gas emissions\nthrough green power procurement, which in turn\nwill help the signatories reduce their Scope 3\nemissions. We anticipate being able to report\ninitial progress from this endeavor next year.\nProduct stewardship and green and sustainable science\nOur product stewardship program focuses on identifying and either preventing or minimizing potential\nsafety and environmental hazards throughout a product’s life cycle. We are also committed to\nunderstanding, managing and reducing the environmental impacts of our products and the materials\nassociated with discovering and producing them. Our green and sustainable science program uses\na “green-by-design” approach. By using more efficient and innovative processing methods and\ntechnologies, we are reducing the amount of energy, water and raw materials we use to make our\nproducts, thereby minimizing the amount of waste we generate and lowering our production costs.\nFor more information on our product stewardship approach, see our Global Antimicrobial Resistance\nAction Plan, policy on the Responsible Disposal of Medicines and our approach to Pharmaceuticals in\nthe Environment on our corporate website.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 22"
  },
  {
    "page": 23,
    "source": "text",
    "content": "ESG focus area:\nEthics & Values\nEthics and integrity are the foundation for how we operate, and\nthrough our unwavering commitment to transparency, we earn the\ntrust and confidence of our stakeholders. A fully ethical, values-based\nand accountable culture improves the Company’s decision-making,\nadaptability and reliability. We strive to maintain a culture where\nemployees can and are encouraged to speak up and ensure our ethics\nand values are represented in everything we do.\nApproach to ethics\nand compliance\nMerck’s Office of Ethics is responsible for ensuring that employees\nare aware of and trained on the Code of Conduct, Our Values and\nStandards, and Corporate Policies addressing ethics and compliance.\nOur Code of Conduct details clear ethical expectations and principles\nto guide the operations of the Company. It is available in 19 languages\nand applies to all employees worldwide. The Code of Conduct sets out\ncore values and principles and helps us to protect the reputation we\nhave earned.\nAt Merck, we recognize that when we invest in compliance, risk\nOur Code of Conduct training series is\nmanagement and transparency, it enhances stakeholder trust and\nannually completed by more than\nconfidence in our ability to consistently deliver high-quality products\nand services for future generations. 99% of our employees\nWe use our Business Partner Code of Conduct to communicate our\nexpectations for human rights; labor unemployment; health, safety\nand environment; and ethical business practices. This code, along with\nour Company's supplier performance expectations, is communicated\nto existing and potential third parties with which we now, or\npotentially will, engage in support of our sourcing initiatives. We offer\nFor more information on our ethics and compliance policies,\nthese documents in 26 languages to promote these standards across\nplease see GRI 205 on page 78.\nour thousands of suppliers.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 23"
  },
  {
    "page": 24,
    "source": "text",
    "content": "Promoting a “Speak Up” culture\nIn the U.S., Merck’s “Speak Up” reporting tool is operated by an\nindependent third party and is available 24 hours a day, seven days\na week to allow employees and suppliers to raise concerns or ask\nquestions in their chosen language online or via telephone. Outside\nof the U.S., we have three regional ethics officers who manage a\nnetwork of site-based ethics ambassadors. The ethics ambassadors\nare trained to answer employee questions about the Company's\nreporting and investigation process, guide employees to appropriate\nchannels for raising concerns and actively support the “Speak Up”\nculture. These services are anonymous where permitted by local law,\nbut always confidential.\nGoal\nOn an annual basis, we will endeavor to foster this “Speak Up”\nculture by maintaining or exceeding the average percentage\nof employees responding favorably to the “Willingness to\nReport” question in our Pulse survey, which is conducted\nmultiple times a year. Managing digital risk\nWe recognize that cybersecurity events and innovative uses of data\npose an increased risk to our business and stakeholders. In response,\nwe are continually refining our global privacy program, which is\ndesigned to promote organizational accountability for privacy, data\nEthical Leadership workshops\ngovernance and data protection across our business and with our\nAs an example of an industry-leading best practice to build on an collaborative partners and suppliers.\nalready strong culture of ethics and integrity, in 2021 our Company\nhosted Ethical Leadership workshops focusing on workplace\nrespect in all eight Latin American markets. These workshops\nGoal\nhelped train leaders in building and sustaining a culture of ethics\nand integrity and provided tools for successful team conversations. Commitment to maintain 100% compliance to regulatory\nrequirements for active incident monitoring, risk/harm\nA post-workshop survey revealed that in comparison to previous analysis and on-time notification of data breaches.\nsurveys, employee responses had improved in willingness to\n“Speak up and be open minded” and to “Challenge the status\nquo.” Both categories are now performing three points above the\nCompany average for these markets.\nTo learn more about our approach to data security and privacy,\nplease visit GRI 418 on page 175.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 24"
  },
  {
    "page": 25,
    "source": "text",
    "content": "References\n1 As defined by the World Bank Country and Lending Groups. Includes only human health products.\n2 As of December 31, 2021.\n3 Social investments include our Company's philanthropic partnerships, programs and impact\ninvestments. Underserved populations are defined as those that face health disparities due to\ndisadvantages related to insurance status, social determinants of health, race, ethnicity, gender\nidentity/sexual orientation, age and/or language preference. The goal is cumulative across the reporting\nperiod of 2021-2025, and is independent of a baseline period.\n4 Third-party reporting is used to calculate the number of people reached through social investments. In\nsome cases, third-party reports may include cumulative people reached for the reporting period, and/or\ndata that is attributable to other partners as well as our Company's philanthropic investment.\n5 Countries are as defined by the World Bank Country and Lending Groups. Includes only human\nhealth products.\n6 100 million total is cumulative. Access strategies, solutions and partnerships include U.S. patient\nassistance programs, voluntary license agreements and partnerships. “Enable more people” is defined\nas implemented and launched in market and is in comparison to the baseline in 2020. “Access” is defined\nas products registered, launched and available in the market. Portfolio of products include Oncology,\nVaccines, HIV treatments and COVID-19 treatments.\n7 Senior management roles reflect Band 700, which comprises our vice presidents and senior\nvice presidents.\n8 The inclusion index is the average favorability score for employees’ responses to three items in the\nemployee Pulse survey (manager supports inclusion, sense of belonging, leaders value perspective)\nacross all surveys in that year.\n9 The employee engagement index is the average favorability score for employees’ responses to items in\nthe employee Pulse survey (happiness, recommend the Company, intent to stay).\n10 Scope 1 emissions are direct greenhouse gas (GHG) emissions that occur from sources that are\ncontrolled or owned by an organization (e.g., emissions associated with fuel combustion in boilers,\nfurnaces or vehicles). Scope 2 emissions are indirect GHG emissions associated with the purchase of\nelectricity, steam, heat or cooling.\n11 We have defined “purchased electricity” as electricity sourced from external suppliers as well as\nrenewable electricity that was generated and utilized on site, where we retained the renewable\nattributes or where we have obtained renewable attributes through contract.\n12 Scope 3 emissions are the result of activities from assets not owned or controlled by the reporting\norganization, but that the organization indirectly impacts in its value chain.\n13 Favorable response indicates the percentage of respondents who respond “yes” to the question stating,\n“I am willing to report employee misconduct and potential ethics or compliance issues.” To align with\nwhere the industry is moving regarding future-oriented ethics and business integrity metrics, this year\nwe have selected a Pulse survey question directly focused on measuring how well Company culture aligns\nwith ethics and integrity principles.\n14 Regulatory requirements differ by region.\n15 Product donations and funding to Ukraine remain on-going in 2022.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 25"
  },
  {
    "page": 26,
    "source": "text",
    "content": "GRI/SASB\ndisclosures\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 26"
  },
  {
    "page": 27,
    "source": "text",
    "content": "General\ndisclosures\nSee our GRI Index on page 178.\nOrganizational profile We are a global health care Company that delivers innovative health\nsolutions through our prescription medicines, vaccines, biologic\ntherapies and animal health products. In the U.S. and Canada, we\nare known as Merck & Co., Inc., Rahway, NJ, USA. Elsewhere we are\nknown as MSD.\nGRI 102-1 Organization name (Core)\nGRI 102-2 Primary brands, products, and services (Core) Operating segments\nGRI 102-3 Headquarters location (Core)\nOur operations are principally managed on a products basis and include\nGRI 102-4 Location of operations (Core) two operating segments:\nGRI 102-5 Ownership and legal form (Core) • Pharmaceutical\n• Animal Health\nGRI 102-6 Markets served (Core)\nGRI 102-7 Scale of the organization (Core) Our Pharmaceutical segment includes human health pharmaceutical\nand vaccine products. Human health pharmaceutical products consist\nGRI 102-8 Information on employees and other workers (Core)\nof therapeutic and preventive agents, generally sold by prescription,\nNumber of drugs (1) in portfolio and (2) in research for the treatment of human disorders. We sell these human health\nSASB 000.B\nand development (Phases 1-3) pharmaceutical products primarily to drug wholesalers and retailers,\nhospitals, government agencies and managed health care providers\nsuch as health maintenance organizations, pharmacy benefit managers\nand other institutions.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 27"
  },
  {
    "page": 28,
    "source": "text",
    "content": "CONTINUED: GRI 102-2 | GRI 102-3 | GRI 102-4 | GRI 102-5 | GRI 102-6 | GRI 102-7 | GRI 102-8 | SASB 000.B\nHuman health vaccine products consist of preventive pediatric, Ownership\nadolescent and adult vaccines. We sell these human health vaccines\nThe principal market for trading of our common stock is the New York\nprimarily to physicians, wholesalers, physician distributors and\nStock Exchange (NYSE) under the symbol MRK. As of January 31,\ngovernment entities.\n2022, there were approximately 99,900 shareholders of record of the\nThe Animal Health segment discovers, develops, manufactures Company’s common stock.\nand markets a wide range of veterinary pharmaceutical and vaccine\nproducts, as well as health management solutions and services, for the Employees\nprevention, treatment and control of disease in all major livestock and\nAs of December 31, 2021, we had approximately 68,000 employees\ncompanion animal species. We also offer an extensive suite of digitally\nworldwide, which includes approximately 27,000 employed in the\nconnected identification, traceability and monitoring products. The\nU.S. (including Puerto Rico) and approximately 14,000 third-party\nprimary customers for our animal health products are veterinarians,\ncontractors globally. Approximately 67,000 employees are full-time.\ndistributors and animal producers.\nWomen and individuals with ethnically diverse backgrounds comprised\nYou can find a list of our products, as well as our pipeline, on our approximately 50 percent and 32 percent of the workforce in the\ncorporate website. U.S., respectively.\nFor more information on our financials, please see GRI 201-1 on\npage 52, as well as our 2021 Form 10-K.\nLocations\nOur corporate headquarters are located in Rahway, New Jersey, USA.\nWe will be consolidating our New Jersey campuses into Rahway by the\nend of 2023. We maintain operational or divisional headquarters in\nMadison, New Jersey, and Upper Gwynedd, Pennsylvania.\nPrincipal U.S. research facilities are located in Rahway and Kenilworth,\nNew Jersey; West Point, Pennsylvania; Boston and Cambridge,\nMassachusetts; South San Francisco, California; DeSoto, Kansas\n(Animal Health); and Elkhorn, Nebraska (Animal Health).\nPrincipal research facilities outside the U.S. are located in the\nUnited Kingdom, Switzerland, China, Germany (Animal Health) and\nthe Netherlands (Animal Health). Our manufacturing operations\nare currently headquartered in Rahway, New Jersey. We also have\nproduction facilities for human health products at seven locations\nin the U.S. and Puerto Rico. Outside the U.S., the Company owns or\nhas an interest in manufacturing plants or other properties in Japan,\nSingapore, South Africa, and other countries in Western Europe,\nCentral and South America, and Asia. A number of properties were\ntransferred to a new, independent, publicly traded company named\nOrganon & Co. that was spun-off from Merck in June 2021, and more\ninformation on this transaction can be found in GRI 102-10 on page 34.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 28"
  },
  {
    "page": 29,
    "source": "text",
    "content": "CONTINUED: GRI 102-2 | GRI 102-3 | GRI 102-4 | GRI 102-5 | GRI 102-6 | GRI 102-7 | GRI 102-8 | SASB 000.B\nEmployees by region (2021)\nNumber of Worldwide\nemployees percentage1\nCanada Europe (Western) Japan\n562 | 0.8% 17,943 | 26.3% 3,147 | 4.6%\nU.S.\n26,727 | 39.1% China\n6,396 | 9.4%\nAsia-Pacific\n5,997 | 8.8%\nLatin America\n4,672 | 6.8%\nEastern Europe,\nMiddle East and Africa\n2,855 | 4.2%\n1 Numbers may not add up to 100 percent due to rounding.\nFor more information on our diversity, equity and inclusion figures, please see GRI 405-1 on page 159.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 29"
  },
  {
    "page": 30,
    "source": "text",
    "content": "Our Sustainable Sourcing program has the following key elements:\n• Integration into our Global Sourcing & Procurement Strategy\nGRI 102-9 Supply chain (Core)\nand processes\n• A cross-functional team that oversees program development and\nOur Company is committed to the highest ethical standards to help the processes and guidelines to encourage best practices, prevent\nmaximize the long-term sustainability of our business and of the violations of supply chain standards and limit risk\ncommunities in which we operate. We strive to conduct business with • Established sustainability requirements that are communicated\nthird parties that share our commitment to high ethical standards and to our suppliers and included in supplier selection\noperate in a responsible and ethical manner. The term “third party” is\n• Review, tracking and communication of supplier\nbroadly interpreted to include any individual or entity that provides any sustainability programs\ntype of goods or services in support of our sourcing initiatives.\n• Collaboration as we educate and learn from our supply chain,\nWe expect all third parties with whom we engage to comply with all\npeer companies and best-in-class organizations\napplicable regulations, as well as share in our commitment to the\nprinciples outlined in our Business Partner Code of Conduct.\nThird-Party Risk Management team\nWe manufacture, package and distribute products to more than 140\nTo help manage and address potential areas of risk associated with\nmarkets around the world. We have established business relationships\nthird party business relationships, we have an established Third-Party\nwith thousands of suppliers including direct suppliers (including\nRisk Management program and committee chaired by the senior\nexternal manufacturing providers), capital expenditure suppliers,\nvice president for Global Procurement. The committee establishes,\nindirect suppliers and research providers. Our direct suppliers provide\nimplements and monitors environmentally, socially responsible and\nus with goods such as packaging, components and ingredients. Capital\nethical sourcing practices to ensure that performance is aligned\nexpenditure suppliers provide goods and services such as engineering\nwith our purpose. The cross-functional team includes leaders from\nand construction. Our indirect suppliers include those that provide\nour business areas as well as functional areas that monitor risk,\nservices such as logistics, travel and meetings, facility management\nincluding Compliance, Global Safety and the Environment, Information\nand marketing. Our research providers include lab supplies and other\nTechnology Risk Management & Security, Business Development,\nresearch and development-related services.\nand ESG Strategy & Engagement. Representatives from each function\nmeet regularly to discuss, assess and manage issues on a risk-driven\nOur approach to sustainable sourcing\nbasis.\nWe have a sourcing management process in which environmental\nsustainability, social responsibility, and economic inclusion and supplier Supplier selection and setting expectations\ndiversity (EI&SD) principles are integrated in each stage. Throughout\nWe select suppliers that share our commitment to our values and\nthe supplier life cycle, our Company establishes expectations, assesses\nprinciples. We expect appropriate standards of conduct and respect\nrisk, supports supplier development and manages performance.\nfor human rights from our suppliers, contractors, vendors and external\nOur Global Supplier Management Group (GSMG) is responsible partners to be consistent with our own. We use our Business Partner\nfor driving our Sustainable Sourcing program and maintaining the Code of Conduct to communicate our expectations for Human Rights,\nassociated standards and processes by which suppliers are identified, Labor & Employment, Health, Safety & Environment, and Ethical\nqualified and managed. Business Practices. Our Business Partner Code of Conduct, along\nwith our Supplier Performance Expectations, are communicated to\nexisting and potential third parties. They are included in requests for\ninformation, proposals and quotes, as well as in our purchase order\nterms and conditions. We make our Business Partner Code of Conduct\navailable in 26 languages.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 30"
  },
  {
    "page": 31,
    "source": "text",
    "content": "CONTINUED: GRI 102-9\nOur Business Partner Code of Conduct references the Pharmaceutical Additionally, we initiated and participated in a collaborative research\nSupply Chain Initiative (PSCI) Principles for Responsible Supply project with PSCI to identify risks associated with our suppliers,\nChain Management (the Principles). PSCI is a group of more than 50 including prioritizing materials that are considered sensitive. PSCI has\npharmaceutical and health care companies which promotes sustainable identified materials commonly used within our industry that warrant\nsourcing and better business conditions across the industry, and the further examination.\nPrinciples set the standard for human rights, ethics, labor, health\nThese materials include:\nand safety, environment and related management systems. In 2020,\nthe Principles were updated to include a specific reference to human • Rubber • Glass • Soy\nrights, the UN Guiding Principles on Business and Human Rights, an\n• Corn • Sugar • Cellulose\nenhanced ethics section and new clauses on resource efficiency and\nsustainable sourcing. • Palm oil • Talc • Ethanol\n• Aluminum • Fish oil • Carnaúba wax\nSupplier certification and material review • Shellac • Castor seed/oil\nIn 2021, GSMG continued a program to certify our suppliers’ social and\nenvironmental sustainability program capabilities. We request select We are incorporating findings from the PSCI joint project into our\nsuppliers provide sustainability certifications and assurance, which are internal risk assessment and mitigation approaches. In addition, we\nevaluated to determine if the supplier can be certified as a member of have developed a method for evaluating certifications and materials\nour GREEN Supplier Program. of concern. We have also been mapping our supply chain to identify\nwhich of our suppliers operate in countries that are known to present\nTravel and Meetings (including Fleet), Integrated Logistics and significant risks. We use this information to help us decide the\nPaper-based Packaging Categories are currently included in this appropriate level of due diligence.\nprogram, which:\nWe recognize that potential risks associated with these materials may\n• Encourages supplier engagement\nalso exist beyond our Tier 2 suppliers, and we plan to participate in\n• Shares best practices and improves sustainability practices efforts (in collaboration with PSCI) to ensure that the materials we use\n• Tracks supplier sustainability goals are sourced responsibly.\n• Generates a list of GREEN Suppliers and proposed In 2022, we also surveyed select packaging suppliers and found that\nsustainability projects\nmost of the suppliers were able to offer certified materials.\n• Monitors progress utilizing a key performance indicator (KPI)\non the GSMG Scorecard\nSupplier due diligence assessments\nWe have a defined risk-management process and our supply base is\nmeasured against the process criteria. Using a risk-based approach,\nsupplier assessments and audits are conducted based on multiple\nfactors (e.g., risk profile, engagement and activity type, geography).\nThe assessments and audits evaluate a supplier’s ability to meet both\nindustry and our own standards for quality, safety and ethical business\npractices. Results are reviewed with senior management across\nthe Company.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 31"
  },
  {
    "page": 32,
    "source": "text",
    "content": "CONTINUED: GRI 102-9\nOur due diligence includes: Protecting the privacy of personal information\n• Anti-bribery and corruption • Intellectual property\nSome of our suppliers, such as contract research organizations, market\n• Conflict minerals • Labor and human rights research agencies, information technology systems developers,\ncorporate card suppliers, and travel and meeting agencies process\n• Denied-party screening • Privacy (data protection)\npersonal information in connection with their performance of services\n• Ethics and compliance • Supply-chain security\nfor our Company. We require these suppliers to provide appropriate\n• Financial solvency privacy protection for personal information that they handle in\n• Information security and accordance with our privacy policies and applicable privacy laws,\ncybersecurity regulations and guidelines.\nProtecting against cyberattacks and assuring\nWhere assessments and audits identify deficiencies or opportunities\nbusiness continuity\nfor improvement, we monitor suppliers to ensure that our concerns\nare addressed in a responsible and compliant manner. As part of our\nWe recognize that cybersecurity events at suppliers pose an increased\noversight and monitoring, we have established mechanisms to report,\nrisk to our business continuity. In 2021, we continued our supplier\ntrack and monitor supplier plans to address nonconformance and help\ncyber resiliency risk management program to conduct assessments\ndrive continued improvement. Additional review(s) are performed for\nand review risks and remediation actions with key suppliers. We also\nexternal manufacturing suppliers and suppliers that manage personal\nexpanded the program by rolling out cybersecurity contract language\nand private information.\nwith selected key suppliers. The program fosters mutually beneficial\nworking relationships with our suppliers. We continue to enhance\nExternal manufacturers of our products the program to improve operational excellence and continuous\nmonitoring capabilities.\nProspective external manufacturers of active pharmaceutical\ningredients and finished products are screened for environmental,\nCollaboration is key\nhealth and safety (EHS) compliance in addition to quality, supply and\ntechnical competence requirements. The EHS screening includes a\nWe are an active member of PSCI. The member companies share a\nsurvey covering such topics as regulatory compliance, fatalities and\nvision of better social, health, safety and environmental outcomes\nmajor incidents.\nin the communities where we buy. Collectively, PSCI members share\nknowledge and expertise across our industry to drive complex,\nBased on the screening results and activities undertaken by the\nglobal change more effectively with our suppliers than any one\nsupplier, certain external manufacturers are subject to a more detailed\norganization alone.\non-site assessment conducted by a multidisciplinary team, which\nmay include our Quality, Global Safety and the Environment, Global\nIn 2021, our Company held a one-year position on the PSCI board.\nTechnical Operations and GSMG representatives.\nWe also continue to co-lead the Environment Team, and be active\nmembers on the Capability Committee and the Human Rights and\nThe external manufacturers we contract with are periodically reassessed\nLabor team.\nusing a risk-based approach; higher-risk external manufacturers\nare subject to more frequent on-site assessments. We expect that\nobservations made during the audit process will be remediated by our\nexternal manufacturers, and we monitor and track corrective actions\nthrough completion.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 32"
  },
  {
    "page": 33,
    "source": "text",
    "content": "CONTINUED: GRI 102-9\nTraining Communication to our stakeholders\nWe understand the importance of training and, in 2021, developed We have an internal webpage maintained by GSMG that provides\nand provided numerous training events assigned to employees, information on our Sustainable Sourcing programs to employees and\nindustry peers and suppliers. Most of our internal classes are assigned contractors. Examples of materials provided include our program\nthrough our centralized learning system. In addition to providing summary, supplier data, benchmarking, supplier programs, training\ntraining through our internal systems, we also work with PSCI to materials and newsletters. We also have a quarterly GREEN Supplier\ndevelop and provide training to our suppliers and peers. Spotlight newsletter, where we provide an overview of a supplier with\na robust sustainability strategy.\nSome examples of our training and associated tools include:\nAdditional details regarding our supplier-focused ESG programs\n• Procurement Onboarding\ncan be found in GRI 204 on page 75, GRI 308 on page 122, and GRI 414\n• Third-Party Risk Management\non page 164.\n• Business Partner Code of Conduct Training (Edition 2)\n• Mitigating Modern Slavery Risks in Our Supply Chain\nAssessing the effectiveness of our program\n• 10 Environmental Sustainability Guides*\nDuring 2021, we reviewed the following KPIs to help us assess the\n• 14 Responsible Sourcing Guides for Key Materials*\neffectiveness of our efforts in our business and supply chain. We use\n• Responsible Sourcing of Raw Materials Training* these measures to monitor our performance and identify opportunities\n• Sustainable Packaging* to help improve our programs.\n• Revised PSCI Principles*\n• Regulatory Overviews*\n• Supplier Maturity Matrix*\n* Training is available internally and externally; all other trainings are available for internal\nuse only.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 33"
  },
  {
    "page": 34,
    "source": "text",
    "content": "CONTINUED: GRI 102-9\nSupply chain 2017 2018 2019 2020 2021\nEmployees trained on mitigating modern slavery risks in our supply chain1,2 N/A 451 4 8 4\nEmployees trained on updated Business Partner Code of Conduct (Edition II)1 195 148 190 183 137\nEmployees trained on Third-Party Risk Management1,3 N/A N/A N/A 185 997\nSupplier Self-Assessments4 466 595 706 547 127\nSupplier Labor and Human Rights (LHR) audits conducted5 32 104 39 47 10\nSupplier Labor and Human Rights (LHR) audit observations addressed/remediated6 100% 100% 99% 99% 13%\nSupplier personnel trained in ESG7 N/A N/A N/A 1,492 1,856\nGREEN supplier spend (in millions)8,9 N/A N/A N/A $247 $212\nN/A: Not available.\n1 Primary target: Procurement and business development staff with responsibility for supplier management.\n2 Training on modern slavery risks in our supply chain began in 2018 with applicable employees and is provided to all new relevant hires going forward.\n3 Formal training was created and rolled out in late 2020; prior to 2020, informal training was provided on an as needed basis.\n4 Undertaken as part of initial supplier due diligence, managed and overseen by GSMG; Scope includes labor and human rights, environment and safety, and ethical business practices. Decrease in\nnumber of assessments was due to the change in criteria in late 2020 for when a Supplier Self-Assessment is required using a risk-based approach.\n5 Announced on-site audits, independently performed by third-party audit firms; primary focus on direct material (Tier 1) supplier facilities located in China, India, Mexico and Indonesia. Decrease\nin number of LHR audits was due to the ongoing COVID-19 related restrictions and challenges for conducting on-site audits. A virtual LHR audit program is being adopted.\n6 Monitoring closure of past audit observations revealed by supplier LHR audits; not all Corrective Action Plan Assessments (CAPAs) are due within the same year. Remediation of LHR audits\nobservations are in progress; some of these LHR audits were conducted in Dec 2021, hence the lower percentage for remediation.\n7 Formal training was created and conducted as joint effort with PSCI for responsible sourcing, environmental, and human rights and labor topics.\n8 2021 metric represents 2020 spend data for the 2021 list of GREEN Suppliers.\n9 Our GREEN supplier program officially launched in 2020. The spend decreased in 2021 as a result of the Organon & Co. spin-off and the associated change in our supplier base.\ndiversified brands franchise. Our existing research pipeline programs\ncontinue to be owned and developed within Merck as planned.\nOrganizational changes during\nGRI 102-10\nthe reporting period (Core)\nIn November 2021, Merck acquired Acceleron Pharma, Inc. (Acceleron),\na publicly traded biopharmaceutical company, which is evaluating\nIn April 2021, Merck acquired Pandion Therapeutics, Inc., a clinical-stage the TGF-beta superfamily of proteins through the development of\nbiotechnology company developing novel therapeutics designed to pulmonary and hematologic therapies.\naddress the unmet needs of patients living with autoimmune diseases.\nIn certain instances, to aid year-to-year comparability, we have restated\nOn June 2, 2021, we completed the spin-off of products from our data from prior years to exclude facilities that were part of the Organon\nwomen’s health, biosimilars and established brands businesses into spin-off. In the event that information from prior years has been\na new, independent, publicly traded company named Organon & Co. restated, these changes are described in the footnotes beneath the\n(Organon) through a distribution of Organon's publicly traded stock specific performance data tables.\nto Company shareholders. The established brands included in the\nFor more information on these organizational changes, please visit\ntransaction consisted of dermatology, non-opioid pain management,\nour 2021 Form 10-K, pages 65–66, 83, 89–90, and 92–93.\nrespiratory, select cardiovascular products, as well as the rest of our\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 34"
  },
  {
    "page": 35,
    "source": "text",
    "content": "• International Council for Harmonisation: Good Clinical Practice\n(ICH-GCP)\nGRI 102-11 Precautionary principle (Core)\n• International Federation of Pharmaceutical Manufacturers &\nAssociations (IFPMA) Code of Practice\nWe take a precautionary approach when evaluating potential human • Kigali Declaration on Neglected Tropical Diseases\nexposures and environmental impacts resulting from our manufacturing\n• U.S. National Academy of Sciences guidelines\nprocesses. Conservative assumptions are made when data is limited,\nand safety factors are added to address uncertainty and variability in For more information on our approach to access, please see GRI 203\nour assessments. on page 55. For more information on Merck Animal Health, please visit\nour Animal Health website.\nThis type of approach is particularly relevant to our work in toxicology,\nindustrial hygiene, biosafety and environmental protection.\nEmployees\nFor more information on our approach to the precautionary principle,\nplease refer to the following sections: • CEO Action for Diversity and Inclusion\n• International Labour Office (ILO) Code of Practice on Recording and\nGRI 301 – Materials (page 83) Notification of Occupational Accidents and Diseases\nGRI 302 – Energy (page 88) • OneTen Initiative\nGRI 303 – Water and Effluents (page 93) • Paradigm for Parity\nGRI 305 – Emissions (page 104) • United Nations Women’s Empowerment Principles\nGRI 306 – Waste (page 110)\nFor more information on our employees, please see GRI 401 to GRI 405\nGRI 307 – Environmental Compliance (page 116) on page 124.\nGRI 403 – Occupational Health and Safety (page 131)\nEnvironmental Sustainability\n• American Chemistry Council’s (ACC) Green Chemistry Initiative\n• Eco-Pharmaco-Stewardship (EPS) initiative\nGRI 102-12 External initiatives (Core)\n• Paris Climate Agreement\n• Science-Based Target initiative (SBTi)\nBelow are select examples of external charters, principles and initiatives\nwhich guide our work in our four ESG focus areas, or which we have • UN CEO Water Mandate\nendorsed. There is more information on each of these charters, principles\n• We Mean Business Coalition\nand initiatives throughout this report, in addition to other multi-party\n• Conference Board Product Stewardship Council\ncollaborations mentioned in relation to specific disclosures.\n• ACS Green Chemistry Institute Pharmaceutical Roundtable\n(ACS GCIPR)\nAccess to Health\nFor more information on our approach to environmental\n• AMR Alliance Common Antibiotic Manufacturing Framework\nsustainability, please see GRI 301 to GRI 308 on page 83.\n• Antibiotic Commitment\n• Declaration of Helsinki\n• Industry Roadmap for Progress on Combating AMR\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 35"
  },
  {
    "page": 36,
    "source": "text",
    "content": "CONTINUED: GRI 102-12\nEthics & Values For more information on our approach to ethics and values, please see\nGRI 102-16 and GRI 102-17 on page 39, and GRI 412 on page 161. For more\n• European Federation of Pharmaceutical Industries and\ninformation on our supply chain, please see GRI 102-9 on page 30, GRI 204 on\nAssociations (EFPIA) Code of Practice\npage 75, GRI 308 on page 122 and GRI 404 on page 142.\n• International Covenant on Civil and Political Rights\n• International Covenant on Economic, Social and Cultural Rights\n• International Federation of Pharmaceutical Manufacturers &\nAssociations (IFPMA) Code of Practice GRI 102-13 Membership associations (Core)\n• International Labor Organization core labor standards\n• Organization for Economic Cooperation and Development Our Company is a member of numerous industry and trade groups.\nGuidelines for Multinational Enterprises\nWe work with these groups because they represent the pharmaceutical\n• Pharmaceutical Supply Chain Initiative (PSCI) Principles for\nindustry and business community in debates led by governments and\nResponsible Supply Chain Management\nother stakeholders, and because they help the industry reach consensus\n• PhRMA Code on Interactions with Health Care Professionals on policy issues.\n• UN Guiding Principles on Business and Human Rights\nOur top three trade associations in 2021:\n• UN Global Compact\n• Pharmaceutical Research and Manufacturers of America (PhRMA)\n• UN Universal Declaration of Human Rights\n• U.S. Chamber of Commerce\n• Biotechnology Industry Organization (BIO)\nWhen our trade associations actively lobby on our core business issues, we\nseek to align their positions with our own. There are times, however, when\nwe may not share the views of our peers or associations—both on issues\nthat are central to our business and on those that, while important, are\nnot directly material to our purpose. With representatives on the boards\nand committees of industry groups and trade associations, we can voice\nquestions or concerns we may have about policy or related activities. We\nmay even recuse ourselves from related trade association or industry group\nactivities when appropriate.\nThe Governance Committee of the Board of Directors has ongoing oversight\nof our membership in trade associations and grassroots lobbying activities.\nEach year, the full Board of Directors receives a report that lists for the\nprevious year (a) the U.S. industry and trade groups in which we are a\nmember for which our dues are greater than $25,000 and (b) the amount of\nour dues that were spent by these groups on lobbying and political activity in\nthe U.S.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 36"
  },
  {
    "page": 37,
    "source": "text",
    "content": "CONTINUED: GRI 102-13\nBelow is a list of these U.S. industry and trade groups:\nTrade association dues used for lobbying 2017 2018 2019 2020 2021\nAnimal Health Institute $39,271 $70,687 $70,687 $56,550 $49,481\nBio New Jersey* $4,860 $5,100 $10,140 $8,490 $13,200\nBiotechnology Industry Organization $231,679 $237,468 $274,964 $320,471 $345,716\nCalifornia Life Sciences Association $11,300 $49,980 $49,980 $47,760 $36,740\nCouncil of the Americas* $1,250 $1,250 $1,250 $1,500 $1,500\nChemistry Council of New Jersey $8,775 $8,951 — — $9,000\nHealthcare Distribution Alliance (HDA) — — — — $2,538\nHealthcare Institute of New Jersey $122,100 $114,404 $113,645 $116,983 $147,342\nHealthcare Leadership Council $90,000 $90,000 $90,000 $90,000 $90,000\nLife Sciences Pennsylvania* $4,500 $4,520 $6,360 $4,858 $5,200\nMassachusetts Biotechnology Council $9,884 $10,164 $10,461 $11,055 $11,715\nNational Association for Biomedical Research $20,000 $20,000 $20,000 $20,000 $20,000\nNational Association of Manufacturers $61,792 $56,443 $59,083 $62,132 $80,882\nNew Jersey Chamber of Commerce $4,142 $4,245 $4,374 $3,003 $4,641\nNew Jersey Civil Justice Institute $30,000 $30,000 $30,000 $30,000 $13,500\nPersonalized Medicine Coalition — — — — $3,158\nPharmaceutical Research and Manufacturers of America $11,630,454 $12,548,663 $11,743,028 $18,730,134 $18,146,820\nTexas Healthcare & Bioscience Institute* $5,500 $5,500 $5,500 $5,500 $13,200\nU.S. Chamber of Commerce $206,250 $237,500 $297,000 $130,000 $311,250\nU.S. Council for International Business — $3,445 $3,728 $7,456 —\n*Includes associations where dues are > $25,000. Because the U.S. tax law that requires this reporting does not apply outside the U.S., trade associations that are not subject to this do not provide\nbreakouts of lobbying expenditures from membership dues.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 37"
  },
  {
    "page": 38,
    "source": "text",
    "content": "CONTINUED: GRI 102-13\nThrough our top three trade associations (listed on the previous page), In 2022, we conducted a climate policy alignment assessment of\nwe engaged on the following policy issues in 2021. the trade associations listed above by determining whether they\nhad publicly disclosed formal positions on climate change and, if so,\nIn the U.S., the top issues at the federal level for which our Company reviewing those positions in the context of our Company's own\nlobbied were: position on climate change. This assessment can be found on the\n• Medicare Part B ESG Resources page on our corporate website.\n• Medicare Part D\nInformation on our approach to climate change, and related\n• Corporate tax reform performance data, can be found in GRI 305 on page 104.\nIn the U.S., we lobbied at the state level to address these key issues:\n• Drug price transparency and price controls\n• Market-based solutions for access to innovative pharmaceutical,\nvaccine and biologic products\n• Maintaining a strong business environment for U.S. operations in\nthe states\n• Support for a strong immunization infrastructure\n• Advocating for legislative and regulatory structures that support\naccess to animal health products\nIn Europe, the top issues we focused our advocacy on included:\n• Addressing the European Commission’s review of incentives\nfor biopharmaceutical products\n• Fostering frameworks for sound pricing and procurement regimes in\nand across diverse European Union (EU) member state economies\n• Supporting government vaccination, hepatitis and diabetes programs\n• Advancing the dialogue for sustainable models to fund future\ncancer care\n• Improving standards for health technology assessment\nand health literacy\n• Ensuring science-based policies for biological medicines\n• Strengthening access to animal health products\n• Science-based trade policy\n• New Veterinary Regulation (NVR)\n• Pharmaceuticals in the Environment\n• Antimicrobial Resistance (AMR)\n• One Health strategy\n• New technological developments\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 38"
  },
  {
    "page": 39,
    "source": "text",
    "content": "Strategy Ethics and integrity are the bedrock of all that we do, and the Company\nstrives to maintain a transparent work environment where employees\ncan and are encouraged to report concerns without fear of retaliation.\nThe Office of Ethics also serves as a channel for the receipt, triaging\nand redress of ethics and compliance related concerns. Depending\nGRI 102-14 CEO letter (Core)\non the concern type, the concerns will be investigated by the Office\nof Ethics, the Office of General Counsel, Global Security or Human\nPlease see the letter from our President and CEO on page 3. Resources. Employees are encouraged, prepared and empowered to\nraise their concerns to their management, Human Resources, Legal,\nCompliance or the Office of Ethics.\nEthics and integrity\nThe Office of Ethics maintains a global Speak Up program and the\nMSDethics.com reporting tool. The reporting tool is operated by\nan independent third party and is available 24/7. MSDethics.com\nValues, principles, standards, and norms allows employees and suppliers to raise concerns or ask questions\nGRI 102-16\nof behavior (Core) confidentially and anonymously (where permitted by law) in their\nGRI 102-17 Mechanisms for advice and concerns about ethics preferred language via phone or internet. The Company communicates\nregularly with employees to ensure they understand how they can\nCode of ethics governing interactions with\nSASB 510a.2 report potential misconduct or concerns.\nhealth care professionals\nIn alignment with our priority to protect and enhance our Company’s\nreputation through safe, ethical and compliant behaviors, and to foster\nOur Company’s Office of Ethics is responsible for ensuring that\na strong culture of ethics and compliance, Regional Ethics Officers\nemployees are aware of and trained on the Code of Conduct and\nmanage a network of site-based volunteer Ethics Ambassadors outside\nCorporate Policies addressing ethics and compliance.\nof the U.S. The Ethics Ambassadors are trained to answer employee\nOur Code of Conduct is available in 19 languages and applies to all questions about the Company’s reporting and investigation process\nemployees worldwide. Our Code of Conduct establishes clear ethical and actively support the Speak Up Program.\nexpectations and principles to guide the operations of the Company.\nWe maintain a fulsome process for escalation and investigation of\nIt sets out core values and principles and helps us to protect the\npotential compliance related concerns. The process is designed to\nreputation we have earned. In addition to publishing a PDF version\nensure that we promptly and discreetly investigate all reports of\nof our Code of Conduct to our external website, our Company’s\nconduct and/or behavior that could violate our Company’s policies,\ninternal website allows employees to download a PDF of the Code of\nvalues or standards.\nConduct, search for a policy, ask a question or raise a concern through\nMSDethics.com. It also offers tools and resources to help employees\nIf allegations of misconduct are substantiated, appropriate\nmake appropriate decisions and take appropriate actions by putting\nremediation and disciplinary actions are taken to ensure that\nour values and ethical standards into practice.\nthose who were responsible are held accountable and recurrence\nis prevented. Disciplinary actions can include, but are not limited\nCorporate policies are reviewed every three years by business content\nto, dismissal from the Company, issuance of final written warning\nowners and updated as needed. We abide by strict ethical standards\nletters and/or financial penalties. In addition, we take appropriate\nin our own operations and, to the extent applicable, we insist on\nsteps to address any needed improvements in organizational and\nequivalent standards from our suppliers. Our Business Partner Code\nprocess controls.\nof Conduct presents similar and consistent principles for our business\npartners. We expect all our business partners to adhere to these\nThe Company also has the discretion to reduce incentive payments\nprinciples and operate in full compliance. Our Business Partner Code of\nmade to employees in certain instances of misconduct. This may apply\nConduct is based on the PSCI Pharmaceutical Industry Principles and\nwhen employees engage in misconduct that results in a material policy\nthe Ten Principles of the UN Global Compact.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 39"
  },
  {
    "page": 40,
    "source": "text",
    "content": "CONTINUED: GRI 102-16 | GRI 102-17 | SASB 510a.2\nviolation relating to the research, development, manufacturing, sales Code of ethics governing interactions\nor marketing of Company products where the policy violation causes\nwith health care professionals\nsignificant financial or reputational harm to the Company.\nOur Continuing Medical Education (CME) and Continuing Education\nRetaliation against employees who report concerns is a violation of (CE) programs support independent medical education to maintain,\ncorporate policy and is strictly prohibited. develop or enhance the knowledge, skills and/or professional\nperformance of health care professionals. We are committed\nThe Office of Ethics and the Office of General Counsel are responsible\nto ensuring that our CME/CE programs are primarily driven by\nfor oversight of the global processes for managing investigations\neducational needs. Through these programs, we seek to increase\ninto potential ethics and compliance concerns to ensure consistent\nhealth care professionals’ knowledge about the latest scientific\nand timely resolution of potential concerns and implementation of\ndata in relevant therapeutic areas and health care topics, thereby\nremediation actions.\nimproving patient care.\nThe environment in which we sponsor or support educational\nprograms worldwide is complex, governed by a multitude of laws,\nregulations and medical or industry association guidelines. We are\ncommitted to honoring all applicable laws, regulations and guidelines\nrequired for CME/CE in the countries in which we operate.\nCME programs that we support or sponsor are governed by an\ninternal policy that is aligned with the appropriate standards and\nregulations to which the programs are held including, among other\nthings, transparency reporting, independence and financial disclosure.\nU.S. Medical Forums\nWe deliver balanced medical and scientific information to health\ncare professionals within the U.S. through our Company’s Medical\nForums, which are conducted by external speakers. Speakers are\nselected based on their expertise in the relevant subject matter. By\nattending one of our Medical Forums, health care professionals learn\nabout therapeutic and health care industry topics. The goal of these\ninteractions is to help attendees achieve improved medical results for\ntheir patients.\nWith our strict standards for conducting these Medical Forums,\nwe comply with the PhRMA Code on Interactions with Health Care\nProfessionals as well as with U.S. Food and Drug Administration\n(FDA) regulations, which ensure that any product presentation is\nappropriately balanced with information regarding both the product’s\npotential benefits and its risks, and is consistent with approved\nproduct labeling.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 40"
  },
  {
    "page": 41,
    "source": "text",
    "content": "Governance Board\nThe work to address our environmental footprint and social impact\nbegins with the Board, which, as a whole and through its committees,\nhas responsibility for overseeing ESG matters.\nGRI 102-18 Governance structure of the organization (Core)\nGRI 102-19 Delegation of responsibility\nGRI 102-20 High-level accountability for sustainability topics\nResponsible Oversight for ESG topics\nGRI 102-21 Access to the Board\nparty\nGRI 102-22 Composition of the Board and its committees\nBoard Provides oversight with respect to the\nGRI 102-23 Chair of the highest governance body\nCompany’s ESG matters and strategy\nrelated thereto.\nThe primary mission of our Board is to represent and protect the\nGovernance Monitors and assists the Board in its oversight\ninterests of our shareholders. The Board generally meets at least six\nCommittee of our ESG matters, including ensuring that\ntimes per year to provide strategic direction and to review our progress\napplicable ESG matters are subject to review\non a wide variety of measures. In overseeing the affairs of the Company,\nby Board committees with relevant areas of\nincluding our governance, the Board has established four committees,\ncompetency, by monitoring and evaluating\neach of which is composed solely of independent directors:\nprograms and activities, reviewing strategy\n• Audit regarding political engagement and reviewing\n• Compensation & Management Development environmental sustainability practices.\n• Governance Compensation Assists the Board with its oversight of human\n• Research & Management capital management, including our policies and\nDevelopment practices related to talent management, culture,\nAll of these committees are governed by Board-approved charters Committee diversity, equity and inclusion. This includes\nthat are available on our corporate website. Additional information maintaining fair hiring and promotion practices\non these committees can be found in our 2022 Proxy Statement and a commitment to sustain pay equity for\n(pages 14-16). employees of all genders, races and ethnicities.\nRobert M. Davis, our chief executive officer and president, currently Audit Monitors compliance with the Company’s\nserves on our Board. Our former chief executive officer, Kenneth C. Committee policies on ethical business practices.\nFrazier, is currently the executive chairman of the Board.\nResearch Monitors compliance with the highest standards\nEnvironmental, Social and Governance (ESG) Committee of scientific integrity in the conduct of our\nresearch and development.\nmanagement structure\nWe are committed to governance policies and practices that serve Management Management is responsible for reviewing, refining\nthe interests of the Company and its shareholders. Our reporting and and implementing long-term ESG strategy,\ngovernance structure is an integral part of this commitment. including through its Public Policy & Responsibility\nCouncil comprising diverse cross-functional\nmembers, and for updating the Board and its\ncommittees, as applicable, on ESG matters.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 41"
  },
  {
    "page": 42,
    "source": "text",
    "content": "CONTINUED: GRI 102-18 | GRI 102-19 | GRI 102-20 | GRI 102-21 | GRI 102-22 | GRI 102-23\nPublic Policy and Responsibility Council (PPRC) ESG Strategy Management Team\nThe PPRC is a high-level forum for strategic input and guidance on our This team, comprising functional experts throughout our Company,\nsocial business investments, ESG approach and public policy issues helps drive our long-term ESG strategy. This includes identifying\nand positions. The diverse, cross-functional membership of the PPRC risks and opportunities and advising on long-term goals and\nprovides vision, leadership and cross-divisional input and alignment on metrics. Members of this team include senior leaders from each of\npolicy and responsibility strategy, issues and initiatives. Specifically, the our four focus areas (Access to Health, Employees, Environmental\nPPRC enables policy and ESG issue identification and debate; makes Sustainability and Ethics & Values), as well as leaders in our Office\nrecommendations to our CEO's Executive Team, as necessary; informs of the Secretary, Investor Relations and Corporate Strategy,\npolicy and ESG strategy; and reviews performance and reporting against among others.\ndefined objectives. Overall, the PPRC promotes further integration of\nESG and policy considerations into our business activities.\nCorporate governance 2017 2018 2019 2020 2021\nIndependent directors on the Board 12 11 12 12 12\nPercent of Board members who are independent 92% 92% 92% 92% 86%\nSeparate chairman of the Board and CEO1 No No No No Yes\nLead independent director Yes Yes Yes Yes Yes\nIndependent audit committee Yes Yes Yes Yes Yes\nIndependent compensation and management development committee Yes Yes Yes Yes Yes\nIndependent governance committee Yes Yes Yes Yes Yes\nWomen on the Board 23% 33% 46% 46% 43%\nMembers of underrepresented ethnic groups on the Board 15% 17% 23% 31% 21%\nNumber of Board meetings scheduled or held2 8 6 6 7 7\nShareholder support of the advisory vote on executive compensation3 95% 93% 92% 91% 92%\nNote: Except as otherwise noted, all figures above are derived from our proxy statement filed the following year and are rounded.\n1 As of July 1, 2021, the positions of Board chairman and CEO are separate.\n2 Refers to number of meetings held in the given calendar year; meetings were held in person and/or via video conference.\n3 Percentages derived from Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission after the applicable annual meeting of shareholders.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 42"
  },
  {
    "page": 43,
    "source": "text",
    "content": "CONTINUED: GRI 102-18 | GRI 102-19 | GRI 102-20 | GRI 102-21 | GRI 102-22 | GRI 102-23\nESG Strategy & Engagement For information on our Board of Directors nomination process,\nplease see our 2022 Proxy Statement on pages 21–23.\nOur ESG Strategy & Engagement team is responsible for raising the\nvisibility of ESG issues and activities across the Company. This includes Information on our Board conflict of interest policy can be found\nfostering connections across business units and functional areas to in our Policies of the Board, in Section 13 (pages 8–9).\nintegrate our approach to ESG into business policies, strategies and\nFor information on the development, approval and updating of our\npractices, including the enterprise risk management (ERM) process.\nCompany’s purpose and values, strategies and policies, see GRI 102-16\nIts aim is to bring the views of external stakeholders into our decision-\non page 39 of this report, GRI 102-19 and GRI 102-20 on page 41, and\nmaking processes. The ESG team also coordinates the development,\npage 17 of our 2022 Proxy Statement.\nimplementation and communication of our global approach and,\nwith strategic guidance from the ESG Strategy Management Team,\nPublic Policy and Responsibility Council (PPRC), Executive Team and\nthe Board's Governance Committee is responsible for publishing our GRI 102-27 Board ESG knowledge\nannual ESG Progress Report.\nBoard identification of ESG impacts, risks,\nGRI 102-29\nand opportunities\nESG Report Working Group\nGRI 102-30 Board review of ESG risk management processes\nThe members of the ESG Report Working Group, a diverse selection of\nemployees from all divisions of the Company, serve as subject matter GRI 102-31 Frequency of Board review\nexperts in their respective areas and work closely with the ESG Strategy Highest committee or position that formally\n& Engagement team to help set goals and develop metrics that support GRI 102-32 reviews and approves the organization’s\nand measure our overall ESG strategy and objectives. Individual members ESG report\nhave been chosen to be active advocates for ESG within their respective\ndepartments, and coordinate the content writing for this report with\nOur Board has responsibility for overseeing ESG matters, and does so\nsubject-matter experts in their functional areas.\nas a whole and through its four independent Committees, depending\nFor more information on our approach to governance, please visit GRI on the topic.\n102-29 to 102-32.\nThis oversight includes participating in periodic reviews and\ndiscussions related to risks, impacts and opportunities related to ESG.\nFor information on communicating with the Board, please see our\nManagement is responsible for reviewing, refining and implementing\n2022 Proxy Statement on pages 26 and 95.\nlong-term ESG strategy, including through its Public Policy &\nResponsibility Council (PPRC) comprising diverse cross-functional\nteam members, and for updating the Board and its Committees, as\napplicable, on ESG matters.\nGRI 102-24 Board nomination and selection processes\nGRI 102-25 Board conflicts of interest Chaired by our independent lead director, the Governance Committee\nis responsible for monitoring and assisting the Board in its oversight\nBoard’s and senior executives’ roles in the\nof ESG matters and related strategy. This includes ensuring that\ndevelopment, approval, and updating of the\napplicable ESG matters are subject to review by Board Committees\nGRI 102-26 organization’s purpose, value or mission\nstatements, strategies, policies, and goals with relevant areas of competency. The Governance Committee’s role\nrelated to ESG topics also includes reviewing public policy positions, strategy regarding\npolitical engagement and ESG-related initiatives with significant\nfinancial and/or reputational impact.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 43"
  },
  {
    "page": 44,
    "source": "text",
    "content": "CONTINUED: GRI 102-27 | GRI 102-29 | GRI 102-30 | GRI 102-31 | GRI 102-32\nThis Committee also monitors and evaluates our Company’s ESG independent Directors as a group or other members of the Board by\nprograms and activities, including the support of charitable, political emailing office.secretary@merck.com, or by writing to the following address:\nand educational organizations and political candidates and causes.\nIn addition, the Governance Committee is responsible for reviewing Board of Directors\nour environmental sustainability practices, supply chain manufacturing Merck & Co., Inc.\nstrategy and governance, and third-party sourcing programs. 126 East Lincoln Avenue\nP.O. Box 2000\nThe Governance Committee reviews trends against our current Rahway, NJ 07065 USA\npractices and structures, and considers input received from\nshareholders and other stakeholders as part of this review. Lastly, For information on communicating to the Board, please visit our\nit identifies and communicates external and internal training and 2022 Proxy Statement (page 26).\neducational opportunities for directors in various areas, including ESG.\nThe Compensation & Management Development Committee assists\nRemuneration policies for the Board\nthe Board with its oversight of human capital management. This GRI 102-35\nand senior executives\nincludes overseeing the programs, policies and practices related to\nGRI 102-36 Process for determining remuneration\ntalent management, culture, diversity, equity and inclusion; maintaining\nfair hiring and promotion practices; and sustaining our pay equity GRI 102-37 Remuneration shareholder resolutions\ncommitment for Merck employees of all genders, races and ethnicities.\nIn addition to the Governance Committee and the Compensation A full discussion of our approach to remuneration for our Board and\n& Management Development Committee, the Board’s other two for Named Executive Officers (NEOs) can be found on pages 40–64 of our\nCommittees oversee certain ESG matters as well. For example, the 2022 Proxy Statement.\nResearch Committee monitors compliance with the highest standards\nTo learn more about the non-binding advisory vote to approve the\nof scientific integrity in the conduct of the Company’s research and\ncompensation of our NEOs, please see our Form 8-K from May 26, 2022.\ndevelopment, and the Audit Committee monitors compliance with our\nThis proposal received a 91.88 percent approval vote at our annual meeting\npolicies on ethical business practices.\non May 24, 2022.\nInformation on our Board’s and its Committees’ responsibilities\ngenerally and with regard to ESG can be found on pages 14–16 and 20 of\nour 2022 Proxy Statement, and in its Committees’ charters, which are\navailable on our corporate website. GRI 102-38 CEO/employee pay ratio\nFor information on our Board structure, please see GRI 102-19 and The total annual compensation of our median employee in 2021 was\nGRI 102-20 on page 41. $102,803. This figure was comprised of base salary, annual incentive,\nsavings plan Company match and change in pension value. The total\nannual compensation for our CEO was $13,722,121. A reasonable\nestimation of the ratio of our CEO’s compensation to our median\nProcess for communicating critical concerns\nGRI 102-33 employee’s compensation was 133 to 1. Under the SEC rules, companies\nto the Board\nmay identify the median total annual compensation using a wide variety\nof methods, including reasonable assumptions and estimations. It is\nThe Board welcomes input from shareholders and other interested parties therefore difficult to compare this ratio to those of other companies.\nand has established a process to receive these communications.\nShareholders and interested parties may communicate directly with the For more information on our methodology for determining this ratio,\nBoard, the independent lead director, the non-management or please see page 65 of our 2022 Proxy Statement.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 44"
  },
  {
    "page": 45,
    "source": "text",
    "content": "Stakeholder engagement In our interactions with patient communities, we are guided by\nthese principles:\n• Human connection: We strive for our interactions with patient\ncommunities to be “human”—in other words, health literate,\nuncomplicated (clear), meaningful, authentic and natural\nA list of stakeholder groups engaged by the\nGRI 102-40\norganization (Core) • Commitment to health equity: We are actively working to\nreduce health inequities, as we believe everyone should have the\nGRI 102-41 Union representation (Core)\nsame chance to be as healthy as possible. This means seeking\nBasis for identifying and selecting stakeholders more chances to work with people who have not had the same\nGRI 102-42\nwith whom to engage (Core) opportunities to access health care and medicines, and those with\ngreater need.\nGRI 102-43 Approach to stakeholder engagement (Core)\n• Ethics and integrity: We follow applicable laws, regulations and\nKey topics and concerns raised by stakeholders ethical codes in the regions and countries where we operate\nGRI 102-44\n(Core)\n• Independence: The independence of patient communities,\nespecially patient organizations, is of utmost importance. We\nWe engage with a diverse group of stakeholders to gain insights support patient communities and respect their need for autonomy,\nthat can inform our efforts to improve access to health care and transparency and fairness.\nfoster progress toward solutions that benefit society and support • Purpose: We want our work with patient communities to have\nour business. meaning and purpose\nMany of these engagements with partners can be found throughout For more information on our work with patient groups, please see our\nthis report. The groups of stakeholders with which we regularly Patients & Caregivers page on our corporate website as well as our work\nengage include: on health equity on page 55 of this report.\nPatients and caregivers\nShareholders\nFor patient communities, which includes individual patients, their\nWe strive to create shareholder value by identifying opportunities to\ncaregivers and family members, patient advocacy leaders and\nmeet customer needs and by managing our business responsibly to\npatient organizations, it is critical that we respect and honor their life\nachieve superior financial results over the long term. Throughout the\nexperiences to better understand their health care journeys, expected\nyear, we regularly engage with our investors on both financial and ESG\noutcomes and decision-making considerations.\nperformance, and seek to better understand their perspectives.\nThrough patient engagement and active listening we can:\nWe have established a proactive shareholder engagement program,\n• Understand patient and caregiver perspectives and insights in which members of Investor Relations, the Office of the Secretary,\n• Learn how we can better help them Human Resources and the ESG Strategy and Engagement Team, as\nwell as other subject-matter experts within the Company, engage with\n• Ask for guidance and consult with them on issues that directly\nour shareholders to remain well informed regarding their perspectives\naffect them\non current issues and to address any questions or concerns. These\n• Take their views and opinions into account in our Company strategy\nteams serve as liaisons between shareholders, members of senior\nand all that we do, from the very early stages of research to the\nmanagement and the Board.\ntime that a medicine is widely available\nIn addition, we conduct an extensive shareholder outreach program\ntwice a year focused on governance, executive compensation and ESG\nmatters. We believe it is most productive to discuss these matters\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 45"
  },
  {
    "page": 46,
    "source": "text",
    "content": "CONTINUED: GRI 102-40 | GRI 102-41 | GRI 102-42 | GRI 102-43 | GRI 102-44\nwell in advance of the Annual Meeting to enable management and the For our disclosures on payments to health care professionals, visit the\nBoard to gather information about investor perspectives and make Transparency Disclosures page on our corporate website.\neducated and deliberate decisions that are balanced and appropriate\nfor our diverse shareholder base and in the Company’s best interests.\nEmployees\nDuring 2021, we held discussions with a number of our shareholders\nWe strive to foster a positive and inclusive working environment for\nin the spring before the annual meeting, and once again in late fall.\nour employees by providing resources to improve their health and\nOur lead director, who is also chair of the Governance Committee,\nthat of their families, opportunities to further their professional\nparticipated in substantive engagements with some of the\ndevelopment and ways to get more involved in the communities where\nCompany’s shareholders.\nthey live.\nIn February 2022, we hosted a virtual investor event with our CEO and\nAs part of our purpose to maintain a satisfying and productive work\nother members of his Executive Team to discuss our Company’s ESG\nenvironment, we routinely survey all employees to learn about their\npriorities and goals, and how this strategy is fundamental to our long-\nperspectives on the business and on how we are responding to the\nterm business value and success. A webcast of this event is available\nneeds of our global workforce. The Employee Pulse Survey, our\non our corporate website.\nCompany’s all-employee engagement survey, is our flagship employee\nfeedback mechanism and is conducted multiple times a year.\nFor more information on our engagements with shareholders,\nincluding topics discussed, please see our 2021 Form 10-K (pages 34,\nTo learn more about our work with employees, please see GRI 401 to\n51, 67 and 113) as well as our 2022 Proxy Statement (pages 3, 20–21\n405 on page 124.\nand 24–26).\nPayers\nHealth care professionals\nWe work with payers worldwide to inform their understanding of the\nWe are committed to providing appropriate and balanced information\nrelationship between the prices of our products and the true value\nto physicians and other health care providers about our medicines,\nthey deliver to patients and health care systems.\nvaccines and ongoing research.\nFor more information on our work with payers, please visit our\nFor more information on our work with health care professionals,\n2021 Form 10-K, pages 7–12, and our Pricing and Access Position\nplease see GRI 102-16 on page 39, GRI 206 on page 80 and GRI 417 on\nStatement, as well as our 2021 Pricing Action Transparency Report.\npage 174.\nUnion membership 2017 2018 2019 2020 2021\nEmployees represented by an independent trade union or covered 29% 30% 30% 30% 23%\nby a collective bargaining agreement (approximate)\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 46"
  },
  {
    "page": 47,
    "source": "text",
    "content": "CONTINUED: GRI 102-40 | GRI 102-41 | GRI 102-42 | GRI 102-43 | GRI 102-44\nGovernments, multilateral organizations Veterinary professionals and animal caretakers\nand regulators\nWe value our partnership with veterinary professionals and animal\ncaretakers to contribute to the health of their animals with innovative\nWe work with policy makers, legislators, multilateral organizations\nproducts and services for farm and companion animal species. We\nand governments worldwide to ensure that policy and regulatory\nregularly communicate and collaborate with our customers and\nenvironments globally, nationally and locally foster patient access to\nindustry leaders in our shared pursuit of continuously improving the\nmedicines and vaccines, and that these environments are conducive\nhealth of animals.\nto ethical business practices, science and innovation.\nTo learn more about our work with veterinarians and animal\nFor more information on these engagements, please see GRI 415 on\ncaretakers, please visit the Animal Health website.\npage 166, as well as in our 2021 Form 10-K, pages 7-12.\nLocal communities\nSuppliers and business partners\nWe work toward developing culturally appropriate mechanisms to\nWe strive to engage a diverse supplier base and to encourage\nengage and build relationships with our local community stakeholders\nresponsible approaches on the part of suppliers regarding labor,\nand nongovernmental organizations (NGOs). We conduct this\nemployment, human rights, health and safety, ethics, diversity and\nengagement predominantly through our philanthropic efforts, which\nprotection of the environment.\ncan be found on the Philanthropy page on our corporate website.\nTo learn more, please see GRI 102-9 on page 30, GRI 204 on\npage 75, GRI 308 on page 122, GRI 412 on page 161, and GRI 414\non page 164.\nTrade and industry associations\nWe engage with stakeholders through membership in numerous\norganizations. Within these groups, we aim to inform relevant debates\nin ways that are constructive and that ultimately foster improved\npatient access to medicines and vaccines globally.\nTo learn more about work with membership organizations, please\nsee GRI 102-13 on page 36.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 47"
  },
  {
    "page": 48,
    "source": "text",
    "content": "Reporting practice\nGRI 102-45 Entities included in financial statements (Core) GRI 102-46 Defining report content and topic boundaries (Core)\nGRI 102-47 Material aspects included (Core)\nAll of our Company’s global operations, including those of subsidiaries,\nare in scope for this report unless stated otherwise. This report\nincludes activities at all facilities, owned and leased, over which we An ESG materiality assessment helps us to prioritize the environmental,\nhave operational control, unless otherwise noted. social and governance topics that matter most to our stakeholders, our\nCompany and the world. Our assessment provides insight into future\nThe basis for reporting on other matters specific to the operations of trends and potential business risks and opportunities.\nour business can be found in our 2021 Form 10-K.\nFor information regarding spin-off and acquisitions that occurred in\n2021, please see GRI 102-10 on page 34.\nOur priority ESG topics\nIn our 2021 ESG materiality assessment, the following 10 topics emerged as the most critical for our Company to address, and are grouped below by\nour four ESG focus areas:\n• Access to medicine • Employee health and safety\n(pages 55-74) (pages 131-141)\nAccess\n• Product quality and safety Employees • Employee engagement\nto Health\n(pages 30-34, 55-74, 78-79, a nd diversity\n167-175, Clinical trials page) (pages 29, 45-47, 148-161)\n• Public health risks\n(pages 55-74)\n• C limate change • B usiness ethics • Ethics in R&D\n(pages 53-54, 88-92, 104-109) (pages 39-40, (pages 39-40, 55-74,\nEnvironmental Ethics\n78-79, 174-175, 167-173, Clinical\nSustainability & Values\nCode of Conduct & trials page)\nCompliance)\n• G overnance structures\n• D ata security and mechanisms\nand privacy (pages 39, 41-47,\n(pages 175-177) 132-136, 159-161, 177)\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 48"
  },
  {
    "page": 49,
    "source": "text",
    "content": "CONTINUED: GRI 102-46 | GRI 102-47\nOur approach\nTo conduct the assessment, we partnered with Datamaran, a materiality and ESG risk-management software company that uses a comprehensive\nand data-driven process for evaluating the relevance of ESG topics and trends to our business and our stakeholders. We leveraged Datamaran’s\nbusiness intelligence platform, which applies SASB Accounting Metrics and is GRI-certified software, to evaluate the external landscape.\nWe began our assessment focused on the following 32 topics specific to the pharmaceutical sector.\n• Access to health care and medicine • Employee engagement and diversity • Product design and life cycle\n• Air quality • Employee health and safety • Product quality and safety\n• Business ethics • Energy management • Public health risks\n• Business model resilience • Ethics in R&D • Responsible and smart transportation\n• Climate change risks • GHG emissions • Selling practices and product labeling\n• Community relations • Governance • Supply chain management\n• Competitive behavior • Human rights • Transparency\n• Critical incident risk management • Inclusion and affordability • Waste and hazardous materials\nmanagement\n• Customer welfare • Innovation and technology\n• Water and wastewater management\n• Data security and customer privacy • Labor practices\n• Workforce management\n• Ecological impacts • Regulation\nESG materiality assessment process\nSector\nExternal\nlandscape\nscore\nreview\nAnalysis ESG material\nand\ntopics\nexternal\nvalidation identified\nInternal\nInternal\nstakeholder\nscore\nsurvey\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 49"
  },
  {
    "page": 50,
    "source": "text",
    "content": "CONTINUED: GRI 102-46 | GRI 102-47\nThe external sources drawn from included: To facilitate year-to-year comparability in certain performance data\ntables, we have restated data from prior years to exclude facilities that\n• Corporate reports (financial, sustainability/ESG and integrated\nwere part of this spin-off. These exclusions are noted in the footnotes\nannual reports)\nof the applicable tables. To the extent other information from prior\n• Global regulations and initiatives (mandatory laws and soft norms)\nyears has been restated, these changes are described in the footnotes\n• Social media (Twitter) beneath the specific performance data tables as well.\n• Online news sources\nTo supplement the data-driven analysis, we also engaged with internal\nGRI 102-50 Reporting period (Core)\nstakeholders through an online survey, and interviews with external\nstakeholders, to validate and prioritize the topics that have the GRI 102-51 Date of most recent report (Core)\ngreatest impact to our business and our stakeholders.\nGRI 102-52 Reporting cycle (Core)\nWe have included the management approach disclosures for our\nGRI 102-53 Report contact (Core)\ntop 10 priority topics in this report as well as disclosures for many\nof the 32 material topics above that are specific to our industry. We\nused this assessment in the development of our ESG goals (found on Except as otherwise noted, we report on our ESG policies, initiatives\npage 8), and we will continue to leverage the findings to help to set and performance annually. The data in this report cover the prior\nthe direction of our future work. calendar year, from January 1 to December 31, 2021. In some cases,\nthe narrative in the report also includes content regarding decisions\nand initiatives that took place in the first half of 2022.\nOur last report was published in September 2021.\nGRI 102-48 Restatements (Core)\nWe welcome your feedback on this ESG Progress Report as well as any\nGRI 102-49 Reporting changes (Core)\nother comments or questions you may have. You may contact us at the\naddress, email, phone number or web address below.\nAll entities that were part of Merck & Co., Inc. on December 31, 2021\nare represented in this report.\nMerck & Co., Inc.\nESG Strategy & Engagement\nOn June 2, 2021, we completed the spin-off of products from\n126 East Lincoln Avenue\nour women’s health, biosimilars and established brands businesses\nP.O. Box 2000\ninto a new, independent, publicly traded company named\nRahway, NJ 07065 USA\nOrganon through a distribution of Organon's publicly traded stock\ninvestor_relations@merck.com\nto Company shareholders. The established brands included in the\n908-740-4000\ntransaction consisted of dermatology, non-opioid pain management,\nmerck.com/contact-us/\nrespiratory and select cardiovascular products, as well as the rest\nof our diversified brands franchise. Our existing research pipeline\nprograms continue to be owned and developed within the Company\nas planned.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 50"
  },
  {
    "page": 51,
    "source": "text",
    "content": "Claims of reporting in accordance with the GRI\nGRI 102-54\nStandards (Core)\nGRI 102-55 GRI content index (Core)\nThis report has been prepared in accordance with the GRI Standards\nat the Core option. An index for all our GRI disclosures, as well as other\nframeworks disclosures, can be found on page 178.\nGRI 102-56 External assurance (Core)\nERM CVS conducted an independent third-party review of our\n2021 greenhouse gas and water inventories, and provided limited\nassurance for the data that we submit to CDP and for inclusion in this\nreport. To view their limited assurance letter for our environmental\ndata, please visit the ESG Resources page on our corporate website.\nWe did not obtain external verification for this ESG Progress Report\nin its entirety.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 51"
  },
  {
    "page": 52,
    "source": "text",
    "content": "Economic\nSee our GRI index on page 181.\nEconomic performance Impact investing\nImpact investing is one of our core approaches to advancing\nsustainable global health solutions in line with our Company’s overall\nobjectives. Through impact investing, we are able to deploy financial\nGRI 201-1 Direct economic value generated and distributed resources in ways that may generate not only improved access to\nhealth care for underserved populations, but also financial returns\nand commercial opportunities—all while growing a sustainable global\nWe believe that addressing the environmental, social and governance\nhealth ecosystem and attracting additional capital and partners.\naspects of our business is critical to our Company’s success and can\nprovide us with new opportunities to create shared value and to Impact investing is led by our Office of Social Business Innovation with\ndemonstrate our purpose to stakeholders. Our principal economic guidance from the Impact Investing Committee. Established in 2019,\ncontribution to society is made through the discovery, development, the Impact Investing Committee is a cross-functional team of senior\nmanufacturing and marketing of our products, which help to save and Company leaders that reviews and approves new investments in line\nimprove lives around the world. with established policies and guidelines and monitors the financial and\nsocial returns of the impact portfolio.\nFor additional information about our business and economic\nperformance, please see our 2021 Form 10-K for the year ended We are members of the Global Impact Investing Network (GIIN),\nDecember 31, 2021, on our corporate website. through which we can contribute to and benefit from the growing body\nof expertise in the impact investing ecosystem.\nFor information on our overall tax strategy, please see 207-1\non page 82. For more information, please visit our Impact Investing page on our\ncorporate website.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 52"
  },
  {
    "page": 53,
    "source": "text",
    "content": "CONTINUED: GRI 201-1\nFinancial information 2019 2020 2021\nSales1 $39.1B $41.5B $48.7B\nResearch and development expenses1,2 $9.7B $13.4B $12.2B\nNumber of employees (approximate) 71,000 74,000 68,000\nNumber of stockholders of record3 109,500 104,900 99,900\nAnnual cash dividend declared per share $2.26 $2.48 $2.64\nGlobal tax expense as reported on income statement1 $1.6B $1.3B $1.5B\nNote: Financial information is in accordance with Generally Accepted Accounting Principles in the U.S. (GAAP).\n1 The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements\nthrough the date of the spin-off and are therefore excluded from the figures presented.\n2 Includes restructuring costs, acquisition-related charges and upfront payments related to collaborations and licensing arrangements.\n3 Approximate number as of January 31 of the year immediately following the reported year.\nto our facilities as well as those of our suppliers. Such risks include\nlosses incurred as a result of physical damage to facilities, loss or\nFinancial implications and other risks and\nGRI 201-2 spoilage of inventory, and business interruption caused by such natural\nopportunities due to climate change\ndisasters and extreme weather events. Other potential physical\nimpacts due to climate change include reduced access to high-quality\nClimate change, or legal, regulatory or market measures to address\nwater in certain regions and the loss of biodiversity, which could\nclimate change, may negatively affect our business, results of\nimpact future product development. These risks could disrupt our\noperations, cash flows and prospects.\noperations and our supply chain, which may result in increased costs.\nWe believe that climate change has the potential to negatively affect\nNew legal or regulatory requirements may be enacted to prevent,\nour business and results of operations, cash flows and prospects. We\nmitigate or adapt to the implications of a changing climate and its\nare exposed to physical risks (such as extreme weather conditions or\neffects on the environment. These regulations, which may differ\nrising sea levels), risks in transitioning to a low-carbon economy (such\nacross jurisdictions, could result in our Company being subject to\nas additional legal or regulatory requirements, changes in technology,\nnew or expanded carbon pricing or taxes, increased compliance\nmarket risk and reputational risk) and social and human effects\ncosts, restrictions on greenhouse gas emissions, investment in new\n(such as population dislocations and harm to health and wellbeing)\ntechnologies, increased carbon disclosure and transparency, upgrade\nassociated with climate change. These risks can be either acute (short-\nof facilities to meet new building codes, and the redesign of utility\nterm) or chronic (long-term).\nsystems which could increase our operating costs, including the cost of\nThe adverse impacts of climate change include increased frequency electricity and energy we use. Our supply chain would likely be subject\nand severity of natural disasters and extreme weather events such as to these same transitional risks and would likely look to pass along any\nhurricanes, tornados, wildfires (exacerbated by drought), flooding and increased costs to our Company.\nextreme heat. Extreme weather and sea-level rise pose physical risks\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 53"
  },
  {
    "page": 54,
    "source": "text",
    "content": "CONTINUED: GRI 201-2\nWhile we understand the potential risks to our Company, there is\nlimited data around the potential financial implications of these\nrisks. Therefore, in 2021, we began performing a Task Force on\nClimate-related Financial Disclosures (TCFD) gap analysis and will be\nconducting a scenario-planning analysis to examine which parts of\nour business are at highest risk due to climate change, and the costs\nassociated with them.\nThese potential risks are integrated into our business planning,\nincluding investment in reducing energy usage, water use and\ngreenhouse gas emissions (GHG).\nFor more information, please see GRI 305 on page 104. Our CDP\nWe have made it a priority to reduce our demand for energy, and\nClimate Change Questionnaire is available on CDP's website, which CDP\nhave established internal policies and practices focused on reducing\nhas aligned to the TCFD reporting recommendations.\nenergy use at our sites and minimizing GHG generation throughout\nthe Company. By taking these steps, we are not only minimizing\nGHG emissions but also reducing operating costs and mitigating 1 As defined by the Ellen MacArthur Foundation, “a circular economy is based on the\nprinciples of designing out waste and pollution, keeping products and materials in use,\nthe business impacts expected to be associated with future climate and regenerating natural systems.”\nchange requirements.\nOur Sustainability Capital Fund is used exclusively for sustainability\nprojects at our sites around the world that bring long-term value to\nthe Company and focus on carbon footprint, water use and solid waste\nGRI 201-3 Benefit plan coverage\nreduction. The fund allocates up to $12 million per year, which allows\nus to adopt low carbon technology, better positions us to respond\nOur compensation and benefits programs are rooted in maintaining\nto climate change and supports a more circular1 economy. Since\nour competitive position in the market by providing a comprehensive\n2015, our sites have completed more than 124 projects through the\nand valuable package to attract and retain a talented and diverse\nSustainability Capital Fund, which has avoided the production of an\nworkforce while building a supportive culture. Our compensation\nestimated 50,000 metric tons of carbon emissions per year.\nprograms include competitive base pay, short-term and long-term\nIn December 2021, we completed our inaugural issuance of a $1 billion incentives, and recognition awards. These programs target different\nsustainability bond, which was part of an $8 billion underwritten aspects of individual and Company performance. They are monitored\nbond offering. Our Company intends to use the net proceeds from the to ensure that they are competitive with those of other companies—\nsustainability bond offering to support projects and partnerships in our and appropriate for the markets in which we compete for talent.\npriority ESG areas and contribute to the advancement of the United\nOur health, insurance, retirement and wellbeing programs draw\nNations Sustainable Development Goals.\nfrom best practices to ensure quality, competitive value, financial\nManagement does not believe that expenditures related to our protection, and access to resources to help employees and their\nenvironmental sustainability initiatives should have a material adverse families live their lives well—no matter what that looks like for them.\neffect on our financial condition, results of operations, liquidity or Benefits vary based on region and country, employee group and status,\ncapital resources for any year. collective bargaining agreements and local legal requirements.\nFor more information on these benefits, please see GRI 401-2\non page 127.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 54"
  },
  {
    "page": 55,
    "source": "text",
    "content": "Indirect economic impacts Global burden of disease\nAs defined by the Global Burden of Disease (GBD) Visualization\ntools developed by the Institute for Health Metrics and Evaluation\n(IHME), the diseases that our products address rank high on the list\nGRI 203 Management approach of worldwide causes of illness, disability and death. Our research\ninto vaccines and infectious diseases seeks to address major burdens\nAccess to health care for priority diseases\nSASB 240a.1\nand in priority countries of disease that are prevalent in all countries, and our preventative\ntreatments could have the greatest impact in lower income countries,\nProducts on WHO’s List of Prequalified\nSASB 240a.2 where health care infrastructure may be limited or nonexistent.\nMedicinal Products\nPercentage change in: (1) average list price and Considering our pipeline, the list of products we currently market and\nSASB 240b.2 (2) average net price across U.S. product portfolio\nour external collaborations, we estimate that our Company is seeking\ncompared to previous year\nto address 71 percent of the top 20 global burdens of disease as defined\nPercentage change in: (1) list price and (2) net price by the IHME. This figure excludes road injuries, age-related hearing\nSASB 240b.3 of product with largest increase compared to loss and neonatal disorders. This number is lower in 2021 than in 2020\nprevious year due to spinoff of products to Organon in June 2021.\nFor more than a century, we have been inventing medicines and\nCompliance\nvaccines for many of the world’s most challenging diseases. We are\ncommitted to addressing unmet medical needs through innovative Ensuring compliance with applicable laws and requirements in\nresearch and development (R&D). R&D expenses in 2021 reflected all business areas is critical. As such, the stated objective of the\nrobust clinical development spending as well as increased investment Compliance Committee Charter within our research laboratories is\nin discovery research and early drug development. to ensure ongoing compliance through appropriate management\nstructure, processes and training.\nOur success is largely dependent on our continued ability to attract and\nretain highly qualified scientific, technical and management personnel, The Compliance Committee is composed of members of the Research\nas well as personnel with expertise in clinical R&D, governmental Leadership Team (RLT). Including the RLT in the Compliance Committee\nregulation and commercialization. ensures cross-functional awareness and ownership of ethics and\ncompliance at the senior-management level and throughout the whole\nWe have strategically located discovery centers in regions with active\norganization. As a result, compliance is focused not only on the conduct\nbiomedical research communities in California and Massachusetts,\nof clinical trials but well beyond it, helping to ensure robust oversight\nas well as principal sites outside of the U.S., including the United\nof effective policies and procedures, training, auditing and risk\nKingdom, Switzerland and China. These centers allow us to recruit\nmanagement, as well as sponsoring risk identification, prioritization\ntalented local scientists and facilitate collaboration with local academic\nand mitigation for all of Merck Research Laboratories (MRL).\ninstitutions and companies. These discovery sites complement and\nconnect with our strong R&D capabilities and expertise based at our The Compliance Committee promotes ethical science and provides\nNew Jersey and Pennsylvania sites. guidance to our employees within the research organization on our\nCompany’s standards and corporate policies, as well as necessary\neducation related to specific requirements applicable to the\nresearch community.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 55"
  },
  {
    "page": 56,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nClinical research IMPACT is a three-year pilot study that strives to improve patient\nenrollment, retention, minority participation and equitable access in\nOur Global Clinical Development organization is responsible for\noncology trials. We also have developed and implemented novel tools\nconducting clinical trials worldwide to evaluate the safety and efficacy\nand approaches intended to build relationships and reach potential\nof our products.\nstudy participants within their own communities (e.g., partnerships\nwith local pharmacies and mobile study sites).\nIn accordance with our Public Policy Position Statement on Clinical\nTrial Ethics, all investigational studies in human subjects are\nConsistent with ICH-GCP requirements, as part of the informed\nconducted in a manner consistent with laws, regulations and guidelines\nconsent process, clinical trial patients are made aware of the\nfor the protection of human subjects, including those issued by the\ncompensation and/or treatment available to them in the event of\nInternational Council for Harmonisation: Good Clinical Practice\na trial-related injury. They are also informed of the person(s) to\n(ICH- GCP). However, individual country regulations and guidelines\ncontact in the event of a trial-related injury. We maintain policies\nremain the primary determinant of specific requirements for the\nand procedures that address the costs of treatment of trial subjects\nconduct of medical research.\nin the event of trial-related injuries in accordance with applicable\nregulatory requirement(s).\nWe are committed to the study of appropriately diverse patient\npopulations—including underrepresented groups, women and children,\npeople of varying ages, sexual orientation and gender identities, various Genetic research\nsocioeconomic backgrounds and other characteristics—in our clinical\nThe rapid development of new technologies that interrogate variability\ntrials in all appropriate regions of the world. Currently we conduct our\nin human DNA and RNA, combined with powerful computing hardware\nclinical trials in more than 50 countries worldwide.\nand software, has made it practical to investigate genetic and genomic\ndeterminants for risk of human disease or predictors of human\nIn support of this commitment, we have implemented a number of\nresponse to drugs.\ninternal and external programs and processes over the past\nseveral years.\nWe conduct genetic and genomic research within our own clinical trials\nand in collaboration with external organizations that have collected\nInternally, we have a team of clinical trial operations experts focused\nhuman genetic and genomic samples and health data.\non promoting the inclusion of patients from diverse backgrounds\nand on identifying and implementing best practices in the conduct of\nWe also conduct genetic and genomic analysis of our clinical trial\nclinical trials globally. This begins with selection of clinical trial sites\nsamples, primarily to understand how genetic and genomic variation\nin communities serving underrepresented ethnic groups. We provide\nimpacts patient response to medicines. This enables us to communicate\nresources and training to increase awareness of the importance of, and\ninformation to regulatory authorities and prescribers that will improve\nbest practices for, inclusion of underrepresented populations in clinical\nthe use of our medicines and understand how genetics contribute to the\nresearch. Clinical research studies sponsored by our Company are also\nunderlying disease, which has the potential to identify new drug targets.\nbeing planned and conducted in a way that incorporates enrollment\nand other diversity-focused goals to help drive inclusion and access We obtain subject consent for use of genetic and genomic samples\nacross our programs with our clinical trial sites. in accordance with ethical principles of human-subjects research,\nwhich include respect for persons/autonomy, beneficence and justice,\nExternally, our Company continues to be a vocal contributor and\nconsistent with the Declaration of Helsinki, U.S. FDA requirements,\nparticipant in various partnerships and sponsorships intended to\nICH E6 Good Clinical Practices guidelines and the 1997 UNESCO\nconnect with, support and train more U.S.-based clinicians from\nDeclaration on the Human Genome and Human Rights. When\ndiverse backgrounds to help drive access to clinical research at the\ncollaborating with external organizations, we ensure that consent has\ncommunity level. We also co-sponsor the Improving Patient Access\nbeen obtained by individuals who have contributed DNA or RNA and/or\nto Clinical Trials (IMPACT) study at the Lazarex Cancer Foundation.\nhealth-related data to the organization via these same standards.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 56"
  },
  {
    "page": 57,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nUse of stem cells Academy of Sciences guidelines as well as those of the International\nSociety for Stem Cell Research.\nTogether with the scientific community, we believe that research using\nstem cells has the potential to help identify medicines, therapies and Our Regenerative Medicine Oversight Committee, which comprises\nvaccines to help treat, cure or prevent disease. both internal and external experts, oversees Company-sponsored\nresearch involving stem cells, including highly targeted research using\nMany of the most advanced scientific technologies in regenerative\nhuman embryonic stem cells and induced pluripotent stem cells. The\nmedicine involve animal or human embryonic stem cells. For more\ncommittee is responsible for ensuring that all projects involving stem\nthan a decade, we have been applying advances made in stem-cell\ncells adhere to our policies.\ntechnologies to support our research and development. The capacity\nof stem cells to differentiate into specific cell types underscores their For more information on our R&D efforts, please visit the\nversatility and utility, from early target validation and identification, to Research & Products page on our corporate website.\nscreening and testing of potential new therapeutics, disease-modeling\nand pre-clinical proof of concept.\nAccess to Health\nWe conduct research using stem cells in full accordance with all\nAs we pursue our core purpose to use the power of leading-edge\napplicable laws and regulations, and our own internal research policies.\nscience to save and improve lives around the world, we also work with\nOur research policy involving stem cells adheres to the U.S. National\nkey stakeholders to help ensure that our science advances health care\nand that our products are accessible and affordable to those in need.\nResearch and development 2017 2018 2019 2020 2021\nResearch and development expenses (in billions)1,2 $10.3 $9.8 $9.7 $13.4 $12.2\nEmployees involved in research activities (approximate)3 9,800 12,900 13,600 14,800 17,500\nNew Human Health products approved (U.S.)4 4 2 2 1 3\nNew Animal Health products approved (global) 18 14 15 18 16\nProducts in the pipeline and under regulatory review5 26 24 36 39 31\nTop 20 global burdens of diseases addressed by our products and pipeline6,7 88% 88% 100% 88% 71%\nEstablished significant external licenses and collaborations 55 64 78 123 92\n1 R&D expenses include a 2020 $2.7 billion charge related to the acquisition of VelosBio and a 2017 $2.4 billion charge related to the formation of a collaboration with AstraZeneca.\n2 The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements\nthrough the date of the spin-off and therefore are excluded from the 2019, 2020 and 2021 figures presented. Recast figures for 2017 and 2018 are not available.\n3 A change in methodology to ensure greater accuracy, together with a restatement of the Company’s Medical Research Laboratories organization in 2021 resulted in revised numbers of\nemployees from prior years.\n4 Approval of new products only. This does not include approvals for supplemental indications.\n5 Candidates in our Company’s research pipeline or under regulatory review as reported in the Company’s Form 10-K, filed on February 25, 2022. When candidates attain regulatory approval,\nthey are removed from this pipeline view.\n6 As defined by the Institute for Health Metrics and Evaluation (IHME) using GBD 2019 data excluding road injuries, age related hearing loss and neonatal disorders.\n7 This number is lower in 2021 than in 2020 due to spin-off of products to Organon in 2021 in categories of Lower back pain, Headache disorders and Other musculoskeletal.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 57"
  },
  {
    "page": 58,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nWe do this in several ways, including: When a drug or vaccine candidate with the potential to address\nsignificant public health burden in underserved health care settings is\n• Discovering and inventing medicines and vaccines that address\nidentified, the access planning process includes engaging all parts of\nvital global health needs where we can have the greatest impact,\nour enterprise, as well as external stakeholders, to identify the most\nnow and in the future\noptimal solution.\n• Making available a reliable, safe global supply of quality medicines\nand vaccines, and investing in solutions to enable timely access to\nOnce a product is approved, we commit to registration and availability\nour products in a responsible and sustainable manner\nof the product in all countries where clinical trials have been\n• Developing, testing and implementing innovative solutions that conducted, including LMICs. Products continue to be evaluated for\naddress barriers to access and affordability of our medicines their potential throughout their life cycle to account for changes in the\nand vaccines external environment.\n• Through partnerships, investment and innovation, applying our\nexpertise and investing our human and financial resources to Sometimes the evaluation of a candidate reveals barriers to access\naddress systematic barriers to access to health and health equity in an underserved setting. In these situations, the evaluation process\ncan inform our approach to strengthening health systems and\nOur multi-pronged, enterprise-wide approach to access is guided improving health equity. We recognize that addressing the complex\nby our Access to Health Guiding Principles, and is responsive to and multi-faceted challenges to accessing health care in LMICs\ninternationally recognized standards and priorities. requires the collaboration of multiple stakeholders. We actively seek\npartnerships to achieve solutions that enable access.\nSystematic evaluation to inform product access strategies\nOne example of our approach to early planning is our global access\nEmbedded within our research and development process, we\nstrategy for our Company’s investigational COVID-19 antiviral\nsystematically evaluate our candidates to identify the potential to\ncandidate. In the face of the global pandemic, and realizing our\naddress significant public health burden and unmet medical needs in\nopportunity to help meet a significant unmet medical need globally,\nunderserved health care settings. This evaluation process informs our\nincluding in under-resourced settings, we implemented a global\nproduct access strategies, with the goal of making our medicines\nstrategy to facilitate timely and widespread access. To accelerate broad\nand vaccines available to as many people as possible through\nglobal access, our comprehensive supply and access approach includes\nsustainable solutions.\nproducing millions of courses of our investigational COVID-19 antiviral\nTo facilitate this access, we undertake a systematic evaluation at candidate through our global network, which includes manufacturing\nthe onset of Phase 2 clinical studies to determine a candidate’s sites in nine countries across three continents.\npotential to meet unmet medical needs in low- and middle-income\nAdditionally, we have entered into advance purchase and supply\ncountries (LMIC). Our approach involves evaluating the level of disease\nagreements with the governments of several countries worldwide\nburden that exists, the availability of alternative medications and\nand are currently in discussions with additional governments. We have\nthe appropriateness of our candidates to improve public health. For\nsigned voluntary license agreements with multiple established Indian\ncandidates with significant potential in underserved settings, access\ngeneric manufacturers and the Medicines Patent Pool to facilitate\nplanning may start in the pre-clinical phase.\nthe availability of generic versions of our medicine to more than 100\nAdditionally, understanding where health system infrastructure low- and middle-income countries. Through our licensing agreements\nand funding mechanisms are in place is an important component with generics manufacturers and the Medicines Patent Pool, more\nof enabling safe and effective usage, which ultimately facilitates than three million courses of generic therapy have been delivered to\nmeaningful patient access. Our R&D Governance Committee more than 15 low-and-middle-income markets included in the licenses\nis accountable for the evaluation process, and all recommendations through March 2022. We’ve also allocated up to three million courses\nare reviewed by our Public Policy and Responsibility Council (PPRC), of therapy to UNICEF for low-and-middle-income countries.\nan internal cross-divisional forum of senior leaders.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 58"
  },
  {
    "page": 59,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nWe welcomed the Bill & Melinda Gates Foundation’s commitment of Solving affordability challenges through dedicated\n$120 million to accelerate access to generic versions of our medicine. sustainable access solutions\nThis commitment complements our voluntary license agreements with\nWe aspire to enable solutions and shape the ecosystem that delivers\ngeneric manufacturers and highlights the importance of actions from\nsustainable access to innovative medicines for patients. We collaborate\nmultiple stakeholders to effectively increase timely access to medicines\nwith different stakeholders, including private, governmental, multilateral\nfor patients globally.\nand non-profit organizations, to design and deliver solutions that address\nthe access challenges at the payer, provider and patient levels.\nMaintaining a global supply network\nOur approach is predicated on the belief that broadening access\nThrough our manufacturing and supply division, we strive to maintain\nrequires sustained effort and is best achieved through solving the\na compliant, reliable and highest-quality global supply network. Our\nunderlying challenges in the health care system that constrain access\nsupply chain is designed to ensure we operate a lean and efficient\nfor patients from care delivery to capacity and financing. We also\nnetwork that produces our medicines and vaccines to the highest\nbelieve that we exist within a wider ecosystem, comprising multiple\nquality, safety and environmental standards in full compliance with\nstakeholders, each playing a unique and varied role. Therefore, key to\nregulations and Good Manufacturing Practices (cGMPs) based on U.S.\nour approach is a focus on solutions and collaboration that help make\nand international requirements and industry best practices.\naccess to care affordable.\nThrough digitally enabled “end-to-end supply planning,” we are\nWe have focused on making this approach systematic. We have\ndigitizing our shop floors and conducting efficient and balanced\nestablished a framework, which is available to all our markets, for\nplanning decisions to maximize business results and deliver medicines\nassessing, designing and delivering practical solutions that solve\nand vaccines to customers, which include hospitals, retail outlets\naccess and affordability challenges. We have also established a\nand patients, when and where they need them. With both an\ndedicated internal unit to systematically accelerate innovation,\nenvironmental and socially conscious mindset, our facilities, along\ndevelop the relevant capabilities and capture learnings across various\nwith our external contractors, suppliers and partners, make up an\ncountries. Through this approach we have been able to accelerate the\nintegrated, interdependent global manufacturing network.\ndevelopment of innovation in patient access models and solutions to\nexpand the accessible population across the globe.\nWe also recognize that the policy environment is critical to solving\nAvailability1 2020 2021\naccess and affordability challenges. Therefore, we engage with\ngovernments, industry associations, trade and economic forums,\nLogistics partners with security 100% 100%\nthink tanks and academia to advocate for evidence-based policy\nrisk assessment completed,\nsolutions. For example, we are actively involved in the Asia-Pacific\nannually (Target: 100%)\nEconomic Cooperation’s (APEC) Health Financing initiatives including\nthe creation of a roadmap that outlines priorities, objectives and\nCountries2 around the world 78% 79%\ntargets for strengthening health care financing, sharing best\nreached annually with our\npractices from APEC economies and strengthening the dialogue\nproducts (Target: 75%)\nacross industry, governments and academia to diagnose and solve\nOrders shipped on time and in full 98.3% 98.3% pressing affordability challenges. Similarly, we are engaged in the\n(Target: 95%) Global Coalition for Value in Healthcare to accelerate the transition\nto value-based health care throughout the world. We also work\n1 Reporting on KPIs started with 2020 performance data. with organizations like ThinkWell and the Financial Times to study,\n2 As defined by the World Bank Country and Lending Groups. Includes only human document and advocate for policies that promote sustainable financing\nhealth products.\nfor immunizations and cancer care.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 59"
  },
  {
    "page": 60,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nOur current portfolio of projects is focused on dedicated sustainable\naccess solutions globally, inclusive of the U.S. and LMICs. These\nWe expand access to our products through dedicated,\nprojects are in various stages of development, from diagnosing\nmarket-based sustainable access solutions that expand\nthe access challenges to delivering solutions in the market.\nthe reach to at-need populations and patients—\nWe operate as an integrated Company across global, regional and including those in LMICs—taking into consideration\nmarket teams to address affordability through multiple initiatives. public health need, economic conditions and health\nThe goal is always consistent: helping to establish a more sustainable care infrastructure.\naccess environment that delivers broader and more equitable access\nto medicines and vaccines for people wherever they might be.\nFor example, one of the recurring access challenges in LMICs is the\nfinancing via supplemental medical insurance in China. This provides\npotentially high out-of-pocket costs for critical illness treatments.\nmuch needed optionality for the population and drives greater health\nRecognizing this issue, we have continued collaboration with reinsurers\ncare inclusion.\nand insurance companies in South Africa, Thailand and Indonesia\nto enable them to develop affordable health insurance products for As the reach of insurance products further expands, we expect\nthe population, including covering innovative cancer therapies. We major access hurdles to be solved and access to innovative cancer\nare also actively collaborating with public health authorities through therapies for patients widened in a commercially sustainable way.\na public-private partnership to provide access to immunotherapy This collaborative approach to addressing out-of-pocket costs\nAffordability 2019 2020 2021\nNumber of countries where dedicated affordability solutions have been initiated 40 40 NR\nNumber of people reached directly with innovative products through access strategies, NR NR 9.1\nsolutions and partnerships (in millions)*\nPeople reached with sustainable access solutions that enable access to innovative medicines NR NR 57.6\nand vaccines (in millions)*\nPeople reached globally through product donation and patient assistance programs 404 268 197\nand partnerships (estimate in millions)*1,2\nPatents filed in low-income countries, as defined by The World Bank in its country 0 0 0\nand lending groups classifications (annual)*\nNR: Not reported.\n* New key performance indicators (KPI) in this table starting in 2021 to provide more information on the reach of our access strategies, partnerships and solutions to support our Access to\nHealth goals.\n1 Estimate includes product donations through our Company’s Office of Social Business Innovation and patient assistance program.\n2 The significant decrease in people reached in 2020 and 2021 vs 2019 is due to postponed mass drug administration programs as well as shipping delays as a result of the COVID-19 pandemic\nin 2020 and 2021.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 60"
  },
  {
    "page": 61,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nreinforces our commitment to being part of a wider ecosystem, impact investing. To be most effective, where appropriate we align our\ncollaborating with others with complementary capabilities to investments with country and community-led priorities and partner\ntackle these challenges. Additional information on sustainable with governmental, multilateral and non-profit organizations.\nsolutions for innovative treatments can be found on the\nsustainable access website. Our investments are guided and approved by internal and external\nexpert advisory bodies, including an internal advisory board for our\nWe also recognize that in some environments, the challenge lies in corporate Foundation, an internal Impact Investing Council, an internal\nhaving resilient health care systems able to reach patients at the right Economic Inclusion, Workforce Development and Health Equity\ntime with the right intervention. That is why we also collaborate with Council and external expert advisory committees for the MECTIZAN®\nhealth care and service providers to understand challenges in the care Donation Program and Merck for Mothers.\npathway and help advance solutions that can establish a more efficient\nand effective health care system. Health equity investments and commitments\nOur efforts focus on utilizing our deep clinical understanding, In 2021, we invested $35.8 million in partnerships, programs and\nparticularly in oncology, to better understand inefficiencies in the impact investments that support health care capacity building and\npathway and the use of infrastructure and services, and to help address underlying barriers to access to health. We are improving\nsupport health care system efforts to achieve more impact with the cancer prevention, diagnosis and treatment, strengthening the\nsame or less resources. Through these efforts, health care systems vaccination ecosystem and increasing diversity in clinical trials to\nmight better ensure that people receive the care they need when they advance equitable health outcomes for all patients.\nneed it, whether to treat or prevent disease, while also better coping\nwith growing fiscal pressures. Addressing cancer disparity\nThrough a range of collaborations, we are strengthening cancer\nAddressing barriers to access prevention, care and support systems to help improve health equity\nPursuing health equity—addressing preventable differences in the in underserved communities. In the U.S., we have supported the\nburden of disease and health outcomes—is deeply embedded in our American Cancer Society’s (ACS) Get Screened Initiative aimed at\nDNA. Through partnerships, investment and innovation, we apply reducing existing disparities in cancer screening that have been\nour expertise and invest our human and financial resources to address exacerbated by the COVID-19 pandemic.\nsystemic barriers to access to health where we believe we can make\nThrough the CEO Roundtable on Cancer, we partner with Historically\nthe strongest contributions to health systems, communities and our\nBlack Colleges and Universities and Hispanic Serving Institutions in\npatients around the world. We provide this support in several ways,\n“Going for Gold” to help improve health equity, education, navigation\nincluding through philanthropic social investments, key initiatives and\nPatient assistance programs 2017 2018 2019 2020 2021\nPatients utilizing our U.S. Patient Assistance Programs1 244,000 233,000 239,000 189,500 130,002\n30-day prescriptions filled (in millions) 2.1 2.1 2.2 1.6 0.82\n1 Totals represent 2017–2021 volumes of our U.S. Patient Assistance Program. Volumes vary across years based on changes in covered product offerings and changes across the health care\nlandscape. Volumes in 2021 reflect a decline as a result of products transitioned to Organon.\n2 Overall volumes were impacted by products transitioned to Organon.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 61"
  },
  {
    "page": 62,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nand access in communities disproportionately affected by cancer. Our Globally, we collaborate with City Cancer Challenge Foundation to\nUnderstand Cancer Together website provides selected information improve equitable access to quality cancer care in nine cities around\nfrom various organizations that are experts in cancer to help patients the world by strengthening patient navigation, care coordination\nimprove their cancer health literacy and better partner with their and data capacity through the integration of digital platforms in\ndoctors to make informed decisions. To address disparities among health systems. And, in working with Go Further, we have created\nBlack women who are at increased risk of triple negative breast cancer a partnership that aims to reduce the incidence of cervical cancer in\n(TNBC), our Uncovering TNBC initiative sheds light on the challenges women living with HIV who reside in one of 12 African countries, which\nthey face and empowers women to advocate for themselves with their have some of the highest rates of HIV prevalence and cervical cancer\nhealth care team. incidence in the world.\nContent on this page was updated September 16, 2022.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 62"
  },
  {
    "page": 63,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nAdvancing clinical trial diversity In addition to measuring impact through our health equity target of\nreaching 30 million people in LMICs and U.S. underserved populations,\nWe are committed to the study of appropriately diverse patient\nprogress on internal efforts is tracked using a key performance\npopulations—including underrepresented groups, women and\nindicator dashboard that is reported into an internal Health Equity\nchildren, people of varying ages, sexual orientation and gender\nSteering Committee comprised of senior leaders. The KPI dashboard\nidentities, various socioeconomic backgrounds and other\nenables alignment, accountability, and transparency and acceleration\ncharacteristics—in our clinical trials in all appropriate regions of\nof efforts across the organization.\nthe world. Currently we conduct our clinical trials in more than\n50 countries worldwide.\nInvestments in capabilities building\nInternally, we have a team of clinical trial operations experts focused\nWe are making a commitment to our people, investing in our talent to\non promoting the inclusion of diverse patients and identifying and\nstrengthen their capabilities and evolve our ways of working. In 2022,\nimplementing best practices in the conduct of clinical trials globally.\nwe launched a $1 million Health Equity Catalyst Fund to empower\nThis begins with selection of clinical trial sites in communities serving\nteams at the local and regional levels to create solutions that promote\nunderrepresented ethnic groups. We provide resources and training\nmore equitable health outcomes and care experiences, particularly for\nto increase awareness of the importance of, and best practices for,\npopulations who are underserved, by engaging at the community level\ninclusion of underrepresented populations in clinical research. Clinical\nto remove barriers to care and/or strengthening health systems to\nresearch studies sponsored by our Company also are being planned and\ndeliver on high quality and accountable care.\nconducted in a way that incorporates enrollment and other diversity-\nfocused goals, to help drive inclusion and access across our programs We are investing in strengthening internal data capabilities to ensure\nwith our clinical trial sites. we can utilize and apply social determinants of health data to support\nthe design and rollout of effective solutions and partnerships, as well\nExternally, we continue to be a vocal contributor and participant in\nas track key metrics that help us to better understand the impact of\nvarious partnerships and sponsorships intended to connect with,\nour actions/investments. We are ensuring that our employees have\nsupport and train more diverse U.S. clinicians to help drive access\nthe latest knowledge and data through the development of training\nto clinical research at the community level. We also co-sponsor the\nresources, guidelines, tools and a new health equity learning network.\nImproving Patient Access to Clinical Trials (IMPACT) program of the\nLazarex Cancer Foundation, striving to remove financial barriers to\nVaccines\nimprove cancer health outcomes within marginalized communities\nto diversify trial enrollment and ensure equitable access to cancer\nKey accomplishments and milestones\nclinical trials. We have also developed and implemented novel tools and\napproaches intended to build relationships and reach potential study The total number of our vaccine doses that have been distributed\nparticipants within their own communities, including partnership with has increased significantly since 2013, and our global reach has also\nlocal pharmacies and mobile study sites. increased dramatically. In 2021, approximately 76 percent of our\nvaccines were distributed outside the U.S., up from 34 percent in\nIntegrating health equity across our business 2013. More than 73 million doses of two of our vaccines—GARDASIL®\n[Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18)\nOur approach to health equity is key to our ESG and Global Diversity &\nVaccine, Recombinant] and RotaTeq® (Rotavirus Vaccine, Live, Oral,\nInclusion (GD&I) commitments, and is reflected in how business units\nPentavalent)—have been distributed in Gavi-eligible countries through\nacross the enterprise and value chain are integrating health equity goals\n2021. This represents important progress toward ensuring that these\nand capabilities in their business strategies and performance objectives.\nvaccines reach people in low-income settings who are at high risk for\nThese efforts are guided by an enterprise Health Equity Strategic\ncertain vaccine-preventable illnesses.\nFramework that lays out clear goals, a roadmap and implementation\nplan that guides how we integrate health equity across our core business\nfunctions and practices.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 63"
  },
  {
    "page": 64,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nBy December 2019, ERVEBO® (Ebola Zaire Vaccine, Live) had been in those countries, while also ensuring that they remain affordable and\napproved by the U.S. FDA and conditionally approved by the European sustainable in the long term. In the short period of time since we made\nMedicines Agency, received WHO prequalification and been approved our price commitment to countries transitioning out of Gavi support,\nin two African countries, including the Democratic Republic of Congo numerous countries have taken advantage of the offer to introduce or\nand Burundi. As of April 2022, the vaccine has also been approved in continue existing national HPV vaccination programs.\nnine African countries, the United Kingdom and Switzerland.\nWe also remain actively engaged with Gavi on policy efforts to improve\nIn January 2021, our Company confirmed an agreement with UNICEF access to vaccines in Gavi-transitioned countries. We believe that our\nto establish the world’s first global Ebola vaccine stockpile with ERVEBO, pricing approach contributes to broader access to our vaccines while\nwhich represents a new and important tool in supporting future taking into account our need to continue investing in vaccine research,\noutbreak preparedness and response efforts. The stockpile inventory development and production.\nis being built over time and will be maintained by our Company.\nManufacturing and supply\nSince establishing the agreement to build the stockpile, we have been\nworking with UNICEF to deliver licensed doses. As of August 2022, In the last few years, countries around the world have enacted\nthe currently available doses of licensed vaccine in the stockpile is new or expanded vaccination programs. This has contributed to\nover 400,000. The global stockpile, governed by the International an unprecedented increase in global demand for vaccines. We are\nCoordinating Group on Vaccine Provision, will offer a critical, rapid- committed to increasing our capacity and supply capability.\nresponse tool to help combat future outbreaks of disease caused by\nOur commitment across the Company to invest in capital projects\nZaire ebolavirus.\nover five years has increased to $20 billion, with a portion dedicated\nto vaccines. We continue to invest in manufacturing and end-to-end\nAccess pricing\nsupply improvements in both capability and capacity to help ensure\nWe work with governments, international health and development a sustainable, reliable supply of quality and affordable vaccines to\norganizations, donor groups, nongovernmental organizations (NGOs) serve global needs. Our manufacturing division continuously works\nand others to support countries’ population health aims and help to improve manufacturing processes and reduce operating costs by\nimprove sustainable vaccination programs. increasing efficiency, minimizing procurement spending and improving\nsupply performance.\nOur commitment to helping protect global health by improving the\naffordability, availability, accessibility and use of our vaccines around Maintaining product quality is paramount. To provide high-quality\nthe world is fundamental to our business and overall purpose. We vaccines to people who need them, we manage our supply chain\noffer GARDASIL, which is indicated to help reduce the risk of certain through policies and procedures designed to keep the distribution\nHPV-related diseases later in life, at an access price that is significantly system secure. That is why we continue to explore potential strategic\nless than the value-based price in other countries. The access price for partnerships with other manufacturers to increase supply and promote\nvaccines is exclusive to the public sectors of the countries eligible for greater access in local markets.\nsupport from Gavi, the Vaccine Alliance.\nCOVID-19 manufacturing agreements\nIn 2015, we extended our current Gavi prices for GARDASIL through\n2025 to Gavi-graduated countries with a per-capita gross national In response to the COVID-19 pandemic, we entered multiple\nincome (GNI) not exceeding $3,200, as well as Gavi-accelerated agreements to support efforts to expand the manufacturing capacity\ntransition or fully self-financing countries that meet Gavi’s Exceptional and supply of COVID-19 medicines and vaccines. Under our agreement\nOpportunity criteria. This greatly assists countries that have with the Biomedical Advanced Research and Development Authority\ntransitioned out of Gavi support by facilitating access to these vaccines (BARDA), a division of the Office of the Assistant Secretary for\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 64"
  },
  {
    "page": 65,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nPreparedness and Response (ASPR) within the U.S. Department of WHO prequalification can facilitate product procurement by\nHealth and Human Services (HHS), we received funding that allowed international procurement agencies. WHO’s prequalification program\nus to adapt and make available a number of existing manufacturing covers medicines for HIV, tuberculosis (TB), malaria, neglected tropical\nfacilities for the production of COVID-19 vaccines and medicines. diseases, influenza, reproductive health and diarrhea, in addition\nto vaccines. In the absence of reliable national medicine authorities\nRegistration and prequalification that can certify that health care products meet required quality,\nsafety and efficacy standards, stringent regulatory authority and\nWe seek to ensure global access to our vaccines by obtaining and\nWHO prequalification can serve as a basis for quality assurance for\nmaintaining up-to-date product registrations around the globe. In order\nprocurement by international agencies and national programs in lower-\nto make our products available to the people who need them throughout\nincome countries.\nthe world, we registered 141 products and devices in 2021. The majority\nof these products were registered in LMICs in the Asia-Pacific, Central We have made efforts to address the unique needs of low-income\nand Eastern Europe, Middle East and Africa, and Americas regions. countries where the infrastructure and personnel to deliver immunization\nservices can be severely limited. Specifically, we focused on product\nIn addition to having our medicines and vaccines approved by stringent\nimprovements that included features such as vaccine vial monitors (VVMs)\nregulatory authorities, when relevant to enhancing access in LMICs we\nand use in controlled-temperature-chain conditions. In May 2022, we\nalso work to have certain medicines and vaccines prequalified through\nobtained WHO Prequalification for GARDASIL and GARDASIL 9 vaccines\nthe WHO prequalification process so that our products may be easily\ncompatibility for use outside the cold chain for up to four days. This helps\nobtained and distributed to underserved populations.\nenhance accessibility for hard-to-reach populations.\nThe table below summarizes the registration and WHO prequalification\nstatus of a select list of our vaccines.\nGARDASIL®\n[Human GARDASIL® 9\nPapillomavirus (Human ROTATEQ® M-M-R®II\nQuadrivalent Papillomavirus (Rotavirus (Measles,\nSelect vaccine (Types 6, 11, 16 9-valent Vaccine, Mumps & VARIVAX® ERVEBO®\nregistrations and and 18) Vaccine, Vaccine, Live, Oral, Rubella Virus (Varicella Virus (Ebola Zaire\nprequalification Recombinant] Recombinant) Pentavalent) Vaccine Live) Vaccine Live) Vaccine, Live)\nProduct is WHO Yes Yes Yes Yes Yes Yes\nprequalified\nDate of prequalification May 20, 2009 February 9, 2018 October 7, 2008 January 6, 2009 February 9, 2018 November 12, 2019\nApproximate number of 130 87 125 77 86 44\ncountries where product\nis registered\n(as of March 2022)\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 65"
  },
  {
    "page": 66,
    "source": "text",
    "content": "CONTINUED: GRI 203 | SASB 240a.1 | SASB 240a.2 | SASB 240b.2 | SASB 240b.3\nU.S. product pricing In our sixth annual report, our 2021 U.S. Pricing Transparency\nReport shows an average annual net price increase for our products\nWe have a long history of making our medicines and vaccines\nof 1.7 percent in 2021.\naccessible and affordable through responsible pricing practices and\nindustry-leading patient access programs. In 2017, we began disclosing The average annual list price across our portfolio increased by\ninformation about the price of our medicines in the U.S. 4.4 percent in 2021, and the Company’s gross U.S. sales were reduced\nby 43.5 percent as a result of rebates, discounts and returns.\nWe are working to bring our medicines and vaccines to more people\naround the world in ways that are as accessible and affordable as\nMedicine Assistance Tool (MAT)\npossible for the patients who need them.\nAs a demonstration of our commitment to helping low-income,\nWhile each individual situation varies based on factual circumstances\nuninsured patients gain access to our medicines and adult vaccines,\nand market dynamics, generally we consider:\nwe also participate in Pharmaceutical Research and Manufacturers\n• Value provided to patients of America’s Medicine Assistance Tool (MAT). MAT is a search engine\n• Value provided to health care systems designed to help patients, caregivers and health care providers\nlearn more about access resources available through the various\n• Unmet need\nbiopharmaceutical industry programs. MAT provides information to\n• Access approximately 900 public and private assistance programs that help\n• R&D sustainability those with financial need get access to their prescriptions.\n• Competition\nTo date, this tool has helped millions of Americans get free or reduced-\ncost prescription medicines.\nU.S. product portfolio pricing1,2 2017 2018 2019 2020 20216\nList price change (wholesale acquisition cost) vs. prior year3 6.6% 5.5% 4.3% 3.1% 4.4%\nNet price change vs. prior year4 -1.9% 2.99% 1.8% -0.9% 1.7%\nAverage discount5 45.1% 44.3% 43.7% 45.5% 43.5%\nNote: The amount of rebates, discounts and returns is estimated by the Company, and methodologies used may differ from methodologies used by other companies. This data is not audited\nand should be read in conjunction with the Company’s filings with the U.S. Securities and Exchange Commission.\n1 U.S. Product Portfolio includes human health pharmaceutical and vaccine products marketed by the Company, excluding partnered products. The product sales utilized in the analysis\nrepresent ~97 percent of the total U.S. Product Portfolio in 2010 and approached 100 percent of coverage in 2021. 2021 values exclude the impact of LAGEVRIOTM given all revenue was\nthrough the U.S. Emergency Use Authorization (EUA).\n2 Annual percent change vs. prior year was calculated at a product level and weighted across the Company’s U.S. Product Portfolio.\n3 Represents the year-over-year change in the average list price or wholesale acquisition cost (WAC).\n4 Represents the year-over-year change in average net price, which is WAC less rebates, discounts and returns.\n5 Weighted average annual discount is calculated by dividing annual rebates, discounts and returns by annual gross sales.\n6 2021 values exclude the impact of our Organon portfolio; prior year values have not been restated.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 66"
  },
  {
    "page": 67,
    "source": "text",
    "content": "GRI 203-1 Infrastructure investments and services supported\nGRI 203-2 Indirect economic impacts\nProduct registration 2017 2018 2019 2020 2021\nNew product and device registrations (annual)1,2 143 124 97 79 141\nProducts submitted that have achieved WHO prequalification 13 13 13 13 7\n(cumulative)3,4,5\nNumber of patent applications filed in low-income countries6 NR NR 0 0 0\nNR: Not reported.\n1 Data include new products and new indications.\n2 Data for all years have been updated based on a tracking system upgrade that corrected miscounts in prior years.\n3 Three products previously reported are no longer part of the Company’s product portfolio due to the Organon spin-off in 2021.\n4 The three GARDASIL products that had been previously reported separately are reported as one product starting in 2021.\n5 CRIXIVAN® (indinavir sulfate) was removed from our product list in 2019 and is no longer included in the total number of products that have achieved WHO prequalification.\n6 Countries classified as low-income countries in the 2019 World Bank Country and Lending Group classifications.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 67"
  },
  {
    "page": 68,
    "source": "text",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nBelow is a list of products that have been prequalified by WHO as of April 1, 2021.\nProducts prequalified by WHO International Nonproprietary Name (INN) Date of prequalification\nVaccines\nMMR-II® Measles, Mumps, Rubella Virus Vaccine Live January 2009\nROTATEQ® Rotavirus Vaccine, Live, Oral, Pentavalent October 2008\nGARDASIL® Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, May 2009\nRecombinant (including a VVM)\nHuman Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, October 2014\nRecombinant (two-dose regimen to support its programmatic\nfeasibility in developing countries)\nHuman Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, May 2016\nRecombinant (compatibility for use for up to three days in a\ncontrolled temperature chain to facilitate its administration\nin high-temperature, low-cold chain infrastructure areas of\ndeveloping countries)\nGARDASIL®9 Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, February 2018\nRecombinant (including a two-dose-regimen variation)1\nVARIVAX® Varicella Virus Vaccine Live February 2018\n(first varicella vaccine to receive WHO prequalification)\nERVEBO® Ebola Zaire Vaccine, Live November 2019\nHIV/AIDS treatments\nSTOCRIN® Efavirenz (600mg tablet, Oral Solution 30mg) May 2006\nEfavirenz (50mg tablet, 200mg tablet) May 2008\n1 Not currently available through UNICEF procurement; awaiting Vaccine Vial Monitor (VVM).\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 68"
  },
  {
    "page": 69,
    "source": "text",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nLong-standing access initiatives\nWe have made substantial contributions to strengthening health\nsystems and access to health through long-standing key initiatives.\nThese initiatives include Merck for Mothers, the MECTIZAN®\nDonation Program and our Medical Outreach Program (MMOP).\nMerck for Mothers\nMerck for Mothers is our $650 million global initiative to help create\na world where no woman has to die while giving life. For a decade\nand counting through Merck for Mothers, we have brought Merck’s\nscientific and business expertise to help improve maternal health\noutcomes. Our efforts are focused on generating fresh thinking and\ninfusing new approaches to help end the longstanding challenge of\nmaternal mortality. We focus on strengthening health systems to\nsustain the delivery of high-quality maternity care services that benefit\nwomen and their communities. With our grantees and collaborators,\nwe are improving health systems for women today and for the long\nterm by advancing quality standards, catalyzing solutions that respond\nto community needs and harnessing private sector innovations for\nmaternal health.\nFor more information, please visit the Merck for Mothers website.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 69"
  },
  {
    "page": 70,
    "source": "text",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nThe MECTIZAN Donation Program\nThe MECTIZAN Donation Program (MDP) is the longest-running\ndisease-specific drug donation program and partnership of its kind and\nis widely regarded as one of the most successful public-private health\ncollaborations in the world. MDP operationalizes the commitment\nwe made 35 years ago to donate MECTIZAN for the treatment of\nonchocerciasis (also known as river blindness) to all who need it, for\nas long as needed. Since then, the program has expanded to include\nadditional commitments to donate MECTIZAN for the treatment of\nlymphatic filariasis. Since the program’s inception, we have donated\nmore than four billion MECTIZAN treatments. In addition to providing\ndirect access for communities in need of treatment, the program has\nmade significant impacts on health systems in some of the hardest-to-\nreach communities.\nFor more information on our efforts, please see the MECTIZAN story\non Merck.com.\nMECTIZAN Donation Program 2017 2018 2019 2020 2021\nDirect financial investment in the program (in millions)1, 2 $3.10 $2.20 $3.10 $2.74 $1.88\nTotal treatments approved (in millions) 300 346 403 417 364\nTreatments approved for river blindness (in millions) 97 111 131 139 105\nTreatments approved for lymphatic filariasis (LF) in river blindness 89 140 141 141 95\nendemic countries (in millions)\nTreatments approved for joint river blindness and LF programs (in millions) 114 83 70.7 75 101\nTreatments approved for lymphatic filariasis (LF) in countries N/A 12 60 62 63\nnot endemic for river blindness2\nRiver blindness endemic countries where elimination of LF 1 1 2 3 3\nhas been validated by the World Health Organization (Target: 30)\nLatin American countries where the elimination of river blindness 4 4 4 4 4\nhas been verified by the World Health Organization (Target: 6)\nN/A: Not available.\n1 Direct investment includes operational support and grants.\n2 F ollowing our Company’s commitment in 2017 to expand the donation of Mectizan to support the implementation of triple-therapy for the elimination of LF in certain settings,\nthe Mectizan Donation Program expanded in 2018 to include donations for LF elimination in countries not endemic for river blindness.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 70"
  },
  {
    "page": 71,
    "source": "text",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nMedical Outreach Program\nOur Company’s Medical Outreach Program (MMOP) is the primary\nmeans through which we donate pharmaceuticals and vaccines\nfor humanitarian assistance in the developing world and in support\nof disaster relief worldwide. The MMOP helps expand access to\nour products, particularly in developing countries, by donating\npharmaceuticals and vaccines to a limited number of qualified,\nU.S.- based NGO partners. The scope and reach of the MMOP varies\nfrom year to year and is influenced by changing medical needs in\ndeveloping countries, the quantity of our medicines available for\ndonation and the unpredictable nature of emergencies or disasters.\nFor more information, please visit the MMOP page on our\ncorporate website.\nDisaster relief\nWe are committed to supporting communities around the world that\nare affected by natural disasters. We look to local authorities and\nhumanitarian relief agencies to first assess need and then respond in a\ntimely, coordinated manner. We provide aid through financial and product\ndonations to meet the immediate needs of affected communities.\nMedical Outreach Program (MMOP) 2017 2018 2019 2020 2021\nCountries and territories reached by the MMOP1 62 72 56 46 56\nEstimated number of people reached2,3 376,300 349,570 457,520 283,100 138,900\n1 Distribution of product by country is managed and provided by third party partners who provide the related reporting.\n2 Estimated figures, which assume all product reached patients, are based on converting volume of medicines and vaccines donated. Conversion factors for this estimate were developed using\na combination of QuintilesIMS SMART Data and U.S. product information found on our product website.\n3 Decline in patients reached in 2020 and 2021 primarily due to the decreased availability of certain products offered for donation because they moved to Organon in the 2021 spin-off.\nDisaster relief 2017 2018 2019 2020 2021\nTotal giving value of disaster relief contributions $23.9 $10.2 $16.7 $20.3 $9.0\n(cash and products, in millions)1, 2\n1 Support provided through the Office of Social Business Innovation.\n2 We set the value of our product donations based on the U.S. wholesale acquisition cost.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 71"
  },
  {
    "page": 72,
    "source": "text",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nAddressing barriers to health 2017 2018 2019 2020 2021\nHealth care workers trained through major programs and 74,000 67,000 68,000 78,000 99,000\npartnerships (estimate)1\nAnnual investment in partnerships, programs and impact $40 $37 $63 $49 $36\ninvestments that support health care capacity-building and\naddress underlying barriers to access to health (in millions)1,2\nPeople reached through investment in partnerships, programs 311 357 422 285 212\nand impact investment that support health care capacity-building\nand address underlying barriers to access to health1,2,3\n(estimate in millions)\nInvestment in patient-and-provider education programs $90 $115 $102 $96 $90\n(estimate in millions)\n1 Represents investments made by our Office of Social Business Innovation.\n2 Support provided through the Office of Social Business Innovation.\n3 The decrease in people reached in 2020 and 2021 is due to postponed mass drug administration programs as well as shipping delays as a result of the COVID-19 pandemic.\nPhilanthropic social investments innovative programs and partnerships to improve the health and\nwellbeing of people around the world. Through these programs, we\nOur philanthropic investments help advance health equity around the\nbelieve that by working closely with others—governments, donors,\nworld by addressing the barriers that many individuals face in seeking\npatient groups, health care professionals, nonprofit organizations,\nand receiving high-quality health care.\nacademic institutions, multilateral agencies and the private sector—\nwe can help build stronger health systems that provide better and more\nOur approach to these investments is guided by several key principles:\nequitable care.\nmeeting critical global health needs where we can have a meaningful\nimpact; promoting health equity by helping to reduce health disparities\nOur Foundation has invested in programs that help people living with\nin underserved communities; collaborating with diverse partners\nchronic conditions, including cancer, receive high-quality health care.\nacross sectors to build healthier, stronger communities; and leveraging\nOver the past five years, we have supported efforts to increase timely\nour range of resources (financial, product and expertise) to improve\naccess to patient-centered care and reduce disparities in cancer care\npopulation health outcomes.\nacross the U.S. through the Alliance to Advance Patient-Centered\nCancer Care. This $15 million initiative supported evidence-informed,\nEstablished in 1957, our Foundation is funded entirely by the\nmulti-faceted programs to enhance the delivery of equitable cancer\nCompany and is our chief source of financial support for qualified,\ncare in underserved communities across six U.S. cities.\neligible nonprofit organizations whose programs align with our\nphilanthropic priorities. Our Company and Foundation support\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 72"
  },
  {
    "page": 73,
    "source": "text",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nBuilding on the successes of the Alliance to Advance Patient- Our community engagement programs aim to strengthen communities\nCentered Cancer Care, the Foundation launched a new U.S.-based where our employees live and work by helping address critical health\ninitiative—Alliance for Equity in Cancer Care—in 2022 to address and social needs. Our Neighbor of Choice (NOC) grants program\npersistent disparities across the cancer care continuum and improve supports the work of local nonprofit organizations dedicated to\nthe delivery of high-quality, culturally-responsive care in underserved promoting the wellbeing of community residents in areas where we\ncommunities. With a $20 million commitment over five years, the have a major presence.\nFoundation will support the development and implementation of\ninnovative, comprehensive cancer care programs that can improve Additionally, our Partnership for Giving (P4G) matching gift program\npatient outcomes and help ensure equitable care by addressing access doubles the donations made by employees in the U.S. and Puerto\nbarriers related to social determinants of health. Rico to causes that are important to them. Through a dollar-for-dollar\nmatch of employee contributions, our Foundation supports nonprofits\nThe Foundation also supports programs that aim to improve the that promote a healthier society, advance education, foster the arts,\ndelivery of cancer care in low- and middle-income countries. Through address the welfare of animals and preserve the environment.\nan approximate $2 million grant over five years, the Foundation\nis supporting the American Cancer Society to establish patient\nnavigation programs in resource-limited settings in sub-Saharan\nAfrica and develop a toolkit to help other countries adopt navigation\nprograms as part of delivering comprehensive cancer care.\nFor more information on our philanthropy programs, please visit\nthe Philanthropy page on our corporate website.\nFor information on philanthropic programs specific to our Animal\nHealth business please visit our Animal Health website.\nWe also recognize that our success depends in large part on our\nrelationships and interactions with local communities, including\ncommunity leaders, nonprofit organizations, local businesses, schools,\nelected officials and local media. The communities where we operate\nare home to our workforce as well as many of our suppliers. It is critical\nto understand the concerns and needs of our communities and address\nlocal challenges so that we can help build stronger communities and\nsupport the sustainability of our business.\nWe contribute to the economy of local communities directly and\nindirectly through employment, training, support of local suppliers,\nlocal R&D and paying taxes. We also strive to have a positive impact\non communities by protecting the environment, maintaining safe\noperations and respecting human rights.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 73"
  },
  {
    "page": 74,
    "source": "text",
    "content": "CONTINUED: GRI 203-1 | GRI 203-2\nGrants and contributions 2017 2018 2019 2020 2021\nGrants and contributions (total cash, in-kind and product) $2,722 $2,793 $3,096 $2,988 $1,849\n(estimate in millions)1,2\nCash grants and contributions (estimate in millions) $94 $84 $82 $104 $102\nProduct donations through U.S. Patient Assistance Program $1,112 $1,242 $1,460 $1,603 $1,455\n(in millions)\nProduct donations for ex-U.S. programs and U.S. disaster relief $1,513 $1,464 $1,550 $1,280 $284\n(in millions)2,3\nValuation of employee volunteer time (in-kind, in millions)4,5 $3.2 $3.1 $4.1 $0.9 $3.5\n1 Total contributions for 2021 include approximately $4.9 million for in-kind donations of PPE and other equipment in response to COVID-19 pandemic.\n2 In 2021, we stopped reporting on the market value of donated MECTIZAN, leading in large part to a decrease in our overall reporting of the value of product donations for ex-U.S. programs.\n3 Includes our Medical Outreach Program, the MECTIZAN Donation Program, and MSD division and subsidiary donations.\n4 Includes valuation of volunteer time for only those employees who participated in the MSD Fellowship for Global Health program and our Pro Bono Legal and other skills-based\nvolunteer programs.\n5 2020 decrease in employee volunteering valuation was due to the temporary suspension of the MSD Fellowship for Global Health Program and decreased in-person volunteering as a\nresult of COVID-19.\nPartnership for Giving (P4G) 2017 2018 2019 2020 2021\nTotal contribution (in millions)1, 2 $25 $22 $15.1 $19.3 $18\nNumber of organizations that benefited3 8,770 7,350 5,645 6,468 5,757\nNumber of employee participants4 8,302 6,503 5,083 5,396 5,370\n1 Total contribution includes Foundation matching funds for Dollars for Doers and P4G matching gift programs, and 2021 active-employee participant funds donated through the P4G Direct\nGiving program.\n2 2020 increase is largely due to increase in employee giving and matching gifts to support COVID-19 response efforts.\n3 Includes organizations receiving funds through the P4G matching gift and Dollars for Doers programs.\n4 Includes active employee participants in the P4G matching gift program.\nFor more information on access and pricing, see GRI 203 on page 55.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 74"
  },
  {
    "page": 75,
    "source": "text",
    "content": "Procurement practices Designed in collaboration with Drexel University and Diversity Alliance\nfor Science (DA4S), this experiential development program focuses\non application, and is supported by evidenced-based research and\npractitioner-industry experience. Participants have an opportunity to\nengage with Drexel University faculty, their peers and organizational\nGRI 204 Management approach\nleaders from our Company in thought-provoking, facilitated discussion\nthat enhances self-reflection and personal development while building\nGlobal Economic Inclusion & Supplier Diversity relationships across the broader community network.\nGlobal Economic Inclusion & Supplier Diversity (EI&SD) is integrated The ALP integrated program modules support an overarching theme\ninto our overall Global Diversity & Inclusion (GD&I) strategy and of growing and scaling small and/or diverse businesses by building\nsupports our corporate aspiration. The EI&SD Center of Excellence the leadership abilities and business acumen of diverse business\n(CoE) is a member of the GD&I Business Consortium, where EI&SD is owners. Led by an interdisciplinary faculty and subject-matter-expert\none of four target areas focusing on: team, each module provides an experiential and applied approach to\nexecutive development.\n• Increasing business performance through diversity and inclusion\n• Creating a competitive business advantage Topic areas include:\n• Attracting and retaining top talent\n• Leadership, Communication • Financial Reporting, Planning\n• Driving shareholder value and Teams and Budgeting\n• Building Personal Brand and • Short-term and Long-term\nEI&SD is the epicenter of our Company’s diverse and inclusive\nStorytelling Business Decisions\nprocurement practices. We create economic opportunities for\n• Strategic Networking • Intersecting Finance and\nunderrepresented communities by procuring products and services\nOperations\nfrom minority-; women-; veteran-; lesbian-, gay-, bisexual- and • Digital Presence and Strategy\ntransgender- (LGBT); and disability-owned enterprises. • Customer Digital Journey • Operations and Production\nPlanning\nOur goals go beyond the amount of dollars we spend with small- • Digital Media Metrics and\n• Purchasing and Contract\nMeasurement\nand diverse-owned businesses, as we focus on the growth and Management\ndevelopment of our suppliers to drive economic impact and value\ndelivery to our Company. We are committed to supporting the small\nRequest for Proposal Culminating\nand diverse businesses that are the economic engine of growth\nCapstone Challenge\naround the world through global economic inclusion.\nThe ALP concludes with a Request for Proposal (RFP) Culminating\nAdvanced Leadership Program Capstone Challenge. Participants use the RFP portfolio elements they\nhave been building throughout the program to prepare and present\nfor Diverse Suppliers\ntheir business to the challenge panel. The RFP Challenge offers an\nHigh-performing businesses not only build diverse workforces, but invaluable experience through the coaching and feedback participants\nalso effectively leverage talent to fully realize diverse perspectives. receive on their presentations and overall performance.\nPart of leveraging diverse talent involves partnering with suppliers\nthat understand how to lead and motivate others to achieve common Participants also complete a customized Drexel LeBow leadership\ngoals, communicate strategies effectively and make sound financial assessment, which provides them with an individualized report used to\ndecisions. The Advanced Leadership Program for Diverse Suppliers guide their leadership and development plan.\n(ALP) provides an executive development opportunity for diverse\nIn 2021, we had 19 diverse suppliers graduate from our inaugural\nbusiness owners to enhance their leadership and business acumen\ncohort. We are proud to continue with this program in 2022.\nto strengthen and grow their business.\nMerck ESG Progress Report 2021/2022 Overview PerfGoRrI/mSASaBn: cGeeneral disclosures Economic Environmental Social Indices 75"
  },
  {
    "page": 76,
    "source": "text",
    "content": "CONTINUED: GRI 204\n2021 Economic Inclusion Virtual Lab Performance\nThe challenges posed by the COVID-19 pandemic haven’t changed our In 2021, diverse spend represented 12 percent of our total procurement\ncommitment to economic inclusion and supplier diversity. Instead, spend, exceeding our corporate goal in spend with minority-owned,\nthey’ve continued to inspire innovation. women-owned, veteran-owned, LGBT-owned and disability-owned\nbusiness enterprises.\nThe Economic Inclusion Virtual Lab is an evolution of our Virtual\nBusiness Opportunity Fair. The Economic Inclusion Virtual Lab was\na successful new approach to reach and teach diverse suppliers\ninterested in growing capacity and accessing procurement\nopportunities. Even during times like these when in-person contact $2.9 billion\nis limited, we continued our commitment to developing relationships\nwith scalable, sustainable diverse suppliers, which positively impacts in spending with diverse\nthe communities in which we all live and work. suppliers globally\nAttendees of the virtual events included nearly 550 diverse suppliers,\npartners and advocacy representatives from the U.S., Puerto Rico,\nCanada, Brazil, Mexico, Colombia, the United Kingdom, Germany,\nIndia, China, Vietnam and South Africa. We also had senior leader\nrepresentation from Latin America and Asia-Pacific engaging with\nattendees of the Virtual Lab. The event included webinars, speaker\nsessions, panel discussions and a virtual tradeshow. Throughout the\ncourse of the event, attendees engaged in over 1,900 chats connecting\nsuppliers, our procurement specialists and advocacy groups. This\nevent was recognized as “2021 Best DIY Virtual Event” by Notified,\nthe world’s only communications cloud for events, public relations\nand investor relations to drive meaningful insights and outcomes.\nSupplier diversity (in millions) 2017 2018 2019 2020 2021\nDiverse-supplier spend: Global1 N/A N/A N/A N/A $2,858\nDiverse-supplier spend: U.S. $1,962 $2,111 $2,433 $2,270 $2,374\nSmall-business spend: U.S.2 $802 $973 $979 $775 $1,027\nN/A: Not available.\n1 Starting in 2021, our reports include global spend data.\n2 The acquisition of small suppliers may have impacted their small business status and therefore affected the small business spend reflected above.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 76"
  },
  {
    "page": 77,
    "source": "text",
    "content": "CONTINUED: GRI 204\nImpact spend in the U.S.1,2\n$2.374 billion $5.0 billion\nspending with diverse suppliers economic impact through supplier diversity\n31,815 $1.4 billion\njobs supported through small and diverse suppliers earnings through jobs created/sustained\n1 Based on 2021 data.\n2 Billion Dollar Roundtable Economic Impact Study. University of Washington, Foster School of Business.\nBillion Dollar Roundtable In addition to the Billion Dollar Roundtable, we work in partnership\nwith others, including:\nOur ongoing economic inclusion and supplier diversity efforts will\nenable us to continue our membership in the Billion Dollar Roundtable • Disability:IN\n(BDR), an exclusive industry organization that recognizes and • Integrare—Integrare Centro de Integração de Negócios (Brazil)\ncelebrates corporations that achieve spending of at least $1 billion with\n• LGBT-owned Business Certification in Canada (CGLCC)\nminority-, women-, veteran-, LGBT- and disability-owned enterprises\n• Minority Supplier Development Council UK (MSDUK)\nheadquartered in the U.S. and globally.\n• Minority-owned Business Certification in Canada (CAMSC)\nOur membership in the BDR allows us to share and access best\n• National LGBT Chamber of Commerce (NGLCC)\npractices in supply chain diversity excellence with other organizations\nthat have also achieved this status. As part of our 35 years of inclusion • National Minority Supplier Development Council (NMSDC)\nand impact, we hosted the 2022 Billion Dollar Roundtable Summit • National Veterans Business Development Council (NVBDC)\nwith the theme, “The Future is Now: Supplier Diversity as a Force of\n• United States Hispanic Chamber of Commerce (USHCC)\nSustainability, Economic Equality and Societal Impact.” The Summit\n• United States Pan Asian American Chamber of Commerce (USPAACC)\nprovided another opportunity to chart a course for the bold and\ntransformative steps which are urgently needed to ensure we are • South Africa Supplier Diversity Council (SASDC)\noptimizing positive economic impact to some of our most distressed • SupplyNation\nareas, share best practices and encourage global partners to continue\n• WeConnect International\nto deliver on our purpose.\n• Women Business Enterprise National Council (WBENC)\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 77"
  },
  {
    "page": 78,
    "source": "text",
    "content": "CONTINUED: GRI 204\nAnticorruption\n377,293 8\nmeals served NGOs supported\nGRI 205 Management approach\nOur Company is built on its reputation for ethics and integrity forged\nwith health care professionals (HCPs), patients and other stakeholders.\n2021 meal program for Bribery and corruption are illegal, tarnish our reputation and undermine\npublic trust. Offering or paying bribes or kickbacks is against the laws of\nunderrepresented communities\nthe markets where we do business.\nWhen the COVID-19 pandemic hit, our cafeterias stepped\nWe are committed to observing the laws and regulations that govern\nup to serve people in need. A meal distribution program that\nour operations and activities wherever we do business. To that end,\nstarted at the beginning of the pandemic continues to deliver\nwe maintain policies, procedures and processes that apply to Company\nthousands of meals a week to underserved communities\nactivities involving transfer of value (TOV), including TOV to HCPs\nthrough nonprofit organizations serving communities in New\nand third-party intermediaries that perform agreed-to services on\nJersey and Pennsylvania, such as:\nour behalf.\n• Raphael’s Life House\nWe have a well-established global ethics and compliance program that\n• New Community Harmony House\nis consistent with the International Federation of Pharmaceutical\n• St. Johns Hospice\nManufacturers & Associations (IFPMA) Code of Practice requirements,\n• MTN Organizations, Inc. as well as with other applicable regional or country industry codes of\n• City Team Chester conduct, including those issued by the Pharmaceutical Research and\nManufacturers of America (PhRMA) and the European Federation of\n• Community Food Bank of New Jersey\nPharmaceutical Industries and Associations (EFPIA).\n• The Hoboken Shelter\nOur Board of Directors and senior management, including the Chief Ethics\n• DePaul USA\nand Compliance Officer, provide the foundational elements of leadership,\naccountability and structure to oversee the Company’s global ethics and\ncompliance program. The Chief Ethics and Compliance Officer reports\nFor more information on our procurement practices and supplier directly to our CEO, and provides regular updates to senior leaders and\ndiversity, please also see GRI 102-9 on page 30, GRI 308 on page 122 the Audit Committee of the Board of Directors on key indicators of ethical\nand GRI 405 on page 148. culture and compliance and risk trends. This reporting structure supports\ntransparent and independent communication of relevant risk information\nrelating to ethics and compliance issues.\nOur Company’s anti-bribery/anticorruption program and policies give\nemployees (and third-parties with whom we engage) the awareness,\nknowledge and resources to operate with integrity and comply with\napplicable laws and regulations, and to understand that we will not\ntolerate any act, or even the appearance, of impropriety.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 78"
  },
  {
    "page": 79,
    "source": "text",
    "content": "CONTINUED: GRI 205\nOur corporate anticorruption policy prohibits the offer, promise or giving Training is an important part of creating a strong ethics and\nof any payment or benefit at any time to an individual or entity for the compliance culture. To ensure that all employees understand our\npurpose of improperly influencing decisions or actions with respect ethical expectations and principles, we provide an annual ethics and\nto our business. The policy also prohibits any act that may give the compliance training series that includes relevant content to enable\nappearance of offering anything of value for a business advantage. It employees to perform with integrity and to make appropriate value-\napplies to direct engagements (i.e., those conducted by our Company) based decisions in the course of their work.\nas well as to indirect engagements (i.e., those managed through a third-\nIn 2021, more than 99 percent of our employees completed assigned\nparty intermediary or partner). There are additional divisional policies\ntraining on four specific modules:\nreinforcing these principles in connection with certain activities.\n• Code of Conduct\nOur Business Partner Code of Conduct presents similar and consistent\n• Speaking up\nprinciples for our business partners. It states that business partners\nshall not offer pay, ask for or accept anything of value—or give the • Anti-bribery and anti-corruption\nappearance that they do—in order to improperly influence decisions\n• Privacy\nor actions with respect to any Company business or government\nactivities. We expect all our business partners to adhere to these Supplemental training on anti-bribery and anti-corruption is provided\nprinciples and operate in full compliance, including maintaining for employees who engage with non-U.S. government officials. As\nprocesses and procedures to prevent and detect corrupt activities. our Company is headquartered in the U.S., with a global footprint,\nour employees in the Human Health Division outside of the U.S. are\nmade aware of the implication of statutes like the Foreign Corrupt\nPractices Act.\nGRI 205-2 Communications and training on anticorruption\nEmployees in the Human Health Division in the U.S. are also required\nto understand, among other things, their responsibilities under the\nAnti-Kickback Statute, the U.S. Prescription Drug Marketing Act and\nAnnual ethics and policy certification applicable FDA promotional regulations.\nAn important component of our corporate ethics and compliance\nprogram is our annual ethics and policy certification. The annual\nreview process requires selected employees to certify adherence to\nthe Code of Conduct and corporate policies on preventing bribery and\n>99%\ncorruption, antitrust-law compliance, conflict of interest and insider\ntrading. These employees are also expected to regulate their outside\nemployees trained on the\nactivities to avoid any conflicts of interest and to certify, in writing,\nEthics and Compliance\nwhether actual or potential conflicts of interest exist. Where potential\ntraining series\nconflicts are identified, the Office of Ethics will work with management\nto take actions to mitigate the potential conflict.\nIn addition, U.S.-based (including Puerto Rico) employees must certify\ncompliance with our policy on the effects of exclusions, debarments,\nsuspensions and health care-related criminal convictions, reporting\nand screening. The annual compliance certification process is\nsupplemented by periodic market and regional risk-based discussions\nand ongoing risk data monitoring.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 79"
  },
  {
    "page": 80,
    "source": "text",
    "content": "Anti-competitive behavior Our ethics and compliance program seeks to address and prevent\ninappropriate practices, and we evaluate our policies and practices as\nappropriate. Our practices are monitored, and compliance is enforced,\nto ensure that our interactions with customers and consumers do not\ninclude making unsubstantiated competitive claims.\nGRI 206 Management approach\nAlso, a part of the business requires the Company to communicate\nOur Company believes that our customers—and society as a whole— with policy makers or other stakeholders to address certain gaps in\nbenefit from fair, free and open markets. While ours is a competitive a market and promote patient access. In such interactions, we are\nindustry where it is important that we compete aggressively, it is careful not to develop tactics aimed at preventing or delaying access\nequally important that we do so fairly, legally and based on the merits of generic products into the market and such communications are\nof our products and services. governed by our marketing communications principles.\nOur interactions with customers, suppliers and competitors are\ngoverned by antitrust and competition laws and corporate policies. We\nenforce these external and internal standards through our ethics and\ncompliance program.\nWe recognize that our reputation for integrity, trust, honesty and\nfair dealing continues to be dependent on our ethical practices.\nConsequently, we want to make certain that the ways in which\nwe promote customer choice, business relationships and business\npractices are positive and fair. Our professional sales representatives\nare guided through our policies to recognize that competitive\nadvantage is gained through the merits of our products and services,\nnever through unethical or illegal business practices.\nFostering pro-competition practices\nWe believe that our marketing, sales, and advertising activities make\nan important contribution to medicine by informing our customers of\ntreatment options based on the most recent scientific information and\nfindings from rigorous clinical studies.\nOur sales and marketing practices are governed by external laws\nand regulations and industry codes of conduct, and by our own global\nCode of Conduct, our corporate policies and procedures, and our ethics\nand compliance program.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 80"
  },
  {
    "page": 81,
    "source": "text",
    "content": "GRI 206-1 Anti-competitive behavior\nAll new employees receive training and testing and must be certified\non relevant policies and our Company’s ethical operating standards.\nAlthough many of our employees who market and sell our medicines\nand vaccines have advanced scientific or medical degrees and\nbackgrounds, all our sales representatives must complete general\nsales and product training. Training is specific to the country where\nan employee is based and covers the scope of the employee’s\nresponsibilities in ensuring compliance with applicable laws and\nregulations. We stress that if our employees are unsure about the\nappropriateness of the conduct that they ask for help. There are\nseveral places where employees can turn for assistance.\nThe first option is to talk with their manager. If they do not feel\ncomfortable with that course of action, the other resources they\nmay contact are:\n• Divisional Compliance Departments\n• Office of Ethics\n• Privacy Office\n• Office of General Counsel\n• Human Resources Department\n• MSDethics.com\nIn addition to mandatory training on our Code of Conduct, employees\nreceive training on other levels of business practice and compliance\naccording to their roles and responsibilities. We evaluate and update\nthe content for all marketing and sales training periodically to ensure\nthat it remains relevant and current.\nWhile antitrust and competition laws may differ in the countries where\nour Company operates, the fundamental principles remain the same.\nFrom a broad perspective, antitrust and competition laws are legislated\nto promote competitive markets with the notion that when competitors\nand sellers can compete effectively against each other, customers will\nbe the ultimate beneficiary. All employees are educated on the overall\nprinciples and, with the help of the relevant legal and compliance\nfunctions, they are expected to carry out their duties in a pro-competitive\nmanner while safeguarding and advancing the Company’s interests.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 81"
  },
  {
    "page": 82,
    "source": "text",
    "content": "Tax We monitor proposals and changes to tax incentives and regulations\nin the countries in which we operate in order to assess their impact on\nour business, and we actively participate in industry groups interacting\nwith government representatives to support the development of\nGRI 207-1 Approach to tax\neffective tax systems that encourage innovation and growth. We\nutilize available tax incentives and opportunities, such as Research\nWe recognize our role as a responsible taxpayer to pay our full share\nand Development tax reliefs, in the spirit in which they were intended.\nof taxes, including corporate income taxes. We also recognize that our\ncontribution is much more than the corporate income tax we pay. The effective income tax rates from continuing operations were\n11.0 percent in 2021, 22.9 percent in 2020 and 21.8 percent in 2019.\nWe pay a significant amount of taxes to national and local governments\nin the form of employment taxes, value-added taxes, sales taxes, excise To learn more, please see our Global Tax Strategy on our corporate\ntaxes, property taxes and customs duties. We also collect numerous website, as well as page 63 of our 2021 Form 10-K.\ntaxes paid by our employees. We pay all taxes due in full and on time in\nthe jurisdictions in which we operate. The way we conduct business,\nincluding the economic impact from the taxes we pay, also reflects our\ncommitment to striving to reach those in need with our medicines and\nvaccines and helping to build robust, durable health systems worldwide\nthrough partnership, investment and innovation.\nOur chief financial officer (CFO) is ultimately responsible for our overall\ntax position. The day-to-day management of tax is performed by\nthe Company’s global corporate tax department, which is led by the\nsenior vice president of Tax. Effective oversight of the tax function\nis maintained by at least an annual tax presentation to the Audit\nCommittee of our Board and regular meetings with the CFO; senior\nvice president, Tax and Treasury; and other executive leaders to\ndiscuss emerging tax matters.\nWe comply with tax rules and regulations on a worldwide basis and\nonly engage in tax planning that is aligned with our commercial\nbusiness activities and reputation. We are committed to the arm’s\nlength standard in transfer pricing and Organisation for Economic\nCo-operation and Development (OECD) guidelines for international\ntax matters. We have a zero-tolerance approach to tax evasion and\nthe facilitation of tax evasion. Where uncertainty exists, and when\nappropriate, we seek clarification from our external advisors and/\nor governmental authorities. This can take the form of tax rulings or\nadvanced pricing agreements from governmental authorities.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 82"
  },
  {
    "page": 83,
    "source": "text",
    "content": "Environmental\nSee our GRI Index on page 182.\nMaterials Products\nWe conduct extensive testing of our products to identify and understand\nany potential safety, health and environmental hazards. We manage\nand communicate information about hazardous materials to keep\nGRI 301 Management approach\nour employees, contractors, transporters and other partners safe.\nWe are actively engaged in conversations on product stewardship to\nBy using more efficient and innovative processing methods and understand and act on the issues specific to our industry worldwide.\ntechnologies, we are reducing the amount of energy, water and raw\nmaterials we use to make our products, thereby minimizing the We share best practices within the industry via our membership in the\namount of waste we generate. We go to great lengths to ensure Conference Board Product Stewardship Council, the American Chemistry\nthat our products are designed and made in a safe, effective and Council’s (ACC) Green Chemistry Initiative, the EFPIA, the International\nenvironmentally sound manner. Federation of Pharmaceutical Manufacturers & Associations (IFPMA)\nand the ACS Green Chemistry Institute Pharmaceutical Roundtable\nWe deliver on this commitment by maintaining a highly trained and (ACS GCIPR).\ncapable scientific staff and by actively pursuing manufacturing process\nimprovements that minimize environmental impacts. Our objective is to maintain compliance and assure supply of life-saving\nmedicines as we look to further minimize our future environmental footprint.\nWe have set environmental sustainability goals with concrete targets\nand timelines to demonstrate this commitment. To ensure that our Governance\nknowledge stays current with that of thought leaders and experts in\nOur efforts in this area are overseen by our Green & Sustainable\nthe industry, we also collaborate with external resources and industry\nScience Steering Committee and our Environmental Health and Safety\ngroups, such as the American Chemical Society (ACS) and the European\n(EHS) Council.\nFederation of Pharmaceutical Industries and Associations (EFPIA).\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 83"
  },
  {
    "page": 84,
    "source": "text",
    "content": "CONTINUED: GRI 301\nPrograms and initiatives We have adopted “Design for Environment” practices that help\nour engineers design new product packages that are better for\nOur chemists and engineers are trained in green-design principles\nthe environment by minimizing package sizes and using more\nand are provided with tools and resources to help them develop\nenvironmentally friendly materials, where possible.\nmanufacturing processes that use safer chemicals and reduced\nquantities of raw materials. We use innovations like nanotechnology\nAs a standard business practice, we review all of our new human\nto make our products more effective, while ensuring that product\nhealth packaging designs prior to launch to understand and minimize\nsafety always remains of utmost importance.\nenvironmental impacts as much as possible, while still providing\nadequate protection for our products.\nComplying with chemical substance and product requirements is\na top priority for us. We track numerous existing and emerging\nTo help us evaluate the differences in environmental impacts between\nchemical control regulations that require us to register specific types\npackaging options, we use a simplified life-cycle assessment (LCA) tool\nof chemicals with the proper authorities. To meet these requirements,\nthat provides information on the environmental impacts generated by\nour scientists complete assessments of the environmental and human\nthe materials used in our packaging.\nhealth risks of the substances with which we work and submit the\nrequired regulatory notifications. In addition, we are working to establish foundational, environmentally-\nfocused packaging principles for the future of our packaging design.\nAdditionally, we provide details on product use and risk-based control\nThese principles, in addition to our LCA tool, serve to guide decision\nmeasures in accordance with applicable regulations.\nmaking for packaging design.\nPackaging We continue to monitor global trends around material use, such\nas the New Plastics Economy, and how we might incorporate\nOur product stewardship program extends to our customers and circular economy concepts into the critical functions of packaging\npatients through the design of effective, low-impact product for pharmaceuticals. It is unclear how these trends will impact our\npackaging. Our Company also supports the development of science industry, however, these are important signals of a changing external\nbased, cost-effective and environmentally sound programs that approach to the use and recovery of specific materials like fiber-based\npromote the proper disposal of unused medicines and their packaging products, plastics such as PVC, metals and others.\nin accordance with regional requirements. For more information, see\nour position statement on responsible disposal of medicines, which\nGovernance\ncan be found on our corporate website.\nPackaging design is managed by the Global Pharmaceutical Operations\nThe materials we use for packaging our finished products serve a range area of the Company with oversight from our Environmental Health\nof important purposes; the foremost purpose is to protect the purity, and Safety Council.\nefficacy and physical integrity of the product.\nIn 2021, we responded to the CDP forest questionnaire for timber\nPackaging also provides the customer with information and products, specifically for paper and secondary and tertiary packaging.\nconvenience, the pharmacist or provider with accurate dispensing CDP graded our disclosure with a C “Awareness” rating, indicating that\ninformation at the point of purchase and our business with marketing we have “Knowledge of impacts on, and of, forests issues”. According\nvalue. For some products, packaging also serves safety functions such to CDP, our Company is among 60 percent of companies that reached\nas child resistance and tampering evidence. “Awareness” level in our Activity Group (Biotech and pharma) for\ntimber. We performed a gap assessment of our questionnaire\nIn addition to these critical functions of packaging, there is also the response and developed a roadmap for improvements in this area\nconsideration of the environmental impact of the materials we use. over the next several years. We are in the early stages of our program\nAfter it has served its critical function(s), packaging becomes our development and are in the process of assessing the impact of other\ncustomer’s waste and therefore must be accounted for in our designs. forest risk commodities.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 84"
  },
  {
    "page": 85,
    "source": "text",
    "content": "CONTINUED: GRI 301\nSolvent use production processes, we work with suppliers who recover the spent\nsolvents for resale to other industries or safely burn them as a source\nSolvents play a key role in the research and manufacturing of\nof energy, where feasible. Any used solvents that leave our site as\nour products, as well as in equipment cleaning. Because of their\nhazardous waste are managed at off-site facilities that are on our list\nsignificance to our business and the life-cycle impact they represent,\nof approved waste management sites.\nwe focus on designing our processes to minimize or avoid their use\nwhere practical. Where we do use solvents, we maximize efficiency and\nChemical management\ncontrol them in our emissions, effluents and waste.\nA comprehensive and effective chemical management program is\nWe have an active Green and Sustainable Science program\ncritical to the safety and protection of our employees, the communities\n(see page 86) to design our new processes using fewer, less toxic,\nin which we operate and the environment.\nsolvents and other hazardous materials, and to reuse and recycle\nmore of the solvents we do use. We have put in place procedures, systems and processes to manage\nthe approval, procurement, inventory, receipt, transfer, storage, use\nFor cleaning our manufacturing equipment, we use water-based\nand disposal of chemicals at all of our sites. We provide our employees\nmethods where they are as effective as solvents. At each of our\nand others with information about the identities and potential hazards\nmanufacturing sites, we have engineers who are responsible for\nof the chemicals in our operations and final products through proper\nidentifying and driving process-improvement projects. When\nlabeling of chemicals and the creation of safety data sheets.\nit is not practical to reuse regenerated solvents in our own\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 85"
  },
  {
    "page": 86,
    "source": "text",
    "content": "CONTINUED: GRI 301\nGreen and sustainable science\nDeveloping innovative, cost-efficient manufacturing processes with\nlow environmental impact aligns with our Company’s environmental\nsustainability strategy. Green and sustainable science is the design\nof new products and processes that reduce or eliminate the use or\ngeneration of hazardous substances.\nThe concept applies across the life cycle of a product, including its\ndesign, manufacture, use and ultimate disposal. There is a trend\ntowards more regulatory restrictions and increased oversight in many\njurisdictions around the world. Our strategy for green and sustainable\ncommercial chemical route development could help to avoid potential\nfuture issues in the supply chain.\nOur Company’s overall objective is to be viewed as the industry leader\nfor the development of innovative, efficient, green and sustainable\ncommercial syntheses of our small molecule active pharmaceutical\ningredients (API) from sustainable commodity raw materials. We are\nalso exploring ways to reduce the environmental impact of biologics\nand vaccine manufacturing.\nGovernance\nPrograms and initiatives\nOur Company’s Process Research and Development department is\nAs part of our Green & Sustainable Science program, we calculate the\nresponsible for process development. The progress toward our goals\nprocess mass intensity (PMI) of our small molecule human health products.\nis overseen by various internal bodies including the Scientific Advisory\nPMI represents the number of kilograms of raw materials (including water)\nCouncil (SAC), the Development and Commercialization Oversight\nused to produce one kilogram of an API. PMI indicates the efficiency by\n(DCO) and our Environmental Health and Safety (EHS) Council.\nwhich we convert raw materials into final products. We use this metric\ninternally to compare different manufacturing methods, identify process\nStrategy improvement opportunities and track our progress.\nOur integrated strategy involves several stages and aims to provide\nWe have developed aggressive PMI targets for our API processes that\ninnovative solutions rather than incremental improvements\nleverage an internally developed SMART PMI tool and regularly evaluate\nto historical practices. We see transformative science/\nPMI at every stage of development. We continue to use this tool to drive\nengineering and innovation as critical enablers to developing\nthe development of all our new small molecule processes to achieve\nsustainable, low-cost manufacturing processes that provide both\nour aspirational goals for green and sustainable processes. For our\nenvironmental and economic benefits over the life cycles of our\nlarge molecule processes, we are still evaluating different sustainability\nproducts. We aim to develop the most efficient and sustainable\nmetrics and ways to reduce the environmental impact of biologics and\nprocesses at product launch, with the goal of minimizing material\nvaccine manufacturing.\nuse and waste from our commercial manufacturing. Our Company’s\nresearch laboratories utilize an innovative “green-by-design”\nWe are also using LCA tools to further evaluate the environmental impacts\ndevelopment strategy to progress from an initial early clinical\nof our processes.\nsupply route to a fully optimized and sustainable commercial\nmanufacturing process.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 86"
  },
  {
    "page": 87,
    "source": "text",
    "content": "CONTINUED: GRI 301\nAmerican Chemical Society (ACS)\nGreen Chemistry Institute (GCI)\nWe are a founding member of the ACS Green Chemistry Institute®\nPharmaceutical Roundtable, a partnership between the ACS GCI\nand member pharmaceutical companies. The Roundtable assists with\nthe development of tools, such as solvent selection, reagent guides\nand the PMI calculator, which drive the integration of sustainability\ninto process design. Roundtable members also work together to\nsupport and advance academic research and education on new ways\nto apply green and sustainable science to pharmaceutical discovery\nand manufacture, which have resulted in several industry publications\non more sustainable processes and technologies. More recently, the\nACS GCI member companies are exploring tools and guidelines for\nsustainable production practices relevant to bioprocessing.\nAwards and recognition in green chemistry\nFor the last five years, our Company has been honored by the\nEnvironmental Protection Agency (EPA) and the ACS as a winner of\nthe Green Chemistry Challenge Awards. Since the establishment of\nthe annual Green Chemistry Challenge Awards in 1996, we have been\nrecognized with eight Green Chemistry Awards for innovative process\nimprovements. In both 2020 and 2021, our Company was honored by\nthe ACS as the winner of the Peter J. Dunn Award for Green Chemistry\n& Engineering Impact in the Pharmaceutical Industry.\nIn 2021, we were recognized for the application of an immobilized\nbiocatalytic process to convert a biorenewable feedstock into a key\nintermediate for the commercial manufacture of nemtabrutinib,\na novel investigational oral Bruton’s tyrosine kinase inhibitor.\nWe were again recognized in 2021 for combining green chemistry\nprinciples and a SMART PMI prediction tool to spur the development\nof a green and sustainable commercial manufacturing process for\ngefapixant citrate, an investigational medicine for refractory and\nunexplained chronic cough.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 87"
  },
  {
    "page": 88,
    "source": "text",
    "content": "Energy\nGRI 302 Management approach\nAs a global biopharmaceutical Company, we recognize the important\nrole we play in identifying, adapting and responding to the public health\nrisks associated with climate change, such as threats to clean air and\nwater, insufficient food supplies and the spread of disease. We believe\nour long-standing support of stronger health systems in underserved\nareas is even more important given the evidence that certain disease\npatterns are associated with changing climate conditions.\nOur Energy Management Standard requires responsible and efficient\nenergy management and associated greenhouse gas (GHG) emission\nreductions. Energy-demand reduction and efficiency will always be\npart of our energy management strategy, as it positively impacts our\nefforts to reduce our global footprint.\nUtilization of renewable energy is a growing expectation of industry.\nThe advancements in renewable technology, and incentives through\nlegislation, have facilitated the creation of a robust renewable\nenergy market.\nPrograms and initiatives\nOur Global Energy & Sustainability Center of Excellence (CoE)\nWe have made it a priority to reduce our demand for energy and identifies, shares and standardizes best practices and prioritizes the\nhave established internal policies and practices focused on reducing funding of energy projects to reduce energy use across our Company.\nenergy use at our sites and minimizing GHG generation throughout Our manufacturing facilities, warehouses, laboratories, offices and\nthe Company. By taking these steps, we are not only minimizing GHG vehicle fleet are the primary targets of our energy-demand-reduction\nemissions but also reducing our operating costs and mitigating the programs, as they represent the majority of our energy consumption.\nbusiness impacts expected to be associated with future climate change\nOur Sustainability Capital Fund is used exclusively for sustainability\nrequirements.\nprojects at sites around the world that bring long-term value to the\nEnergy-efficiency and demand-reduction projects will continue to Company, and focuses on carbon footprint, water use and solid waste\ncontribute to reducing both our energy consumption and direct reduction. The fund allocates up to $12 million per year to adopt low-\nGHG emissions. In addition, we will continue to optimize systems, carbon technology, better position us to respond to climate change and\nconsolidate excess facility space when possible and utilize renewable support a more circular economy. Since 2015, our sites have completed\nenergy sources. We have launched initiatives around the world to more than 124 projects through the Sustainability Capital Fund, which\nimprove energy use, reduce GHG emissions from our operations and has avoided the production of an estimated 50,000 metric tons of\nunderstand our supply chain-related impacts. carbon emissions per year.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 88"
  },
  {
    "page": 89,
    "source": "text",
    "content": "CONTINUED: GRI 302\nFacilities All new laboratories, offices and major renovations are built following\ncost-effective and energy-efficient practices, and are designed to meet\nWe continuously strive to make our facilities energy-efficient. Our\nthe Leadership in Energy and Environmental Design (LEED) rating\nGlobal Energy & Sustainability CoE has created an “energy road map”\nsystem, or a comparable country standard (e.g. BREEAM, EXEED,\nto help our facilities reduce energy demand and associated GHG\nHQE, etc.). Offices and laboratories are expected to achieve LEED Gold\nemissions. The energy road map’s foundation includes large-scale\ncertification at a minimum.\nmetering and monitoring to assess and identify opportunities for\ncontinuous improvement. As facility energy-management programs • Our South San Francisco, California, research facility is certified as\nLEED Gold, WELL Silver and Fitwel® (2 star). In 2021, it became the\nmature, energy savings are sought by improving the reliability of the\nfirst facility of its kind to achieve LEED Zero Carbon and LEED Zero\nequipment, the efficient operation of utility systems and building\nEnergy certification.\nefficiencies into systems design.\n• Our China head office is certified as LEED Gold\nWe have also created a Low Carbon Transition Playbook (LCTP). The\n• An operations support facility at our facility in Durham, North\nLCTP was a result of a cross-functional effort at our Company that\nCarolina, is certified as LEED Silver\npulled together experts into a “design-thinking” workshop organized\n• Our lab in Carlow, Ireland, received LEED Gold and Excellence in\nto develop strategies to reduce GHG emissions. The LCTP includes\nEnergy Efficiency Design (EXEED) certifications\na gap assessment for sites to evaluate the maturity of their energy\nprograms and helps create short- and long-term plans to reduce sites’ • Development labs in New Jersey and Pennsylvania are pursuing\nLEED Silver certification\ncarbon intensity and build toward a low carbon future.\n• Two sites, one in New Jersey and one in Virginia, have received\nAll our new facilities are required to comply with our Energy Design LEED Campus certification\nGuide and Energy Conservation Planner. When we purchase a facility,\nit is evaluated for energy efficiency and assessed against our energy We require our facilities to have a plan to manage their energy use.\nscorecard as part of its integration into our Company. Examples of these plans and resources include:\n• Eleven European sites have adopted energy management programs\nto manage their energy use and maintain and/or achieve their\ncertification of ISO 50001:2018 for energy management in order to\ncomply with the EU Energy Efficiency Directive audit requirements\n• The EU Energy Efficiency Directive (EED) Phase Two compliance\nassessment was completed for all entities in the EU region, and all\nqualifying sites are undertaking energy audits to ensure compliance\n• Our Global Energy & Sustainability CoE has provided tools for\nfacility managers to identify opportunities to reduce energy use\nand eliminate waste. These tools include the Low Carbon Transition\nPlaybook, Global Energy Scorecard, and sustainability meetings\nand newsletters for best practices sharing.\n• All of our employees have access to a training curriculum that\nallows them to learn more about energy management and energy\nsystems. Through this program, employees can earn an Energy\nManager Certification. Site energy managers from more than 70 of\nour facilities are expected to complete the basic energy efficiency\ntraining curriculum.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 89"
  },
  {
    "page": 90,
    "source": "text",
    "content": "CONTINUED: GRI 302\nWork practices and recognition Renewable energy\nWe take advantage of technological advances to save energy, time and We have committed to sourcing 100 percent of our purchased\nmoney while also reducing emissions. electricity from renewable energy by 2025. Photovoltaic arrays, wind\nturbines and other renewable-energy installations avoid emissions,\nThe strategies we employ include: help reduce energy demand peaks and postpone or preclude adding\n• Site energy use is tracked monthly by our Global Energy & new power plants. We continually look for opportunities for new\nSustainability CoE through a centralized system. A global energy on-site installations, power-purchase contracts, vendor-supplied\nscorecard is issued monthly, and sites receive a letter grade renewable energy through the electrical grid and virtual power\nbased on an internal assessment of their energy intensity and purchase agreement (VPPA) projects.\nperformance. Our Companywide average score dropped from an\n“A-” to “B” in 2021 due to capital expansion. In 2021, three sites in Europe completed the installation of solar arrays\nwhich are expected to generate about 0.5 MW worth of renewable\n• A rollout of Energy Utility Analytics Technology for multiple sites\nthat will enable continuous commissioning, energy efficiency energy. By the end of 2022, one site in the U.S. and two sites in Europe\nimprovements and reliability of assets are expected to complete the installation of solar arrays, generating an\nadditional 10.8 MW of energy.\n• The development of an energy management strategy that seeks\nto achieve energy savings through continuous improvement,\nWe signed three VPPAs in 2021 for utility-scale energy projects based\nreliability, operations and design\nin Texas and Spain. These agreements follow a 2018 U.S. wind VPPA,\n• A rail-travel option is included in our online business-travel booking which has added 60 MW of new renewable energy capacity while\ntool to make it easier to travel by train when appropriate. Train\nproviding us with the associated renewable energy credits.\ntravel has a smaller carbon footprint than traveling by either\nairplane or personal vehicle.\nVehicle fleet\nThroughout the year, sites are encouraged to share their sustainability\nApproximately nine percent of our total Scope 1 and 2 GHG emissions\nprojects relating to energy, waste and water savings. Each quarter, a\nare associated with our vehicle fleet. We calculate our fleet’s\nproject is chosen to be featured in the Global Energy & Sustainability\nGHG emissions based on estimated fuel economy and actual total\nCoE’s newsletter.\nmiles driven.\nSelected energy/greenhouse gas (GHG) reduction projects in\nWe have a roadmap to transition to a full battery electric vehicle fleet.\n2021 included:\nThe implementation depends on the availability of like-for-like electric\n• A Condensate Kaizen Task Force was created to monitor vehicles and the development of public charging infrastructure. Our\napproximately 75 Condensate Recovery Units (CRUs) for potential current emphasis is on introducing hybrid vehicles as a bridge, which\nenergy and water losses and to enter work orders to correct\naccount for 12 percent of our fleet in Europe, Middle East and Africa\nidentified issues. The team then estimates water, energy and\n(EMEA); 56 percent in Japan, China and Asia Pacific; 1 percent in Latin\nGHG emission reductions due to the work.\nAmerica; and 2 percent in North America. However, the worldwide\n• A site has implemented a new automated monitoring and metering vehicle supply shortage has slowed our transition.\nproject in order to support its 10-year sustainability strategy.\nThe new system will allow the site to track real-time data from\nthe site’s significant energy users (SEUs) at designated equipment\nand buildings.\n• South San Francisco’s LEED Zero Carbon & LEED Zero Energy\ncertifications and their ambitious sustainability strategy\n• A site’s completion of a multi-year wastewater treatment plant\nupgrade to fine bubble aeration\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 90"
  },
  {
    "page": 91,
    "source": "text",
    "content": "Energy consumption within the organization\nGRI 302-1\n(Scopes 1+2)\nGRI 302-4 Energy reductions\nTotal energy use1 2017 2018 2019 2020 2021\nTotal energy use (GJ) 18,402,400 18,274,900 17,710,000 17,182,600 17,224,600\nScope 1 and location-based Scope 2 energy use\n2017 2018 2019 2020 2021\n(% of total)1,2\nNatural gas (Scope 1) 59% 63% 62% 64% 62%\nRenewable energy generated and used on site (Scope 1)3 0.05% 0.06% 0.07% 0.06% 0.06%\nFleet fuel (Scope 1) 13% 10% 9% 7% 8%\nFuel oil (Scope 1) 2% 2% 2% 2% 2%\nBiofuel (Scope 1) 0.7% 0.7% 0.6% 0.7% 0.8%\nSpent solvents (Scope 1) 0% 0% 0% 0% 0%\nCoal (Scope 1) 0% 0% 0% 0% 0%\nPurchased electricity (Scope 2)4,5 22% 21% 23% 23% 24%\nPurchased steam (Scope 2) 3% 3% 3% 3% 3%\nNote: We have defined “purchased electricity” as electricity sourced from external suppliers, as well as renewable electricity that was generated and utilized on site, where we retained the\nrenewable attributes or where we have obtained renewable attributes through contract. GHG figures have been changed from our 2020/2021 report due to a collection methodology update\nsince our last report.\n1 Values are adjusted to reflect the effects of the Organon spin-off on our energy consumption.\n2 May not add to 100 percent due to rounding.\n3 Includes solar, wind and other renewables generated on site, where renewable energy credits or guarantees of origin have been retained or retired.\n4 Reported using Scope 2 location-based value in accordance with the Greenhouse Gas Protocol.\n5 Includes solar, wind and other renewables generated on site, where renewable energy credits (RECs) have been sold.\nERM conducted an independent third-party review of our 2021 GHG and water inventories, and provided limited assurance for the data that we submit to CDP and for inclusion in this report.\nTo view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’ assurance\nmethodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 91"
  },
  {
    "page": 92,
    "source": "text",
    "content": "CONTINUED: GRI 302-1 | GRI 302-4\nIn 2021, our purchased electricity consumption increased due to capital • A data center in New Jersey that obtained a perfect score of 100\nexpansion, but our sites’ fuel usage continued to decrease due to\n• A research office in Pennsylvania for the 11th consecutive year\nenergy efficiency projects.\n• One office building in New Jersey for the second consecutive year\nIn March 2021, the U.S. EPA again recognized our Company with our\nOur Puerto Rico facility was awarded the ENERGY STAR Pharma\n15th consecutive Sustained Excellence Award. This is also the 17th\nEnergy Performance Indicator (EPI) for superior energy efficiency\nconsecutive year in which we have been recognized by ENERGY STAR\nand environmental performance among U.S. pharmaceutical\nfor excellence in energy management.\nmanufacturing plants for the 13th consecutive year.\nIn 2021, we continued to successfully use ENERGY STAR benchmarking\nFor more information, please see GRI 305-5 on page 106.\ntools such as the ENERGY STAR Portfolio Manager to obtain the\nOur CDP Climate Change Questionnaire is available on CDP's website.\nENERGY STAR Certified Building label for four buildings including:\nScope 1 & market-based Scope 2 energy use (% of total)1,2 2017 2018 2019 2020 2021\nNatural gas (Scope 1) 58% 61% 61% 63% 62%\nRenewable energy generated and used on site, or purchased (Scope 1)3 1% 3% 6% 9% 10%\nFleet fuel (Scope 1) 13% 10% 9% 7% 8%\nFuel oil (Scope 1) 2% 2% 2% 2% 2%\nBiofuel (Scope 1) 0.7% 0.6% 0.6% 0.7% 0.8%\nSpent solvents (Scope 1) 0% 0% 0% 0% 0%\nCoal (Scope 1) 0% 0% 0% 0% 0%\nPurchased electricity (Scope 2)4,5 23% 20% 18% 15% 14%\nPurchased steam (Scope 2) 3% 3% 3% 3% 3%\n1 May not add to 100 percent due to rounding.\n2 Values are adjusted to reflect the effects of the Organon spin-off on our energy consumption.\n3 Includes solar, wind and other renewables generated on site, where renewable energy credits or guarantees of origin have been retained or retired.\n4 Reported using Scope 2 market-based value in accordance with the Greenhouse Gas Protocol.\n5 Includes solar, wind and other renewables generated on site, where renewable energy credits (RECs) have been sold.\nERM conducted an independent third-party review of our 2021 GHG and water inventories, and provided limited assurance for the data that we submit to CDP and for inclusion in this report.\nTo view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’ assurance\nmethodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 92"
  },
  {
    "page": 93,
    "source": "text",
    "content": "Water and effluents\nGovernance\nEach site is responsible for management of water resources. Water\nGRI 303 Management approach management is overseen globally by the Water Center of Excellence\n(CoE). This CoE reviews water data to monitor sites’ progress and provides\nassistance as needed to support sites’ work towards meeting our goals.\nAs we strive to meet the health needs of our patients, we understand\nThe Environmental Review Committee provides oversight in establishing\nthat we may encounter water risks in the areas in which we operate.\nour internal Environmental Quality Criteria (EQC) standards.\nOur global water strategy aims to achieve sustainable water\nmanagement within our operations and our supply chain, which\nFor more detailed information on our environmental management\nsupports UN SDG 6, “Clean Water and Sanitation.”\nand governance, please see GRI 307 on page 116.\nTo achieve these strategic objectives, we are focusing on the\nfollowing commitments:\n• Ensuring that our wastewater discharges comply with local and\nnational standards, as well as internal requirements\nWe have established water goals to help us\n• Understanding and controlling our operational water footprint\nmanage water-related risks in our operations\n• Managing water risk at our facilities and in our supply chain\nand supply chain:\n• Reporting publicly on our water use and goals\nIn our Business Partner Code of Conduct, we request that suppliers\nInternal operations\nconserve natural resources and engage in activities aimed at reducing\nwater usage. We also ask that they have systems in place to quantify\nthe amount of water used.\nGoal\nFor more information on supplier engagement on water related By 2025, we will maintain global water use\ntopics, please see GRI 308 on page 122. at or below 2015 levels.\nProgress:\n3.6 million m3 below 2015 levels (16% reduction).\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 93"
  },
  {
    "page": 94,
    "source": "text",
    "content": "CONTINUED: GRI 303\nStewardship Our 2020 contribution of $100,000 to the One Tree Planted Keystone\n10 Million Tree Partnership project funded the planting of 100,000 trees\nWe have endorsed the UN CEO Water Mandate, a public commitment to\nin Pennsylvania to help protect the Chesapeake Bay. Over the years,\nadopt and implement a comprehensive approach to water management,\nthe Chesapeake Bay has suffered degradation due to development\nand we have aligned our water program with its principles.\nand changing sea levels, as well as pollution. Planting trees restores\ndegraded areas as well as assists in the restoration and filtration of\nCEO Water Mandate endorsers have a responsibility to make water\nthis sensitive water system. This project resulted in the contribution\nresource management a priority and to work with governments,\nof 64 different native species in the riparian, suburban and abandoned\nUN agencies, NGOs, local communities and other interested parties\nmine-land properties, across 387 hectares along streams, streets and\nto address global water challenges. We are working to identify\nother landscapes. A coalition of 188 organizations collaborated on this\npartnerships that will help us advance our water stewardship priorities\nproject. The planting of trees upstream of the bay in Pennsylvania will\nin the areas in which we operate.\nresult in improvements in biodiversity, reduce pollution and benefit the\nThese projects also support the goals of SDG 15, which strives to local community. Our site located in Riverside, Pennsylvania, is within\n“protect, restore and promote sustainable use of terrestrial ecosystems.” the Chesapeake Bay catchment.\nWe report our water security annually through CDP. In 2021, CDP\ngraded our disclosure with a B “management” rating, indicating that\nwe “provide evidence of actions associated with good environmental\nmanagement” and are “taking coordinated action on water security.”\nIn 2021, through The Nature Conservancy (TNC), we supported a\nreforestation project in Montes Claros, Minas Gerais, Brazil, with a\ncontribution of $100,000 to the Belo Horizonte Water Fund. This\nproject included the restoration of native forest, implementation of soil\nconservation techniques, improvements to dirt roads and conservation\nof existing forests in the Juramento River watershed. The Juramento\nRiver is a source of potable water for the City of Montes Claros. TNC\nexpects that this project will improve water security in the city of\nMontes Claros through:\n• Increasing rainwater infiltration\n• Creating a more stable outflow of water over the course of the year\n• Reducing erosion and sedimentation.\nWater security at our manufacturing operations located in Montes\nClaros is directly impacted by this project.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 94"
  },
  {
    "page": 95,
    "source": "text",
    "content": "The sites that use the most water in our network are located in\nthe U.S. Of these, two are in areas of “high” Baseline Water Stress\nGRI 303-1 Water as a shared resource according to the Aqueduct Water Risk Atlas tool but, through the\nassessment process described above, are considered medium risk.\nAccess to clean water is critical for human health and is a key input to\nour manufacturing operations, and we assess water risk throughout our\nnetwork as a standard business practice.\nOur process is as follows: GRI 303-2 Water discharge-related impacts\n1. The World Resource Institute’s (WRI) Aqueduct Water Risk Atlas\ntool is used as an initial step to map water risk. Sites are categorized We conduct environmental risk assessments on our products\nannually using the “Baseline Water Stress” indicator, which is the (small molecules, biologics and vaccines) from the development\nratio of total annual water withdrawals to total annual renewable phase through product launch, to understand and manage product\nsupply and accounts for upstream consumptive use. Higher stress impacts both from manufacturing and patient use. We assess\nvalues indicate more competition among water users. products in a manner consistent with the most stringent applicable\n2. Sites that are identified as high risk are further assessed utilizing global regulations, including the regulatory review processes of the\na catchment-specific approach to confirm that the catchments are U.S. Food and Drug Administration and the European Medicines\nexperiencing high water stress. Agency. Product environmental safety profiles are reassessed during\nperiodic renewals of product filings, and risk-mitigation actions are\n3. Sites that are known to experience water risk, regardless of the\nAqueduct Water Risk Atlas tool assessment, are included as high- implemented when needed.\nrisk sites.\nWe use the information from our risk assessments to establish or\n4. Water conservation plans are put in place at high-risk sites that use\nupdate our internal, compound-specific Environmental Quality Criteria\nmore than 100,000 m3 of water per year. We work with a third party, (EQCs), which are used to confirm that wastewaters discharged from\nwater-use expert to evaluate opportunities for water-use reductions our facilities do not contain levels of residual products that present a\nat these sites, resulting in site-specific water conservation plans. risk to human health or the environment. Our manufacturing facilities\n5. Sites that do not meet the water-use threshold will continue to be are required to use these EQCs, along with industry-accepted risk-\nmonitored for operational risk and conservation plans will be put in assessment methods, to establish procedures for managing and\nplace as needed. controlling active pharmaceutical ingredients (APIs) in their wastewater.\nPerforming this assessment ensures that we can adapt our strategy to Each facility uses the internal EQC standards to:\nchanging stressors in each catchment. It enables us to better prioritize\n• Assess the potential risk from its operations using science-based\nfacilities and catchments for water stewardship activities and lays the and industry-accepted risk assessment methods\nfoundation for potential future water targets in priority locations.\n• Minimize environmental impacts from wastewater discharges in\nthe local watershed\nIn 2021, the WRI Aqueduct Water Risk Atlas tool identified two of\nour manufacturing and/or research facilities as being in areas with • Establish procedures for managing, treating or controlling APIs in\n“extremely high” Baseline Water Stress and eight as being in areas wastewater prior to discharge where needed\nwith “high” Baseline Water Stress. In 2021, there were three fewer\nOur production facilities have, or will be provided with, API-treatment\nsites in areas of “extremely high” risk than in 2020 due to changes to\ntechnology such as advanced oxidation where needed, so that our\nour site network.\nwastewater discharges meet both regulatory requirements and these\nAs a result of the above methodology, we have two sites that have internal standards.\nwater conservation plans in place.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 95"
  },
  {
    "page": 96,
    "source": "text",
    "content": "CONTINUED: GRI 303-2\nWe also provide EQC information to suppliers that manufacture have worked together to develop the Eco-Pharmaco-Stewardship (EPS)\npharmaceutical compounds for us and have initiated detailed assessments initiative. The EPS initiative considers the environmental impacts of a\nof our suppliers to better understand and address potential impacts. medicine throughout its entire life cycle and addresses the roles and\nresponsibilities of all parties in managing those impacts. This includes\nIn addition, as a member of the Antimicrobial Resistance (AMR) public services, the pharmaceutical industry, environmental experts,\nIndustry Alliance and signatory to the Industry Roadmap for doctors, pharmacists and patients.\nProgress on Combating AMR, we are working to deliver on our\ncommitments to reduce the environmental impacts from antibiotic For more information on our supply chain, please see section\nresidues in wastewater through implementation of the AMR Alliance GRI 102-9 on page 30.\nCommon Antibiotic Manufacturing Framework. We have reviewed\nthe operations of our human health antibiotic chemical synthesis Please refer to the following resources for additional information\nfacilities and third-party human health antibiotic suppliers to assess related to water related discharge impacts on the ESG Resources page\ntheir wastewater treatment controls. This includes recommended of our corporate website:\nimprovements where needed, which we will follow through to\n• Public Policy Statement: Water Stewardship\ncompletion. We have developed a mechanism for transparently\ndemonstrating that our supply chain meets the standards in this • Public Policy Statement: Pharmaceuticals in the Environment\nframework, which is presented in the AMR Industry Alliance 2021 • Global Antimicrobial Resistance Action Plan\nProgress Report.\n• CDP-Water Security\nWe participate in efforts to address water discharge related impacts • Business Partner Code of Conduct\nwith various organizations, including the European Federation\nof Pharmaceutical Industries and Associations (EFPIA) and the\nInternational Federation of Pharmaceutical Manufacturers and\nAssociations (IFPMA). The EFPIA, Medicines for Europe and the\nGRI 303-3 Water withdrawal\nAssociation of the European Self-Medication Industry (AESGP)\nWater use by source (million m3)1 2015 2016 2017 2018 2019 2020 2021\nGroundwater 12.0 10.2 10.0 10.3 10.2 10.1 9.7\nPurchased water 7.1 6.5 6.1 7.2 6.9 7.0 7.1\nSurface water 3.9 3.1 2.7 2.3 2.6 2.9 2.6\nTotal2 23.0 19.8 18.8 19.9 19.7 20.0 19.4\nERM conducted an independent third-party review of our 2021 GHG and water inventories, and provided limited assurance for the data that we submit to CDP and for inclusion in this report.\nTo view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’ assurance\nmethodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\n1 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired and sold. For example, prior-year data in this table\nhas been adjusted to remove facilities that were spun-off as part of the Organon spin-off. Adjustments also reflect changes in methodology to ensure consistency from year to year.\n2 All values above are rounded to one decimal place. As a result, the total values shown may not equal the sum of the individual source totals.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 96"
  },
  {
    "page": 97,
    "source": "text",
    "content": "CONTINUED: GRI 303-3\nWater use by risk in the following tables is categorized according to data obtained via the WRI Aqueduct Water Risk Atlas tool\nand our internal risk assessment.\nNorth America\n79%\nEurope, Middle East and Africa\n13%\nRisk breakdown\nExtremely high (0.21%)\nAsia Pacific\nHigh (13.94%)\n6%\nMed to high (14.49%)\nLatin America\nLow to med (42.80%)\n2% Low (14.30%)\nWater use and risk by\nregion (million m3)—\nWRI Aqueduct Risk Extremely Med to Low to % of\nTool output (2021) high High high med Low N/A Total Total\nNorth America 0.00 2.18 2.90 7.88 0.23 2.08 79% 15.27\nEurope, Middle East 0.03 0.41 0.02 0.41 1.40 0.20 13% 2.48\nand Africa\nAsia Pacific 0.01 0.00 0.08 0.00 0.94 0.21 6% 1.24\nLatin America 0.00 0.11 0.00 0.00 0.20 0.07 2% 0.38\nTotal1 0.04 2.70 3.00 8.29 2.77 2.57 100% 19.37\nN/A: Not available.\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 97"
  },
  {
    "page": 98,
    "source": "text",
    "content": "CONTINUED: GRI 303-3\nWater use in areas of high to extremely\nhigh water risk by region (million m3)— Purchased\nWRI Aqueduct Risk Tool output (2021) Groundwater Surface water water Total\nNorth America 0.32 0.00 1.86 2.18\nEurope, Middle East and Africa 0.03 0.00 0.41 0.44\nLatin America 0.00 0.00 0.01 0.01\nAsia Pacific 0.03 0.00 0.08 0.11\nTotal1 0.39 0.00 2.36 2.75\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nWater use in areas of high to\nextremely high water risk by region\n(million m3)—after internal risk Purchased\nassessment methodology (2021) Groundwater Surface water water Total\nNorth America 0.00 0.00 0.00 0.00\nEurope, Middle East and Africa 0.03 0.00 0.04 0.07\nLatin America 0.00 0.00 0.64 0.64\nAsia Pacific 0.03 0.00 0.08 0.11\nTotal1 0.07 0.00 0.75 0.82\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nFor information on our water risk assessment approach, please see GRI 303-1 on page 95.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 98"
  },
  {
    "page": 99,
    "source": "text",
    "content": "CONTINUED: GRI 303-3\nIn 2021, we used 19.4 million cubic meters of water globally, versus In 2021, the Sustainability Capital Fund was utilized to fund water\n23.0 million cubic meters in 2015, representing a 16 percent reduction reduction projects at our site in Rahway, New Jersey. These projects\nin water use. Water withdrawal is variable based on manufacturing and included a smart irrigation system and condensate return projects.\nresearch activities year to year.\nFor information on the specific water sources affected in areas\nApproximately 13 percent of the total water we used in 2021 was supplied experiencing high and extremely-high water risk, please see our CDP\nfrom surface water sources, and 50 percent was supplied by groundwater Water Security response. For our water assurance letter, please visit\nwater sources, with the balance sourced from municipal water supplies. the ESG Resources page on our corporate website.\nOur sites employ a variety of technologies and techniques aimed at\nreducing our water footprint and improving operational performance.\nClosed-loop cooling systems, which reduce freshwater use, are\nemployed at many of our facilities worldwide. Reverse osmosis (RO)\n“reject water” is reused for non-potable and non-process applications\nsuch as cooling tower feed water. In all, 1.0 million cubic meters of\nwater was recovered, reused or recycled at our facilities in 2021,\nwhich is equivalent to five percent of our total water use.\nOur water-use-reduction initiatives include:\n• Consideration of water use in process design\n• Cooling-system optimization\n• Prompt repairs and maintenance of steam-distribution\nsystems and traps\n• Recovery and reuse of steam condensate and “reject water”\n• Process-water purification system optimization\n• Avoiding the use of water in mechanical seals, such as those\nin pumps\nAn innovative project was completed at MSD Oss Biotech in the\nNetherlands in 2021. The site constructed an energy-neutral site\nentrance building and a new parking area for staff and visitors.\nUnderneath the parking area a large underground rainwater storage\narea was created. During heavy showers, the basin collects and stores\nrainwater for soil infiltration. As a result of climate change, maintaining\ngroundwater levels has proved to be increasingly challenging, even in a\nrelatively wet country such as the Netherlands. This initiative not only\nreduces the amount of rainwater discharged to the sewer, but also has\na beneficial impact on the surrounding area’s ecosystem.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 99"
  },
  {
    "page": 100,
    "source": "text",
    "content": "GRI 303-4 Water discharge\nIn the following tables, water discharge by receiving water body\nrisk is categorized according to data obtained via the WRI Aqueduct\nWater Risk Atlas tool and our internal assessment. We understand\nthat following the annual assessment, site water-risk categorization\ncould change.\nTotal water discharge External treatment\nby region (million m3) (2021) Surface water facilities Total1 % of total\nNorth America 9.86 3.82 13.68 80%\nEurope, Middle East and Africa 1.03 1.28 2.31 13%\nAsia Pacific 0.04 0.79 0.84 5%\nLatin America 0.00 0.28 0.28 2%\nTotal1 10.93 6.17 17.11 100%\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nWater discharge in areas of high to\nextremely high water risk, by region\n(million m3)—WRI Aqueduct Risk External treatment\nAssessment output (2021) Surface water facilities Total\nNorth America 0.53 1.64 2.17\nEurope, Middle East and Africa 0.02 0.36 0.38\nAsia Pacific 0.00 0.01 0.01\nLatin America 0.00 0.10 0.10\nTotal1 0.55 2.11 2.66\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 100"
  },
  {
    "page": 101,
    "source": "text",
    "content": "CONTINUED: GRI 303-4\nWater discharge in areas of high to extremely External\nhigh water risk, by region (million m3)—after treatment\ninternal risk assessment methodology (2021) Surface water facilities Total\nNorth America 0.00 0.00 0.00\nEurope, Middle East and Africa 0.02 0.03 0.05\nAsia Pacific 0.02 0.38 0.40\nLatin America 0.00 0.10 0.10\nTotal1 0.03 0.51 0.54\n1 All values above are rounded. As a result, the total values shown may not equal the sum of the individual source totals.\nWastewater from our facilities is managed and treated to meet\nregulatory standards and minimize environmental impacts prior\nto discharge. On-site wastewater treatment facilities are operated\nat many of our production and research facilities. Where on-site\ntreatment is not provided, wastewater is discharged to local municipal\nwastewater treatment facilities that have the technology and capacity\nto treat our wastewater. We currently do not differentiate discharges\nto freshwater and seawater in our enterprise system. The majority of\nour facilities discharge to freshwater environments.\nAs described in GRI 303-2 on page 95, many of our production facilities\nare equipped with advanced wastewater treatment technologies to\nensure that our facilities meet both regulatory requirements and the\ninternal standards required by our EQC Program.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 101"
  },
  {
    "page": 102,
    "source": "text",
    "content": "Biodiversity\nSignificant impacts of activities, products,\nGRI 304-2\nand services on biodiversity\nDue to human influence on the world's ecosystems, the Convention on\nBiological Diversity (CBD) notes that species have been disappearing at\n50-100 times the natural rate. This is predicted to rise dramatically as\nclimate change continues and population grows. Without biodiversity,\necosystem services are not as productive, which, along with other\nthings, exacerbates the rate of climate change. To slow climate\nchange, we need to slow biodiversity loss by aligning our demands been awarded accreditation to the All-Ireland Pollinator Plan (AIPP).\nwith nature's ability to produce and safely absorb our waste. The AIPP is run by the National Biodiversity Data Centre and aims to\nreverse the dramatic downward trend in the number of pollinators in\nLoss of biodiversity will reduce our ability to discover and develop Ireland over the past decade by supporting businesses, communities\nmedicines. Plants and bacteria are well-recognized sources of new and individuals to take small actions to help our native pollinators.\nmedicines. According to the World Economic Forum (WEF), more\nthan half of the world’s total gross domestic product, or $44 trillion,\nAnimal Health and biodiversity\ninvolves activities that are moderately or highly dependent on nature,\nincluding around half of pharmaceutical products. Through our Animal Health aqua business, our Company monitors\nnumerous aquatic species by utilizing passive integrated transponder\nWhile we recognize that protecting biodiversity is important to the (PIT) tags. In 2021, we sold over four million PIT tags which provide\nplanet and our Company’s growth, we do not fully understand the lifetime identification and tracking for the animals they tag. The\nimpacts we have on biodiversity either directly or indirectly through technology can also be used to provide real-time monitoring of fish and\nour products. We do, however, have a long history of managing wildlife without impacting their natural behavior. The insights gleaned\npharmaceuticals in the environment and remediation projects. These from the monitoring data allow for more accurate estimations of wild\nactions prevent and reduce pollution in the areas in which we operate, populations, survival rates and migration patterns. That data provides\nprotecting species and ecosystems from harm. fish and wildlife managers with information for the conservation of\nkeystone, threatened and endangered species.\nWe are currently conducting an ingredient risk assessment to better\nunderstand if the sourcing of certain inputs to the manufacture of our These tools also track invasive species, helping researchers assess how\nproducts potentially contribute to global deforestation. This assessment these animals distribute throughout the environment and interact\nis in support of our CDP Forest response, which includes high-risk with native flora and fauna. The management of invasive population\ndeforestation commodities such as timber, palm oil derivatives, soy, spread is a key factor to maintaining current levels of native species\ncattle by-products and rubber. The results of this assessment will be and encouraging recovery of endangered species. Characterizing the\nincorporated into our responsible sourcing strategy. spread of invasive species also allows stakeholders to predict how that\nspread may be influenced by human-impacted habitat and ecosystems.\nEach of our sites in Ireland has developed a biodiversity team to\nperform biodiversity assessments. These sites worked with external When stakeholders initiate a habitat restoration or enhancement\nbiodiversity professionals to identify areas that could be improved project, these tools aide researchers in adaptive management by\nfrom a biodiversity perspective, with particular emphasis on pollinators measuring the project’s benefits on animal species. This data refines\nsuch as wild bees and butterflies. As a result of our commitment to mitigation of habitat degradation while also improving overall\nthese actions, we are delighted to announce that MSD Dunboyne has ecosystem health.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 102"
  },
  {
    "page": 103,
    "source": "text",
    "content": "Our Neighbor of Choice program supports the work of local nonprofit\norganizations dedicated to the wellbeing of community residents\nGRI 304-3 Habitats protected or restored\nin areas where we have a presence. Through charitable grants and\nemployee volunteerism, we support community efforts to improve\nSince 2016, as part of our UN CEO Water Mandate commitment,\nthe health and quality of life for underserved populations. This\nwe have invested annually in habitat restoration and/or reforestation\nincludes support for projects that protect the environment and/or\nprojects that improve water quality, restore biodiversity and remove\nenvironmental health of the local community, improve the quality of\ncarbon dioxide from the atmosphere. Working with organizations such\nlocal water sources, mitigate the impacts of climate change, reduce\nas The Nature Conservancy and One Tree Planted, we have identified\nwaste generation and improve waste recycling capabilities.\nprojects near our sites in which to invest. By investing in watershed\nmanagement with these collective-action projects, we have also been For example, in 2021 we provided a $50,000 charitable grant to the\nable to integrate community mobilization by facilitating volunteer Shenandoah National Park Trust to support biodiversity and climate\nopportunities for our employees that live near our sites and for the change resilience in the Shenandoah National Park and surrounding\ncommunities in which they reside. region. Our support helped the Shenandoah National Park Trust to\nidentify and remove targeted invasive plants in high-priority acres,\nFor more information on the most recent water-related projects,\nplant native trees, treat threatened tree species and support volunteers.\nplease see GRI 303 on page 93 for more information.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 103"
  },
  {
    "page": 104,
    "source": "text",
    "content": "Emissions GHG emissions goals\nGoal\nGRI 305 Management approach Reduce our operational greenhouse gas (GHG) emissions\n(i.e., Scopes 1 & 2) 46% by 2030 from a 2019 baseline.\nScientific data support that climate change is occurring, and we are\nProgress:\ntaking action to reduce the economic and public health risks associated\nwith a changing climate. 9% reduction in Scope 1 and 2 emissions from 2019 baseline.\nWe have adopted a set of environmental sustainability goals to help\nposition our Company to succeed in an increasingly resource-constrained\nworld. These were developed to address the rising expectations of our Goal\ncustomers, investors, external stakeholders and employees regarding\nReduce our value chain (Scope 3) GHG emissions by 30%\nthe environmental impact of our operations and supply chain.\nby 2030 from a 2019 baseline.\nWe have made progress on these goals and remain on track to achieve\nProgress:\nthem. We continue to find ways to decrease energy demand and\nhave increased the amount of renewable energy we purchase. Our 9% increase in Scope 3 emissions from 2019 baseline.\nprocurement team is engaging our strategic suppliers in our efforts\nto reduce the environmental footprint outside of our operations. In\nour Business Partner Code of Conduct, we request that suppliers\nconserve energy and engage in activities aimed at reducing Goal\ngreenhouse gas emissions. Achieve carbon neutrality across our operations by 2025\n(Scopes 1 & 2 emissions).\nThe World Resource Institute’s Greenhouse Gas Protocol defines\nScope 1 greenhouse gas (GHG) emissions as emissions from owned or\nProgress:\ncontrolled sources such as on-site fuel combustion and fleet vehicles.\nScope 2 emissions are those from indirect sources such as purchased In progress. Any remaining emissions will be offset with high-quality\nelectricity. Scope 3 includes indirect emissions in a company’s offsets in 2025.\nvalue chain.\nRenewable energy goal\nGoal\nSource 100% of our purchased electricity from\nrenewables by 2025.\nProgress:\n41% of purchased electricity sourced from renewables in 2021.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 104"
  },
  {
    "page": 105,
    "source": "text",
    "content": "CONTINUED: GRI 305\nWe have committed to becoming carbon neutral across our operations Governance\n(Scopes 1 & 2 GHG emissions) by 2025, to reduce our Scopes 1 & 2\nOur climate strategy is overseen by our Environmental Sustainability\nGHG emissions 46 percent by 2030 from a 2019 baseline (including\nCenter of Excellence (CoE), in partnership with our Global Energy &\nbiogenic emissions and removals from bioenergy feedstocks), and\nSustainability CoE and Energy Procurement CoE. Each CoE reviews\nto reduce our value chain (Scope 3 GHG emissions) by 30 percent\nand reports data, monitors progress and provides assistance as\nby 2030, also from a 2019 baseline. Our Scopes 1 & 2 and Scope 3\nneeded to support sites’ work toward meeting our goals and review\nreduction targets have been verified by the Science-Based Target\npotential virtual power purchase agreements (VPPAs). Leadership\ninitiative (SBTi). We have also committed to sourcing 100 percent of\nfrom the Environmental Sustainability CoE and Global Energy &\nour purchased electricity from renewable energy by 2025.\nSustainability CoE meet quarterly with an internal Environmental\nWe will achieve carbon neutrality in our operations with ongoing Sustainability Steering Committee to provide updates on progress and\ninnovation to increase energy efficiency, applying sustainable building to seek guidance on our initiatives. Furthermore, the EHS Council is\nstandards and continuing to transition away from fossil fuel use. responsible for approving new corporate environmental sustainability\nRemaining Scope 1 emissions will be balanced each year by investing in goals that the Environmental Sustainability CoE proposes in order\nhigh-quality carbon offsets, including carbon removal offsets. to align with stakeholders’ expectations. Both the Environmental\nSustainability Steering Committee and EHS Council are comprised of\ntop-level executives.\nEach site is responsible for the management of its energy use. In many\ncases, we partner with our third-party Integrated Facility Management\n(IFM) providers to manage energy use and work toward achieving the\ncorporate goals.\nIn 2022, we conducted a climate policy alignment assessment of\nthe trade associations listed in GRI 102-13 by determining whether\nthey had publicly disclosed formal positions on climate change and,\nif so, reviewing those positions in the context of our Company's own\nposition on climate change. This assessment can be found on the\nESG Resources page on our corporate website.\nFor information regarding our environmental management and\ngovernance, please see GRI 307 on page 116.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 105"
  },
  {
    "page": 106,
    "source": "text",
    "content": "GRI 305-1 Direct GHG emissions (Scope 1)\nGRI 305-2 Indirect GHG emissions (Scope 2)\nGRI 305-3 Other indirect GHG emissions (Scope 3)\nGRI 305-4 GHG emissions intensity\nGRI 305-5 Reduction of GHG emissions\nGHG Emissions in 2021\nScope 1: 695,700 MT CO e\n2\nScope 2 (market-based): 230,000 MT CO e\n2\nScope 3: 6,958,900 MT CO e\n2\nTotal GHGs (MT CO e)1 2017 2018 2019 2020 2021\n2\nScope 11,3, 5 777,400 768,900 732,900 715,000 695,700\nScope 2 location-based1,3, 5 420,300 398,600 381,900 367,000 374,200\nScope 2 market-based1,3, 5 438,100 363,300 285,900 227,800 230,000\nTotal GHGs (Scope 1 & 2 market-based)1,3 1,215,500 1,132,200 1,018,800 942,800 925,700\nScope 3 GHGs1,3 5,940,500 5,668,400 6,380,500 6,457,800 6,958,900\nGHG intensity2,4 19.73 18.38 16.02 14.16 13.61\n1 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired, sold or spun-off. Adjustments also reflect changes in\nmethodology to ensure consistency from year to year, including Scope 2 emission factor updates [E-GRID (2021), IEA (2021), EU Residual (2021), UK Defra (2021) & Inventarios Corporativos\n(2021)] and Scope 1 & 3 emission factor updates [EPA Climate Leaders (2021)].\n2 Total Scope 1 & Scope 2 market-based metric tons COe per employee.\n2\n3 Values are adjusted to reflect the effects of the Organon spin-off on our emissions.\n4 Adjusted to remove employees transferred to Organon in connection with the spin-off.\n5 The operational control approach is used to account for GHG emissions for Company facilities globally. Only those facilities over which Merck has operational control are included in the\nGHG inventory.\nERM conducted an independent third-party review of our 2021 greenhouse gas and water inventories and provided limited assurance for the data that we submit to CDP and for inclusion\nin this report. To view ERM’s limited assurance letter for our environmental data, please visit the ESG Resources page of our corporate website. The verification standard used is ERM CVS’\nassurance methodology, which is aligned with the International Standard for Assurance Engagements ISAE 3000 (Revised) and ISO 14064:3 for the verification of GHG emissions.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 106"
  },
  {
    "page": 107,
    "source": "text",
    "content": "CONTINUED: GRI 305-1 | GRI 305-2 | GRI 305-3 | GRI 305-4 | GRI 305-5\nScope 3 GHG details (MT CO e) 2017 2018 2019 2020 2021\n2\nPurchased goods and services1,2 4,671,300 4,295,500 4,827,900 5,050,900 5,465,800\nCapital goods1,2 186,700 221,800 329,000 455,100 453,200\nGHG emissions from fuel and energy-related activities 250,600 232,100 220,200 194,100 216,500\nnot included in Scopes 1 & 22,3\nUpstream transportation and distribution1,2 236,400 242,600 240,000 232,800 237,800\nWaste generated in operations (excluding recycled and 16,400 17,700 18,800 21,900 23,800\ncomposted waste)2,4,5\nGHG emissions related to employee business travel2,6,7 209,800 289,400 327,200 208,600 241,100\nEmployee commuting2,8 213,400 213,400 243,700 114,800 117,200\nDownstream transportation and distribution2,9 114,200 113,200 124,800 136,000 155,200\nGHG emissions from use of sold products2,10 2200 600 600 600 700\nEnd-of-life treatment of sold products2,11 39,500 42,100 48,300 43,000 47,600\nTotal2,12 5,940,500 5,668,400 6,380,500 6,457,800 6,958,900\nLimited Data Assurance was granted for 22,652 or 9% emissions calculated from primary travel vendor data and employee reimbursable travel mileage data. The total reported here includes\nnon-primary travel vendor data emissions, which were based on our 2021 third-party spend data and an Economic Input-Output Model performed by Climate Earth, Inc.\n1 Based on third-party spend data and an Economic Input-Output Model performed by Climate Earth, Inc.\n2 Values are adjusted to reflect the effects of the Organon spin-off on our emissions.\n3 Emission factors from Argonne National Laboratory's GREET Model (https://greet.es.anl.gov/) were used in conjunction with primary fuel and energy-use data.\n4 Primary-waste data were used with the U.S. EPA’s WARM Model (https://www.epa.gov/warm).\n5 Including recycled and composted waste in these calculations would result in negative emissions in 2017 (-41,200 MT CO₂e), 2018 (-43,700 MT CO₂e), 2019 (-62,400 MT CO₂e), 2020\n(-48,900 MT CO₂e) and 2021 (-46,300 MT CO₂e).\n6 Based on primary travel vendor data, employee-reimbursable mileage and UK Defra factors.\n7 Emissions are based on primary vendor data where available and economic input-output modeling performed by Climate Earth, Inc., using spend data.\n8 2020 and 2021 reductions caused by shifts to remote working due to the COVID-19 pandemic.\n9 Emissions were calculated using our “Upstream transportation and distribution” spend data as a worst-case estimate entered into the WRI Quantis tool. We assumed that all “downstream”\nmaterial would first have been stored, transported and handled “upstream.”\n10 Due to recent acquisitions, we are currently evaluating the applicability of additional products to this category. This category currently includes the impacts of our Animal Health products\nENGEMYCIN® (oxytetracycline), NEO SPRAY CAF® (oxytetracyclinum), OXYTETRIN® LA (oxytetracycline) only.\n11 Calculated assuming that all primary, secondary and tertiary packaging purchased was disposed of by our customers. Packaging material data was used with the U.S. EPA’s WARM Model.\n12 May not add up to total due to rounding.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 107"
  },
  {
    "page": 108,
    "source": "text",
    "content": "CONTINUED: GRI 305-1 | GRI 305-2 | GRI 305-3 | GRI 305-4 | GRI 305-5\nReduction of GHG emissions For more information on our initiatives, policies and accomplishments,\nplease see Section GRI-302 energy and the following resources on the\nFrom 2020 to 2021, our year-over-year Scope 1 and Scope 2 market-\nESG Resources page of our corporate website:\nbased GHG emissions decreased by about 2 percent due to our\ncontinued focus on energy efficiency and an increased utilization • Corporate Policy: Respect for Environmental Health\nof renewable energy. While we implemented several projects that and Safety (EHS)\nreduced our GHG emissions, we also experienced capital expansion,\n• Public Policy Position Statement: Climate Change\nwhich resulted in a smaller drop in GHG emissions than last year.\n• Business Partner Code of Conduct\nWe have analyzed and reported our Scope 3 impacts using primary\noperating data, and accepted emission factors and an economic input-\noutput model based on our third-party spend. In 2021, our Scope 3\nGHG emissions increased as compared to 2020. While our business\nGRI 305-6 Ozone-depleting substances (ODS)\ntravel decreased sharply due to the pandemic and many employees\nwere able to work from home offices, we continued our manufacturing GRI 305-7 NOx, SOx and other emissions\nand research operations, as well as continued the execution of many\nongoing capital projects. We are committed to controlling air emissions from our facilities to\nreduce local, regional and global environmental impacts.\nOur analysis shows that our Scope 3 GHG emissions impacts are\nnearly eight times greater than our combined Scope 1 and Scope 2 Air emissions are generated by our manufacturing and research\nemissions. We are working to reduce those impacts through activities operations, as well as by burning fuel in on-site equipment and fleet\nsuch as reducing waste in our operations, creating more sustainable vehicles. Our Air Management Standard requires our facilities to\npackaging, and changing the way we commute to work and travel for quantify and control air emissions to comply with both applicable\nbusiness. We are also engaging with our strategic suppliers to identify regulations and emission standards.\nways to reduce GHG emissions in our supply chain. These actions not\nAny increase in production can negatively impact our emissions\nonly reduce our environmental impact, but also benefit the business\ntrends. Though there are efforts to minimize solvent use in\nby reducing costs.\nproduction, solvents are needed for cleaning and disinfecting\nWe report our GHG emissions as required by regulations in certain purposes. As we transform from manufacturing of pharmaceuticals\ncountries and annually through CDP (formerly Carbon Disclosure to biopharmaceuticals, mandatory cleaning and disinfection protocols\nProject). In 2021, CDP graded our Climate Change disclosure as a associated with biologics and vaccines are increasing solvent-based\n“B” or a rating of “management,” indicating that we are “taking emissions. The Montreal Protocol mandates phase-out of refrigerants\ncoordinated action on climate issues.” Additionally, we received an that are ozone-depleting substances (ODS) per schedules approved\n“A-” on our Supplier Engagement Rating (SER) score, which puts us for individual countries. Our facilities strive to maintain compliance\non CDP’s supplier engagement leaderboard. By receiving an A-, we with applicable regulatory requirements that have been established in\nare demonstrating our commitment to engaging with our suppliers accordance with each country’s commitments.\non climate change.\nOur Air Center of Excellence (CoE) provides assistance as needed to our\nOur CDP Climate Change Questionnaire is available on CDP's website. facilities to obtain appropriate environmental permits, and to quantify\nand control air emissions to comply with applicable regulations and\nemission standards.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 108"
  },
  {
    "page": 109,
    "source": "text",
    "content": "CONTINUED: GRI 305-6 | GRI 305-7\nProduction and research emissions These combustion processes result in emissions of carbon dioxide\n(CO₂), nitrogen oxides (NOx), sulfur oxides (SOx) and volatile\nMany of our pharmaceutical manufacturing processes, cleaning/\norganic compounds (VOCs). We strive to make our facilities more\ndisinfection operations and research laboratories require the use of\nenergy efficient through our energy-management programs and\nsolvents. Evaporation of solvents into the air is our primary source\nto improve the fuel efficiency of our fleet vehicles. By making these\nof volatile organic compound (VOC) emissions. In an effort to reduce\nimprovements, we also reduce emissions of CO, NOx, SOx and VOCs\nVOC emissions, reduction in solvent usage has been incorporated as an 2\nfrom our operations.\nelement of our Green & Sustainable Science program (see GRI 301 on\npage 83 for more information). The increase in SOx emissions from 2020 to 2021 can be attributed\nto more accurate emission-tracking methods, increase in combustion\nKey elements of the program include designing efficient processes\nof diesel fuel at one of our facilities, and contribution from increase in\nthat use fewer and less-hazardous organic solvents, and using water-\nusage of jets.\nbased methods for cleaning our process equipment where they are\nas effective as solvent-based methods. To reduce emissions from The decrease in NOx emissions from 2020 to 2021 can be attributed\nprocesses where organic solvents are used, we use pollution-control to the reduced combustion of fuel due to variations in production,\ntechnologies such as conservation vents, carbon filters, thermal as well as our reduced use of emergency generators. VOC emissions\noxidizers, condensers and scrubbers. decreased from 2020 to 2021 due to variations in production, as well\nas data collection improvements with the adoption of more accurate\nFossil fuel combustion emissions emission-tracking methods. Emissions of ozone-depleting substances\nare the result of non-routine releases from temperature-control and\nAir emissions are also generated by burning fuel in our boilers and\nfire-suppression systems and can vary from year to year.\npower-generation turbines (for heat and energy), and by other\ncombustion processes such as thermal oxidizers (for treating air For more information, please refer to the other sections of GRI 305\nemissions) and incinerators (for destroying waste). Our fleet vehicles and GRI 307 on pages 104 and 116, respectively.\nand aircraft also burn fuel and generate air emissions.\nAir pollutant emissions (MT)1 2017 2018 2019 2020 2021\nNitrogen oxides (NOx) 458 470 369 367 348\nSulfur oxides (SOx) 36 29 26 22 25\nVolatile organic compounds (VOCs) 354 382 368 356 310\nOzone-depleting substances (ODS) 0.1 0.3 0.6 0.3 0.3\nNote: Previously reported data have been restated per our methodology, which includes adding facilities that have been acquired and removing facilities that have been sold as operating sites\nor spun-off.\n1 Data are estimated using conservative assumptions and factors, not measured or weighed.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 109"
  },
  {
    "page": 110,
    "source": "text",
    "content": "Waste\nGRI 306 Management approach\nThe proper management of waste from our facilities is important\nto the communities in which we operate and is a focus of our\nenvironmental permits and other regulatory requirements.\nOur waste management standard requires our facilities to comply\nwith applicable generation, management and disposal regulations\nand standards. To minimize our environmental footprint and\nalign with the UN Sustainable Development Goals, we look for\nopportunities to avoid the use of hazardous materials, to reuse or\nrecycle materials and to prevent the generation of waste. When\nprevention, reuse and recycling are not practical or feasible, we\napply controls and treatment technologies to prevent human health\nimpacts and minimize environmental impacts.\nGovernance\nWaste management is overseen globally by our Waste and Dangerous\nGoods Center of Excellence (CoE).\nEach site is responsible for the management of its waste. In many\ncases, we partner with our third-party Integrated Facility Management\n(IFM) partners to manage site waste and work toward realizing the\nwaste goals.\nFor information regarding our environmental management and\ngovernance, and processes used to collect and monitor waste-related\ndata, please see GRI 307 on page 116.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 110"
  },
  {
    "page": 111,
    "source": "text",
    "content": "Waste types are defined differently in various parts of the world. For\nthis report, we have divided our operational waste into two categories:\nWaste generation and significant\nGRI 306-1\nwaste-related impacts • Hazardous waste: Highly regulated or high-risk waste streams that\nneed to be neutralized, treated or destroyed to address a particular\nGRI 306-2 Management of significant waste-related impacts\nhazard such as toxicity, flammability, corrosivity, radioactivity,\npharmaceutically active or infectious\nOperational waste • Non-hazardous waste: This includes all other operational waste\nThe amount of waste we generate reflects the efficiency of our The amount of construction project-related waste can vary\nmanufacturing processes. significantly from year to year based on the number and size of\nprojects. Therefore, our definition of operational waste does not\nOperational waste is primarily generated from the following activities:\ninclude construction or demolition waste from construction projects.\n• Manufacturing\nOver the past few years, a number of countries in Asia have enacted\n• Packaging\nlegislation restricting the acceptance of solid waste from other\n• On-site wastewater treatment countries. Historically, a large percentage of recyclable waste collected\n• Research in the U.S. has been shipped to Asia for recycling, so this change had\nand continues to have the potential to affect the percentage of our\nWaste minimization begins with the upfront evaluation of our product non-hazardous waste sent for recycling. However, this change had\ndesigns and manufacturing processes. Through our Green and minimal impact on our recycling rates in the past year. The percentage\nSustainable Science program (see GRI 301 on page 83), we design of our non-hazardous waste sent for recycling increased from\nprocesses that use safer chemicals, consume less energy, use less 39 percent to 42 percent from 2020 to 2021.\nwater and other resources, and generate less waste. Our process\ndevelopment biologists, chemists and engineers have the expertise In 2021, we allocated approximately $100,000 to waste projects\nto create more sustainable ways to make our products. through the Sustainability Capital Fund.\nWe continuously strive to reduce the amount of operational waste\nwe generate and to maximize the use of environmentally beneficial\ndisposal methods such as recycling, composting and waste-to-energy.\nTo ensure our waste is managed in an environmentally responsible\nmanner, we use only approved waste disposal facilities. Approved\nfacilities demonstrate that they have the systems, technologies and\npractices to manage our waste streams responsibly and in compliance\nwith all applicable requirements. We routinely audit these facilities to\nverify the acceptability of their systems and practices.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 111"
  },
  {
    "page": 112,
    "source": "text",
    "content": "CONTINUED: GRI 306-1 | 306-2\nValue chain waste\nPotential waste-related impacts are also associated with upstream\nactivities such as external manufacturing of active ingredients,\nthe purchase of raw materials and goods, and the return of off-spec\nproduct. Similarly, the impacts downstream of the packaging and\nwaste generated from the use of our products is estimated in our\nScope 3 GHG emissions.\nFor more information, please refer to section GRI 305 on page 104.\nWhile we may not be in full control of the waste generated in our value\nchain, we pursue various initiatives to reduce the impact, for instance,\nthrough our product and material choices.\nSome of these waste-reduction initiatives across our value\nchain include: Waste management goals\n• Eliminating substances of concern from packaging\n• Our Green Supplier program\nGoal\n• Solvent recovery and beneficial reuse\nBy 2025, no more than 20% of our global operational\n• Packaging design efficiency\nwaste will be sent to landfills and incinerators\n• Re-usable shippers (in product distribution) (without energy recovery).\nAccording to our Business Partner Code of Conduct, partners shall\noperate in an environmentally responsible and efficient manner\nProgress:\nto minimize adverse impacts on the environment. Partners are\nencouraged to conserve natural resources, to avoid the use of In 2021, 33% of operational waste was sent to landfill\nhazardous materials where possible and to engage in activities that and incinerators (without energy recovery).\nreuse and recycle.\nFor more information on supplier engagement, please see GRI 308\non page 122.\nGoal\nBy 2025, at least 50% of our sites will send zero\nwaste to landfills.\nProgress:\nIn 2021, 52% of sites sent zero waste to landfill.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 112"
  },
  {
    "page": 113,
    "source": "text",
    "content": "GRI 306-3 Waste generated\nGRI 306-4 Waste diverted from disposal\nGRI 306-5 Waste directed to disposal\nAmount of product accepted for takeback, reuse,\nSASB 250a.4\nor disposal\nGlobal operational waste (% of total) 2017 2018 2019 2020 2021\nIncinerated (without energy recovery) 19% 24% 19% 23% 28%\nLandfilled 10% 9% 7% 5% 5%\nTotal (2025 Goal <20%) 29% 33% 26% 28% 33%\nHazardous waste (MT) 2017 2018 2019 2020 2021\nIncinerated (without energy recovery)1 13,462 17,639 14,025 16,649 22,086\nEnergy recovery 9,538 10,300 13,655 15,330 14,029\nRecycled 7,979 6,827 8,034 8,685 9,824\nOther 2,423 2,221 1,865 1,662 2,824\nReused 1,505 695 1,147 480 1,510\nLandfilled 745 731 938 198 315\nComposted 0 0 0 0 0\nTotal 35,652 38,413 39,674 43,004 50,588\nNote: Data from the Animal Health Intelligence facilities, which were acquired in 2019 and thereafter, are not included in the figures above. These metrics will be reported in the future as\nthese sites become fully integrated into the Company internal reporting processes.\n1 A data collection error was discovered at one of our sites in 2021 that resulted in the amount of hazardous waste being sent for incineration (without energy recovery) to be underreported\nby that site. The data collection process was revised in 2021 to correct this. As a result, the reported values for Hazardous Waste Incinerated (without energy recovery) show an increase\nfrom the values reported in 2020. This is primarily due to this error and is not an actual increase in the quantity of waste sent for incineration (without energy recovery).\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 113"
  },
  {
    "page": 114,
    "source": "text",
    "content": "CONTINUED: GRI 306-3 | GRI 306-4 | GRI 306-5 | SASB 250a.4\nApproximately 19 percent of our hazardous waste was sent offsite\nfor recycling and was either returned to us for reuse or sold to other\nindustries. Another 28 percent was burned to generate power,\ndown from 36 percent in 2020. Regarding the hazardous waste that\ncould not be recycled or beneficially reused, 44 percent of the total\nhazardous waste generated was incinerated without energy recovery,\nup from 39 percent in 2020. Less than one percent was sent to\nhazardous-waste landfills.\nNon-hazardous waste (MT) 2017 2018 2019 2020 2021\nRecycled 15,188 12,975 14,188 13,537 13,073\nEnergy recovery 8,576 9,273 10,030 8,280 7,066\nComposted 4,668 4,798 4,843 4,892 5,872\nLandfilled 6,633 5,684 4,603 4,061 3,702\nOther 212 209 1,025 1,717 266\nReused 1,071 2,204 660 963 583\nIncinerated (without energy recovery) 426 374 477 1,124 850\nTotal 36,774 35,517 35,826 34,574 31,412\nNote: Data from the Animal Health Intelligence facilities, which were acquired in 2019 and thereafter, are not included in the figures above. These metrics will be reported in the future as\nthese sites become fully integrated into the Company internal reporting processes.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 114"
  },
  {
    "page": 115,
    "source": "text",
    "content": "CONTINUED: GRI 306-3 | GRI 306-4 | GRI 306-5 | SASB 250a.4\n19 percent of our non-hazardous waste was composted in 2021,\nan increase from 14 percent in the previous year. Approximately\n42 percent of our non-hazardous waste was sent offsite for recycling,\nan increase from 39 percent in 2020. Another 22 percent was burned\nto generate power, down from 24 percent in 2020. Regarding the\nnon-hazardous waste that could not be recycled or beneficially\nreused, three percent of the total non-hazardous waste generated\nwas incinerated without energy recovery, and 12 percent was sent\nto non-hazardous waste landfills, both unchanged from 2020.\nTotal waste (MT) 2017 2018 2019 2020 2021\nRecycled 23,167 19,802 22,222 22,222 22,897\nEnergy recovery 18,114 19,573 23,685 23,610 21,095\nComposted 4,668 4,798 4,843 4,892 5,872\nLandfilled 7,378 6,415 5,541 4,259 4,017\nOther 2,635 2,430 2,890 3,379 3,090\nReused 2,576 2,899 1,807 1,443 2,093\nIncinerated (without energy recovery)1 13,888 18,013 14,512 17,773 22,936\nTotal 72,426 73,930 75,500 77,578 82,000\nNote: Data from the Animal Health Intelligence facilities, which were acquired in 2019 and thereafter, are not included in the figures above. These metrics will be reported in the future as\nthese sites become fully integrated into the Company internal reporting processes.\n1 A data collection error was discovered at one of our sites in 2021 that resulted in the amount of hazardous waste being sent for incineration (without energy recovery) to be underreported by\nthat site. The data collection process was revised in 2021 to correct this. As a result, the reported values for Hazardous Waste Incinerated (without energy recovery) show an increase from\nthe values reported in 2020. This is primarily due to this error and is not an actual increase in the quantity of waste sent for incineration (without energy recovery).\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 115"
  },
  {
    "page": 116,
    "source": "text",
    "content": "CONTINUED: GRI 306-3 | GRI 306-4 | GRI 306-5 | SASB 250a.4\nIn 2021, we managed approximately 82,000 metric tons of waste Environmental compliance1\nfrom our operations, a 6 percent increase from 2020. Of this total,\n50,588 metric tons were hazardous waste.\nOf the hazardous waste we generated in 2021, 50 percent was\nbeneficially reused (reused, recycled or sent for energy recovery), GRI 307 Management approach\ndown from 57 percent in 2020.\nProtecting our people, our communities and the environment is\nfundamentally important to the way our Company operates, and we\nWe beneficially reused 85 percent of the 31,412 metric tons of\nstrive every day to conduct business in a safe and environmentally\nnonhazardous waste we generated in 2021. We are evaluating and\nresponsible manner. We are committed to providing a safe and healthy\nrefining the programs currently in place at our manufacturing,\nworkplace for our employees and to reducing the environmental\nresearch and office sites to reduce waste generation and\nimpact of our operations around the world. Our core values are focused\nincrease recycling.\nupon promoting the health and safety of our employees and respect\nApproximately 52 percent of our facilities sent zero operational waste for the environment. This is reflected in our Corporate Policy: Respect\nto landfill in 2021, up from 48 percent in 2020, and the percentage of for EHS.\nwaste sent to landfill was unchanged from 2020 at five percent.\nIn addition to complying with all applicable country, regional, state,\nWe continue to work to identify alternate methods of waste provincial and local safety and environmental laws, we strive for\nmanagement that will reduce the amount of waste sent to environmental, health and safety (EHS) performance that is among\nincinerators (without energy recovery) and landfills. the best in the pharmaceutical industry.\nWe do not collect data on the amount of product accepted for We also adhere to the following key operating principles:\ntakeback, reuse or disposal.\n• Maintain a safe and healthy working environment for all employees,\ncontractors and guests\nFor additional information on this topic, please review the following\ndocuments located on the ESG Resources page of our corporate website: • Foster a culture of EHS excellence that is built on science, integrity,\naccountability, personal responsibility, collaboration and active\n• Corporate Policy: Respect for Environmental Health employee participation\nand Safety (EHS)\n• Seek to continuously improve our EHS systems, processes\n• Public Policy Position Statement: Responsible Disposal and standards\nof Medicines in the Household\n• Minimize our impact on the environment by identifying and\n• Sharps Management Plan-CalRecycle implementing approaches to reduce the resources we use during\nthe design, development and manufacture of our products\n• Understand the potential hazards associated with our products\nand take action to minimize any potential risks or adverse impacts\n• Promote EHS excellence in our supply chain by entering into\nbusiness relationships with partners that share our commitment\nto responsible EHS stewardship\n1 Note: Data from the Animal Health Intelligence facilities, which were acquired in 2019 and\nthereafter, are not yet included in the figures above. However, NOVs and fines from these\nfacilities are included in this section.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 116"
  },
  {
    "page": 117,
    "source": "text",
    "content": "CONTINUED: GRI 307\nThe Global Safety and Environment (GSE) department is responsible Training\nfor the global EHS Management System which is based on the “Plan,\nTraining is critical to building worldwide employee competencies\nDo, Check, Act” model. This enables us to assess and continually\nthat will improve compliance, reduce risks and drive continuous\nimprove our practices over time.\nperformance improvement.\nThe model is implemented globally through a set of interwoven\nWe have a global standard that defines the EHS training expectations\nbusiness processes that span the corporation:\nfor employees in three categories:\n• Our planning process includes developing goals, objectives and\n• Manager training covers specific management responsibilities with\nmetrics based on a review of our performance, EHS programs,\nregard to safety and environmental compliance and promoting a\napplicable regulations and external factors that may impact our\n“safety-first” culture\nbusiness (PLAN)\n• EHS professional training designed to expand technical expertise\n• Activities are performed by using standards, guidelines and tools\nand improve our EHS capabilities around the world\nthat are integrated into the EHS Management System and include\nspecific expectations for sites and operating organizations (DO) • Employee training covering the specific information our employees\nneed to perform their jobs in a safe and environmentally compliant\n• Governance committees, from the executive-level EHS Council\nmanner, focusing on hazards they encounter on the job and the\nthrough site-based compliance committees, review business unit\nperformance and progress against objectives throughout the year. corresponding control measures\nEHS audits and self-assessments are also performed throughout\nThese training programs are updated when there are changes to our\nthe year. (CHECK)\nEHS Standards and/or applicable national, regional, state or local\n• Corrective actions and continuous-improvement initiatives are\nrequirements, and are reviewed periodically to ensure that they\nestablished to resolve EHS concerns that have surfaced during\nremain current. Site EHS professionals complete an assessment of the\nperiodic assessments, audits and routine surveillance of the\nactivities performed at their sites and ensure that relevant topics are\nregulatory landscape. We track our corrective actions centrally to\nensure proper oversight. (ACT) included in their site-specific training plans. They develop employee\ntraining curricula to comply with both regulatory and internal training\nWe have robust programs and initiatives to address global challenges requirements specific to their country.\nand opportunities related to achievement of our short- and long-term\nenvironmental management and compliance objectives. Our EHS training program materials are available in both instructor-led\nand e-learning formats. We also conduct periodic web-based seminars\nto inform EHS professionals of changes in regulations, standards and\nCompany practices.\nRecently, we developed a new e-learning course to build organizational\nawareness about environmental sustainability. The training’s objective\nis to help employees understand how they might be able to promote\nenvironmental sustainability in their role at the Company. It defines the\nconcept of environmental sustainability and then takes a closer look at\nwhat it means for our business and our industry.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 117"
  },
  {
    "page": 118,
    "source": "text",
    "content": "CONTINUED: GRI 307\nEHS governance Our corporate EHS organization is responsible for:\nOur commitment to the environment and employee health and • Developing corporate policies, procedures, guidelines,\nstandards, tools and programs to set expectations and to\nsafety begins with our Executive Team, which has established the\nsupport EHS compliance\nEHS Council. The EHS Council comprises senior-level executives\nrepresenting all business units, and is responsible for overall EHS • Providing technical and regulatory support to site-based EHS\ngovernance, as well as for leading and driving enterprise-wide staff and operating organizations\nexcellence in EHS management and performance. The EHS Council • Managing and implementing an internal audit program charged\nmet on a quarterly basis in 2021. with understanding the current state of compliance and identifying\npotential issues\nThe EHS Council’s responsibilities include:\n• Tracking and communicating internal and external trends that\n• Establishing EHS strategy, policy and business risk should be addressed\nmitigation controls\n• Anticipating, tracking and commenting on new regulations\n• Ensuring cross-divisional engagement in the design and affecting our business and, where appropriate, developing plans\nimplementation of EHS business processes to address them\n• Sponsoring and implementing a sustainability strategy • Tracking EHS performance of individual sites, divisions and the\nCompany as a whole, and communicating performance versus\n• Monitoring our EHS performance and establishing continuous\nestablished targets\nimprovement targets\n• Enhancing visibility and transparency of EHS risks, processes Our site-based safety and environmental professionals around the\nand issues world support the EHS needs of their business areas, which include\nmanufacturing, research operations, sales and administrative\nAn EHS Standards Committee has been chartered by the EHS Council\nactivities by:\nto provide stewardship over our EHS Standards and enable business\nengagement in the development of new or revised Standards. • Ensuring that line management fully understands EHS\nEach area of the business is responsible for executing against these requirements, including applicable regulations, permit\nrequirements and EHS Standards\nStandards, contributing to the development of programs, supporting\ninternal audits and communicating significant EHS events. Divisional • Establishing, assessing and improving programs\nEHS compliance committees have also been established to manage,\n• Providing regulatory and technical support to employees and the\nexecute and resolve EHS issues as they arise. operating areas\nThe vice president (VP) of GSE is responsible for communicating to • Routinely assessing performance against our standards, regulatory\nrequirements and performance targets\nour Board of Directors, Executive Team and the EHS Council regarding\nprogress on goals, objectives and metrics, as well as other material • Acting as the primary liaison with local regulators and inspectors\nissues. In addition, this VP partners with business leaders to establish\n• Investigating incidents and near-miss events to identify root\nlong- and short-term goals and performance metrics to drive EHS causes and developing corrective and preventive actions to\nexcellence. Safety and environmental performance targets are prevent recurrence\nincluded in divisional management objectives.\nLearn more about corporate governance at our Company in GRI 102-18\non page 41.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 118"
  },
  {
    "page": 119,
    "source": "text",
    "content": "CONTINUED: GRI 307\nInternal auditing Remote audits were accomplished using technology tools such as\nvideo conferencing, use of electronic document repositories and\nWe have a detailed and rigorous EHS audit program. Our audit leaders\nboth real-time and recorded videography, and 92 percent of the\nare full-time professional EHS auditors with extensive experience in\nremote audits were followed up with an on-site field review of the\nauditing a broad range of EHS programs. The individual audit teams\nfindings identified.\nconsist of EHS professionals with extensive site and subject-matter\nexpertise. In many cases, particularly outside of the U.S., our internal A survey by the National Association for Environmental, Health &\nauditors work with independent consultants who have regulatory Safety and Sustainability Management (NAEM) found that remote\nexpertise in the laws of the host country. EHS auditing has increased since the onset of the pandemic for the\ncompanies responding to the survey. Most companies (68 percent)\nAll audit findings are addressed through the development of corrective\nresponded that they were currently piloting or conducting virtual\nand preventive action (CAPA) plans, which are reviewed, approved by\naudits in some capacity.\nthe audit leader and regional EHS leader, and tracked to completion.\nThis process includes senior management oversight. Findings from Regular internal Quality Assurance Reviews of the program are\nour audit program are communicated to appropriate parts of the performed by our Corporate Audit and Assurance Services at least\norganization so that learnings may be shared and preventative actions every three years. The most recent review of the EHS auditing\ncan be taken, and audit performance and key program metrics are program was performed in March 2021, and resulted in a rating of\nreviewed as part of our governance process. “Effective” with controls and practices deemed to be in line with our\nrequirements and expectations.\nWe use multiple factors to determine the audit frequency of our\nfacilities, including facility size, operational complexity, compliance In addition to our corporate EHS audit program, our sites regularly\nstatus and performance history. Our most complex operations are perform self-inspections and review compliance with permit\naudited every year, and all manufacturing and research operations conditions, regulatory requirements and Company EHS Standards,\nare audited at least every three years. Less complex facilities, such with all programs being evaluated at least once every three years.\nas sales and business offices, are audited less frequently. In 2021,\nwe performed 53 corporate EHS audits, involving 669 auditor days\nCertification\nof remote review and on-site activities.\nWe are certified in the Responsible Care Management System®\nTo support safety and environmental compliance on our capital Technical Specification RC101.06, 2019. The RCMS® recertification\nprojects, EHS audits of selected Global Engineering Solution (GES) occurred on December 4, 2019.\nprojects were initiated in 2021. Three GES capital projects were\naudited in 2021, and four project audits are planned in 2022. According Additionally, our corporate EHS management system is generally\nto the 10th Biennial EHS Audit Practices Survey by International aligned with the requirements of the International Standards\nAudit Practice Consortium (IAPC©), approximately 25 percent of the Organization (ISO), but we do not pursue certification under the\ncompanies surveyed include major capital/construction projects in the Environmental (ISO 14001) or Safety (ISO 45001) frameworks at the\nscope of their EHS audit programs. global level. Some of our facilities have individually achieved ISO 14001\ncertification to meet customer requirements.\nIn 2021, the EHS audit process continued to be affected by COVID-19\npandemic restrictions, with a remote audit methodology predominant.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 119"
  },
  {
    "page": 120,
    "source": "text",
    "content": "CONTINUED: GRI 307\nRemediation\nEnvironmental management practices have evolved significantly over\nthe past few decades.\nWith research and manufacturing operations dating back more than\n100 years, some of our facilities operated at a time when there were\nfew regulations and little understanding of good environmental\npractices. Because we are responsible for remediation of these\nsites, we have launched investigations, developed science-based\nremediation plans and implemented cleanup projects to protect the\nhealth and safety of our neighbors, communities, employees and the\nenvironment, and comply with all applicable requirements.\nOver time, we have acquired properties and manufacturing facilities\nthat may not have been subject to the same EHS management\nstandards that we have in place today. We are also investigating and\nremediating those properties where necessary.\nExpenditures for remediation and environmental liabilities were\n$12 million in 2021 and are estimated to be $24 million in the\naggregate for the years 2022 through 2026. In management’s opinion,\nthe liabilities for all environmental matters that are probable and\nreasonably estimable have been accrued and totaled $40 million\nand $43 million at December 31, 2021 and 2020, respectively.\nEnvironmental data collection\nWe measure and monitor environmental data for all global\nmanufacturing and research sites, as well as large office buildings.\nAll metrics are entered quarterly by sites into an enterprise data\ncollection and reporting software system as part of our internal\nEnvironmental Data Collection (EDC) process. The data is reviewed at\nthe corporate level on a quarterly basis to monitor sites’ progress and\nassist the sites as needed to support work toward our goals.\nFor additional information on this topic please review the following\ndocuments located on the ESG Resources page of our corporate website:\n• Corporate Policy: Respect for EHS\n• Public Policy Position Statement: Pharmaceuticals in the Environment\n• Public Policy Position Statement: Responsible Disposal of Medicines\nin the Household\n• Global Antimicrobial Resistance Action Plan\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 120"
  },
  {
    "page": 121,
    "source": "text",
    "content": "Notices of violations, fines and settlements\nNon-compliance with environmental laws We report all forms of EHS compliance notices using the term Notices\nGRI 307-1\nand regulations of Violation (NOVs), which includes citations, letters of warning and\nnotices of noncompliance from environmental and safety-focused\nOur centralized EHS information system allows us to collect, manage,\nregulatory agencies.\nlearn from and share our safety and environmental performance data\nmore efficiently. In 2021, we had 156 EHS-related regulatory agency inspections\nof our facilities around the world. We received two safety-related\nWe collect and analyze data in both leading and lagging metrics to\nand 16 environmental-related NOVs, and paid $192,606 in fines in\nlook for potential trends and identify opportunities that can help drive\n2021. None of the environmental-related NOVs were the result of\nperformance improvement. We continuously explore new ways to\na significant spill.\nlearn from and report on our performance.\nSafety and environmental performance targets are included in divisional\nmanagement objectives. In addition, all employees are eligible for special\nrecognition for innovative ideas and projects related to improving EHS\naspects of our operations.\nNotices of violations (NOVs)\nand citations 2017 2018 2019 2020 2021\nEnvironmental 5 6 9 9 16\nSafety 3 1 4 3 2\nFines 2017 2018 2019 2020 2021\nEnvironmental fines paid $0 $0 $17,690 $21,022 $191,870\nNumber of environmental fines 0 0 3 3 4\nSafety fines paid $0 $0 $0 $0 $736\nNumber of safety fines 0 0 0 0 1\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 121"
  },
  {
    "page": 122,
    "source": "text",
    "content": "Supplier environmental External manufacturing\nExternal manufacturers of active pharmaceutical ingredients\nassessment\nand finished products are screened for Environmental Health and\nSafety (EHS) compliance, in addition to quality, supply and technical\ncompetence requirements. The EHS screening and on-site assessment\nis led by Global Safety and the Environment (GSE) and includes a\nGRI 308 Management approach survey covering such topics as regulatory compliance, fatalities\nand major incidents.\nEnvironmental sustainability principles are integrated in each stage\nBased on the screening results and activities undertaken by the\nof our supplier management program. Our Global Supplier\nsupplier, certain external manufacturers are subject to a more\nManagement Group (GSMG) drives the program and maintains the\ndetailed on-site assessment conducted by a multidisciplinary team,\nassociated standards and processes by which suppliers are identified,\nwhich may include our Quality, GSE, Global Technical Operations\nqualified and managed. The environmental sustainability program\nand GSMG representatives.\nis integrated with social responsibility and economic inclusion and\nsupplier diversity (EI&SD).\nThe external manufacturers we contract with are periodically\nreassessed using a risk-based approach; higher-risk external\nPlease visit GRI 102-9 on page 30, GRI 204 on page 75 and GRI 404\nmanufacturers are subject to more frequent on-site assessments.\non page 142 for additional information regarding our integrated approach\nwith our suppliers.\nWe expect that observations made during the audit process will be\nremediated by our external manufacturers, and we monitor and track\ncorrective actions through completion.\nSince 2020, the EHS audit schedule has been impacted by the\nCOVID-19 pandemic. Priority was given to new supplier reviews\n(due diligence) versus current supplier reviews, in our support of the\nsupply chain. Whenever possible, assessments were completed in\nperson. However, some assessments were completely virtual or a\ncombination thereof.\nPharmaceutical Supply Chain Initiative\n(PSCI) Environment Task Team\nWe co-lead the PSCI Environment Team and work together with GSE\nand peer organizations to develop supplier survey(s), training, tools\nand maturity modeling.\nSince 2016, this team has been working together to standardize\nPSCI’s environmental supplier data request to reduce the number of\ndifferent requests to suppliers and to minimize the number of surveys\nsuppliers receive.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 122"
  },
  {
    "page": 123,
    "source": "text",
    "content": "CONTINUED: GRI 308\nThe survey covers greenhouse gas emissions, energy, waste and water, Pharmaceutical Environmental Group (PEG)\nand is in four sections:\nPEG is a group of large pharmaceutical organizations that develop\n• Established program: alignment with the Code of Conduct training and strategy for environmental matters specific to the\n• Manage impact: data for each environmental indicator pharmaceutical industry. We are active members and are involved with\nall PEG sub-teams. In 2021, the PEG Climate sub-team developed the\n• Reduce emissions: environmental targets\nEnergize program to educate suppliers on sourcing renewable energy.\n• Apportion emissions: supplier emissions that are specific\nTen members worked with Schneider Electric to design the Energize\nto each company\nwebsite, training materials and outreach programs. We are currently\nworking with numerous organizations to ensure supplier awareness\nIn 2020, we updated the survey to include questions related to science-\nand utilization of the program.\nbased targets (SBT) for greenhouse gas (GHG) emissions reductions.\nIn 2021, we focused on collecting GHG data at the category level in\nlieu of the PSCI Environmental Survey in the Ecodesk system. We are\ncontinuing to evaluate our supplier environmental data and what is\nrequired to track progress toward our new, more robust Scope 3 goals.\nExternal\nBelow is a summary of the training and tools developed and/or\nmanufacturing\nprovided by the Environment Team in 2021:\nEHS assessments 2017 2018 2019 2020 2021\n• 10 environmental sustainability guides\n• 14 responsible sourcing guides for key materials Prospective external 37 65 43 50 42\nmanufacturers\n• Responsible Sourcing of Raw Materials training\n• Sustainable Packaging training Current external 53 61 48 27 54\n• Revised PSCI Principles training manufacturers\n• Scope 3 Guidance Total 90 126 91 77 96\n• Scope 3 Awareness Training\n• Supplier Maturity Model\n• Supplier Training Matrix\n• Responsible Sourcing Training\n• Product Stewardship Regulation Overview\n• Chemical Legislation Overview\nWe worked with PSCI to provide environmental training to our\nsuppliers. These initiatives ensure a consistent message and approach\nwith our suppliers across the industry. Working together with PSCI,\nwe provide these tools and resources on PSCI’s platform and in\nwebinars. We also provide these tools for our employees on an internal\nGSMG webpage.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 123"
  },
  {
    "page": 124,
    "source": "text",
    "content": "Social\nSee our GRI index on page 183.\nEmployment We expanded our enterprise-wide leadership development\nprograms in 2021 by offering new affinity group offerings that are\nfocused on developing strengths and addressing challenges that\nare unique to a given demographic. In the U.S., underrepresented\nethnic groups represented 38 percent of our enterprise-wide\nGRI 401 Management approach\nleadership development program participants in 2021.\nThroughout 2021, we remained anchored in driving greater cultural\nWe hire passionate people who believe in taking on the world’s most transformation by focusing on our Ways of Working mindsets and\npressing health issues. Our people are one of our greatest assets, and behaviors. We encouraged colleagues to engage deeper in the five\nwe seek to maximize each employee’s potential and the contributions behavioral and mindset shifts, reinforcing a culture that values how\nthey bring each day to deliver on the Company’s purpose. Our focus we work as much as what we achieve.\nis to enable every employee to continuously learn and grow, creating\na greater connection to the organization and accelerating the We continue to measure the impact of our Ways of Working. At the\ndevelopment of all talent. end of 2021, approximately 18,000 employees completed a self-\nassessment on the Ways of Working to build their capabilities and\nWe aspire to enrich the entire employee career experience while achieve the mindsets required to foster innovation. We piloted\nalso ensuring we develop and execute on talent strategies aligned to a new Ways of Working 360 assessment to help leaders identify\nour business priorities. Our commitment to our employees remains behavior strengths and areas of opportunity. Colleagues continue\nunchanged throughout the years. We believe our employees are at to use our internal recognition platform, INSPIRE, to recognize\nthe center of everything we do. Leading from this foundation fuels our others in their Ways of Working journey. In 2021, we surpassed\nefforts to ensure we are succeeding in attracting, developing, retaining 1,000,000 INSPIRE moments of recognition in the platform.\nand inspiring our employees. To execute on these priorities and ensure\nsuccess, we have enhanced our development program offerings while\nalso remaining anchored in driving our culture transformation forward.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 124"
  },
  {
    "page": 125,
    "source": "text",
    "content": "GRI 401-1 New employee hires and turnover\nSASB 330a.1 Talent recruitment and retention efforts for R&D personnel\nSASB 330a.2 Voluntary and involuntary turnover rate for: executives and senior managers, midlevel managers, professionals and all others\nTurnover Overall Voluntary Turnover\n(global) 2017 2018 2019 2020 2021 Turnover by turnover turnover distribution\ndivision (2021) rate 1 rate by gender and\nOverall\n10.7% 11.8% 9.9% 8.5% 11.1% region (2021) Female Male\nturnover rate1 Animal Health 8.4% 6.2%\nVoluntary Overall 48% 52%\n6.5% 6.8% 6.9% 6.0% 8.8% Communication 8.4% 7.9%\nturnover rate\nand Policy Asia Pacific 49% 51%\n1 I ncludes all types of turnover of regular employees. Regular employees\nare defined as employees who do not have a predetermined end date Corp Compliance 4.4% 4.4% EEMEA 50% 50%\nto employment.\nGlobal Services 9.8% 8.2% Latin America 48% 52%\nOverall Voluntary Global Human Health 16.2% 12.6% Europe 45% 55%\nTurnover by turnover turnover Human Resources 13.9% 9.5% Japan 42% 58%\nregion (2021) rate 1 rate\nLegal, Security, 8.3% 6.9% U.S. 47% 53%\nAsia Pacific 12.6% 10.3% Safety &\nChina 52% 48%\nEnvironment\nLatin America 11.3% 5.7%\nCanada 54% 46%\nEEMEA (Eastern Manufacturing 8.7% 6.1%\nEurope, Middle 15.5% 9.4% Division Notes: Data above includes all types of turnover of regular employees.\nEast and Africa) Regular employees are defined as employees who do not have a\nResearch 9.6% 8.9% predetermined end date to employment. To align with U.S. government\nreporting requirements, the ESG data for gender diversity in this\nJapan 3.1% 2.6% Laboratories\nreport uses the terms men and women. We recognize and embrace the\ngender spectrum and diversity in our employees, and have internally\nEurope 8.6% 5.4% Population Health & 9.2% 7.4% established voluntary Self-ID options for employees to self-report\non their gender identity. The totals in this report may not equal 100\nU.S. 8.7% 8.0% Sustainability percent due to rounding or employees who have not reported their\ngender and/or race/ethnicity.\nChina 29.2% 25.0% Strategy, BD, IT 8.0% 6.7%\nCanada 9.5% 8.4% Note: As of third quarter, 2021, new divisions (Communication and\nPolicy, Population Health & Sustainability and Strategy, BD, IT) added\nto our organization.\n1 I ncludes all types of turnover of regular employees. Regular employees\n1 I ncludes all types of turnover of regular employees. Regular employees\nare defined as employees who do not have a predetermined end date\nare defined as employees who do not have a predetermined end date\nto employment.\nto employment.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 125"
  },
  {
    "page": 126,
    "source": "text",
    "content": "CONTINUED: GRI 401-1 | SASB 330a.1 | SASB 330a.2\nEmployee hires by region 2017 2018 2019 2020 2021\nAsia Pacific (excl. China for years 2020 & 2021)\nNumber of hires 1,909 3,071 2,727 597 588\nHire rate1 16.1% 24.4% 20.8% 8.9% 10.0%\nEEMEA\nNumber of hires 378 505 605 360 373\nHire rate1 13.7% 16.7% 18.8% 10.7% 13.8%\nLatin America\nNumber of hires 1,246 714 558 459 496\nHire rate1 23.8% 13.1% 10.5% 8.4% 10.5%\nEurope and Canada (excl. Canada for years 2020 & 2021)\nNumber of hires 1,865 2,495 2,624 1,754 1,709\nHire rate1 9.8% 12.3% 12.3% 8.4% 9.5%\nJapan\nNumber of hires 109 153 121 143 120\nHire rate1 2.8% 4.3% 3.4% 4.4% 3.8%\nU.S.\nNumber of hires 2,173 3,019 2,654 3,193 3,443\nHire rate1 9.1% 12.4% 10.5% 11.9% 13.1%\nChina\nNumber of hires NR NR NR 2,149 1,907\nHire rate1 NR NR NR 29.5% 31.5%\nCanada\nNumber of hires NR NR NR 50 73\nHire rate1 NR NR NR 7.5% 12.8%\nNR: Not reported.\n1 Percentage of new hires in the total onboard head count; regular employees only. Regular employees are defined as employees who do not have a predetermined end date to employment.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 126"
  },
  {
    "page": 127,
    "source": "text",
    "content": "CONTINUED: GRI 401-1 | SASB 330a.1 | SASB 330a.2\nWe use a strategic approach to ensure recruiting, retention and Our aim for 2022 is to increase our hiring commitments across both\nleadership development goals are systematically executed throughout programs along with other early talent initiatives, in addition to\nthe Company. We hire talented leaders to achieve improved gender introducing a new apprenticeship program. Overall, we were successful\nparity and representation across all dimensions of diversity. We in identifying, sourcing and attracting critical talent during another\nprovide training to our managers and external recruiting organizations highly unusual year.\non strategies to mitigate unconscious bias in the candidate\nselection and hiring process. In addition, we utilize a comprehensive\ncommunications strategy, marketing outreach, social media and\nstrategic alliance partnerships to reach a broad and diverse pool of GRI 401-2 Benefits provided to full-time employees\ntalent across our business. Talent recruitment and retention efforts for\nSASB 330a.1\nR&D personnel\nIn 2021, our turnover increased by 2.6 percent from 2020. This is a\nVoluntary and involuntary turnover rate for:\ncurrent trend we continue to see across the general marketplace.\nSASB 330a.2 executives and senior managers, midlevel\nHowever, we are thankful we still remain below external market\nmanagers, professionals and all others\nbenchmarks. Our largest area of turnover was China, which is an\nextremely buoyant market. From a divisional perspective, our Human\nHealth division experienced the highest turnover. We recognize that our employees are vital to our purpose of improving\nand saving lives worldwide. One way we recognize the importance\nHowever, despite a continuing pandemic, we did not see a slowdown of our people is to provide a valuable suite of benefits and wellbeing\nin recruitment. Hiring in 2021 saw consistent or increased demand for programs and resources for every stage of life.\nheadcount in line with our 2020 needs. In the U.S., our highest volume\nhiring market, hiring increased in 2021 versus 2020 by eight percent, Our comprehensive benefits package is aligned to the Company’s\nlargely due to growth and investment in our U.S. manufacturing values and culture, designed to provide high-quality and cost-efficient\ndivision plants and continued growth in our R&D division. programs that support the needs of our business and those of our\ndiverse workforce with what they need when they need it.\nChina’s 2021 hiring also remained on pace with 2020, which was\nas expected to support our growth strategy in that market across Health and wellbeing\nOncology and Vaccines in Global Human Health, and in our R&D\ndivision. We continue to focus on securing digital, analytical and Employees across the world enjoy health and welfare coverage, which\nautomation skillsets across all divisions. varies by region and country, and focuses on our commitment to\nphysical, mental and social wellbeing.\nWe significantly increased our efforts around creating a diverse\nworkforce through our sourcing, branding and selection processes. Our integrated approach to wellbeing is based on employee needs.\nWe successfully collaborated with a number of external partners to It offers our employees and their dependents a wide range of health\nattract diverse candidates across many different demographics to programs, resources, activity challenges and tools to cultivate healthy\nour Company. Our 2021 hiring achieved an overall 50/50 split across behaviors and enhance their lives.\ngender. We have continued to invest in two diversity hiring programs\nOur Wellbeing Report demonstrates the priority we place on\nin the U.S.:\nemployee wellbeing and our commitment to hold ourselves\n• OneTen: Focused on creating sustainable jobs for Black Americans accountable to measure our progress, celebrate successes and\nwithout a four-year degree\nconstantly raise the bar for our employees and their families.\n• Year Up: A diverse, early talent intern program\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 127"
  },
  {
    "page": 128,
    "source": "text",
    "content": "CONTINUED: GRI 401-2 | SASB 330a.1 | SASB 330a.2\nHealth advocacy (U.S.) Other programs to support wellbeing (U.S.)\nWithin the U.S., our medical plan helps support our members with We offer many programs to help make it easier for employees\nan advocacy solution, designed to help them navigate the health care to balance their various responsibilities. The following is a\nsystem and save time by: non-exhaustive sampling:\n• Providing help with health care insurance claims and estimates • Caregiving support\n• Finding providers, specialists, facilities and experts • Transportation services\n• Coordinating care and helping to manage complex • Backup dependent care\nmedical conditions\n• Childcare support\n• Scheduling appointments for physicians, treatments and tests\n• K–12 educational guidance\n• Offering referrals to other Company programs\n• Special-needs counseling\n• Adoption and surrogacy assistance\nCommitment to mental health (global)\n• Fast access to high-quality cancer care\nWe firmly believe in the importance of emotional wellbeing awareness,\n• Employee assistance and work-life services program\nand pride ourselves in providing colleagues globally with resources to\nhelp them balance their personal and professional lives. • Summer hours\n• Paid parental time off (for more information, please see GRI 401-3\nAs part of this offering, every employee and their household\non page 131)\nmembers have access to our global Employee Assistance Program,\nwhich provides: • Disaster relief benefits\n• Breastmilk shipping\n• In-the-moment telephone support for daily relationship\nchallenges, work issues and everyday stress • Tobacco cessation\n• Professional counseling sessions\nHow we have helped employees through COVID-19\n• Work-life services for everyday help and everyday needs,\nsuch as finding assisted living for an aging parent or support During the pandemic, we updated and added programs to assist\nwith childcare services employees and their families with the many challenges resulting\n• Crisis support for unanticipated events from COVID-19.\nIn addition to this program, we provide other resources such as mental Outside the U.S., we support 100 percent coverage of COVID-19-\nhealth awareness training and webcasts by world-class speakers on related testing, diagnosis and treatment, as well as paid leave\nmental health topics. Also available are live and recorded exercise during quarantine.\nclasses, mindfulness sessions and a network of mental-health\nchampions that provide local support. In 2021, we introduced Calm,\nan app designed to reduce stress and anxiety, free for all employees\nand their dependents globally. Also in 2021, we added Lyra Health in\nthe U.S. This high-quality mental health provider network matches\nemployees in need with clinically appropriate treatments to help them\nget better faster.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 128"
  },
  {
    "page": 129,
    "source": "text",
    "content": "CONTINUED: GRI 401-2 | SASB 330a.1 | SASB 330a.2\nIn the U.S., we have offered: To show our commitment to workplace flexibility, we provide a wide\nrange of resources to help employees with home office setup, including\n• 100 percent coverage for testing, diagnosis and treatment\ntips for ergonomics, wellbeing office stretches and more. In 2021, we\nof COVID-19 and telemedicine for any reason through the\nmedical plan introduced an employee purchase program to make ordering supplies\nand equipment easy for employees in the U.S.\n• Subsidized on-site daycare centers with expanded safety protocols\n• Regular and backup childcare\nTime off and leave policies\n• Remote tutoring\nFor employees outside the U.S., time off and leave benefits are based\n• Caregiving coordinator for employees and their loved ones on local laws and market practices. For U.S.-based employees not\n• Flexible Spending Account updates (e.g., allow rollovers and subject to a collective bargaining agreement, we offer three to six\nmidyear changes) weeks of vacation depending on years of service, 16 holidays and\nvarious other paid time off or leaves of absence to help employees\n• Free online fitness classes\ntake time off when they need it.\n• High-quality mental health provider network\n• Mental health training for managers and employees Financial security and retirement benefits\n• 401(k) withdrawals Worldwide, we offer core and ancillary financial security and\nretirement benefits that routinely rank amongst the most valuable\nFlexible work arrangements (global) and progressive of other large multinational corporations.\nWe believe flexible work arrangements offer a different way of working Outside the U.S., we have more than 80 pension plans (including\nand can enhance employees’ commitment to the Company, foster defined benefit, cash balance and defined contribution plans) in over\nteamwork, increase productivity and support work-life balance. We 40 countries. These plans often supplement government-sponsored\nhave had a global flexible work arrangement policy since 2008. social security pension benefits to improve employees’ financial\nsecurity through added retirement income.\nIn 2021, we expanded our policy and introduced a hybrid workplace\nstrategy for employees in office-based roles. This model helps us In the U.S., we offer a defined benefit pension plan as well as a 401(k)\nbe even more agile and productive as we deliver outcomes for the plan with matching contributions. The average contribution rate of pay\npeople who depend on our work. Flexibility reflects our belief that job into this plan is approximately 9.26 percent. Approximately 97 percent\neffectiveness is determined by employee performance and results, of U.S.-based employees participate in this retirement plan, and\nnot by the number of hours seen in the office. What is produced or 100 percent participate in the pension plan. Additionally, U.S.-based\naccomplished is more important than when or where the work employees who are at least age 55 and those who have at least 10 years\nis completed. of service after age 40 are eligible for subsidized medical benefits\nat retirement.\nEmployees and compensation 2017 2018 2019 2020 2021\nTotal compensation paid to employees/payroll, $8.65 $8.98 $9.56 $10.18 $9.92\nincluding benefits (in billions)\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 129"
  },
  {
    "page": 130,
    "source": "text",
    "content": "CONTINUED: GRI 401-2 | SASB 330a.1 | SASB 330a.2\nAlso, in the U.S., we offer: Skills-based volunteer program\n• Comprehensive financial planning, a valuable benefit provided at Our skills-based volunteer program operated through 2021 and\nno cost to employees. This service helps with budgeting, saving, offered employees the opportunity to donate their professional skills\ninvesting, estate and tax planning, as well as selecting benefits through virtual, short-term projects that provide important capacity-\noptions and other financial planning guidance.\nbuilding support for nonprofit organizations. The program expanded\n• Educational assistance, which provides financial support for opportunities for employees to grow and develop while giving back to\nhigher education the community.\n• Access to student loan consolidation and refinancing options\nPro bono program\n• Banking through our credit union, which offers competitive\ninterest rates on savings accounts and lending Our Company’s pro bono program provides voluntary legal services\n• Employee discounts on a wide range of products and services to those in need and has been serving the poor and disadvantaged\nfor 27 years. It is led by the Office of General Counsel. The program\n• Pet insurance for the eligible other members of our\nprovides opportunities for our staff and legal professionals worldwide\nemployees’ families\nto provide their expertise, free of charge, to members of the\n• Access to legal services benefit\ncommunity who would otherwise be unable to access legal advice or\nsupport on a range of issues including family law, veterans’ affairs,\nEmployee volunteering child advocacy and others. Throughout 2021, attorneys, non-attorney\nprofessionals, paralegals and administrative associates provided more\nEach year, our employees around the world take an active role in giving\nthan 2,300 hours of pro bono legal services.\nback to their communities by donating thousands of volunteer hours\nto help improve health and wellbeing through a range of volunteer\nMedical volunteering—COVID-19\nactivities. In 2021, we saw an increase in employee volunteer hours\nover 2020. However, the COVID-19 pandemic continued to impact the In 2020, in response to the pandemic, we changed our volunteer\ntotal number of hours reported by employees. policy to support employees with medical backgrounds. Recognizing\nthe need for additional health care professionals—including doctors,\nFellowship for Global Health nurses and medical laboratory technicians—to assist in regions where\nCOVID-19 had spread, we removed the cap of 40 hours of paid time\nOur purpose to save and improve lives underpins the idea behind the\noff to volunteer for these individuals. We continued this policy in 2021\nFellowship for Global Health.\nas the pandemic continued to challenge health systems globally. In\nthe U.S. for example, employees with a medical background reported\nThe Fellowship for Global Health is a three-month, corporate pro\nvolunteering more than 2,800 hours in 2021.\nbono program designed to leverage the skills and talents of our\nemployees worldwide. The Company continually seeks innovative ways\nto increase access to health around the world while also growing and\ndeveloping our talent. The Fellowship for Global Health is one way that\nwe can accomplish both objectives. In 2021, the program resumed in\nOver 2,800 Over 2,300\na completely virtual format.\nhours volunteered hours of pro bono legal\nLearn more about how our Fellows are helping communities.\nthrough COVID-19 medical services in 2021\nvolunteering program in 2021\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 130"
  },
  {
    "page": 131,
    "source": "text",
    "content": "CONTINUED: GRI 401-2 | SASB 330a.1 | SASB 330a.2\nEmployee volunteering 2017 2018 2019 2020 2021\nEmployees who volunteered 1 6,560 6,557 14,395 985 1,786\nEmployees who used paid time off (PTO) 2 4,870 4,795 7,301 411 883\nTotal recorded volunteer hours (TRVH) 114,903 114,393 136,014 46,278 68,300\nSkilled volunteer hours 3 19,468 18,317 19,907 3,977 16,904\n1 2021 figures are based on employee self-recorded volunteer hours and volunteer hours communicated directly to the Office of Social Business Innovation for certain countries and functions.\n2 Figures based on estimated data.\n3 Figure includes aggregate reported hours from our major skills-based volunteer initiatives—the MSD Fellowship for Global Health, SkillShare and Pro Bono program. It also includes hours\nrecorded for U.S. employees with a health care background that volunteered to assist with the COVID-19 pandemic.\nunplanned events from all aspects of our operations through a\ncomprehensive EHS program. Each year, we set targets and track\nGRI 401-3 Parental leave leading and lagging safety metrics. These metrics include safety\nobservations, near-miss incidents, peer safety reviews, Recordable\nInjury Rates (RIR), Lost Time Injury Rates (LTIR) and Days Away,\nIn 2021, we increased the amount of paid parental time off in the Restricted or Transferred (DART) rates. Please see GRI 403-9 on\nU.S. from six weeks to 12 weeks for employees who become parents page 138 for our performance on these metrics.\nthrough the birth, adoption or surrogacy of a child regardless of\nthe employee's sex, marital status, sexual orientation or gender All employees, service providers and Company-managed contractors\nidentity. A 12-week minimum of paid parental leave will be applied to must follow the standards and requirements in our EHS management\nemployees globally by the end of 2022. In addition to parental leave, system. Compliance with these requirements is measured through site\nU.S. employees receive separate, paid, unpaid and job-protected leave audit processes and through peer reviews for construction.\nto care for a newborn child, adopted child or child placed in foster care\nMore information on our approach to occupational health and\nfollowing the child’s birth.\nsafety, specifically our key operating principles, EHS governance, internal\nauditing and certification, can be found in GRI 307 on page 116.\nOccupational health and safety\nFor more information regarding the occupational health and safety\nexpectations in our value chain, please refer to our Business Partner\nCode of Conduct.\nGRI 403 Management approach\nAs a global health care Company, we strive to provide a safe and\nhealthy workplace. We seek to reduce environmental, health and\nsafety (EHS) risks to eliminate work-related injuries, illnesses and\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 131"
  },
  {
    "page": 132,
    "source": "text",
    "content": "CONTINUED: GRI 403\nInternational standards An example of employee EHS engagement is our active Employee\nSafety Committees. These Committees include workers and\nWe are committed to providing a safe and healthy workplace\nmanagement and are designed to allow for a partnership to proactively\nthat complies with all applicable safety laws and regulations. In\naddress EHS issues.\naddition, we aim for EHS performance that is among the best in\nthe pharmaceutical industry. We address the following areas in our approach to employee and\ncontractor safety, which are discussed in more detail in GRI 403-2 on\nOur Company has processes in place that are consistent with the\npage 132 and GRI 403-3 on page 136:\nInternational Labour Office (ILO) Code of Practice on Recording and\nNotification of Occupational Accidents and Diseases (the Code) in • Hazard identification, risk assessment and incident investigation\ncountries that have adopted the Code. In countries that have not (403-2)\nadopted the Code, we report to governments in a manner that is\n• Non-routine hazardous work (403-2)\nconsistent with applicable law.\n• Capital projects construction safety (403-2)\nFor consistency across the Company, and to enable us to compare our • Safety for non-Company personnel (403-2)\ninjury rates with those of other multinational companies, we use the\n• Motor-vehicle safety (403-2)\nU.S.-based OSHA recordkeeping criteria for recording and tracking\nwork-related injuries and illnesses. We require all injuries, illnesses and • Emergency response (403-2)\nincidents involving our employees to be reported and investigated to • Loss prevention (403-2)\ndetermine their cause. We also require corrective and preventative\n• Industrial hygiene (403-3)\nactions be taken to prevent recurrence. We have reviewed the ISO\n• Biological safety (403-3)\n18001 Standard; however, we have not pursued certification because\nwe believe that our current EHS management systems are robust and • Ergonomics (403-3)\nachieve our desired levels of EHS performance.\nFor information on our Global Safety and Environment (GSE)\nEHS Management System, please visit GRI 307 on page 116.\nOccupational health and safety\nGRI 403-1\nmanagement system\nHazard identification, risk assessment,\nGRI 403-2\nand incident investigation\nOur Company’s EHS management system includes comprehensive\nprograms focused on reducing risks, work-related injuries/illnesses and\nother safety incidents from our operations. We focus on safe facility\nOur process safety program identifies controls and manages risks\ndesign, process controls, operation and maintenance procedures,\nassociated with the manufacturing and handling of our human and\nprotection systems and emergency-response capabilities.\nanimal health products. The program applies to operations that are\nsubject to process safety regulations and also to our pilot plants,\nOur EHS Management System supports a proactive EHS culture and\nmanufacturing operations and utility areas where process hazards\nour Company’s objectives. We strive to achieve a strong EHS culture\nmay exist. In addition, we have implemented a structured chemical-\nthrough visible leadership, active employee engagement and a focus\nreaction-hazard review program for our research laboratories.\non proactive identification and elimination of hazards.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 132"
  },
  {
    "page": 133,
    "source": "text",
    "content": "CONTINUED: GRI 403-2\nIn the early stages of product development, we conduct chemical Our construction safety program mandates pre-job planning, hazard\nreaction and thermal testing of our intermediate materials and assessments and daily safety checks. We also conduct peer reviews\nproducts to identify potential reactivity, fire and explosion hazards by bringing together in-house engineers, contractors, the EHS\nand environmental risks. This testing continues throughout the life construction team and other partners to conduct thorough project\ncycle of each product to assure that we are aware of the process safety evaluations and sharing of best practices. We completed\nrisks of each material and can properly manage these risks. Global 125 peer safety reviews in 2021, covering 95 percent of our active\nprocess safety professionals work with operations and engineering projects that were chosen for Peer Safety Reviews.\npersonnel to conduct process hazard analyses to thoroughly\nThe construction industry continues to see a negative trend related\nevaluate our operations. These structured reviews take place\nto the availability of contractor and craft resources. The impacts of\nduring the initial process design, final process design, initial start-up\nthis trend require management of resource availability issues, varied\nand throughout the life of the process. This ensures our facility\nlevels of experience and safety competencies. GES continues to use\ndesign, equipment, operating controls and maintenance procedures\na “hyper-care” program to ensure additional supervision and safety\nare effective in identifying, evaluating, managing and mitigating\noversight of new contractors, high-risk work scope contractors and\nprocess-related hazards.\nless-experienced contractors.\nNon-routine hazardous work GES also uses a rigorous, third-party prequalification program to\nevaluate, score and prequalify contractors and subcontractors. This\nIn recognition of industrial safety trends and our own internal\ntool allows the team to evaluate contractors’ safety programs, past\nassessments, we have refined our global approach to managing\nsafety performance, safety incident rates, experience modifier rate\nsafety during non-routine maintenance and repair activities, as these\n(EMR) and training verification of craft, and reviews any regulatory\nwork activities are a leading cause of serious and fatal injuries across\ncitations prior to allowing them to bid on any projects.\nindustries. We have developed global safety standards to minimize\nthe potential for serious incidents when our employees are working at\nheights, entering confined spaces and working on or near machinery, Safety for non-Company personnel\npiping and electrical systems. This global effort is focused on creating\nAll contractors working at our sites are required to follow a\na rigorous and safe approach to risk reduction when performing these\nprequalification and EHS evaluation process. They are assigned an\nnonroutine, high-hazard work activities.\ninternal “contractor liaison” to monitor EHS compliance, perform\nEHS inspections and evaluations and ensure they follow their safety\nCapital projects construction safety compliance plans. Contractors are required to report and investigate\nall EHS incidents and near-miss events. They also work with site-based\nWe have a strong construction safety program with a focus on\nEHS contacts to identify and implement corrective and preventive\nzero harm to people, property and the environment. Our Global\nactions, which are tracked to completion.\nEngineering Solutions (GES) group oversees hundreds of contractors\nand thousands of skilled craftworkers on our construction projects\nIntegrated Facilities Management (IFM) partners are globally sourced\nworldwide. Safety is integrated into all stages of our construction\ncompanies that are responsible for performing various maintenance\nprojects, beginning with the concept and design phases, and is\ntasks at our sites. IFM partners are required to follow our Company's\ncarried through to Detailed Design, Construction and\nEHS standards and site EHS procedures, and to monitor compliance\nCommissioning/Qualification.\nactivities associated with their scope of services and meet safety-\nrelated performance objectives.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 133"
  },
  {
    "page": 134,
    "source": "text",
    "content": "CONTINUED: GRI 403-2\nIFM partners are managed through a central governance team. Many of our manufacturing plants have on-site, trained emergency\nThe governance process includes dedicated resources to measure, response teams and mobile fire and rescue apparatus that can respond\nmonitor and evaluate IFM partner EHS performance and adherence to fires, medical emergencies, technical rescues and spills/releases.\nto Company EHS requirements on an ongoing basis. IFM partners Most of our emergency response teams interact directly with their\nproactively follow a continuous improvement process whereby each local community-based emergency responders and, in some cases,\nyear, in addition to our Company requirements, specific targets are set assist off-site when requested.\nup and monitored at the governance level.\nLoss prevention\nMotor vehicle safety\nWe proactively assess and manage the risks associated with fires\nThe aim of our motor vehicle safety program is to promote a and natural catastrophes (i.e., hurricanes, floods, windstorms and\nstrong safety culture for our employees who operate vehicles while earthquakes) through our Loss Prevention Program. This program\nconducting Company business. Our program is designed to reduce focuses on eliminating or reducing the impact of potential loss events\nthe frequency and severity of motor vehicle injuries and reduce the through:\nnumber of collisions, violations and vehicle-related incidents across\n• Facility and process designs\nour global network. We have implemented a global motor vehicle\n• Inspection, prevention and maintenance procedures\nsafety standard and adopted programs, such as predictive analytics\nassessments that allow us to develop employee-specific defensive • Fire suppression, detection and specialized protection systems\ndriving action plans, to promote safe driving skills and behaviors to\n• Emergency response and business continuity programs.\nour sales and marketing employees who operate the majority of our\nbusiness-use vehicles. We engage globally recognized, external loss-prevention engineering\nservice providers to routinely inspect and review new designs and\nEmergency response modifications of facilities. This helps us to maintain a high standard\nof loss prevention that corresponds to the level of operational risk,\nWe prioritize the prevention of incidents through equipment and\nmonetary value and supply-chain importance.\nfacility design, operational and maintenance procedures and employee\ntraining. However, in the event that unplanned incidents occur, we\nIndustrial hygiene\nmaintain emergency preparedness and response capabilities at our\nfacilities. Emergency response programs help secure the safety Our industrial hygiene program helps safeguard employee\nand wellbeing of our employees and visitors, the protection of the health throughout all stages of research and manufacturing.\nenvironment and nearby communities, as well as protecting our Our professionals identify chemical, physical and biological hazards\nphysical assets. We also conduct pre-emergency planning for credible and assess exposures and control risks. Based on industry-leading\nemergency scenarios such as process upsets, fires, spills, releases, best practices, we accomplish this through a hierarchy of controls.\nsevere weather and security-related incidents.\nThese include:\nSite-specific emergency-response procedures include incident\n• Prevention\nreporting and management, personnel evacuation, medical response\nand incident response and control. We routinely conduct emergency • Substitution\nresponse drills and train employees in both job-and site-specific • Engineering\nemergency-response duties.\n• Administrative\n• Personal protective equipment (PPE)\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 134"
  },
  {
    "page": 135,
    "source": "text",
    "content": "CONTINUED: GRI 403-2\nFor example, when designing new processes and facilities, we build and manufacturing of vaccines and therapeutics to combat endemic\nsafety into our designs organically by eliminating risks, substituting or emerging infectious diseases like COVID-19. In an effort to improve\nless hazardous processes or materials and installing effective biosafety capabilities, the biological risk management team conducted\nengineering and operational controls. We also confirm the ongoing a Biosafety in Project Management training series to increase the\neffectiveness of these controls after installation through a robust biosafety knowledge base of our engineers.\nmonitoring program.\nWe partner with our community of public and private sector biosafety\nWhen addressing existing processes and facilities we use a similar professionals in order to help educate biorisk professionals globally\napproach. First, we seek to eliminate hazardous materials and and develop guidelines that protect human and animal health and\nprocesses. When not possible, we use less hazardous substitutes the environment. In 2021, we presented “Industry Perspective on\nand then evaluate potential engineering controls to mitigate the Biosecurity Management” at ABSA International’s 1st Biosecurity\nremaining risk. Symposium and the Chesapeake Area Biological Safety Association's\nannual symposium. We also volunteered with the ABSA International\nWhere engineering controls are insufficient, or not feasible, we to support ISO Technical Committee 212’s Working Group 5 to develop\nestablish effective work practice controls including those that may ISO 35001 Implementation Guide and to draft a new ISO Biosafety\nrequire selected types of PPE. In 2021, over 13,000 data points were Professional Competency Standard.\ncollected and used to evaluate risk or to confirm effectiveness of risk\nreduction investments, and 250 risk reduction actions were completed. Our biological safety professionals facilitated 369 biorisk assessments\nto support research and development and manufacturing activities\nWe have delivered nearly four million reusable cloth masks to our workers across all Company divisions. By developing an asset called Biorisk\nand their families during the COVID-19 pandemic. These masks follow Assessment and Repository (BAR), we believe that we have set\nthe performance criteria of the ASTM (American Society for Testing new biorisk management standards for the industry. BAR evaluates\nand Materials) International Standard Specifications for Barrier Face biosafety and biosecurity risk associated with biological materials,\nCoverings. Wearing reusable masks supports our mission to preserve and establishes risk-control strategies that protect human health\nsurgical masks and respirators for health care workers who need them, and the environment.\nand to reduce waste by minimizing daily discard of disposable masks.\nErgonomics\nBiological safety\nApproximately 20 percent of our 160 recordable injury cases are\nOur biological safety program aims to protect our employees, ergonomic-related. We have implemented an ergonomic program\ncustomers, vendors, partners and neighboring communities by focused on the reduction of ergonomic risk in process, equipment\nidentifying, assessing and controlling biosafety and biosecurity risks design and the work environment. We identify ergonomic risk\nassociated with the research, development and manufacture of our and exposure of tasks in all areas of the organization. Our site\nvaccines and therapeutic proteins. Our biological risk management ergonomic programs encourage employee participation in workplace\nteam ensures there is an effective biological safety program to prevent assessments, risk identification and implementation of sustainable\nbiological exposure. engineering controls. Where engineering controls are not feasible,\nadministrative and behavioral controls are implemented including,\nIn 2021, our Global Engineering Services (GES) team launched an\nbut not limited to, job rotation, job hazard identification and body\nupdated engineering design standard that governs fit-for-purpose,\nmechanics training. We also use ergonomic design standards for new\nlarge-scale biological facility design. This enabled our Company to\nor renovated facilities to maximize worker comfort and health and\nestablish multiple, production-ready facilities for safe development\nminimize ergonomics hazards and risk factors.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 135"
  },
  {
    "page": 136,
    "source": "text",
    "content": "CONTINUED: GRI 403-2\nIn response to the COVID-19 pandemic, the Company had an increase Prevention and risk minimization\nof non-essential employees working from home. In 2021, a remote\nOur employees are our most valuable asset, and our Company commits\nworker ergonomic assessment process and Work from Home Furniture\nevery day to protecting their health. The best way to maintain the\npolicy was created which resulted in a 75 percent reduction in work-\noccupational health of our employees is to reduce risk and prevent\nfrom-home, OSHA-recordable injuries and a 66 percent reduction\nillnesses and injuries. Occupational Health Services collaborates\nin work-from-home first aid cases when compared with 2020. This\nclosely with the Environmental Health & Safety (EHS) organization\ninitiative was developed and deployed in collaboration with GWES\nto identify and evaluate potential health risks to our employees in an\n(Global Workplace and Enterprise Services), HR, Procurement, IT and\neffort to reduce adverse impacts. We take proactive steps to prevent\nLive It (our health and wellbeing group). This new process provides\noccupational injury and illness through our Medical Surveillance\nworker access to resources that guide proper home office workstation\nprogram. This program evaluates new and existing workplace hazards\nsetup and identify appropriate furniture, equipment and solutions\nand allows the teams to identify and implement procedures and clinical\nneeded to maintain a healthy work-from-home environment.\nprotocols to eliminate these hazards and prevent future occurrences.\nIn the event of an occupational injury or illness, Occupational Health\nServices performs joint follow-up investigations with the EHS\norganization and conducts analyses to further refine our preventive\nGRI 403-3 Occupational health services\nefforts and reduce avoidable risks.\nWhen employees are ill or injured at work or through personal\nOccupational health principles apply to all employees and directly\ncircumstances, we support their recovery so they can return to work\nsupervised contingent workers. We promote compliance with both the\nhealthy to perform their jobs. When an employee experiences an\nletter and the spirit of applicable occupational health laws, Company\noccupational injury or illness, we promote and facilitate appropriate\npolicies and requirements. We prioritize continuous improvement and\ntreatment and rehabilitation.\nassess our improvements objectively through internal measurement\nand external benchmarking, incorporating best practices and\nparticipating in occupational health research where appropriate. Performance management\nOur occupational health programs are not static, and we drive\nTo meet the Company’s objectives, we focus on seven key areas:\ncontinuous improvement in their performance. We establish\n• Prevention and risk minimization\nprograms, policies and procedures that tie our occupational health\n• Performance management performance to corporate and divisional goals and objectives. We\nregularly report our progress against our goals to management and\n• Global standards and communication\nrefine them as necessary at regular intervals.\n• Education and training\n• Management\nGlobal standards and communication\n• Safety\nWe adhere to and promote Company goals, programs, procedures and\n• Global employee health\npolicies designed to provide a high level of respect for the health of\nour employees globally. We foster openness and respectful dialogue\nwith our employees, anticipating and responding to concerns about\nour operations.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 136"
  },
  {
    "page": 137,
    "source": "text",
    "content": "CONTINUED: GRI 403-3\nEducation and training programs, and reports to the team on occupational health matters\nthat impact employee health and human performance. Together,\nWell-informed and trained employees provide the backbone for\nour EVP/chief HR officer, senior vice president of compensation and\nmaintaining employee health in the workplace. We assist in providing\nbenefits, and vice president of global safety and the environment\nappropriate education and training programs for our employees so\npromote effective collaboration on occupational health and safety\nthey understand potential health hazards and necessary precautions\nmatters. Their mission is to achieve the Company’s occupational goals\nrelated to their job duties. We also invest in our occupational\nand other relevant safety policies, and to provide expert subject-\nhealth team’s professional growth to foster business excellence\nmatter advice to management.\nin conscientious execution of their responsibilities.\nManagement\nLeaders of employees or managers of other resources are responsible\nfor implementing and adhering to local and regional occupational health GRI 403-5 Worker training on occupational health and safety\npolicies. They may also provide input into Global Employee Occupational\nHealth policy and strategies that promote the Company’s occupational\nhealth leadership in accordance with our purpose and values. Similarly, EHS training is critical to build employee EHS competencies to improve\nwe expect division and business unit leaders to make sure their teams compliance, reduce risks and drive continuous improvement. EHS\nprovide input on occupational health strategies, policies and programs, professionals complete an assessment of the activities performed and\nas appropriate. Above all, leaders make sure their organization provides identify relevant EHS topics in EHS training plans. These plans comply\nadequate resources to support occupational health performance. with internal and regulatory training requirements specific to each\nparticular country and are reviewed periodically to ensure that they\nremain current.\nSafety\nEHS training program materials are available in both instructor-led\nEHS provides input to Global Employee Occupational Health policy and\nand e-learning formats. We also conduct periodic web-based seminars\nstrategies that promote the Company’s occupational health leadership.\nto inform EHS professionals of changes in regulations, standards and\nActivities include:\nCompany practices.\n• Developing and implementing occupational health programs\n• Assessing potential workplace health hazards (chemical, biological We have a global standard that defines the EHS training expectations\nand physical) for employees:\n• Preventing adverse health effects from hazards • Manager training covers specific management responsibilities with\n• Evaluating employees’ ability to perform job tasks regard to EHS compliance\n• Identifying causal factors associated with injuries and illnesses • EHS professional training is designed to expand technical expertise\n• Working with site health professionals to track the safety • Employee training covers the specific information our employees\nperformance of the Company need to perform their jobs, focusing on hazards they encounter on\nthe job and any corresponding control measures\nGlobal employee health\nDuring the COVID-19 pandemic, the Company ensured social\nOur executive vice president and chief human resources officer distancing during training by modifying classroom training formats\n(EVP/chief HR officer) is the senior Company official who advises when in-person training was required, and shifting to web-based\nthe Executive Team on occupational health strategies, policies and interactive training modules, where possible.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 137"
  },
  {
    "page": 138,
    "source": "text",
    "content": "GRI 403-6 Promotion of worker health GRI 403-9 Work-related injuries\nGRI 403-10 Work-related ill health\nGlobal Employee Health provides workers access to nonoccupational\nmedical and health care services to address major nonwork-related\nhealth risks. The team operates both globally and locally. Global In 2021, our Lost Time Incident rate (LTIR) was 0.08, a 60 percent\nEmployee Health also provides occupational and health care services increase from 2020. Our recordable incident rate (RIR) was 0.20,\nto employees such as: a 25 percent increase from 2020. There were no fatalities in 2021.\n• Medical clearances for job placement and evaluations to assess\nThe increase in our LTIR and RIR from 2020 to 2021 is likely due to the\ncapability to perform a job task\nimpact of the pandemic, with employees returning to sites and regular\n• Regulatory assessments for potential health hazards and operations in 2021. Although we experienced a year-over-year increase\nreproductive health hazards in injury rate, when comparing 2019 (a pre-pandemic year) to 2021\n• Consultations that prevent injury and illness, like those related to safety results, our LTIR decreased by 27 percent and RIR decreased\ntravel and unique workplace hazards by 33 percent. Additionally, our 2021 safety results are within\nthe top 25 percent of our pharmaceutical industry peers, per the\n• Treatment for employees with a work-related injury or illness\nPharmaceutical Safety Group (PSG).\nOn-site Global Employee Health personnel support the Company’s\nIn 2021, our top three types of recordable injuries were as follows:\npeople through employee health services clinics located on many\nsites. All facilities provide occupational and preventive health services • 28% related to “struck-by/caught-in”\nthat work to keep employees healthy, on the job and functioning\n• 27% related to slips, trips and falls\nat optimal capacity. Global Employee Health supports many of the\n• 20% related to ergonomics\nprograms, including biometric screenings for employee personal health\nassessments, flu and other vaccinations.\nWe focus on eliminating high-risk tasks, improving engineering\ncontrols, and performing coaching and training to our workforce to aid\nOur most vital occupational health services relate to medical advice\nin identification and elimination of EHS risks.\nand consultation, medical evaluations, medical surveillance, care of\noccupational injuries and illnesses, identification and reporting of\nIn 2021, we experienced a 21 percent increase in the collisions-per-\nnew potential hazards and adverse health effects, emergency medical\nmillion-miles (CPMM) indicator compared with 2020, and a 13 percent\nresponse and—most importantly—prevention.\nreduction compared with 2019 (pre-pandemic year). We believe\ncomparing 2021 with 2019 is more appropriate because in 2020 we\nTo develop and maintain awareness of all workplace health hazards,\nhad fewer field-based employees due to the pandemic restrictions.\nGlobal Employee Health Services maintains a close functional working\nIn 2021, we focused on a safe and controlled return to work for these\nrelationship with site management, safety and industrial hygiene\nemployees as COVID-19 restrictions lifted. In 2021, we also focused\nprofessionals. They are also responsible for maintaining employee\non deploying a standard predictive analytics approach to increase\nhealth records in accordance with local regulatory requirements.\ndefensive driving awareness in markets where motor vehicle safety\nEmployee health is a Company priority, so we strive to continuously\ndata collection is restricted due to privacy regulations. Our global\nimprove our programs globally and at each site. These efforts include\nvehicle safety program includes a standard duty of care by holding\ncommunication of our global policies, procedures and protocols;\nboth employees and managers accountable for achieving safe\nadministering regulatory and compliance audits; and providing critical\ndriving expectations.\noversight for our occupational health programs.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 138"
  },
  {
    "page": 139,
    "source": "text",
    "content": "CONTINUED: GRI 403-9 | GRI 403-10\nConstruction\nLost time injuries by business\nOur injury rates continue to decrease and are better than construction area (total: 63) (2021) % of total1\nindustry averages.\nManufacturing (MMD) 39.7\nIn 2021, Global Engineering Solutions (GES) received two safety\nexcellence awards for the MSD Biotech Dublin Project and the WP38 Animal Health Intelligence 22.2\nLaboratory Operations Microbiology Sterility Assurance Project\nHuman Health (HH) 17.5\nfrom the Construction Users Roundtable (CURT). CURT is a global\norganization that provides an international forum for the exchange\nAnimal Health 12.7\nof information and expertise to improve safety, productivity and\ncompetitive advantage for the construction industry. Research (MRL) 3.2\nWe had 10.7 million construction hours globally and achieved zero Facility Management 3.2\ninjuries on 95 percent of our capital construction projects. The\nconstruction RIR result was 0.28, reflecting a 53 percent decrease Global Support Functions 1.6\nfrom our 2020 rate. Our capital construction projects also achieved a (Legal, HR, IT, S&E et al.)\nDART rate of 0.11. GES had 15 injuries on projects in 2021, representing\na 50 percent reduction in injuries. The top two 2021 injury categories\nincluded six lacerations requiring stitches and two slips, trips and\nfalls from the same elevation causing strains. In 2021, the impact of\nCOVID-19 did not affect our construction safety performance. Lastly,\nCases by business Lost time Recordable\nconstruction projects also set a record with over 174,000 Tap Ins\narea (#) (2021) cases cases\n(safety observations) being reported in 2021.\nManufacturing (MMD) 25 84\nNon-employees—Integrated Facility\nAnimal Health Intelligence 14 22\nManagement (IFM)\nIn 2021, our IFM partners had a total RIR of 0.60 and a LTIR of 0.27. Human Health (HH) 11 22\nOur IFM providers’ injury rates continue to be significantly better\nAnimal Health 8 12\nthan industry averages.\nResearch (MRL) 2 10\nFacility Management 2 7\nGlobal Support Functions 1 3\n(Legal, HR, IT, S&E et al.)\nTotal 63 160\n1 M ay not total 100 percent due to rounding.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 139"
  },
  {
    "page": 140,
    "source": "text",
    "content": "CONTINUED: GRI 403-9 | GRI 403-10\nRecordable injuries by casual factors (total: 160) (2021) % of total\nSlips/trips/fall 26.9\nStruck by/caught in 28.1\nMotor vehicle 7.5\nErgonomic 20.0\nChemical exposure 3.1\nBiological exposure 2.5\nOther 1.3\nNon-ergonomic 2.5\nPhysical/environmental exposure 8.1\nLost time injuries/illnesses by casual factors (2021) Lost time cases % of lost time cases\nSlips/trips/fall 21 33.3\nStruck by/caught in 10 15.9\nMotor vehicle 8 12.7\nErgonomic 15 23.8\nChemical exposure 2 3.2\nBiological exposure 1 1.6\nOther 0 0.0\nNon-ergonomic 0 0.0\nPhysical/environmental exposure 6 9.5\nTotal 63 100\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 140"
  },
  {
    "page": 141,
    "source": "text",
    "content": "CONTINUED: GRI 403-9 | GRI 403-10\nGlobal safety performance (employees)1, 2 2017 2018 2019 2020 2021\nWorkplace safety\nRecordable incident rate (RIR) 0.33 0.30 0.30 0.16 0.20\nRIR percentage change -6% -9% 0% -47% 25%\nLost time incident rate (LTIR) 0.13 0.10 0.11 0.05 0.08\nFatalities3 0 2 0 0 0\nMotor vehicle safety\nCollisions per million miles (CPMM)4 7.29 6.93 7.01 5.07 6.11\nNote: Injury rates are subject to change over time as new cases are added, and case classifications change in accordance with our own requirements and applicable regulatory requirements.\n1 LTIR/RIR: Calculated per OSHA methodology.\n² Newly acquired facilities are not included in this data set.\n3 In 2018, one fatality was transportation-related, one high-risk work related.\n4 CPMM: Reflects both personal and business use of Company-owned or -leased vehicles.\nGlobal safety performance (non-employees) 2017 2018 2019 2020 2021\nCapital projects construction safety1,2\nRIR 0.59 0.73 0.42 0.60 0.28\nDART3 0.32 0.28 0.15 0.24 0.11\nFatalities 0 0 0 0 0\nFacility management contractor safety4\nRIR N/A 0.71 0.55 0.35 0.60\nLTIR N/A 0.47 0.42 0.26 0.27\nFatalities N/A 0 0 0 0\nNote: Injury rates are subject to change over time as new cases are added, and case classifications change in accordance with our own requirements and applicable regulatory requirements.\nN/A: Not available.\n1 LTIR/RIR: Calculated per OSHA methodology.\n2 Primarily reflects capital projects over $100,000 managed by our global engineering group.\n³ DART: days away, reassigned or transferred, calculated per OSHA 300 methodology.\n⁴ Incident rates for IFM partners; reporting initiated in 2018.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 141"
  },
  {
    "page": 142,
    "source": "text",
    "content": "Training and education\nGRI 404 Management approach GRI 404-1 Average hours of employee training\nWhether we are inventing the next breakthrough treatment or simply\nchallenging and supporting one another for ongoing development,\nwe lead through a culture of applied curiosity.\nTraining and\nThe Global Learning and Development (GL&D) organization’s primary education1 2017 2018 2019 2020 2021\nfocus is to enable a diverse and accessible environment in which all can\nlearn and thrive. We accomplish this by collaborating with business\nTotal course 5.3 4.4 5.3 7.2 6.3\npartners across the Company to understand, align and prioritize\ncompletions for\nlearning solutions to critical business challenges. We then design,\nall learners\ndevelop and execute innovative learning experiences to strengthen\n(in millions)\nour workforce.\nGL&D ensures all learning opportunities are developed to allow for Hours of training 2.6 2.2 2.7 3.6 3.2\ndiversity of thought, experience and an enriched accessible learning for all learners\nenvironment. We identify learning needs of our global diverse (in millions)2\nemployee population through extensive discovery of learner personas,\nrequirements and environments. Our strategy allows us to anticipate,\nAverage course 48 43 55 69 51\nidentify, prioritize, design, develop and implement learning solutions\ncompletions\nthat provide growth and development across six moments of an\nper learner\nemployee’s career.\nThese moments include: 1 “ All learners” is defined as all active regular and part time employees, as well as contingent workers.\n2 B ased on average of 30 minutes per course.\n• Onboarding\n• In-role growth\n• Career acceleration\n• Leader development\n• Culture\n• Mandatory training\nGL&D understands employee skills and capabilities must support\nour aspiration and purpose. As a result, we continuously evaluate our\norganizational capability needs and retool the learning culture and\nstrategy to support employees.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 142"
  },
  {
    "page": 143,
    "source": "text",
    "content": "Management and leadership programs\nPrograms for upgrading employee skills First Line Essentials (FLE) is a program which develops the core,\nGRI 404-2\nand transition assistance programs common and critical capabilities needed by all people managers at our\nCompany, regardless of country, region or division. The program is\nTools and resources designed to enhance the foundational skills and knowledge base that\npeople managers will need to effectively perform their responsibilities.\nOur current talent management practices provide performance There are four pillars of focus within the program:\nmanagement, leadership development, talent assessments, talent\n• Think Like a Leader\nreviews and succession planning. Global Talent Management designs\nand implements the enterprise-wide talent management and • Coach Your Team\nleadership strategy aligned to business strategy in order to retain and • Getting Results Through Others\nattract talent, support and develop a diverse workforce and create a\n• Engage People\nstrong succession pipeline. Talent practices are supported by a human\ncapital management system, which enables managers and employees\nLeaders can continue their development through self-guided resources\nto keep track of business and development priorities, performance\nas curated by Leadership Learning Journeys by level, participate in live\nratings, career aspirations, job experiences, skills, language\nwebinars on focus topics (e.g., developing strategic initiatives, building\nproficiency, certifications and education.\ntrust, correcting performance problems, etc.), as well as engage in\nmulti-modal resources to develop their areas of opportunity.\nManagers and employees are encouraged to meet throughout\nthe year to discuss progress and accomplishments against their\npriorities. Emphasis is placed on creating a culture of ongoing Team and individual development\ncoaching and future-focused feedback. At year-end, colleagues\nEmployees can register for free events and webinars to drive their\nsummarize their achievements and assess the impact they have\ndevelopment in areas of leadership, teaming and professional skills.\nhad on the organization, their team and their own development.\nTraining can be done on the learner’s time and focus can be set to\nManagers conduct annual performance reviews of employees at all\nclose areas of development or to further strengthen skills of interest.\nlevels (except those subject to collective bargaining agreements) to\nThe various platforms offer multi-modal resources with trainings to\nguide individual decisions relating to development, compensation\naccommodate all schedules.\nand rewards. Feedback on employee performance includes how well\nemployees demonstrate our aspirational culture and Ways of Working.\nWe seek to emphasize not just what an employee achieves, but also\nhow they achieve. Managers gather feedback about their employees\nand write performance reviews providing holistic feedback on\nemployees’ accomplishments.\nTransition assistance programs may be provided to support employees\nwho are exited as part of a workforce restructuring. Such benefits\nwhich may include the following, however, are subject to local plans,\nlaws and country guidelines:\n• Severance benefits which may include severance pay based on\nemployee level and service\n• Outplacement job transition assistance\n• Continued health and wellness benefits for a defined period of time\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 143"
  },
  {
    "page": 144,
    "source": "text",
    "content": "CONTINUED: GRI 404-2\nTalent development focus income statement and cash flow. Additionally, concepts and tools are\nincorporated to enhance individual leadership capabilities of leading\nWe advance the learning and development of our global talent at all levels\nothers by learning how to integrate long-term plans with short-term\nof the organization to support the advancement of our future leader\nactions, and how to create a strategy that will drive decisions.\npipeline along with the realization of the diversity and inclusion strategy.\nThese learning experiences include: Business Leadership Program 2021\nGeneral Management Acceleration Program (GMAP) Post-program retention 85%\nThe General Management Acceleration Program (GMAP) is an Lateral moves 34%\napplication-based, early talent development program sponsored by the\nOffice of the CEO. The objective of GMAP is to create a robust global Promotions 31%\nacceleration program for internal and external talent, providing the\nright experiences and learning opportunities to help meet our future\nbusiness demand. This two-year, cross-divisional and global rotational\nprogram enables participants to increase their business and financial Leadership Pathway\nacumen and develop critical strategic thinking abilities through\nThe Leadership Pathway focuses on the director level. The purpose of\ntargeted learning opportunities and networking with key leaders at\nthis nomination-based offering is to develop individuals to be change\nour Company. Successful participants broaden their experience and\nmakers who engender inclusion and trust; inspire experimentation,\nperspective, enhance their leadership abilities, and are well-positioned\nfeedback and learning; and achieve aspirational business outcomes both\nto move into areas of greater responsibility following their rotations.\nfor today and for tomorrow. The Leadership Pathway is designed so that\nparticipants select their area of focus and take responsibility for their\nGMAP 2021 development with the goal of becoming a more confident and capable\nleader. This approach ensures individuals at this mid-level are empowered\nPost-program retention 92%\nand know they have a greater impact than they may realize. As a result,\nLeadership Pathway participants are then able to build and lead teams in\nLateral moves 33%\na way that makes them more productive and engaged.\nPromotions 24%\nLeadership Pathway 2021\nPost-program retention 96%\nBusiness Leadership Program\nLateral moves 23%\nThe Business Leadership program is a global, nomination-based\nprogram on advanced concepts in business and financial management Promotions 14%\nand cross-functional leadership. Participants experience the language\nof finance through simulated experiences focused on developing and\nexecuting a global strategy through marketing, sales, manufacturing,\nsupply chain and R&D across three different regions (North America,\nEurope and China) and managing the Company’s balance sheet,\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 144"
  },
  {
    "page": 145,
    "source": "text",
    "content": "CONTINUED: GRI 404-2\nWomen’s Leadership Program Rise\nThe Women’s Leadership program is a global nomination program Rise is an exclusive experiential program leveraging some of the\nfocused on enhancing women’s capabilities to recognize and seize best-in-class institutions from around the world and designed for\nstrategic career opportunities by developing critical capabilities and our executive directors and associate vice presidents. This program\nconfidence while contributing to core objectives of our Company. increases our talent pipeline and succession planning for critical roles\nAreas of focus include strengthening the ability to navigate within with a focus on critical leadership capabilities. This program submerges\nthe organization while maintaining an authentic leadership style, leaders into creative and critical thinking environments while cracking\nincreasing cultural competence regionally, advancing skills in influence real-world challenges to amplify their enterprise view in preparation\nand negotiations, increasing one’s ability to recognize and manage for future upward succession. The participants have influence to drive\ngender differences and subtle “micro-inequities” by leading through productive change, to attract, retain, lead and develop diverse talent,\ncourageous action. and ultimately to drive business results. We view this talented group as\nchange agents who can lead the organization into the future.\nWomen’s Leadership Program 2021\nRise 2021\nPost-program retention 78%\nPost-program retention 97%\nLateral moves 37%\nLateral moves 12%\nPromotions 27%\nPromotions 12%\nDiverse Leader Program (U.S. only)\nAffinity-based development programs\nThis thought-provoking nomination program is an interactive\nleadership journey designed to create a safe place where participants In addition to the women and ethnically diverse talent offerings\ncan hone their leadership skills while exploring what it means to be a mentioned above, we expanded to offer a greater number of affinity-\nperson of color in a leadership role within the Company. While building based leadership development programs. In 2021, we created several\nleadership proficiency, participants investigate the similarities and development offerings to provide opportunities for diverse talent to\ndifferences of leaders from other racial and ethnic groups. There are accelerate their careers.\nscheduled opportunities to deepen relationships with senior leaders\nthrough engaging activities and conversations. Diverse Leader Acceleration Program\nThe new Diverse Leader Acceleration Program was designed to support\nDiverse Leader Program 2021 the readiness and career growth of Black and Hispanic individual\ncontributors and mid-level leaders to achieve positions at higher levels.\nPost-program retention 82% The program develops leadership capabilities and improves business\nacumen. The program identifies and supports the participants with\nLateral moves 34%\nmanaging diversity-related challenges to development. There is an\nemphasis on empowering strong reporting relationships through\nPromotions 36%\nmanager education and reporting-pairs dialogues. The program creates\na community of support through cohort interaction and peer coaching.\nParticipants also leverage the influence of leaders as mentors/sponsors.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 145"
  },
  {
    "page": 146,
    "source": "text",
    "content": "CONTINUED: GRI 404-2\nMerck Líderes Institute FOCUS\nThe Merck Líderes Institute is a six-month experience designed to The FOCUS program lasers in on exploring the development of\naccelerate the growth and development of Hispanic/Latino leaders. leadership capabilities with our midlevel Black professionals.\nThe program equips participants to drive their own careers and create FOCUS hones in on Leadership and Brand Development. The\npersonal and professional success by providing structured learning program supports building a peer network with whom they can\nand consistent support from managers, sponsors, coaches and peers. exchange perspectives, challenges and insights. Participants create\nParticipants focus on exploring their identity and culture, their unique a values-based leadership philosophy while exploring Black executive\npersonal and workplace experiences, the obstacles to their career and themes related to identity and success. Emphasis is placed on giving\npersonal development and the strategies they can use to increase their and receiving feedback, influence and peer coaching strategies that\ncontribution and personal growth. support proficiency in management and leadership competencies.\nAdvancing Latino Leadership Our partners\nThis research-based virtual program offers a Latino-specific lens\nPartnerships have been formed with global diverse thought leaders,\non leadership opportunities and challenges in the corporate sector.\nalong with academic institutions, to support the Leadership\nIncluded are tailored modules designed to help participants develop\nDevelopment Portfolio and Affinity offerings. We work with these\nself-awareness, self-empowerment and skill development. Also\nexternal partners to provide the highest quality and impactful\nincluded are follow up discussions with small group work, ongoing\nlearning experiences.\nmeetings with participants’ managers and a plan for extended\nlearning beyond the end of the program. Designed around peer- Examples of our partnerships include:\nto-peer interactions, the program provides strategies and tips for\n• Duke Corporate Education\nhow, when and with whom to leverage networks in support of one’s\nprofessional advancement. • Saïd Business School, University of Oxford\n• Cornell University\nDiverse Executive Coaching Circles • Center for Creative Leadership\nThrough the benefits of executive coaching and developing executive • IESE Business School\nleadership strategies, this offering is designed for executive director\n• McKinsey\nand associate vice president level underrepresented ethnic group\n• Korn Ferry\n(UEG) colleagues. This offering provides valuable insights in the areas\nof career development, relationship management, strategic thinking • Hispanic Association on Corporate Responsibility (HACR)\nand decision making. The intent is to support leaders as they ascend to\n• Executive Leadership Council\nnew heights in the Company. Participants gain valuable insights that\ngive them the know-how and confidence to excel, and the program\nconnects the leaders with executive advocates/sponsors to develop a Promotion metrics1 2019 2020 2021\ndefined career action plan.\nMen 47% 48% 47%\nWomen 53% 52% 53%\n1 Breakdown by gender, of all regular employees promoted during the fiscal year.\n“Regular employees” are defined as employees who do not have a predetermined end date\nto employment.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 146"
  },
  {
    "page": 147,
    "source": "text",
    "content": "Percentage of employees receiving regular\nGRI 404-3\nperformance reviews\nPerformance reviews 2017 2018 2019 2020 2021\nExecutives1 100% 100% 100% 100% 100%\nSenior managers2 100% 100% 100% 100% 100%\nAll managers3 100% 100% 100% 100% 100%\nAll employees4 93% 94% 94% 95% 95%\n1 “Executive” is defined as leadership holding the executive vice president title.\n2 “Senior manager” is defined as leadership holding vice president and senior vice president titles.\n3 “All managers” is defined as managers with direct reports other than executives and senior managers.\n4 “All employees” are defined as all active full- and part-time workers only.\nIn 2021, as in years past, the percentage of performance reviews has\nheld steady for managers and employees. As a Company, we continue\nto utilize our current talent management system, which supports\nCompanywide performance management, development, talent\nreviews and succession planning. It helps ensure that our workforce is\naligned with our objectives and focused on their ongoing professional\ndevelopment. The system allows managers and employees to keep\ntrack of business and development priorities, performance ratings,\ncareer aspirations, job experiences, skills, language proficiency,\ncertifications and education.\nThroughout the year, managers are encouraged to discuss with each\nof their employees their strengths and development opportunities to\nalign on ways to grow capabilities and skills.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 147"
  },
  {
    "page": 148,
    "source": "text",
    "content": "Diversity and equal opportunity We have an enterprise-wide plan that demonstrates our commitment\nto diversity and inclusion as a business priority that leads to greater\ncollaboration, innovation and agility. Our business objectives for\ndiversity and inclusion are fully aligned to drive long-term, sustainable\nbusiness performance. In addition, our objectives for diversity and\nGRI 405 Management approach\nequal opportunity support the Sustainable Development Goals (SDGs)\nof advancing gender equality, providing decent work and economic\ngrowth, reducing inequalities within and among countries and\nCultivating a diverse, inclusive and healthy workforce improves all\nstrengthening global partnerships.\naspects of our business and enables us to better address the needs of\nall stakeholders. We embed a culture of inclusion and belonging at\nOur GD&I strategic framework focuses on the following priorities:\nevery level of the organization and strive for inclusiveness in every\n• Continue to build the diversity and inclusion capabilities of our\naspect of work. The diversity of our employees mirrors the external\nglobal workforce\nworld, which enables us to better understand the unique needs of the\ncustomers, health care providers and patients we serve, including • Ensure accountability at all levels of the organization\nthose with different abilities. • Integrate diversity and inclusion into our business practices to\ndrive performance\nWhile our commitment to employee health is long-standing, in the\n• Work to influence the environment, culture and business landscape\nface of COVID-19 and social injustice we placed special emphasis on\nto help achieve a more inclusive and sustainable world\nthe mental wellbeing of our employees to help them address the\nchallenges of working in such uncertain times. We are incredibly proud\nof our employees' resilience during this time, which was reinforced GD&I ambassador teams\nby the legacy we have created of fostering a culture that embraces\nOur GD&I Center of Excellence (CoE) oversees diversity and inclusion\ninclusion as a competitive advantage. We have consistently leveraged\nacross all business practices and systems. The CoE leverages five\ntechnology over the past several years to engage a global workforce.\ndiversity ambassador teams to ensure integration into our business\nThis skill and ability to foster inclusion with employees whether they\nand people strategies.\nwere working on site, remotely, in the field or across global time zones\nwas particularly beneficial as we engaged in hybrid working due to\nThe Global Disability Inclusion Strategic Council\nthe pandemic.\nThis Council recognizes and values the importance of a disability-\nconfident workforce and understands how full inclusion of people\nGlobal diversity and inclusion (GD&I) objectives\nwith disabilities increases creativity and innovation for its employees,\nOur ability to accomplish our objectives is linked to the GD&I customers, external partners and suppliers.\nStrategy—our framework for sustainable competitive advantage.\nThrough it, we align with our purpose to save and improve lives and The GD&I Extended Human Resources Leadership Team\nour purpose to create an environment of belonging, engagement,\nThis team of human resources professionals supports the global\nequity and empowerment that compels a globally diverse and inclusive\norganization by ensuring the successful adoption and integration\nworkforce which works to improve patient health.\nof diversity and inclusion capabilities into all practices, programs,\nWe focus our efforts on: procedures and systems. A key outcome is to enable a diverse and\ninclusive culture—one that attracts, engages, develops, motivates\n• Our People: Strengthen the foundational elements of diversity\nand retains top talent globally.\n• Our Culture: Ensure accountability to drive an inclusive culture\n• Our Business: Continue to leverage diversity and inclusion to\nensure business value\n• Our World: Transform the environment, culture and business landscape\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 148"
  },
  {
    "page": 149,
    "source": "text",
    "content": "CONTINUED: GRI 405\nEmployee Business Resource Group (EBRG) Our commitment to GD&I is further reinforced by our CEO. He advocates\nExecutive Leadership Council for diversity and inclusion as a strategic business imperative through the\nfollowing commitments:\nWith 10 EBRGs representing different constituencies, this Council of\nglobal EBRG leaders work together to support approximately 20,000 • Approving diversity metrics and reviewing progress against\naspirational talent goals\nmembers worldwide, strengthen and diversify the global leadership\npipeline and provide culturally relevant insights that help drive • Driving accountability through meetings with our leaders and\nour success. engaging employees in Companywide events to review key\nstrategic initiatives centered on GD&I\nGD&I Business Consortium • Conferring with our vice president of human resources and chief\ndiversity officer on innovation opportunities and business solutions\nThis Consortium, comprised of members from key business functions,\nenhances our Company’s performance by embedding diversity, equity\nand inclusion principles and strategies into our business processes Pay equity\nand strategies, creating a competitive business advantage and driving\nWe have had a longstanding commitment to diversity and inclusion\nshareholder value. This Consortium develops holistic and inclusive\nand fair and equitable pay for all employees. This commitment is\napproaches which will break through barriers and obstacles many of\nconsistent with our core values of integrity, fairness and treating all\nour patients and customer experiences in their pursuit of optimal\npeople with dignity and respect. Having the right culture, systems and\nhealth outcomes. It brings together a group of internal stakeholders\npractices for talent recruitment and development are critical in driving\nacross the major groups in the organization.\nour ability to compete in global markets where talent is increasingly\nscarce and increasingly diverse. Diversity, equity and inclusion are\nGD&I Line Advisory Council\namong our ethical and strategic imperatives.\nServing as an advisory role to the vice president, GD&I CoE, this\nPay equity is a critical principle at our Company. We maintain a\nCouncil provides input and feedback on the GD&I strategy and key\nPay Equity Council that is deeply engaged in our pay equity initiatives.\ninitiatives and offers perspectives on areas of progress, as well as\nThe Pay Equity Council is jointly led by our vice president of Diversity\nopportunity, in relation to integrating GD&I into our business and\nand Inclusion and senior vice president of Global Compensation,\npeople strategies.\nBenefits and HR Operations. Among its members are leaders within\nour Global Diversity & Inclusion (GD&I), Compensation and Benefits,\nGovernance and commitments\nand Employment Legal organizations.\nGD&I is a strategic business lever for performance and endorsed\nPay equity is a topic that is rightly receiving a great deal of attention\nat the highest levels of the organization. Diversity and inclusion\nand scrutiny. While many other organizations have only recently begun\nrepresent a key dimension of our commitment to our ESG goals. In\nto explore how to pay their employees equitably, providing fair and\naddition, our Board of Directors has a clearly stated Diversity Policy,\nequitable pay has been one of the pillars of our compensation philosophy.\nwhich recognizes that maintaining a truly diverse membership with\nregards to educational and professional background, gender, race,\nOur efforts toward pay equity include:\nage, sexual orientation, ethnic and national background, and other\n• Regularly monitoring and evaluating our pay practices and policies\ndifferentiating personal characteristics promotes inclusiveness,\nto ensure that we are paying our employees equitably across all\nenhances the Board’s deliberations and contributes to the Board’s\ngenders, races and ethnicities\noverall effectiveness to better represent the long-term interests of\nthe Company and its shareholders. • Basing compensation for new hires on their skills, work experience\nand other job-related factors\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 149"
  },
  {
    "page": 150,
    "source": "text",
    "content": "CONTINUED: GRI 405\n• Training our managers on our diversity, equity and inclusion policies at least 30 percent of senior roles. Building upon this commitment,\nto ensure that decisions regarding employees, including those GD&I partnered with Paradigm for Parity in 2021 to launch the Profit\nrelated to compensation, are based on legitimate job-related criteria and Loss Leadership Accelerator Program for Multicultural Women.\nand not personal characteristics such as gender, race or ethnicity The program recognizes that operational oversight of a company's\nprofit and loss, commonly referred to as P&L, is a key benchmark for\nWe have also engaged external experts and legal partners to conduct\nC-suite potential. However, just 31 percent of women say they have\nannual pay equity studies in the U.S. and abroad. As of 2021, we have\nP&L experience compared to 71 percent of men according to research\nconducted such analyses including approximately 75 percent of our\nby Seramount. Of this 31 percent of women who have P&L experience,\nglobal employee population. These studies allow us to identify whether\n74 percent are white and just 26 percent are women of color. The\nany adjustments to compensation would be sensible in order to ensure\nParadigm for Parity Profit and Loss Leadership Accelerator Program\nthat we continue to pay our employees equitably and fairly. By the end\nfor Multicultural Women addresses this gap by providing women of\nof 2022, we expect our pay equity studies will achieve nearly global\ncolor with operational financial management skills.\nworkforce coverage.\nOur 2021 pay equity study for the U.S. showed that we have achieved United Nations Women’s Empowerment Principles\ngreater than 99 percent pay equity for female and male employees, as\nWe continue tracking our progress against the United Nations\nwell as for non-white (including Black, Hispanic and Asian employees)\nWomen’s Empowerment Principles. These principles reflect seven\nand white employees, in each case, in equivalent positions. Where\nareas of focus designed to promote gender equality in business.\nappropriate, based on the determinations of our pay equity studies,\nResearch from the World Economic Forum regularly updates the\nwe make base salary adjustments to support our progress toward\ncurrent rate of progress and estimates it will take over 200 years\nsustained pay equity across gender, race and ethnicity. We also review\nfor women to achieve economic parity. According to McKinsey, the\nand update our compensation policies and practices to minimize the\nfull economic participation of women in the workforce will generate\nrisk of future pay gaps.\n$12 trillion to $28 trillion in GDP. We have committed to gender\nequality as a strategy to drive business results and advance our\nOur continuing focus on pay equity furthers our goal of being the\npurpose. We continue to establish leadership programs to promote\nemployer of choice for workers of diverse backgrounds, and it\nequality and publicly report on our progress to achieve gender equality.\nsupports our efforts to attract and retain the best talent and reward\nperformance consistent with our Leadership Standards. These are\nclear business imperatives for our Company, and we remain firmly Leadership development\ncommitted to them.\nWe remain committed to equity across gender, race and ethnicity\nas a strategy to drive business results and advance our purpose. We\nOur external commitments to pay equity and gender equality include\ncontinue to establish leadership programs to promote equality and\nthe following:\npublicly report on our progress to achieve gender equality. Examples of\nhow we achieve this objective, and our broader diversity and inclusion\nBloomberg Gender-Equality Index\ncommitment, are as follows:\nWe were named to the 2021 Bloomberg Gender-Equality Index (GEI),\nwhich recognizes companies committed to transparency in disclosing The Merck Women’s Network\ngender-related metrics and investment in workplace gender equality.\nThe Women’s Network is one of 10 Employee Business Resource\nGroups (EBRGs) at our Company, with 10,000 members in 72 global\nParadigm for Parity\nchapters, including over 1,000 male allies. The EBRG is designed\nIn 2018, we signed on to support Paradigm for Parity—a call-to-action to develop and empower women within the organization through\nand model for gender equality. The goal of the coalition is to achieve business integration and insights, talent acquisition and development\nfull gender parity by 2030, with a near-term goal of women holding and community outreach and social responsibility.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 150"
  },
  {
    "page": 151,
    "source": "text",
    "content": "CONTINUED: GRI 405\nIn the past year, the Women’s Network has launched the Women’s can hone their leadership skills while exploring what it means\nNetwork Leadership Academy to promote career development, to be a person of color in a leadership role within the Company.\npersonal branding, work life balance, empowerment, self-leadership While building leadership proficiency, participants investigate the\nand building influence. More than 1,700 EBRG members have similarities and differences of leaders from other racial and ethnic\nparticipated in the program. groups and deepen relationships with their mentors through hands-\non activities and conversations. During 2021, program participants\nIn addition, “Sister Circles” were launched with women and ally achieved an 82 percent retention rate, 34 percent received lateral\nmembers of other EBRGs—LEAD, the APA and Alianza (the African moves and 36 percent were promoted.\nAmerican/Black, Asia Pacific Association and Hispanic/Latino EBRGs,\nrespectively)—to address the intersectionality of women of color in\nThe Re-invent program\nthe workplace.\nThis program supports women who are re-entering the workforce.\nIn partnership with the Society of Women Engineers (SWE), we offer\nWomen’s Leadership Program (WLP)\nthe Re-invent program, where individuals who have taken a pause in\nWLP is a global nomination program focused on enhancing women’s their careers can re-enter the workforce with a full-time internship\nkey capabilities to recognize and seize strategic career opportunities role with the Company. This provides individuals with a year-long\nby developing critical capabilities and confidence while contributing to mentoring program where they can learn new skills, such as digital\ncore objectives of our Company. Areas of focus include: strengthening technology, understand the current business environment and build\nthe ability to navigate within the organization while maintaining an new relationships. The work experience enables a manager to assess\nauthentic leadership style; increasing cultural competence regionally; performance of the individual as well.\nadvanced skills in influencing and storytelling; and advancing the\nability to recognize and manage gender differences and subtle\nHiring Our Heroes\n“micro-inequities” by leading through courageous action. During 2021,\nprogram participants achieved a 78 percent retention rate, 37 percent We are proud to support veterans through several programs,\nof participants received lateral moves and 27 percent were promoted. including Hiring Our Heroes. Job-seeking service women and\nmen can use a military occupational specialty code to search for\nopportunities, making it easier for them to match their skills with\nThe Emerging Women’s Leadership Program\npotential careers at our Company.\nThis program is designed for female professionals to begin to develop\ntheir capabilities to take on critical leadership roles in the future.\nNextGen Network global reverse mentoring program\nRecognizing that this is the first time in history that there are\nDiverse Leader Program (DLP)\nfive generations working together in the workforce, the NextGen\nThe Diverse Leader Program (DLP) is a highly interactive, thought- Network EBRG launched a global reverse mentoring program\nprovoking leadership program designed to create a safe place where known as GEN2GEN in 2018 which has grown exponentially since its\ndiverse talent feels included and valued, and where they can further launch. This popular program puts a spin on traditional mentoring\ndevelop their leadership skills. This nomination-based program is relationships by offering co-mentoring partnerships in which\nopen to mid-level managers of color in the U.S. and in 2022 will be our younger generation teaches the more tenured generation.\nexpanding to global markets. GEN2GEN is a proven tool to close knowledge gaps, empower\nemerging and established leaders, and build multi-generational\nDiverse Leader Acceleration Program (U.S. only) networks. The program offers a structured but flexible curriculum\nthat covers meaningful topics like social media, technology,\nThis thought-provoking nomination program is an interactive\ntalent recruiting and soft skills like emotional intelligence.\nleadership journey designed to create a safe place where participants\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 151"
  },
  {
    "page": 152,
    "source": "text",
    "content": "CONTINUED: GRI 405\nBuilding a more inclusive workplace We aim to create more opportunities for underrepresented groups\nby evaluating our hiring processes to determine where we can\nand a culture of belonging\nremove barriers. This includes training our managers on strategies\nEnsuring our employees feel a sense of belonging at our Company is to mitigate unconscious bias in the candidate selection, hiring and\na major priority. We promote programs for managers that support recognition process.\ninclusion and that our leaders use to share their perspectives. Our\nPulse surveys allow us to measure our employees' perceptions on In addition to enterprise-wide Unconscious Bias education, which was\ninclusion and other critical workforce issues. These surveys are just introduced to the organization in 2014, we have introduced programs\none of the avenues we use to directly engage employees and remain to continue to drive our strategic focus and investment in building\naccountable to their needs. It also allows us to be responsive to employee retention, recognition and manager capability.\nemployee feedback on workforce issues and integrate their input into\ndecision-making. We are proud of the fact that in the most recent Gender sensitive recruitment and retention\nsurvey, which occurred during the pandemic (and, in the case of the\nTalent acquisition plays a pivotal role in sourcing and attracting diverse\nU.S., during a period of increased voluntary resignation known as the\ntalent and in consulting with hiring managers to eliminate unconscious\n“Great Resignation”), 80 percent of our employees stated that they\nbias in the selection process. Using a gender decoder tool for job\nfelt a sense of belonging at our Company.\npostings, biased language is highlighted with suggested alternative\nwording, helping to create gender neutral and inclusive job descriptions.\nRelated to our focus on inclusion is our commitment to a decade-\nlong practice of understanding, measuring and acting to sustain high\nRecognition programs for people of color in science\nemployee engagement. Like many companies, and following the\nsocial unrest and injustice witnessed in the U.S. and around the world, The Merck Research Award for Underrepresented Chemists of\nthe practice of listening deeply to our employees was critical to our Color recognizes graduate students and post-doctoral fellows for\nown decision-making and influenced leaders across the organization. their chemical science research across a range of focuses, such\nMany of our EBRGs were highly engaged in offering listening forums as computational, analytical, medicinal, biological and synthetic\nto colleagues to foster authentic and courageous conversations in an chemistry. David Thaisrivongs, who is a director in chemistry based\nemotionally safe environment. in Rahway, started this initiative when, after the social unrest in\n2020, he noticed that there were not many chemists of color at our\nGoing forward, we publicly committed to maintaining or exceeding our\nCompany. We developed a three-month program that attracted over\ncurrent employee engagement index score through 2025 measured\n130 applicants and awarded 12 recipients. The applicants must be\nthrough Pulse surveys, which are conducted multiple times a year.\nthird-year graduate students at a minimum or postdocs doing research\nin chemistry at a U.S.-based institution. Awardees were paired with a\nEmployee retention, recognition Merck mentor and networked with another winner.\nand manager capability\nINSPIRE\nThe past year reflects our ability to continually attract and retain\nResearch indicates as much as 20-30 percent of all written\nhighly qualified people, strengthen our competitiveness and mitigate\ncommunication includes some form of unconscious bias. As companies\nemployee turnover. We have held ourselves accountable for increasing\nshift to a remote or hybrid work model, that poses significant risk\ndiverse representation and have displayed our representation\nto employee engagement. INSPIRE, developed in collaboration with\ninformation each year in our ESG Progress Report. Last year, we also\nWorkhuman® Technology, is one example of how we are building\nshared our aspirational goals for improving diverse representation in\ninclusion capabilities among managers by elevating their awareness\nsenior management, including women and people of Black/African\nof how unconscious bias can influence the selection of candidates\nAmerican and Latino/Hispanic descent.\nwho receive recognition. This is a new feature added to our existing\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 152"
  },
  {
    "page": 153,
    "source": "text",
    "content": "CONTINUED: GRI 405\nprograms to leverage principles of inclusion to recognize and reward Disability inclusion in our supply chain\nperformance and promote retention of talent. We have also worked\nIn 2021, we were recognized as a Top Corporation for Disability-\nwith external talent suppliers to ensure they are focused on these\nOwned Businesses by Disability:IN. This recognition is given\npriorities as well.\nto a corporation that has demonstrated outstanding inclusion\nof Disability:IN certified disability-owned businesses (including\nD&I Learning Journey businesses owned by service-disabled veterans) and demonstrated\ncommitment to disability business inclusion in their supply chain\nThe new D&I Learning Journey, aligned with Global Learning &\nprocesses and corporate supplier diversity programs.\nDevelopment, acknowledges that everyone begins their learning\njourney at different levels. It recognizes that while effective, traditional\nDigital accessibility\nclassroom learning is only as impactful as the ability to leverage\nthe learning in outside settings—in team meetings, in one-on-one In 2021, we implemented a global digital accessibility policy and\nconversations, in evaluations and reviews, etc. The D&I Learning initiated a five-year roadmap to ensure equal access to our internal and\nJourney identifies the core capabilities and behaviors required for external digital landscape. This was supported by the development of\nsuccess. The program, available globally at our Company, creates accessibility training, the formalization of an Accessibility Community\nlearning opportunities for individuals to pause, reflect and consider of Practice, and Companywide change-management communications\nalternative responses to D&I-related questions to build inclusion including global webcasts, townhalls, forums and publications. We\ncapabilities and competence. It reinforces learning for every individual created a cross-organizational leadership team and developed and\nwithin the organization, embedding diversity and inclusion more published the Corporate Accessibility Statement.\ndeeply into everything we do.\nThe built environment\nOpportunities for people with disabilities\nUniversal design in the built environment goes beyond ADA to ensure\nWe encourage a culture of transparency and pledge alliance with spaces are created to allow all people to the greatest extent possible\nexternal organizations that have a shared vision for full disability the ability to access, understand and use the space. Simply put, it\ninclusion in order to foster and support people with disabilities. means “for everyone.” We have created a standard for universal design\nand projects all around the globe are following this standard and\nmaking a difference for our employees and guests.\nThe Valuable 500\nWe announced our membership in The Valuable 500 in January 2020.\nA culture of employee wellbeing\nThe Valuable 500 is dedicated to unlocking the business, social and\neconomic value of people living with disabilities, ensuring individuals with To be truly successful, we prioritize the health, wellbeing and safety\ndisabilities are provided ample resources to thrive in the workplace. of our employees. We placed a special emphasis on our employees'\nwellbeing during the pandemic, and our commitment will not wane\nInternational Labour Organization (ILO) Global Business as we continue to reinforce a collaborative culture and ways of\nand Disability Network (GBDN) working that will drive long-term success for our business. Extensive\nsteps have been taken to ensure that all of our work sites, including\nWe are a member of the ILO’s GBDN, a partnership of multinational\nmanufacturing plants and labs, are as safe as possible. We have listened\ncompanies, national employers’ organizations, business networks and\nto our colleagues carefully to understand their needs, adapting existing\nadvocacy groups working in collaboration to promote the inclusion of\npolicies and introducing new programs to help our extended family deal\npersons with disabilities in the workplace.\nwith the many challenges of the pandemic.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 153"
  },
  {
    "page": 154,
    "source": "text",
    "content": "CONTINUED: GRI 405\nWe promote a culture of mental health and wellness—one that Calm offers tools to help employees find more calm and mindfulness in\nsurrounds employees with the environment, programs and services their everyday life, with programs that are designed to support feelings\nthat support making healthy choices. of creativity, tranquility, resilience, happiness and success.\nOne Mind at Work LIVE IT\nOur CEO signed the One Mind at Work Charter, pledging to make As part of our commitment to becoming a leader in employee health and\nmental health a priority by protecting, supporting and enhancing wellbeing, we brought together our health and wellness offerings under\nemployee wellbeing in the workplace. We collaborate with One Mind one brand called LIVE IT. LIVE IT serves as a call to action for employees\nat Work to enable broad-scale transformation in how mental health is to take control of their health and live their best lives. Our LIVE IT\nviewed and approached in the workplace, and how we can gain equity, continuum of wellbeing includes four pillars: PREVENT IT (promoting\ncollaboration and parity between physical and mental health. up-to-date vaccination scheduling), BALANCE IT (promoting spending\ntime with friends and family), MOVE IT (promoting taking walks\nMind Well outside) and FUEL IT (promoting cooking new and healthy dishes at\nhome). It is a holistic approach to wellbeing designed by and for our\nWe are committed to creating an inclusive culture of wellbeing and a\nemployees and their families. We promote offerings within each of\nsupportive work environment that values the overall health of every\nthese areas to engage and enhance the lives of our employees. LIVE IT\nemployee and their family, which includes their emotional and mental\nwas launched in the United States in 2011. LIVE IT has been adopted by\nwellbeing. Through Mind Well, we are working to reduce mental health\nall of our Company’s markets, globally.\nstigma through storytelling, resilience building, and providing access\nto mental health care and resources.\nSupport for working parents and caregivers\nR U OK? Day—Mental Health and Wellness e-Learning Using multiple listening methods—from employee focus groups and\nfor managers multiple employee surveys—we created a pathway to hear directly\nfrom the workforce on issues and challenges of importance so that\nWe recognize that the struggle with stress and emotional wellbeing\nwe could leverage employee input in the design and development of\ncan be significant, especially during a global pandemic. We also\nresources and benefits to best support their needs. One example of a\nrecognize the critical role managers can play in being aware and\nprogram that provides personalized support to employees is Wellthy\nsupportive of team members who may be feeling down, going through\nConcierge, which provides personalized support when managing care\na tough time or experiencing poor mental health. As such, a Mental\nfor oneself or a loved one for the stress of what can be an otherwise\nHealth Awareness for Managers e-Learning module was launched\nconfusing and lengthy process of finding care for their loved ones.\nas a resource before starting any conversation with an employee\nThe full cost of this program is covered by the Company.\nabout mental or emotional wellbeing. The e-Learning program,\nR U OK?, launched in September 2020, provides facts, talking To learn more about how we support employee wellbeing, please see\npoints and tips managers can use with team members to discuss GRI 401-2 on page 127.\nemotional wellbeing and mental health in a safe, nonjudgmental way.\nOver 4,000 employees have completed the training and approximately\nZero-tolerance policy against violence and harassment\n2,000 employees have signed the Stamp out the Stigma pledge.\nin the workplace\nCALM app Our policy for Prevention of Harassment, Discrimination and Bullying\nin the Workplace includes a section on workplace violence in the\nWe introduced the Calm app at no cost as a resource to our employees in\nU.S. version (including Puerto Rico), as well as other applicable\n2021. The Calm experience provides a nourishing way to use technology\nregional policies.\nthat also empowers employees to take good care of themselves so\nthat they can respond to their lives with energy and enthusiasm.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 154"
  },
  {
    "page": 155,
    "source": "text",
    "content": "CONTINUED: GRI 405\nExpanding our pipeline of diverse talent CEO Action for Diversity & Inclusion\nIn the past year, we greatly expanded outreach to Historically Black Four years ago, we signed a pledge to join the CEO Action for Diversity\nColleges and Universities (HBCUs) by partnering with several & Inclusion. This commitment extends beyond our employees to\norganizations, including the College Diversity Network and the supporting businesses around the world by making a difference\nNational Urban League, to focus on building deep partnerships with in global economic inclusion. We continue to leverage this vital\ncolleges, students, faculty and alumni of HBCUs. organization for best practice sharing and identification of new\nopportunities to foster diversity, equity and inclusion.\nWe also focus on systemic barriers that may limit the employee\ncandidate pool, including the geographic location of open positions Economic inclusion and supplier diversity\nand job prerequisites of prior pharmaceutical experience. To broaden\nIn 2021, diverse spend represented 12 percent of our total procurement\nour access to diverse talent, we post some positions with an option\nspend, exceeding our corporate goal in spend with minority-owned,\nto work virtually, offer relocation services and are agnostic to prior\nwomen-owned, veteran-owned, LGBT-owned and disability-owned\npharmaceutical experience. We leverage key partnerships such as:\nbusiness enterprises.\n• Executive Leadership Council (ELC)\nIt is important to provide definitions and context for diverse suppliers.\n• INROADS College Links\nDiverse suppliers are businesses that are 51 percent managed,\n• National Urban League\ncontrolled and operated by a person or persons of the\n• ALPFA following categories:\n• National Action Council for Minorities in Engineering (NACME) • Minority: Black, Hispanic, Asian and Native American\n• Ascend • Women\n• Out & Equal • LGBTQ+\n• Disability: IN • Veteran, service-disabled veteran\n• Best Buddies • Disability-owned business\n• The International Labour Organization (ILO)\n“Non-Diverse” refers to those suppliers that don’t qualify\nGlobal Business and Disability Network (GBDN)\nper the definition above.\n• Women of Color in Pharma (WOCIP)\nExtending our GD&I commitment beyond\nour employees\n$2.9 billion\nOur work in equity does not stop at the doors of our Company. It\ncontinues outside our employee base and into communities all over the\nspending with diverse\nworld, including communities that have historically been underserved\nsuppliers globally\nor underfunded. We engage with partners to advance the efforts\nof our global diversity and inclusion commitments and to support\nunderserved communities all over the globe.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 155"
  },
  {
    "page": 156,
    "source": "text",
    "content": "CONTINUED: GRI 405\nIn addition to the amount of dollars we spend, we focus on the Low birth weight\ninvestment, impact, growth and development of our suppliers to • Increased spending with minority-owned suppliers leads to\naddress social determinants of health (SDOH), leading to health equity statistically significant reductions in the percentage of Black babies\nand value delivery in the communities where we live and work. The born with low birth weight from 12.9 percent to 12.4 percent in the\ncorrelation between our Company’s diverse supplier spend and SDOH time this study was executed\nwas validated in 2021 through independent research conducted by • As a result of increased spending with minority-owned suppliers,\nProximo Inc., an information technology services firm that specializes Black and Asian child mortality rates show a statistically significant\nin data analytics and business intelligence, data warehousing and reduction of 12 infant lives saved per 100,000 births, and eight\nintegration, and data strategy and governance. infant lives saved per 100,000 births, respectively\n• Increased spending among Black- and Latino-owned suppliers\nTwo unique data sets were integrated to conduct the research:\nleads to statistically significant reductions in both Black and Latino\n1. Spend data for 2020 was enriched to remove duplicate supplier child mortality rates. Increased spending among Asian-owned\nlistings, update incomplete addresses and identify the county suppliers leads to statistically significant reductions in Asian and\nfor each supplier Black child mortality rates\n2. County Health Rankings & Roadmaps data for 2021 is inclusive\nMental distress\nof publicly available measures of health outcomes, health\nbehaviors, clinical care, social and economic factors, and physical • Increased spending with minority-owned suppliers leads to\nenvironment. This data was compiled to create an overall data- statistically significant reductions in the percentage of adults with\ndriven view of the “health” of nearly every county in all 50 states, frequent mental stress from 13.2 percent to 12.7 percent\nexcluding California1 and Puerto Rico.2\nFood environment index\nThe findings of this study are significant, compelling and validate a • Increased spending with minority-owned suppliers leads to\ncorrelation between our Company’s spend and SDOH variables. The statistically significant improvements in healthy food access from\nfollowing key indicators of impact in the community where diverse 8.3 percent to 8.7 percent\nsuppliers are located were identified: household income, percentages\nof babies born with low birth weight, child mortality rates, percentages Uninsured rates\nof adults with frequent mental distress, the food environment index • Increased spending with minority-owned suppliers leads to\nand uninsured rates. statistically significant reductions in the percentage of uninsured\nrates for children (4.0 percent to 3.8 percent) and for adults\n(11.9 percent to 9.0 percent)\nHousehold income\n• Increased spending with “minority-owned” suppliers—suppliers\nOur ongoing economic inclusion and supplier diversity efforts will\nthat are at least 51 percent managed, controlled and operated\nenable us to continue our membership in the Billion Dollar Roundtable\nby individuals from minority backgrounds—leads to statistically\n(BDR), an exclusive industry organization that recognizes and\nsignificant increases for all households\ncelebrates corporations that achieved spending at least $1 billion\n• Increased spending with minority-owned suppliers generates\nwith diverse suppliers headquartered in the U.S. and globally. Our\ndisproportionately greater economic impact vs. increased\nmembership in the BDR allows us to share and access best practices\nspending with non-diverse suppliers among Black households\nin supply chain diversity excellence with other organizations that have\n(4.5x greater economic impact) and Latino households\nalso achieved this status.\n(2.8x greater economic impact)\n1 California was removed from the analysis due to severe housing problems which caused\nthem to be an outlier in terms of nearly all SDOH variables.\n2 The 2021 County Health Rankings & Roadmaps data did not include data for Puerto Rico,\nso those suppliers could not be included in the study.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 156"
  },
  {
    "page": 157,
    "source": "text",
    "content": "CONTINUED: GRI 405\nWe are proud to be hosting the next Billion Dollar Roundtable Summit Through our work with OneTen, we’ve also been able to connect with\nin 2022. The Summit will provide another opportunity to chart a new talent partners, leading non-profits and other skill-credentialing\ncourse for the bold transformative steps which are urgently needed organizations that support the development of diverse talent. By\nto ensure we are optimizing positive economic impact to some of our maximizing roles appropriate for a skills-first approach, both within\nmost distressed areas, share best practices and encourage global the Company and within our supplier network, we’ll continue to fuel\npartners to continue to deliver on our purpose. our OneTen talent strategy and our overall hiring paradigm.\nFor more information on our supplier diversity program, please see To learn more, please visit the story on our corporate website.\nGRI 204 on page 75.\nYear Up\nOneTen Initiative\nWe are among the more than 250 corporations partnering with an\nIn 2020, Kenneth C. Frazier, our executive chairman and former innovative nonprofit organization, Year Up. This nonprofit ensures\nCEO, was co-chair for OneTen, a coalition of leading executives equitable access to economic opportunity, education and justice for\nhelping to close the opportunity gap for Black talent in America, all young adults. They accomplish this goal by closing the opportunity\nand to ignite potential for generations to come. Along with over 50 gap in the job market for economically disadvantaged youth by offering\nleading companies, we have committed to OneTen’s mission of hiring, six months of intensive training and a six-month corporate internship\npromoting, and advancing one million Black individuals who do not in information technology, financial operations, sales and customer\nhave four-year degrees into family-sustaining careers over 10 years. support, business operations or software development and support\nat major corporations. To date over 40 student internships have been\nConsistent with our commitment to diversity, equity, and inclusion, provided through Year Up by our Company, with plans for continued\nour Company is determined to be a role model within OneTen. Over growth and expansion in the future.\nthe past year, an integrated team of our business and HR stakeholders\nhave been working collaboratively with OneTen to experiment with To learn more, please visit Year Up’s website.\nskills-first hiring on a small scale, focusing first on select groups to\nquickly learn and adapt our approach.\nMinorities in Agriculture, Natural Resources\nHighlights of key accomplishments during the first year include: and Related Sciences (MANRRS)\n• Completing skills-first pilots in our manufacturing division Our Animal Health Division partners with Minorities in Agriculture,\n(Durham and West Point) and IT Natural Resources and Related Sciences (MANRRS) to support the\nidentification of diverse talent from the agricultural sciences and\n• Launching an urban marketing campaign in Philadelphia to attract\ndiverse, non-degreed talent related fields and to expose them to the variety of career paths\navailable in animal health in addition to the veterinarian field. The\n• Expanding our strategic partnership with Year Up, a pipeline of\ngrowing areas of connected technology and other smart data products\nskills-first talent\nand services for animal health and wellbeing—where Merck Animal\n• Engaging external SMEs to help accelerate our skills-first\nHealth is a global, world-class leader—are examples of exciting career\ntransformation efforts\npaths that are available to today’s talent.\n• Posting 400+ U.S. roles without a four-year degree requirement,\ndriven by our manufacturing division\n• Developing new approaches to community engagement, such\nas partnering with a local Black church in Durham to execute a\ncommunity career fair on the church campus\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 157"
  },
  {
    "page": 158,
    "source": "text",
    "content": "CONTINUED: GRI 405\nMerck Animal Health veterinary scholarship program Rewarding a culture of inclusion\nOur scholarship program partnerships offer financial awards to Leaders and managers are held accountable for maintaining an\noutstanding veterinary students to further their education as they inclusive culture across the business enterprise. We acknowledge\npursue careers in animal medicine. Through our veterinary scholarship those who excel in demonstrating inclusive behavior through the\npartnerships, we donated $1.3 million in 2021, reaching 275 students Company’s INSPIRE Awards. Launched in 2019, INSPIRE fosters a\nin 70 countries. culture of recognition and engagement by empowering all employees\nto recognize others. By the end of 2021, INSPIRE recorded over\nSince 2017, we have proudly sponsored a scholarship program 600,000 awards across 30 countries.\nin partnership with Tuskegee University College of Veterinary\nMedicine (TUCVM) designed to encourage diversity and inclusion Learn more about how we engage with employees in GRI 401\nin the veterinary profession. TUCVM is the only veterinary medical on page 124.\nprofessional program located on the campus of a historically Black\ncollege or university in the U.S. The college has educated more than\nHealth equity\n70 percent of the nation’s Black veterinarians and has been recognized\nas the most diverse of all 32 schools or colleges of veterinary medicine\nAddressing systemic barriers to enable greater diversity\nin the nation.\nand equity in clinical trials\nLowering barriers to education Clinical trials function as a gateway to bringing forward new medicines\nand vaccines to our patients and our communities. We are advancing\nIn partnership with the American Association of Veterinary Medical\nhealth equity in clinical trials by:\nColleges (AAVMC), we have provided a grant to help offset the costs of\napplying to veterinary school, a gap identified by communities that are • Ensuring our clinical trials are diverse and inclusive through careful\nunderrepresented in the veterinary profession. selection of trial sites, embedding cultural competency and health\nliteracy in engagement materials and clinical trial investigator\ntraining, partnering with community-based organizations and\nMeasuring for impact\nproviding outreach and education within diverse communities\nWomen and underrepresented ethnic group • Pursuing new ways—including partnerships with organizations like\nBlack Health Matters, the National Urban League and the Lazarex\n(UEG) representation\nCancer Foundation—to recruit and engage clinical trial participants\nLeaders and managers are highly encouraged to incorporate clear who are racially, socioeconomically and demographically\ndiversity and inclusion goals as part of their annual performance representative of the communities we aim to serve\npriorities and reviews. In addition, we utilize specific, time-bound\nLearn more about our commitment to diversity in clinical trials\naction plans with aspirational targets to increase the representation\non our corporate website.\nof women globally and UEGs in U.S. leadership positions. We establish\nclear, measurable goals with our leaders and throughout the business\nenterprise and have established goals for global executive women\nrepresentation to 40 percent by 2024 and for both Black/African\nAmerican and Hispanic/Latino employees in the U.S. to 10 percent\neach by 2024.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 158"
  },
  {
    "page": 159,
    "source": "text",
    "content": "GRI 405-1 Diversity of governance bodies and employees\nFemale representation,\nby job category (global) 2017 2018 2019 2020 2021\nBoard1 23% 33% 46% 46% 43%\nExecutives2 22% 20% 20% 33% 33%\nSenior management3 25% 27% 30% 31% 36%\nAll managers4 39% 41% 42% 42% 44%\nAll employees 49% 49% 49% 50% 50%\nNew hires 49% 51% 51% 50% 53%\nPromotions 52% 52% 53% 52% 53%\nNote: We have publicly disclosed EEO-1 information since 1999. Our 2021 data is available on the ESG Resources page of our corporate website. All data, except for those corresponding\nto our Board members, is as of December 31, 2021. All Board figures above are derived from our proxy statement filed the following year. To align with U.S. government reporting\nrequirements, the ESG data for gender diversity in this report uses the terms men and women. We recognize and embrace the gender spectrum and diversity in our employees, and have\ninternally established voluntary Self-ID options for employees to self-report on their gender identity. The totals in this report may not equal 100 percent due to rounding or employees\nwho have not reported their gender and/or race/ethnicity.\n1 Data for Board members are derived from our proxy statement filed the following year.\n2 “Executive” is defined as the executive committee who reports to the chief executive officer.\n3 “Senior management team” is defined as vice presidents and above, not on executive committee.\n4 “Management role” is defined as all other managers with at least one direct report.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 159"
  },
  {
    "page": 160,
    "source": "text",
    "content": "CONTINUED: GRI 405-1\nGender and ethnicity 2017 2018 2019 2020 2021\nWomen in the workforce 49% 49% 49% 50% 50%\nWomen on the Board1 23% 33% 46% 46% 43%\nWomen in executive roles2 22% 20% 20% 33% 33%\nWomen on the senior management team3 25% 27% 30% 31% 36%\nWomen in management roles4 39% 41% 42% 42% 44%\nMembers of underrepresented ethnic groups on the Board 15% 17% 23% 31% 21%\nMembers of underrepresented ethnic groups in executive roles (U.S.)2 33% 30% 40% 25% 42%\nMembers of underrepresented ethnic groups on the senior management 17% 19% 21% 20% 25%\nteam (U.S.)3\nMembers of underrepresented ethnic groups in the workforce (U.S.) 26% 28% 29% 30% 32%\nMembers of underrepresented ethnic groups in management roles (U.S.)4 20% 22% 23% 25% 26%\nNew hires that were female 49% 51% 51% 50% 53%\nPromotions that were female 52% 52% 53% 52% 53%\nNew hires that were members of underrepresented ethnic groups (U.S.) 37% 36% 35% 40% 46%\nPromotions that were members of underrepresented ethnic groups (U.S.) 28% 28% 30% 32% 34%\nNote: We have publicly disclosed EEO-1 information since 1999. Our 2021 data is available on the ESG Resources page of our corporate website. To align with U.S. government reporting\nrequirements, the ESG data for gender diversity in this report uses the terms men and women. We recognize and embrace the gender spectrum and diversity in our employees, and have\ninternally established voluntary Self-ID options for employees to self-report on their gender identity. The totals in this report may not equal 100 percent due to rounding or employees who\nhave not reported their gender and/or race/ethnicity.\n1 All Board figures above are derived from our proxy statement filed the following year.\n2 “Executive” is defined as the executive committee who reports to the chief executive officer.\n3 “Senior management team” is defined as vice presidents and above, not on executive committee.\n4 “Management role” is defined as all other managers with at least one direct report.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 160"
  },
  {
    "page": 161,
    "source": "text",
    "content": "CONTINUED: GRI 405-1\nUnderrepresented ethnic Black/\ngroup (UEG) representation, African Latino/\nby ethnicity (U.S.) (2021) Total American Hispanic Asian All other\nBoard 21% 21% 0% 0% 0%\nExecutives1 42% 25% 0% 17% 0%\nSenior management2 25% 7% 6% 12% 1%\nAll managers3 26% 5% 6% 13% 2%\nAll employees 32% 9% 6% 16% 2%\nNew hires 46% 14% 9% 21% 3%\nPromotions 34% 10% 6% 16% 2%\nNote: We have publicly disclosed EEO-1 information since 1999. Our 2021 data is available on the ESG Resources page of our corporate website. All Board figures above are derived from our\nproxy statement filed the following year. Total values shown may not equal the sum of the individual source totals.\n1 “Executive” is defined as the executive committee who reports to the chief executive officer.\n2 “Senior management team” is defined as vice presidents and above, not on executive committee.\n3 “Management role” is defined as all other managers with at least one direct report.\nHuman rights assessment\nGRI 412 Management approach\nAs stated in our Human Rights Public Policy Statement, we strive\nto avoid causing or contributing to adverse human rights impacts\nthrough our own activities and seek to prevent or mitigate adverse\nimpacts that are directly linked to our operations and products.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 161"
  },
  {
    "page": 162,
    "source": "text",
    "content": "CONTINUED: GRI 412\nHuman rights issue Policies / standards Governance\nLead function\nHealth & safety X X X X Global Safety & Environment\nForced labor and human trafficking X X Human Resources\nDiscrimination and harassment X X X Human Resources\nChild labor X X Human Resources\nFreedom of association X X Human Resources\nWorking hours X X Human Resources\nPrivacy X X X Global Privacy Office\nSecurity X X X Global Security\nAccess to grievance mechanisms X X X X X X X X X X Office of Ethics\nSuppliers and business partners X X X Global Supplier Management\nsthgiR\nnamuH\nyciloP\ncilbuP namuH\nyciloP\nsecruoseR\nnamuH\n& robaL\nyciloP\nsthgiR\n&\nhtlaeH\nyciloP\nytefaS\nreilppuS\n& tnemerucorP yciloP\nsnoitaleR\nrentraP\nssenisuB\ntcudnoC\nfo edoC\ntnemeganaM\nnoitamrofnI\nyciloP\nnoitcetorP\n&\nataD\n&\nycavirP\nyciloP\nnoitcetorP\ngnidnopseR\n&\ngnitropeR\nyciloP\ntcudnocsiM\not\nni\necneloiV\nfo\nnoitneverP\ndradnatS\necapkroW\nsmraeriF\nfo\nnoissessoP dradnatS\nWe’ve put in place appropriate policies, processes, training and monitoring systems to address key human rights issues. Support and respect for the protection of human rights\nis embedded and reflected in our operational policies and procedures, as summarized in the table below.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 162"
  },
  {
    "page": 163,
    "source": "text",
    "content": "CONTINUED: GRI 412\nRemedy\nAs part of our efforts to protect against business-related human Employee training on human rights policies\nGRI 412-2\nrights abuses, we have established a grievance mechanism that and procedures\nallows employees and workers to report concerns in a confidential\nmanner without fear of retaliation (see the Speak Up section in our Business-related human rights issues are embedded within our\nPublic Policy Statement on Human Rights). internal training programs to help maintain employee awareness and\nunderstanding of our Company’s expectations. Examples of human\nThis grievance mechanism and associated reporting channels are\nrights related topics covered by existing training programs include\nfundamental to ensuring that employees and workers have access to\nhealth and safety; privacy and data protection; harassment and\nan effective remedy whenever human rights impacts occur. We expect\ndiscrimination; diversity and inclusion; as well as training that explains\nour suppliers to encourage all workers to report concerns or suspected\nhow to confidentially report concerns, emphasizing the importance\nillegal activities without threat of reprisal, intimidation or harassment,\nof speaking up. Completion of assigned training is closely monitored\nand to investigate and take corrective action if needed. In addition, we\nand reported.\nexpect our suppliers to provide workers with information on how to\nconfidentially report concerns and ensure that reporting workers are For more information on our training and development programs,\nprotected from retaliation. please see GRI 404 on page 142.\nGovernance\nOur oversight and monitoring of business-related human rights\nInvestment agreements and contracts that include\nGRI 412-3\nrisks is supported by relevant internal functions and business human rights clauses or underwent screening\nunits, including Human Resources; Global Safety & Environment;\nGlobal Supplier Management; Supply Chain Management; Ethics &\nAgreements and contracts\nCompliance; Global Security; Global Privacy Office, Information Risk\nManagement; Enterprise Risk Management; and the Office of Social\nOur Global Supplier Management Group (GSMG) function oversees\nBusiness Innovation.\ncontract development and execution activities associated with the\nsourcing and selection of our suppliers of goods and services.\nThrough our standard contracts and agreements, we seek a written\nOperations that have been subjected to human\nGRI 412-1 commitment from suppliers to respect and abide by the principles set\nrights reviews\nforth in our Business Partner Code of Conduct (BPCC). Our BPCC\nstates that business partners are expected to uphold the human\nrights of workers, treat workers with dignity, respect the protection of\nWe perform supplier labor and human rights audits (using\ninternationally proclaimed human rights and ensure that they are not\nindependent third-party service providers) at select direct material\ncomplicit in human rights abuses.\nsuppliers’ facilities located in countries that are known to present\nan increased risk of human rights abuses.\nFor more information on our social assessments for suppliers, please\nvisit GRI 414 on page 164.\nFor more information, please see GRI 414 on page 164.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 163"
  },
  {
    "page": 164,
    "source": "text",
    "content": "Supplier social assessment\nGRI 414 Management approach\nSupplier due diligence assessment for labor\npractices and human rights\nWe respect human rights and support transparency in our supply\nchain. We are committed to upholding the Pharmaceutical Supply\nChain Initiative (PSCI) Principles and we require our suppliers to\noperate in compliance with all applicable laws. We have a formal\nprogram led by our Global Supplier Management Group (GSMG) to\nevaluate the risks for labor and human rights (LHR) in our supply chain.\nWe have a Conflict Minerals due diligence program and complete the\nassociated annual reporting.\nOur policies\nOur policies serve as our standards of conduct for engaging with\nstakeholders. They are founded on our Code of Conduct (Our Values\n& Standards) and are used to navigate and guide our decisions. They\nhelp us identify, address and mitigate risks.\nFor information on our policies, please visit our Policies & Positions\nand ESG Resources pages of our corporate website.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 164"
  },
  {
    "page": 165,
    "source": "text",
    "content": "CONTINUED: GRI 414\nHuman rights and labor risks risks for labor and human rights, including modern slavery and\nhuman trafficking. The information gathered as part of due diligence\nWe recognize that companies with supply chains that extend into\nis used to determine the acceptability of suppliers’ local practices.\nhigh-risk countries potentially face greater LHR risks. Our Company\nResults are then applied by GSMG to inform our supplier selection\ncan be exposed to these risks through our supply chain, as some\nand risk management processes.\nof our third party suppliers and service providers operate in\nhigher-risk countries. Contracts: Seeking written commitment from suppliers to respect the\nprinciples set forth in our Business Partner Code of Conduct through\nTo help manage and address potential risks associated with third party\nour contracts/agreements. Our contract templates contain a Business\nbusiness relationships, GSMG has an established cross-functional,\nPartner Code of Conduct compliance clause that includes provisions\nthird party risk management committee and program. LHR risks are\nrelated to modern slavery.\nconsidered as part of our third party risk management activities. We\nalso recognize that potential risks may exist beyond Tier 2 suppliers. Auditing: Performing LHR audits at select supplier facilities to verify\ntheir conformance with our expectations (as stated in our Business\nDuring 2021, we worked to detect and address the risks in our supply\nPartner Code of Conduct), and working with them to address identified\nchain by:\nnonconformances. We use independent third party audit firms to\nperform announced LHR audits at suppliers’ facilities. When preparing\nSupplier selection: Selecting suppliers that are socially responsible\nour audit schedule, we consider the industry risk, the category of\nand who share our commitments to ethics and integrity. We strive to\nmaterials supplied, the country in which the supplier operates and\nobtain the services, goods, active ingredients, components, finished\nresults of past due diligence.\ngoods or other products in a way that is lawful and fair.\nRemedial actions: Tracking and reporting (to senior management) on\nExpectations: Setting and communicating our expectations of\nthe closure of remedial actions taken by suppliers to address identified\nsuppliers, including those related to child labor, forced labor and\nnon-conformances (gaps/concerns) revealed by supplier LHR auditing.\nhuman trafficking. We use our Business Partner Code of Conduct to\ncommunicate our expectations. It has been translated for all countries\nMonitoring: Assigning relationship managers from within GSMG to\nin which we operate.\noversee and monitor the performance of key suppliers. We continue to\nhold suppliers accountable for meeting their contractual obligations.\nSupply chain mapping: Mapping our supply chain to identify which\nof our suppliers operate in countries that are known to present a\nGovernance: Using our Third Party Risk Committee to help govern\nsignificant risk of LHR issues. We use this information to help us\nand oversee the management of risks associated with third party\ndecide upon the level of due diligence that may be necessary.\nrelationships. This committee is chaired by our senior vice president\nfor Global Procurement. The role of our Third Party Risk Committee\nDue diligence: Conducting appropriate supplier due diligence to\n(and associated Third Party Risk Team) is to assist senior leadership\nhelp determine the level of risk presented by suppliers, including\nby providing independent and objective oversight, monitoring\npotential new (prospective) suppliers as well as our existing suppliers.\nand reporting in relation to the risks presented by third parties.\nOur supplier due diligence process for LHR targets direct materials\nsuppliers, including external manufacturing suppliers and contract\nEngagement: Engaging and seeking input from relevant stakeholders,\nmanufacturing organizations, regardless of their geographic location.\nincluding GSMG, Ethics & Compliance, Legal, Global Safety and\nA self-assessment questionnaire is used to gather information\nEnvironment and Office of Social Business Innovation.\non freely chosen employment, child labor, employment practices,\nemployee disclosures, fair treatment, wages, benefits and working Collaboration: Working with PSCI to develop training, tools and\nhours. Suppliers’ responses are used to judge whether that supplier maturity models and share knowledge across our industry and with\nhas programs and/or procedures in place to address potential our suppliers.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 165"
  },
  {
    "page": 166,
    "source": "text",
    "content": "CONTINUED: GRI 414\nTraining: Training GSMG professionals with responsibility for supplier Public policy\nselection, oversight and monitoring, including the assignment of\nonline courses:\n• Business Partner Code of Conduct\nGRI 415 Management approach\n• Mitigating Modern Slavery Risks in Supply Chains\n• Third Party Risk Management\nThe Merck Political Action Committee (PAC) engages in the political\nIn 2021, we continued to work with PSCI to develop and provide\nprocess, at both the federal and state levels, to educate policymakers,\nsuppliers training:\nlawmakers and candidates on policy issues critical to our industry and\n• Forced Labor & Modern Slavery our Company’s core purpose to invent new medicines and vaccines to\nsave lives. The Center for Political Accountability, at the Zicklin Center\n• Operationalizing the PSCI Human Rights Principles\nfor Business Ethics Research at the Wharton School of the University\n• Human Rights Risks\nof Pennsylvania, has recognized the Merck Political Action Committee\n• Responsible Sourcing of Ingredients as a Trendsetter for the last five years in their annual CPA Index of\n• 14 Material Specific Human Rights and Environmental Impact Corporate Political Disclosure & Accountability report.\nAssessment Guides\nWe continue to make bipartisan contributions that are carefully\n• Human Right and Labor Global Regulations\nconsidered on a case-by-case basis. In establishing our PAC political\ngiving priorities, our Contributions Committee considers various\nNext steps factors to prioritize candidates who support policies that enhance\ninnovation and patient access to health care.\nWe will continue working on our efforts to identify, assess and\naddress LHR risks within our operations and supply chains.\nThese efforts will include:\nGRI 415-1 Political contributions\n• Investigating all reported concerns promptly\n• Conducting supplier labor and human rights due diligence to\nOur Company is committed to participating constructively and\nidentify and address risks\nresponsibly in the political process, and to providing clarifying analysis\n• Auditing select suppliers to verify conformance with standards\nand information regarding the issues that affect our business and\nfor LHR\npatient care.\n• Holding suppliers accountable for addressing non-conformances\nrevealed by LHR audits We spent a total of $799,080 in U.S. corporate political contributions\nin 2021. Of these, $401,180 were used to support the campaigns of\n• Participating in the activities/initiatives of PSCI’s Human Rights\nand Labor Sub-Committee 368 individual candidates in 23 states plus the District of Columbia.\nThe party breakdown of the contributions for individual candidates was\n43.75 percent Democratic, 55.71 percent Republican, and 0.54 percent\nIndependent. Republicans held a majority in 61 chambers, Democrats\nheld the majority in 37 chambers and one chamber holds equal power\nGRI 414-1 New suppliers screened using social criteria\nbetween parties.\nPlease see GRI 102-9 on page 30 for additional information on our\nsupply chain risks and associated KPIs.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 166"
  },
  {
    "page": 167,
    "source": "text",
    "content": "CONTINUED: GRI 415-1\nThe remaining $397,900 of these funds were provided to 36 state Customer health and safety\nlegislative leadership committees, industry-affiliated political action\ncommittees, and several national organizations representing state\nelected officials. Many of these latter groups also meet periodically\nto discuss policy issues. Examples include the Republican Governors\nGRI 416 Management approach\nAssociation and the Democratic Governors Association. The party\nbreakdown of the contributions for these entities was 44.4 percent\nDemocratic and 55.6 percent Republican.\nOur quality strategy is focused on maintaining sustained quality and\ncompliance excellence through the following elements: a digitally\nOur representatives involved in state-government-affairs activities\nenabled Quality Management System (QMS), oversight and periodic\nmade the recommendations for specific contributions based on the\nreview of our quality performance, a Quality Management Maturity\nbudget and priorities approved by the Contributions Committee.\n(QMM) mindset and a learning culture. Our quality strategy is a key\nOutside legal counsel conducted a thorough review of all proposed\nenabler to ensuring patient safety and the overall quality and\ncontributions to ensure that they were permitted under state law.\ncontinuous supply of our products.\nThe only other country in which we provided corporate contributions\nWe operate in a highly complex and ever-changing regulatory landscape\nto candidates or political parties in 2021 was Australia. These\ndriven by many different factors, including novel scientific discoveries\ncontributions are subject to the same policies and governance\nand technological advancements. Specifically, we are leveraging new\nprocedures discussed above.\ntechnological advancements such as integrated IT tools, artificial\nInformation on all of our contributions can be found on the intelligence (AI) and streamlined digital platforms to further enhance\nTransparency Disclosures page of our corporate website. how we manufacture high-quality products. We apply and adhere to a\nstrict set of quality standards, and we have policies and procedures in\nplace to define, measure, control and sustain product quality excellence.\nOur Global Quality Compliance organization is responsible for\nestablishing the standards to ensure that our Company’s products\nare manufactured, tested, released and distributed in compliance with\nregulatory requirements.\nWe continuously strive to enhance these standards in order to ensure\nongoing compliance with current Good Manufacturing Practices (cGMPs).\nWe provide appropriate, ongoing training on cGMP for our employees\nso they are prepared to perform their duties effectively. Our quality\nsystem not only ensures that all applicable employees are trained,\nbut also monitors the effectiveness of the training provided.\nOur medicines and vaccines are widely tested before they are approved\nfor marketing. This testing is governed by a comprehensive regulatory\nscheme and by our research policies. We assess the safety of our\nproducts in rigorous nonclinical and clinical trials prior to seeking\nregulatory approval. Following approval of our drugs, vaccines or\ndevices our Company continues to monitor their safety profiles.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 167"
  },
  {
    "page": 168,
    "source": "text",
    "content": "CONTINUED: GRI 416\nOur chief medical officer (CMO) holds overall responsibility for the Animal Health\nbenefit-risk determination of our human health pipeline and marketed\nWe test our investigative animal health pharmaceuticals and vaccines\nproducts. In addition, the CMO provides medical oversight for all\nvigorously for safety, quality and efficacy before submitting them\nclinical programs, supervises the development and implementation\nfor approval, which can be obtained only after thorough review by\nof medical policies (including those related to data transparency and\nindependent regulatory authorities.\nthe sharing of clinical data), and has responsibility for the design,\nexecution and implementation of pre-registration expanded access\nAll of our pharmaceuticals and vaccines must be tested for product\n(“compassionate use”) programs.\nquality as well as for their safety and efficacy in treated animals.\nIn addition, our submissions to regulatory agencies also include\nOur chief safety officer (CSO) holds overall responsibility for\nrigorous human food safety testing for those products used in food\ndetermining the human health product risk profile and overseeing\nproducing animals, in addition to user safety and environmental\nthe safety of our human health products. Our Global Clinical Safety\nsafety assessments.\nand Pharmacovigilance (GCS&PV) function led by the CSO manages\na global system for the collection, review and reporting of Adverse\nThis testing and refining of the product can take years to complete.\nExperience (AE) reports received by our Company worldwide, and for\nWhen all of the required testing is completed and found to be\nthe continuous assessment of product safety.\nsatisfactory by the appropriate government regulatory agency, the\nproduct is approved to be sold. Once a product is on the market, we\nThe Animal Health senior vice president of R&D holds responsibility\nfollow all applicable pharmacovigilance rules and findings are assessed\nfor the benefit-risk determination for our Animal Health pipeline and\nand reported to regulatory authorities.\nmarketed Veterinary Medicinal Products (VMPs) and oversees all\nAnimal Health clinical programs.\nA consistent, science-based regulatory environment is one of the key\nconditions necessary for innovation and for providing our customers\nOur Animal Health Global Pharmacovigilance (GPV) Team manages a\nwith high-quality products. We support global harmonization of the\nglobal system for the collection, review and reporting of AE reports\nregulatory process for veterinary medicines through our global trade\nreceived by our Company worldwide, and for the continuous assessment\nassociation, HealthforAnimals, which is recognized as an observer\nof product safety. GPV leads all safety monitoring and risk management\norganization. This allows HealthforAnimals to offer input and provide\nactivities for the Animal Health VMP portfolio from the time of initial\nperspectives in meetings with international standards setting\nproduct approval through the end of the product life cycle.\nbodies, including:\nOur industrial hygiene risk assessments require evaluation of the\n• International Cooperation on Harmonisation of Technical\neffectiveness of control measures. Risk-based exposure monitoring Requirements for Registration of Veterinary Medicinal\nis also conducted to verify the effectiveness of installed engineering Products (VICH)\ncontrols and improvements are made as needed. We use conservative\n• Codex Alimentarius\nsafety factors to set low de minimis levels for environmental releases\nuntil we have sufficient data to fully understand their impacts on\naquatic organisms. Levels are reviewed and updated as new data\nbecome available.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 168"
  },
  {
    "page": 169,
    "source": "text",
    "content": "Incidents of non-compliance concerning the health\nGRI 416-2\nand safety impacts of products and services\nProducts listed in the FDA’s MedWatch Safety\nSASB 250a.1\nAlerts for Human Medical Products database\nFatalities associated with products as reported in\nSASB 250a.2\nthe FDA Adverse Event Reporting System\nSASB 250a.3 Recalls issued, and total units recalled\nMethods and technologies used to maintain\nSASB 260a.1 traceability of products throughout the supply\nchain and prevent counterfeiting\nProcess for alerting customers and business\nSASB 260a.2 partners of potential or known risks associated\nwith counterfeit products\nQuality and product safety 2017 2018 2019 2020 2021\nNumber of product recalls in the United States1,2 0 2 1 2 2\nPercentage of sold units recalled during a given year 0.01% 0.17% 0.01% 0.50% 0.22%\n(recall rate globally)1,2\n1 Definition of Recall Classifications.\n2 Starting with June 2021, information for Organon was removed due to spin-off.\nCounterfeit products Our efforts involve raising public awareness about the risks posed by\ncounterfeit medicines and advocating for increased enforcement to\nWe invest in an industry-leading, rigorous and intelligence-led\naddress these challenges.\nproduct-integrity strategy that is solely focused on protecting patients\nfrom the harm associated with counterfeit and diverted medicines. In 2021, we continued our commitment to increasing our focus in this\nOur Global Security Group oversees the global Product Integrity area and have strategically enhanced our ability to make a long-term\nstrategy and leads its execution. The strategy seeks to protect our impact on patient safety through various education campaigns. We\npatients and our Company’s reputation from the negative impacts of are committed to cooperating with relevant government agencies,\ncounterfeit medicines using a three-pronged strategy focused on: other pharmaceutical manufacturers, wholesalers, distributors,\nhealth professionals, consumer groups and key related organizations\n• Securing the supply chain\nin fighting the problem of counterfeit pharmaceutical products and in\n• Investigations and enforcement\neducating the public about the risks of counterfeit products and how\n• Raising public and stakeholder awareness to protect against them.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 169"
  },
  {
    "page": 170,
    "source": "text",
    "content": "CONTINUED: GRI 416-2 | SASB 250a.1 | SASB 250a.2 | SASB 250a.3 | SASB 260a.1 | SASB 260a.2\nThis effort includes a multipronged approach to communicating We enable meaningful enforcement actions as a key strategic priority,\nthe threat that counterfeit medicines pose and to mitigating this and in 2021 our product integrity activity led to 242 arrests and the\nthreat as effectively as possible while recognizing that it cannot be seizure of more than 29,349 units of counterfeit or illicit versions of\nentirely eliminated. our products. There were 57 prosecutions resulting from product\nintegrity investigations in 2021.\nAppropriate collaboration and information-sharing in order to raise\npublic and stakeholder awareness of the issue and risks are a crucial Another crucial aspect of investigations is the forensic analysis of\nfocus of our Product Integrity program. questionable products. This forensic testing is aimed at concluding\nwhether a questionable product is counterfeit, diverted or otherwise\nThrough active partnerships with other pharmaceutical companies, illicit. Counterfeit products are characterized in order to gain further\nand with organizations focused on security, patient safety and intelligence and understanding of the counterfeiters and the threats\npublic health, we provide effective advocacy on high-priority anti- to public health. We also have forensic detection devices in the field to\ncounterfeiting policy initiatives. analyze and detect counterfeits in regions around the world.\nThese collaborative efforts support the production of reports, As counterfeiters improve their skills and techniques, our forensic\nwhitepapers and data-circulation initiatives, as well as promote scientists have pioneered the use of several analytical tools for the\nthe intelligence sharing necessary to combat threats from detection and characterization of counterfeit medicines and continue\ncounterfeit medicines. to explore new analytical tools that would increase their forensic\ntesting capabilities. Lab findings are shared with regulatory and/or\nThe Anti-counterfeiting performance table below details the number\nlaw-enforcement agencies and may be used to support subsequent\nof new suspected and substantiated counterfeit events in 2021 and for\nenforcement actions and legal proceedings.\nthe previous four years. The data above reflects the current status of\neach event for all years presented as of March 2022. There were 497 unique questioned samples received as evidence and\nprepared for forensic testing in relation to active events in 2021. As\nThroughout 2021, Global Security addressed 2,350 product integrity\npart of our proactive awareness program, throughout 2021 Global\nevents in 89 countries, involving counterfeit, diversion, supply chain\nSecurity trained approximately 2,870 law-enforcement personnel in\nsecurity, tampering, financial integrity and brand security (non-\nmore than 50 countries regarding the patient safety risks associated\nMSD, unapproved generic product). Approximately 33 percent of\nwith counterfeit and diverted medication.\nthese events have been proactively investigated by Global Security\nto identify new or emerging product integrity threats, or to further Global Security also launched an internal training program on the\ncharacterize and mitigate known threats. Counterfeit, Diversion and Tampering (CDT) reporting process in late\n2017. To date, more than 67,000 employees and contractors have\ncompleted this training globally.\nAnti-counterfeiting1 2017 2018 2019 2020 2021\nInvestigations of suspected counterfeit products2 137 269 563 554 964\nSubstantiated cases of counterfeit products 76 231 212 77 86\n1 Prior-year data have been adjusted to reflect the current status of each event as of March 2022.\n2 Evidence from ongoing investigations of suspected counterfeit products can result in recategorization.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 170"
  },
  {
    "page": 171,
    "source": "text",
    "content": "CONTINUED: GRI 416-2 | SASB 250a.1 | SASB 250a.2 | SASB 250a.3 | SASB 260a.1 | SASB 260a.2\nSupply chain security and serialization corresponding to a genuine product of our Company. Serialization can\nadd a robust layer to our product security platform. When associated\nOur proactive focus on managing supply chain security risk is based\nwith a regulatory mandate that specifies effective implementation and\non our careful implementation and management of strict policies\nreporting to a national database, this method of product tracking can\nand procedures designed to protect the legitimate distribution of our\nbecome a more meaningful product security tool.\nproducts. We require customers to purchase our products directly\nfrom our Company or from authorized distributors listed publicly on Many jurisdictions around the world are requiring serialization\nour corporate website. on pharmaceutical packages or are considering such mandates.\nSerialization is required today in China, Turkey, Argentina, South\nWe maintain our commitment to ensure compliance with established\nKorea, Nigeria, India, Saudi Arabia, the Middle East, the U.S., EU,\nCompany policies, standards and procedures throughout the supply\nUnited Kingdom, Norway, Iceland, Switzerland, Liechtenstein and\nchain by identifying vulnerabilities and threats to the supply network.\nRussia, and will soon be required in Indonesia, Brazil, South Africa\nResources are positioned globally to monitor and manage our security\nand Pakistan. Each country’s regulations are different, making it very\nprograms and investigate incidents when they occur.\nchallenging for our packaging sites and distribution networks to meet\nthese diverse and intricate requirements, with additional complexity as\nAs a certified Importer under the Customs Trade Partnership Against\nreporting requirements are phased in.\nTerrorism (CTPAT) Program, we are validated by U.S. Customs\nand Border Protection as an elite Tier 3 Member recognized as\nWe launched the Global Product Serialization Initiative in 2012,\nimplementing best practices in supply chain security. This adds an\nwith the goal of meeting these varying requirements in a robust,\nimportant layer to the security of our products and materials imported\nstandardized and effective way based upon GS-1 standards. Through\nto the U.S.\nthese efforts, we are currently in compliance with applicable regulatory\nrequirements related to serialization. We are also working with\nSerialization—adding a 2D barcode with a unique identification\nindustry associations and regulatory authorities to better understand\nnumber on each package that goes to market—is one of the tools\npotential new requirements and to advocate for simple, standardized\nwe are investing in to secure our supply chain and prevent or detect\nand common-sense regulations that can be effective at protecting\ncounterfeiting. A serial number on individual packages may enable\nagainst counterfeit medicines.\nanyone along the supply chain—from a distributor to a pharmacist\nto a patient—to scan the code and verify it as a serial number\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 171"
  },
  {
    "page": 172,
    "source": "text",
    "content": "CONTINUED: GRI 416-2 | SASB 250a.1 | SASB 250a.2 | SASB 250a.3 | SASB 260a.1 | SASB 260a.2\nIn addition to our compliance with regulatory requirements related clinical trials involving patients assigned treatment with investigational\nto serialization, we are also exploring opportunities to deploy and marketed products are registered at trial initiation on\nvoluntary serialization and secondary authentication technologies to www.clinicaltrials.gov, www.clinicaltrialsregister.eu and\nfurther enhance the security and traceability of our products. These www.encepp.eu.\nmultifactor authentication systems would be enabled by blockchain\nnodes and applications that allow for secure and immutable product In accordance with our public policy position statement, all\ntracing that could be accessed by all supply chain partners and end investigational studies in human subjects are conducted in a manner\nusers. We are currently running several proof-of-concept and pilot consistent with applicable laws, regulations and guidelines for\nstudies involving these emerging technologies, as well as participating the protection of human subjects, including those issued by the\nin active industry associations, such as PharmaLedger, to further International Council for Harmonisation: Good Clinical Practice\ndevelop and apply these digital solutions. (ICH-GCP). However, individual country regulations and guidelines\nshould remain the primary determinant of specific requirements for\nthe conduct of medical research.\nClinical trial site monitoring, design, conduct\nand oversight We have a commitment, where appropriate, to the study of diverse\npatient populations, including underrepresented groups, women and\nWe have long been committed to sharing the results of our clinical\nchildren, in our clinical trials in all regions of the world. As a result,\ntrials, regardless of their outcome, in a timely manner. If a clinical\nwe strive to obtain information among diverse populations, ensuring\ntrial of a marketed product is terminated early for safety reasons,\na thorough evaluation of the safety and efficacy of our medicines\nwe promptly disclose medically important information to\nand vaccines. These efforts allow us to seek regulatory approvals\nregulatory authorities and the public, update the status on\nthroughout the world and thereby offer our medicines globally to\nwww.clinicaltrials.gov within 30 days and submit a manuscript to a\npatients who need them.\njournal (or post a summary online) within 12 months after the last\npatient’s last visit occurs. If the trial was terminated for efficacy In addition to complying with our Company’s global standards, the\nreasons, the results will be disclosed within 12 months after the last conduct of our clinical trials adheres to the International Council\npatient’s last visit occurs. Summaries of terminated trials will provide for Harmonisation: Good Clinical Practice standards and to the\ninformation about patient disposition, safety and adverse experiences, principles that have their origin in the Declaration of Helsinki. When\nas well as an explanation as to why the trial was terminated early. appropriate, an internal standing Data-Monitoring Committee (DMC)\nof our research laboratories’ senior managers reviews unblinded data\nWe comply with all applicable laws and regulations associated with\nfrom ongoing trials in a pre-specified, scientifically acceptable manner.\nthe registration of clinical trials in publicly accessible registries and\nThe goals of the DMC are to protect the safety of trial participants\nsubsequent posting of the results from these trials. We have put into\nand assess whether the risk/benefit profile is favorable. The DMC’s\nplace the processes necessary for compliance with the Food and Drug\nrecommendations are communicated internally to relevant scientists\nAdministration Amendments Act of 2007 and the European Clinical\nand can be distributed externally to clinical investigators, review\nTrial Directive 2001/20/EC, including those related to clinical trial\nboards or regulatory agencies, as appropriate.\nregistration and posting results. For those who analyze, report or\npublish the results of clinical trials, a clinical trial registry also provides\ninformation on trials in progress and the ability to track such trials\nover the course of development. Company-sponsored and -conducted\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 172"
  },
  {
    "page": 173,
    "source": "text",
    "content": "CONTINUED: GRI 416-2 | SASB 250a.1 | SASB 250a.2 | SASB 250a.3 | SASB 260a.1 | SASB 260a.2\nPhase II-V clinical trials patients by region1 2017 2018 2019 2020 2021\nAsia Pacific 15% 22% 28% 42% 18%\nCentral & Eastern Europe, Middle East & Africa 7% 7% 8% 8% 29%\nEuropean Economic Area 43% 21% 33% 20% 20%\nThe Americas 6% 9% 7% 15% 14%\nU.S. 29% 41% 24% 15% 20%\n1 May not add up to 100 percent due to rounding.\nTrial disclosures activities 2017 2018 2019 2020 2021\nManuscripts of clinical trial results and related papers submitted 476 527 576 622 611\nto peer-reviewed journals1\nNumber of GCP/PV inspections conducted by regulatory 128 96 99 52 79\nagencies worldwide\n1 Data from previous years have been adjusted to reflect manuscripts submitted from additional Company departments as well as Company collaborators.\nGCP/PV inspections 2017 2018 2019 2020 2021\nGCP/PV inspections by regulatory agencies of the Company or 0 0 0 0 0\nclinical trial investigators that led to significant fines, penalties,\nwarning letters or product seizures\nPlease visit the U.S. Food & Drug Administration’s (FDA) MedWatch website for more information on product safety alerts.\nYou may visit the FDA’s Adverse Event Reporting System (FAERS) website for up-to-date information on fatalities associated with product use.\nFor more information on our approach to clinical trials, please visit the Clinical Trials page on our corporate website.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 173"
  },
  {
    "page": 174,
    "source": "text",
    "content": "Marketing and labeling\nfor the Animal Health VMP portfolio from the time of initial product\napproval through the end of the product life cycle.\nGRI 417 Management approach\nOur chief medical officer (CMO) holds overall responsibility for the Requirements for product and service information\nGRI 417-1\nbenefit-risk determination of our human health pipeline and marketed and labeling\nproducts. In addition, the CMO provides medical oversight for all Code of ethics governing promotion of off-label use\nSASB 270a.2\nclinical programs, supervises the development and implementation of products\nof medical policies (including those related to data transparency and\nthe sharing of clinical data), and has responsibility for the design,\nConsistent with applicable FDA regulations, the label in our product\nexecution and implementation of pre-registration expanded access\npackaging contains information about adverse reactions and other\n(“compassionate use”) programs.\npotential risks that are either serious or otherwise clinically significant.\nOur chief safety officer (CSO) holds overall responsibility for We include contact details in our product packaging and on our corporate\ndetermining the human health product risk profile and overseeing website for patients, human and animal caregivers, farmers and\nthe safety of our human health products. Our Global Clinical Safety producers, and human and animal health professionals to report adverse\nand Pharmacovigilance (GCS&PV) function, led by the CSO, manages experiences in the U.S. Outside the U.S., adverse events are reported in\na global system for the collection, review and reporting of adverse accordance with any additional local country laws and practices.\nexperience (AE) reports received worldwide and for the continuous\nThere are occasions when our Company, in consultation with\nassessment of product safety.\nregulatory authorities, may determine that it is important to\nThe Animal Health senior vice president of R&D holds responsibility communicate new or updated information promptly to health care\nfor the benefit-risk determination for our Animal Health pipeline and providers involved in prescribing or dispensing a drug or in caring\nmarketed Veterinary Medicinal Products (VMPs) and oversees all for patients who receive a drug. In these situations, we work with\nAnimal Health clinical programs. regulatory authorities to communicate this information to health\ncare professionals in a timely manner so that they can inform patients\nthrough appropriate mechanisms.\nClinical safety and risk management\nClinical Safety and Risk Management (CSRM) leads the Risk Management Product label reviews\nSafety Team (RMST) for all products, from the beginning of Phase 2b\nthrough the end of the product life cycle. CSRM is responsible for the The ongoing oversight and monitoring of our product labels are a major\ndevelopment of proactive clinical safety risk-management strategies, focus of our safety efforts. Our label review teams monitor information\nincluding the Risk Management Plan (RMP), which is a regulatory on our products and work with our product Risk Management Safety\nrequirement in many countries for marketed drugs and vaccines. Teams (RMST) to develop or update product labeling. We regularly\ncommunicate relevant information to regulatory authorities worldwide.\nVeterinary medicinal product safety\nHealth literacy\nand risk management\nHealth literacy is essential to our overall strategy. We incorporate\nThe Animal Health Global Pharmacovigilance (GPV) Team manages a\nhealth literacy into all aspects of a product's development and lifetime,\nglobal system for the collection, review and reporting of AE reports\nfrom clinical testing to labeling and packaging to patient education.\nreceived worldwide, and for the continuous assessment of product\nIn 2020, we founded a worldwide community of practice for health\nsafety. GPV leads all safety monitoring and risk management activities\nliteracy, with membership from eight different nations and various\ncorporate divisions.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 174"
  },
  {
    "page": 175,
    "source": "text",
    "content": "CONTINUED: GRI 417-1 | SASB 270a.2\nThis community of practice was established to assist in identifying Our sales and marketing practices are governed by applicable laws\nand organizing health literacy advocates with the goal of training and regulations and industry codes of conduct, and by our own global\nand educating colleagues more broadly, both through formalized, Code of Conduct, our corporate policies and procedures, and our ethics\nconcerted efforts and through incidental collaboration in the course and compliance program.\nof daily work. In the fourth quarter of 2021, the community of\npractice launched an internal health literacy dictionary with more than\nCustomer privacy\n1,000 words, and established an internal health literacy portal for the\nexchange of materials and best practices.\nWe are dedicated to increasing people's health literacy in the U.S.\nand around the world. As part of this commitment, our health GRI 418 Management approach\nliteracy team has developed a novel method to enhance the patient\nlabeling process for new compounds. The purpose of this is to validate\ncomprehension across all the different consumer categories, with a Information about our Company, products and people is one of our\nparticular emphasis on those who have lower levels of health literacy. most valuable assets. We are committed to ethical use, management\nTo date, 10 of our medicines have FDA-authorized patient labels that and protection of information.\nwere produced with input from patients whose health literacy skills\nOur commitment applies not only to our Company’s information\nranged from low to high. Employees who create and assess patient\nbut also to the information entrusted to us by others. Our tools,\nlabeling for novel compounds are required to undergo training in health\nprocesses and procedures ensure that we appropriately collect, use\nliteracy methods for patient labels beginning in 2021.\nand safeguard information throughout its life cycle to ensure integrity\nof information and to prevent unauthorized access and disclosure.\nU.S. Medical Forums\nWe have developed and continue to improve upon a comprehensive,\nWe deliver balanced medical and scientific information to health care global, state of the art information security and cyber resiliency\nprofessionals and health care business professionals within the U.S. program to enable us to fulfill our purpose: inventing for life.\nthrough our promotional Medical Forums. We hire qualified external\nThere is increased pressure for companies to adopt the EU General Data\nmedical, scientific and health care experts (“speakers”) to deliver\nProtection Regulation (GDPR) as the basis for their own privacy policies\nMedical Forums. Speakers are selected based on defined, objective\nand programs. We are well positioned in that we have based our global\ncriteria that are directly related to the identified educational purpose of\nprogram on the GDPR. In addition, our privacy program is flexible and\nthe Medical Forum. The goal of this education is to provide substantive\nadaptable to be compliant to new laws and regulations that take effect\nscientific or educational information to our customers, as well as to\nin the jurisdictions where we conduct business. Examples include the\ninform customers about the benefits and risks of our products.\nCalifornia Consumer Privacy Act (CCPA) and California Privacy Rights\nWe are committed to the PhRMA Code on Interactions with Act (CPRA) in California, the Consumer Data Protection Act (CDPA) in\nHealth Care Professionals and, consistent with U.S. Food and Virginia, the Privacy Act (ColPA) in Colorado, and major revisions to the\nDrug Administration (FDA) regulations, our Medical Forums are Data Protection Acts in China, Ecuador, Japan and Saudi Arabia.\nappropriately balanced to include the product’s potential benefits\nIn addition, there is increased regulatory scrutiny and interest in\nand risks, and are consistent with approved product labeling.\ncompanies that seek to collect and monetize personal information\nWe believe that our marketing, sales and advertising activities make without full transparency and permission from data subjects.\nan important contribution to medicine by informing our customers of Regulators will continue to increase requirements in these areas and\ntreatment options based on the most recent scientific information and levy fines. Again, we believe that we are well positioned for these\nfindings from rigorous clinical studies. changes due to the deployment of a comprehensive closed-loop privacy\nprogram and our active engagement with regulators around the world.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 175"
  },
  {
    "page": 176,
    "source": "text",
    "content": "CONTINUED: GRI 418\nThe Global Privacy Office reports into our chief ethics and compliance We also provide annual mandatory cybersecurity training to\nofficer who reports directly to our chief executive officer. Oversight communicate and reinforce the guidelines in the Information\nof the privacy program is conducted within the Privacy and Data Security Standards Handbook and our commitment to a strong\nProtection Board (PDPB). This is a cross-functional board that connects cybersecurity culture. We have established a systematic approach\nto the Corporate Compliance Committee. The PDPB meets quarterly. for ensuring employees can understand and comply with Company\npolicies. We developed a robust cybersecurity training and\nWe are increasingly reliant on third party partners and service awareness program that frequently and consistently delivers both\nproviders to assist us in our global operations. Just as we need to pay compulsory and voluntary learning opportunities designed to\nclose attention to privacy and data protection, so do the third parties encourage employees to make security-aware decisions regarding\nthat comprise our supply chain. Our Company employs a robust third- our Company’s information security risks. Topics include, but are\nparty due diligence process to ensure that we only do business with not limited to, information protection, identity, email, browsing and\nreputable third parties who share our values and standards. mobile security. Employees are also expected to maintain an up to\ndate record of their qualifications that detail relevant cybersecurity\nOur approach is one of accountability and transparency. The heart of\nwork experience, skills, certifications and internal, industry or\nthis program is a leveraged, world-class Global Privacy Program that\nvendor-provided training they receive.\nmanifests itself throughout the world as a network of over 250 Privacy\nStewards deployed around the globe. Program maturity is measured\nthrough a combination of annual privacy self-assessments at the\nentity and organization level and by comprehensive privacy audits\nconducted by internal audit.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 176"
  },
  {
    "page": 177,
    "source": "text",
    "content": "CONTINUED: GRI 418\nGlobal privacy program\nOver the past 20 years, we have developed and continually improved Substantiated complaints regarding breaches\nGRI 418-1\na comprehensive global privacy program that promotes organizational of privacy or losses of personal data\naccountability for privacy, data governance and data protection across\nour business and with our collaborative partners and suppliers. We\nWe have a well-established process by which privacy incidents can be\nwere the first in the world to obtain regulatory approval in the EU for\nreported to the Global Privacy Office and be investigated. The first\nBinding Corporate Rules (BCRs), based in part on our existing Asia\nstep of this process is to verify the facts reported and to substantiate\nPacific Economic Cooperation (APEC) Cross-Border Privacy Rules\nthe concern. In 2021, we received 426 substantiated privacy concerns,\n(CBPRs) certified program.\nwhich marks a 70 percent increase compared to the previous year.\nThis increase was mainly due to enhanced capabilities for monitoring\nThis achievement demonstrates that organizations can rely on\nand detection of sensitive data in motion (network traffic). Three out\ncommon internal standards and processes to govern international data\nof 426 incidents were deemed to be reportable to data protection\ntransfers across both the EU and APEC regions to simplify their ability\nauthorities and/or data subjects.\nto address the growing regulatory challenges in this area.\nOur holistic approach to privacy has its origins in biomedical research\nethics and the protection of participants in the research studies\nthat we sponsor and conduct. We have adapted human subject\nresearch ethics standards for risk-benefit analysis, transparency,\nanonymization, coding and prior review to other activities and\nprocesses involving data about people.\nGlobal privacy program 2017 2018 2019 2020 2021\nNumber of concerns regarding privacy practices, breaches of 123 315 292 2503 4263\nprivacy and losses of personal data that were substantiated1\nNumber of privacy breaches requiring notification by 0 2 2 0 3\nour Company to individuals or government authorities\n1 P rivacy concerns reported here include all concerns about our privacy practices reported to our Company’s Privacy Office and substantiated or verified. Verified concerns are investigated as\npart of our Incident Management Process, which includes a determination of whether regulatory or data subject notification is required.\n2 Change in reporting criteria to exclude non-privacy, quality related issues from the data.\n3 Increased sensitivity of network traffic monitors contributed to increased number in 2020 and 2021.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 177"
  },
  {
    "page": 178,
    "source": "text",
    "content": "Global Reporting The GRI Standards represent global best practices for reporting publicly on a range of economic,\nenvironmental and social impacts. The table below summarizes where responses to the GRI\ndisclosures can be found throughout this report.\nInitiative (GRI)\nGeneral Disclosures\nGRI 102 Organizational Profile\n102-1 Organization name (Core) Pages 27–29\n102-2 Primary brands, products, and services (Core) Pages 27–29\n102-3 Headquarters location (Core) Pages 27–29\n102-4 Location of operations (Core) Pages 27–29\n102-5 Ownership and legal form (Core) Pages 27–29\n102-6 Markets served (Core) Pages 27–29\n102-7 Scale of the organization (Core) Pages 27–29\n102-8 Information on employees and other workers (Core) Pages 27–29\n102-9 Supply chain (Core) Pages 30-34\n102-10 Organizational changes during the reporting period (Core) Page 34\n102-11 Precautionary principle (Core) Page 35\n102-12 External initiatives (Core) Pages 35-36\n102-13 Membership associations (Core) Pages 36-38\nGRI 102 Strategy\n102-14 CEO Letter (Core) Page 39\n102-15 Key impacts, risks, and opportunities Not reported\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 178"
  },
  {
    "page": 179,
    "source": "text",
    "content": "GRI 102 Ethics & Integrity\n102-16 Values, principles, standards, and norms of behavior (Core) Pages 39-40\n102-17 Mechanisms for advice and concerns about ethics Pages 39-40\nGRI 102 Governance\n102-18 Governance structure of the organization (Core) Pages 41-43\n102-19 Delegation of responsibility Pages 41-43\n102-20 High-level accountability for sustainability topics Pages 41-43\n102-21 Access to the Board Pages 41-43\n102-22 Composition of the Board and its committees Pages 41-43\n102-23 Chair of the highest governance body Pages 41-43\n102-24 Board nomination and selection processes Page 43\n102-25 Board conflicts of interest Page 43\n102-26 Board and executive roles Page 43\n102-27 Board ESG knowledge Pages 43-44\n102-28 Board performance Not reported\n102-29 Board identification of ESG impacts, risks, and opportunities Pages 43-44\n102-30 Board ESG review of risk management processes Pages 43-44\n102-31 Frequency of Board review Pages 43-44\n102-32 Report review Pages 43-44\n102-33 Board communication Page 44\n102-34 Concerns communicated to the Board Not reported\n102-35 Remuneration policies for the Board and senior executives Page 44\n102-36 Process for determining remuneration Page 44\n102-37 Remuneration shareholder resolutions Page 44\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 179"
  },
  {
    "page": 180,
    "source": "text",
    "content": "102-38 CEO/employee pay ratio Page 44\n102-39 CEO/employee pay increase ratio Not reported\nGRI 102 Stakeholder Engagement\n102-40 Stakeholder engagement (Core) Pages 45-47\n102-41 Union representation (Core) Pages 45-47\n102-42 Stakeholder identification (Core) Pages 45-47\n102-43 Approach to stakeholder engagement (Core) Pages 45-47\n102-44 Key topics and concerns raised (Core) Pages 45-47\n2022 Proxy statement (page 25)\nGRI 102 Reporting Practice\n102-45 Entities included in financial statements (Core) Page 48\n102-46 Defining report content and topic boundaries (Core) Pages 48-50\n102-47 Material aspects included (Core) Pages 48-50\n102-48 Restatements (Core) Page 50\n102-49 Reporting changes (Core) Page 50\n102-50 Reporting period (Core) Page 50\n102-51 Date of most recent report (Core) Page 50\n102-52 Reporting cycle (Core) Page 50\n102-53 Report contact (Core) Page 50\n102-54 Claims of reporting in accordance with the GRI Standards (Core) Page 51\n102-55 GRI content index (Core) Page 51\n102-56 External assurance (Core) Page 51\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 180"
  },
  {
    "page": 181,
    "source": "text",
    "content": "Economic\nGRI 201 Economic Performance (2016)\n201-1 Direct economic value generated and distributed Pages 52-53\n201-2 Financial implications and other risks and opportunities due to climate change Pages 53-54\n201-3 Benefit plan coverage Page 54\nGRI 203 Indirect Economic Impacts (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 55-66\nfor evaluating the effectiveness of the company's strategy.\n203-1 Infrastructure investments and services supported Pages 67-74\n203-2 Indirect economic impacts Pages 67-74\nGRI 204 Procurement Practices (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 75-78\nfor evaluating the effectiveness of the company's strategy.\nGRI 205 Anti-corruption (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 78-79\nfor evaluating the effectiveness of the company's strategy.\n205-2 Communications and training on anti-corruption Page 79\nGRI 206 Anti-Competitive Behavior (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 80\nfor evaluating the effectiveness of the company's strategy.\n206-1 Anti-competitive behavior Page 81\nGRI 207 Tax (2019)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 82\nfor evaluating the effectiveness of the company's strategy.\n207-1 Approach to tax Page 82\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 181"
  },
  {
    "page": 182,
    "source": "text",
    "content": "Environmental\nGRI 301 Materials (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 83–87\nfor evaluating the effectiveness of the company's strategy.\nGRI 302 Energy (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 88-90\nfor evaluating the effectiveness of the company's strategy.\n302-1 Energy consumption within the organization (Scopes 1 + 2) Pages 91-92\n302-4 Energy reductions Pages 91-92\nGRI 303 Water and Effluents (2018)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 93-94\nfor evaluating the effectiveness of the company's strategy.\n303-1 Water as a shared resource Page 95\n303-2 Water discharge-related impacts Pages 95-96\n303-3 Water withdrawal Pages 96-99\n303-4 Water discharge Pages 100-101\nGRI 304 Biodiversity (2016)\n304-2 Significant impacts of activities, products, and services on biodiversity Page 102\n304-3 Habitats protected or restored Page 103\nGRI 305 Emissions (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 104-105\nfor evaluating the effectiveness of the company's strategy.\n305-1 Direct GHG emissions (Scope 1) Pages 106-108\n305-2 Indirect GHG emissions (Scope 2) Pages 106-108\n305-3 Other indirect GHG emissions (Scope 3) Pages 106-108\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 182"
  },
  {
    "page": 183,
    "source": "text",
    "content": "305-4 GHG emissions intensity Pages 106-108\n305-5 Reduction of GHG emissions Pages 106-108\n305-6 Ozone-depleting substances (ODS) Pages 108-109\n305-7 NOx, SOx and other emissions Pages 108-109\nGRI 306 Waste (2020)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 110\nfor evaluating the effectiveness of the company's strategy.\n306-1 Waste generation and significant waste-related impacts Pages 111-112\n306-2 Management of significant waste-related impacts Pages 111-112\n306-3 Waste generated Pages 113-116\n306-4 Waste diverted from disposal Pages 113-116\n306-5 Waste directed to disposal Pages 113-116\nGRI 307 Environmental Compliance (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 116-120\nfor evaluating the effectiveness of the company's strategy.\n307-1 Non-compliance with environmental laws and regulations Page 121\nGRI 308 Supplier Environmental Assessment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 122-123\nfor evaluating the effectiveness of the company's strategy.\nSocial\nGRI 401 Employment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 124\nfor evaluating the effectiveness of the company's strategy.\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 183"
  },
  {
    "page": 184,
    "source": "text",
    "content": "401-1 New employee hires and turnover Pages 125-127\n401-2 Benefits provided to full-time employees Pages 127-131\n401-3 Parental leave Page 131\nGRI 403 Occupational Health & Safety (2018)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 131-132\nfor evaluating the effectiveness of the company's strategy.\n403-1 Occupational health and safety management system Page 132\n403-2 Hazard identification, risk assessment, and incident investigation Pages 132-136\n403-3 Occupational health services Pages 136-137\n403-5 Worker training on occupational health and safety Page 137\n403-6 Promotion of worker health Page 138\n403-9 Work-related injuries Pages 138-141\n403-10 Work-related ill health Pages 138-141\nGRI 404 Training & Education (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 142\nfor evaluating the effectiveness of the company's strategy.\n404-1 Average hours of employee training Page 142\n404-2 Programs for upgrading employee skills and transition assistance programs Pages 143-146\n404-3 Percentage of employees receiving regular performance reviews Page 147\nGRI 405 Diversity & Equal Opportunity (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 148-158\nfor evaluating the effectiveness of the company's strategy.\n405-1 Diversity of governance bodies and employees Pages 159-161\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 184"
  },
  {
    "page": 185,
    "source": "text",
    "content": "GRI 412 Human Rights Assessment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 161-163\nfor evaluating the effectiveness of the company's strategy.\n412-1 Operations that have been subject to human rights reviews Page 163\n412-2 Employee training on human rights policies and procedures Page 163\n412-3 Investment agreements and contracts that include human rights clauses or underwent screening Page 163\nGRI 414 Supplier Social Assessment (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 164-166\nfor evaluating the effectiveness of the company's strategy.\n414-1 New suppliers screened using social criteria Page 166\nGRI 415 Public Policy (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 166\nfor evaluating the effectiveness of the company's strategy.\n415-1 Political contributions Pages 166-167\nGRI 416 Customer Health & Safety (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 167-168\nfor evaluating the effectiveness of the company's strategy.\n416-2 Incidents of non-compliance concerning the health and safety impacts of products and services Pages 169-173\nGRI 417 Marketing & Labeling (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Page 174\nfor evaluating the effectiveness of the company's strategy.\n417-1 Requirements for product and service information and labeling Pages 174-175\nGRI 418 Customer Privacy (2016)\nManagement Approach Explanation of the material topic, its boundary, how the topic is managed, and mechanisms Pages 175-177\nfor evaluating the effectiveness of the company's strategy.\n418-1 Substantiated complaints regarding breaches of customer privacy and losses of customer data Page 177\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 185"
  },
  {
    "page": 186,
    "source": "text",
    "content": "Sustainability Accounting SASB is an independent standards-setting organization dedicated to improving the\neffectiveness and comparability of corporate disclosure on ESG factors. The table\nbelow summarizes how our existing reporting aligns with the recommended metrics\nStandards Board (SASB) for the Biotechnology & Pharmaceuticals Standard within the Health Care sector,\nand where this information can be found in this report.\nSafety of clinical trial participants\n210a.1 Discussion, by world region, of management process for ensuring quality and patient safety Not reported\nduring clinical trials\n210a.2 Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance Not reported\nthat resulted in: Voluntary Action Indicated (VAI) and Official Action Indicated (OAI)\n210a.3 Total amount of monetary losses as a result of legal proceedings associated with clinical trials Not reported\nin developing countries\nAccess to medicines\n240a.1 Description of actions and initiatives to promote access to health care products for priority Pages 55-66\ndiseases and in priority countries as defined by the Access to Medicine Index\n240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification Pages 55-66\nof Medicines Programme (PQP)\nAffordability and pricing\n240b.1 Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved Not reported\npayments and/or provisions to delay bringing an authorized generic product to market for a\ndefined time period\n240b.2 Percentage change in: average list price and average net price across U.S. product portfolio Pages 55-66\ncompared to previous year\n240b.3 Percentage change in: list price and net price of product with largest increase compared to Pages 55-66\nprevious year\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 186"
  },
  {
    "page": 187,
    "source": "text",
    "content": "Drug safety\n250a.1 List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts Pages 169-173\nfor Human Medical Products database FAERS MedWatch\n250a.2 Number of fatalities associated with products as reported in the FDA Adverse Event Pages 169-173\nReporting System FAERS MedWatch\n250a.3 Number of recalls issued, and total units recalled Pages 169-173\nFAERS MedWatch\n250a.4 Total amount of product accepted for takeback, reuse, or disposal Pages 113-116\n250a.5 Number of FDA enforcement actions taken in response to violations of current Not reported\nGood Manufacturing Practices (cGMP), by type\nCounterfeit drugs\n260a.1 Description of methods and technologies used to maintain traceability of products throughout Pages 169-173\nthe supply chain and prevent counterfeiting\n260a.2 Discussion of process for alerting customers and business partners of potential or known risks Pages 169-173\nassociated with counterfeit products\n260a.3 Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related Not reported\nto counterfeit products\nEthical marketing\n270a.1 Total amount of monetary losses as a result of legal proceedings associated with false Not reported\nmarketing claims\n270a.2 Description of code of ethics governing promotion of off-label use of products Pages 174-175\nEmployee recruitment, development and retention\n330a.1 Discussion of talent recruitment and retention efforts for scientists and research and Pages 125-131\ndevelopment personnel\n330a.2 Voluntary and involuntary turnover rate for: executives/senior managers, mid-level managers, Pages 125-131\nprofessionals, and all others\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 187"
  },
  {
    "page": 188,
    "source": "text",
    "content": "Supply chain management\n430a.1 Percentage of entity's facilities and Tier I suppliers' facilities participating in the Rx-360 Not reported\nInternational Pharmaceutical Supply Chain Consortium audit program or equivalent third-party\naudit programs for integrity of supply chain and ingredients\nBusiness ethics\n510a.1 Total amount of monetary losses as a result of legal proceedings associated with corruption Not reported\nand bribery\n510a.2 Description of code of ethics governing interactions with health care professionals Pages 39-40\nCode of Conduct & Compliance\nActivity metrics\n000.A Number of patients treated Not reported\n000.B Number of drugs in portfolio, and in research and development (Phases 1-3) Pages 27-29\nPipeline\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 188"
  },
  {
    "page": 189,
    "source": "text",
    "content": "UN Global The UNGC is a strategic initiative that helps companies align their business activities and\nstrategies with ten universally recognized principles in the areas of human rights, labor standards,\nenvironmental protection and the fight against corruption. The table below summarizes how our\nCompact (UNGC) existing reporting aligns with these disclosures and where the information can be found in this\nreport, which serves as our Communication on Progress to UNGC.\nHuman rights\n1 Businesses should support and respect the protection of internationally proclaimed human rights Pages 161-163\n2 Businesses should make sure that they are not complicit in human rights abuses Pages 122-123, 161-166\nLabor\n3 Businesses should uphold the freedom of association and the effective recognition of the rights Pages 161-163\nto collective bargaining\n4 Businesses should support the elimination of all forms of forced and compulsory labor Pages 161-163\n5 Businesses should support the effective abolition of child labor Pages 161-163\n6 Businesses should support the elimination of discrimination in respect of employment Pages 148-161, 161-163\nand occupation\nEnvironment\n7 Businesses should support a precautionary approach to environmental challenges Pages 83-87, 93-101, 110-116\n8 Businesses should undertake initiatives to promote greater environmental responsibility Pages 83-123\n9 Businesses should encourage the development and diffusion of environmentally Pages 83-87, 93-101\nfriendly technologies\nAnti-corruption\n10 Businesses should work against corruption in all its forms, including extortion and bribery Pages 39-40, 78-81, 164-166\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 189"
  },
  {
    "page": 190,
    "source": "text",
    "content": "UN Sustainable The SDGs are a set of 17 global goals whose aim is to end poverty, fight\ninequality and injustice, and tackle climate change by 2030. The table\nbelow summarizes how our reporting aligns with the SDGs and where\nDevelopment Goals (SDGs) this information can be found in this report. More information on our\npriorities can also be found on page 11.\nGoal Description Response\nSDG 1: No Poverty End poverty in all its forms everywhere Pages 55-74, 82\nSDG 2: Zero Hunger End hunger, achieve food security and improved nutrition and promote Merck Animal Health\nsustainable agriculture\nSDG 3: Good Health & Well-being Ensure healthy lives and promote well-being for all at all ages Pages 55-74, 131-141\nSDG 4: Quality Education Ensure inclusive and equitable quality education and promote lifelong learning Pages 142-147\nopportunities for all\nSDG 5: Gender Equality Achieve gender equality and empower all women and girls Pages 124-131, 142-161, 164-166\nSDG 6: Clean Water & Sanitation Ensure availability and sustainable management of water and sanitation for all Pages 93-101, 113-116\nSDG 7: Affordable & Clean Energy Ensure access to affordable, reliable, sustainable and modern energy for all Pages 88-92\nSDG 8: Decent Work & Economic Growth Promote sustained, inclusive and sustainable economic growth, full and productive Pages 27-30, 45-47, 52-54,\nemployment and decent work for all 88-92, 124-141, 142-161, 164-166\nSDG 9: Industry, Innovation & Infrastructure Build resilient infrastructure, promote inclusive and sustainable industrialization Pages 52-74\nand foster innovation\nSDG 10: Reduced Inequalities Reduce inequality within and among countries Pages 27-30, 124-131, 142-161\nSDG 11: Cities & Communities Make cities and human settlements inclusive, safe, resilient and sustainable Not applicable\nSDG 12: Responsible Consumption & Production Ensure sustainable consumption and production patterns Pages 83-116, 174-175\nSDG 13: Climate Action Take urgent action to combat climate change and its impacts Pages 53-54, 88-92, 104-109\nSDG 14: Life Below Water Conserve and sustainably use the oceans, seas and marine resources for Pages 35, 93-103\nsustainable development\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 190"
  },
  {
    "page": 191,
    "source": "text",
    "content": "SDG 15: Life on Land Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably Pages 93-116\nmanage forests, combat desertification, and halt and reverse land degradation and\nhalt biodiversity loss\nSDG 16: Peace, Justice & Strong Institutions Promote peaceful and inclusive societies for sustainable development, provide access Pages 39-40, 41-44, 80-81,\nto justice for all and build effective, accountable and inclusive institutions at all levels 116-121, 132-141, 164-166,\n167-177\nSDG 17: Partnerships for the Goals Strengthen the means of implementation and revitalize the global partnership for Pages 35-36, 45-47, 82\nsustainable development\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 191"
  },
  {
    "page": 192,
    "source": "text",
    "content": "Culture of Health for The Culture of Health for Business (COH4B) is a framework for companies to disclose\ntheir impact on health of employees, families and communities, as well as brand and\nfinancial performance, that lead to both positive and negative business outcomes.\nBusiness (COH4B) The table below summarizes how our reporting aligns with the recommended metrics\nfor the Biotechnology & Pharmaceuticals Standard within the Health Care sector and\nwhere this information can be found in this report.\nStrategic\nHealth culture Promoting an organizational culture of health Pages 127-141, COVID-19\nResponsible corporate Activity that shapes public policy or public opinion Pages 36-38, 166-167,\npolitical activity Transparency Disclosures\nResponsible marketing Commitments to responsible marketing Pages 174-175\npractices\nPolicies & Benefits\nHealth promotion and wellness Providing health promotion and wellness programs Pages 124-141\nPaid family and medical leave Allowing employees to earn pay while away attending to illness, a family member or newborn Pages 124-141\nHealth insurance Providing employer-based health insurance Pages 124-141\nEquality, diversity Managing inequality, discrimination and diversity, including disability Pages 124-131, 148-163\nand impartiality\nFinancial literacy Providing financial literacy resources Pages 124-131\nWorkforce & Operations\nWork time Managing working hours, schedules and schedule control Pages 124-131\nJob security Managing job insecurity Pages 124-131\nPay practices Managing wage policies, minimum wages, wage satisfaction Pages 124-131,\nCompensation and benefits\nOccupational health and safety Mandatory and voluntary occupational health and safety Pages 131-141\nPhysical environment Managing air quality, lighting, green buildings, health promotion attempts through Pages 83-123\nthe built environment\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 192"
  },
  {
    "page": 193,
    "source": "text",
    "content": "Community\nCommunity environmental Managing the environmental impacts of company operations on communities Pages 83-123\nimpacts CDP Water Security\nCDP Climate Change\nSocial capital and cohesion Encouraging links, shared values and understanding Pages 18-20, 124-131\nCommunity involvement Investments in programs to benefit communities, including disaster response and recovery Pages 55-74, 124-131,\nPhilanthropy, Impact Investing,\nMedical Outreach Program\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 193"
  },
  {
    "page": 194,
    "source": "text",
    "content": "Stakeholder At the 2020 Annual Meeting in Davos, 120 of the world’s largest companies supported efforts to\ndevelope a core set of common metrics and disclosures for their investors and other stakeholders.\nBelow is our alignment against the Core metrics from this framework developed by the World\nCapitalism Metrics Economic Forum, as well as select disclosures from the Expanded metrics. Merck currently is not a\nsignatory to the Stakeholder Capitalism Metrics.\nPrinciples of Governance\nGoverning Purpose\nSetting purpose (Core) Not reported\nPurpose-led management (Expanded) Overview (Pages 6-9)\nQuality of Governing Body\nGovernance body composition (Core) Pages 41-43\nProgress against strategic milestones (Expanded) Access to medicine (Pages 55-74),\nProduct quality and safety (Pages 30-34, 55-74, 78-79, 167-175, Clinical trials page),\nPublic health risks (Pages 55-74),\nEthics in R&D (Pages 39-40, 55-74, 167-173, Clincal trials page),\nEmployee health and safety (Pages 131-141),\nEmployee engagement and diversity (Pages 29, 45-47, 148-161),\nClimate change (Pages 53-54, 88-92, 104-109),\nBusiness ethics (Pages 39-40, 78-79, 174-175, Code of Conduct & Compliance),\nData privacy and security (Pages 175-177),\nGovernance structures and mechanisms (Pages 39, 41-47, 132-136, 159-161, 177)\nRemuneration (Expanded) Page 44\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 194"
  },
  {
    "page": 195,
    "source": "text",
    "content": "Stakeholder Engagement\nMaterial issues impacting stakeholders (Core) Pages 45-47, 48-50\nEthical Behavior\nAnti-corruption (Core) Pages 78-79\nProtected ethics advice and reporting mechanisms (Core) Pages 39-40\nAlignment of strategy and policies to lobbying (Expanded) Pages 166-167\nRisk and Opportunity Oversight\nIntegrating risk and opportunity into business process (Core) Pages 41-43, 48-50\nPlanet\nClimate Change\nGreenhouse gas (GHG) emissions (Core) Pages 106-108\nParis-aligned GHG emissions targets (Expanded) Pages 104-109\nTCFD implementation (Core) Pages 53-54\nNature Loss\nLand use and ecological sensitivity (Core) Pages 102-103\nFreshwater Availability\nWater consumption and withdrawal in water-stressed areas (Core) Pages 93-101\nImpact of freshwater consumption and withdrawal (Expanded) CDP Water Security\nAir Pollution\nAir pollution (Expanded) Pages 108-109\nPeople\nDignity and Equality\nDiversity and inclusion (Core) Pages 159-161\nPay equality (Core) Pages 149-150\nWage level (Core) Not reported\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 195"
  },
  {
    "page": 196,
    "source": "text",
    "content": "Risk for incidents of child, forced or compulsory labor (Core) Pages 161-163\nHuman rights review, grievance impact and modern slavery (Expanded) Pages 161-163\nFreedom of association and collective bargaining at risk (Expanded) Pages 45-47, 164-166\nHealth and Wellbeing\nHealth and safety (Core) Pages 138-141\nEmployee wellbeing (Expanded) Pages 131-141\nSkills for the Future\nTraining provided (Core) Pages 142-147\nProsperity\nEmployment and Wealth Generation\nAbsolute number and rate of employment (Core) Pages 124-131\nInfrastructure investments and services supported (Expanded) Pages 55-74\nEconomic contribution (Core) Pages 52-54\n2021 Form 10-K\nFinancial investment contribution (Core) 2021 Form 10-K\nSignificant indirect economic impacts (Expanded) Pages 55-74\nInnovation for Better Products and Services\nTotal R&D expenses (Core) 2021 Form 10-K (page 61)\nCommunity and Social Vitality\nTotal tax paid (Core) Page 82\nAdditional tax remitted (Expanded) Page 82\nMerck ESG Progress Report 2021/2022 Overview GRI/SASB: General disclosures Economic Environmental Social Indices 196"
  },
  {
    "page": 197,
    "source": "text",
    "content": "Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.\nThis publication is intended only for residents of the United States and Canada.\nForward-looking statement\nThis publication of Merck & Co., Inc., Rahway, NJ, USA (the “company”) includes “forward-looking\nstatements” within the meaning of the safe harbor provisions of the U.S. Private Securities\nLitigation Reform Act of 1995. These statements are based upon the current beliefs and\nexpectations of the company’s management and are subject to significant risks and uncertainties.\nThere can be no guarantees with respect to pipeline candidates that the candidates will receive the\nnecessary regulatory approvals or that they will prove to be commercially successful. If underlying\nassumptions prove inaccurate or risks or uncertainties materialize, actual results may differ\nmaterially from those set forth in the forward-looking statements.\nRisks and uncertainties include but are not limited to, general industry conditions and\ncompetition; general economic factors, including interest rate and currency exchange rate\nfluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the\nimpact of pharmaceutical industry regulation and health care legislation in the United States and\ninternationally; global trends toward health care cost containment; technological advances, new\nproducts and patents attained by competitors; challenges inherent in new product development,\nincluding obtaining regulatory approval; the company’s ability to accurately predict future market\nconditions; manufacturing difficulties or delays; financial instability of international economies and\nsovereign risk; dependence on the effectiveness of the company’s patents and other protections\nfor innovative products; and the exposure to litigation, including patent litigation, and/or\nregulatory actions.\nThe company undertakes no obligation to publicly update any forward-looking statement, whether\nas a result of new information, future events or otherwise. Additional factors that could cause\nresults to differ materially from those described in the forward-looking statements can be found\nin the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the\ncompany’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s\nInternet site (www.sec.gov).\nNo duty to update\nThe information contained in this publication was current as of the date presented. The company\nassumes no duty to update the information to reflect subsequent developments. Consequently,\nthe company will not update the information contained in this publication and investors should not Merck & Co., Inc.\nrely upon the information as current or accurate after the presentation date. 126 East Lincoln Avenue\nP.O. Box 2000\nRahway, NJ 07065 USA\nMerck.com\nMerck & Co., Inc., Rahway, N.J., U.S.A., is known as\nMSD outside the United States and Canada."
  }
]